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Metabolic disorders induce a low-grade chronic inflammatory state that is damaging 
to the peripheral vasculature, leading to cardiovascular diseases. In recent years, there 
has been mounting evidence linking metabolic disease to neurovascular disorders and 
cognitive decline. However, the pathophysiological response occurring at the brain 
microvasculature, the blood-brain barrier (BBB), remains largely unexplored.  
 
Using a mouse model of Type II diabetes mellitus, the results of this project 
demonstrate pro-inflammatory mediators and altered immune responses to impair the 
protective BBB functionality. Disruption to tight junctions and basal lamina, due to 
loss of control in activation/production of MMPs and their inhibitors, causes complete 
BBB breakdown. Metabolic stress triggers endothelial dysfunction resulting in altered 
metabolism and receptor expression, enhanced ROS production and up-regulated 
adhesion molecules.  Immunologically, there is an increase in the percentage of 
activated effector and central memory T-cells along with an imbalance in the 
TH17/Treg subsets. Together these factors augment transmigration of leukocytes 
across the BBB to trigger activation and shift of microglia to a pro-inflammatory 
phenotype, initiating neuroinflammation. Loss of the physical, transport and metabolic 
properties of the BBB will consequently have detrimental effects on neuronal function.  
 
Additionally, this thesis explores the use of a pharmacological and dietary intervention 
to reduce and restore the damage incurred to the BBB. Treatment with human 
recombinant annexin A1 (a well know anti-inflammatory molecule) and reversion 
from a high-fat high-sugar diet to a chow diet both attenuate T2DM development, 
reduce peripheral inflammation and dampen the immune response, resulting in 
restored BBB integrity. Both interventions confer neuroprotection through 
stabilisation of cell-cell contacts, consequently limiting leukocyte extravasation and 
downstream pathological events. 
 
This thesis emphasises the growing understanding of long-term impact of metabolic 
disease and their contribution to the development of neuroinflammatory/ 
neurodegenerative disorders. Preventive and therapeutic strategies that mediate anti-
inflammatory effects are key in limiting the disease progression.   
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Metabolic syndrome (MetS) is a complex condition characterised by a series of traits 
including elevated glucose levels, insulin resistance, dyslipidaemia, hypertension and 
central obesity (1,2), which subsequently results in the development of Type II 
Diabetes Mellitus (T2DM). Each trait is associated with inducing a low-grade chronic 
inflammatory state and immune imbalance responsible for exacerbating stress and 
damage upon cells and tissues. Consequently, the traits of MetS and T2DM are risk 
factors for heart and circulatory diseases (cardiovascular disease, CVD) encompassing 
coronary heart disease, atrial fibrillation, heart failure, stroke, and vascular dementia 
(VaD). CVDs are the leading cause of death worldwide, responsible for 17.9 million 
deaths in 2016 (3).  
 
Whilst the effect of metabolic disorders on the peripheral system has been greatly 
investigated, little attention has been provided to investigating the effect of MetS and 
T2DM on the brain, particularly at the blood-brain barrier (BBB) level. The BBB, 
formed of specialised endothelial cells, forms a protective barrier to limit the entry of 
unwanted toxic components into the brain. Studies have found that damage at the BBB 
level can be responsible for the development of neurological disorders such as 
Multiple Sclerosis (MS) and cerebrovascular dementia. This is due to alterations of 
BBB characteristics leading to recruitment of inflammatory cells into the brain, 
resulting in neurological damage (4). In recent years, research has implicated 
metabolic disorders to be a risk factor for cognitive decline (5,6) and the development 
of dementias (7,8). Individuals with T2DM have twice the risk of developing 
dementia, particularly Alzheimer’s disease (AD), compared to those without T2DM 
(9). The underlying feature of metabolic disorders is insulin resistance. Recent 
research has discovered abnormalities in the brain which can be linked to insulin 
resistance ensuing in a course of pathological events similar to AD (10,11). This has 
therefore let to the concept of insulin resistance of the brain, and has been termed Type 
III DM (T3DM) (12).  
 
Both T2DM and dementias are progressive long-term conditions largely affecting 
individuals >65 years old (13). Given that people are living longer and obesity is on 
the rise due to westernisation (increased intake of energy dense foods high in saturated 
fats and sugar and decreased physical activity levels) (14) we are facing an epidemic 
crisis; placing an increasing burden on healthcare systems. The need for preventative 
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and therapeutic strategies to reduce the development of metabolic disorders and 
subsequent cardiovascular and neurological diseases has never been greater. 
 
However, investigations are still required to understand the mechanisms by which 
metabolic disorders lead to T3DM development. In order to achieve this, it is first 
paramount to understand the effect of metabolic disorders on the BBB at the cellular 
and molecular level. This will allow for development and investigation of compounds 
that can help to reduce the progression, restore the damage incurred and combat the 
development of neurovascular/neurodegenerative disorders. This is the broad aim of 
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1.1  Central Nervous System: the brain & its barriers 
The Central Nervous system (CNS) consists of the brain and spinal cord; it is the 
control centre of the body involved in processing information into motor function 
(voluntary and involuntary movements), thoughts, perceptions and emotions (15). To 
allow for optimal neuronal communication and signalling, the surrounding 
microenvironment (ionic balance, pH & nutrient supply) must be precisely regulated. 
Homeostatic maintenance of the neural microenvironment is provided by three 
principal barriers, which are present at the interface between the CNS and the 
peripheral system (16,17). The three principal barriers are the BBB, the blood-
cerebrospinal fluid barrier (BCSFB) and the meninges-arachnoid barrier (Figure 1.1). 
There is also a fourth barrier, the tanycytic barrier that is present at the 
circumventricular organs (CVOs) (18,19). 
 
1.1.1 The blood-brain barrier (BBB) 
The BBB is present at the interface between blood and the cerebral tissue and is 
constructed of endothelial cells that form the capillary walls (Figure 1.1a) (20). The 
BBB has a unique phenotype attributed to the high expression of tight junctions (TJs) 
and specialised transport mechanisms that provide exceptional protection to the brain 
from invading pathogens, toxins and immune cells (21). Basement membranes (BMs), 
pericytes and astrocytes form close associations with the endothelial cells to provide 
a complex and highly restrictive 3D structure (22). Together with basement 
membranes (BMs), pericytes, astrocytes, microglia and neurons, these cells form the 
neurovascular unit (NVU). The highly restricted and regulated structure of the BBB 
gives rises to its ability to function as a physical, transport and metabolic barrier (22). 
Further detail of the BBB structure and the cells of the NVU is provided in Section 
1.3.  
 
1.1.2 The Blood-Cerebrospinal fluid barrier (BCSFB) 
The BCSFB is present within the choroid plexus of the lateral, third and fourth 
ventricles of the brain (23). The choroid plexus is an epithelial-endothelial convolute 
that is comprised of a vascularised stroma containing connective tissue and a 
continuous single layer of cuboidal epithelial cells that are linked together by TJs (24–
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26). It should be noted that the epithelium of the choroid plexus is continuous with the 
ependymal cell layer that lines the ventricular system (24). One of the primary 
functions of the choroid plexus is to produce the cerebrospinal fluid (CSF) that is 
secreted into the brain ventricular system (27,28). Microvilli project from these 
epithelial cells on the CSF-facing surface to increase the surface area to aid in fluid 
secretion (26). Secondly, the choroid plexus serves as a barrier in the brain separating 
the blood from the CSF forming the BCSFB. In comparison to the BBB, the capillaries 
of the BCSFB are fenestrated to allow for the movement of molecules across the 
endothelial cells through intercellular gaps (29). Instead the barrier function is 
performed by the choroid plexus epithelial cells that are linked together by TJs (Figure 
1.1b) (29). Notably, similar to the BBB, the BCSFB is also lined with polarised 
transporters for selective transport of ions and solutes into the brain ventricles (16,23). 
In addition to these vital functions, the choroid plexus also secretes various growth 
factors that maintain the stem cell pool in the subventricular zone of the lateral 
ventricle (30). 
 
1.1.2.1 The Cerebrospinal fluid (CSF) and the interstitial fluid (ISF)  
The CSF is a clear, colourless fluid which is found in the CNS, intracerebrally within 
the brain ventricles (20% of CSF volume) or extracerebrally in the subarachnoid space 
(80% of CSF volume). Within a human, the total volume of CSF is 150mL and within 
24 hours approximately 500-600mL is produced therefore the CSF is replaced 3-4 
times per day (28,31). The CSF functions to provide mechanical support against the 
real weight of the brain, to provide protection as a shock absorber or to sudden changes 
in pressure or temperature and to allow for maintenance of a metabolic equilibrium 
and homeostatic environment by supply of nutrients and disposal of waste products 
(32). 
The CSF is synthesised via two processes. The large majority ~50-70% of secretion 
occurs through the epithelial cells of the choroid plexus and the ventricular ependyma, 
whilst the remainder is produced by ultrafiltration of blood plasma through choroidal 
capillaries (33). The CSF is secreted across the choroid plexus into the brain ventricles. 
The ventricles of the brain are interconnected cisterns and thus the CSF circulates from 
the lateral ventricles through the foramina of Monro into the third ventricle and further 
through the aqueduct of Sylvius to the fourth ventricle. From the fourth ventricle, part 
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of the CSF flow into the central canal of the spinal cord whilst the rest flows into the 
subarachnoid space by the foramina of Luschka and Magendie (32,33). In the 
subarachnoid space, the CSF is separated from the outer surface of the brain by the pia 
matter. Resorption of the CSF takes place by the arachnoid granulations and the 
arachnoid villi, these are protrusions of the arachnoid through the dura mater that 
project further into the intracranial venous sinuses to allow flow of CSF back into the 
blood circulation (34). In some pathological conditions, the increase in intracranial 
pressure can force the CSF into the extracellular space of the periventricular white 
matter (35).  
Whilst the CSF fills the ventricles and the subarachnoid space, the remainder of the 
brain extracellular fluid is the brain interstitial fluid (ISF) (36,37). The brain ISF, 
similar to the CSF, also functions to cushion and support the cells of the NVU. Within 
the brain, the ISF occupies the brain interstitial system (ISS); an irregular and tortuous 
space among neural cells and capillaries (38,39). Of the total brain volume, the brain 
ISS occupies 15-20% and it contains both ISF and the extracellular matrix (ECM) 
(39,40). The brain ISF is a water solvent that contains ions, gaseous and organic 
molecules including proteins, peptides, enzymes and extracellular vesicles. The ISF 
surrounds neural cells to provide a supply of nutrients. There is extensive 
communication between the CSF and ISF and hence the CSF is considered a reservoir 
for the ISF and the site of removal of waste products from the brain ISF (39,41), 
discussed later in Section 1.3.5.  
 
1.1.3 The meninges-arachnoid barrier 
The meninges consist of three layers: the dura mater (pachymeninx) which is an outer 
fibrous sheet adjacent to the skull, the arachnoid mater and the pia mater (together 
referred to as the leptomeninges) which lay under the dura mater and just above the 
brain and spinal cord parenchyma (42,43). The dura mater is a tough, collagenous 
membrane, it is highly vascularised and contains the lymphatics (44,45). In 
comparison to the dura mater, the leptomeninges are relatively thin (42,43). The 
arachnoid mater is formed of several layers of epithelial cells that have tight junctions 
to strictly regulate movement of molecules, similar to the BBB. The regulation by this 
meningeal membrane confers the meninges-arachnoid barrier (Figure 1.1c) (16,21). 
Underneath the arachnoid mater lies the subarachnoid space through which the CSF, 
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produced by the choroid plexus epithelium, flows. The last meningeal membrane, the 
pia mater covers the brain and spinal cord parenchyma and is semi-permeable to the 
CSF (42,43,46).  
The meninges serve to protect the brain and spinal cord from trauma, support blood 
vessels and form a continuous cavity to allow for the flow of the CSF through the 
arachnoid and pia mater (42,43). The purpose of the meninges-arachnoid barrier is to 
completely enclose the brain and the CNS from the rest of the body (21), to prevent 
the mixing of peripheral ISF with brain ISF and CSF (47).   
 
1.1.4 The Tanycytic barrier 
The brain regions located around the brain ventricles are named the CVOs; three 
sensory and four secretory CVOs have been identified. The sensory CVOs include the 
subfornical organ, organum vasculosum of the lamina terminalis, and area postrema; 
the cells located here monitor blood and CSF-derived information (48). The secretory 
CVOs consist of the neurohypophysis, median eminence, and pineal gland that release 
brain-derived hormones into the blood circulation (48). Together the CVOs help to 
maintain homeostasis; allowing for a two-way exchange of metabolic information (49) 
thus the CVOs also form an interface between the blood - brain (50), giving rise to 
another barrier between the blood - CSF called the tanycytic barrier (18,19).  
The CVOs have distinct features such as fenestrated capillaries, lack of tight junctional 
complexes, enlarged perivascular spaces and highly specialised ependymal cells called 
tanycytes (18,51). However, observations of the tanycytes have revealed these cells to 
express TJ proteins in comparison to the fenestrated endothelial cells present at the 
CVOs (19,52,53); suggesting a shift of the barrier from the vascular to the ventricular 
side (18). This shift of the barrier allows for diffusion of blood-borne materials through 
the permeable vasculature into the parenchyma of the CVO and from here the tanycyte 
TJs control their diffusion into the CSF (19,49). Thus, the tanycytic barrier forms a 
barrier between the blood-CSF at the CVOs. Tanycytes were initially identified at the 
median eminence (19) but have since found to be a characteristic feature of all of the 
CVOs (18).   




Figure 1.1 | The three barriers of the brain 
a) A BBB is present in all organisms with a well-developed CNS. It is formed of capillary 
endothelial cells held together by tight junctions, creating the largest surface area for exchange 
between the blood and brain. In the average human adult the surface area of the BBB is 
approximately 12-18m2 (54) b) The endothelial cells of the choroid plexus are fenetestrated 
instead the BCSFB is formed by the epithelial cells of the choroid plexus present at the lateral, 
third and fourth ventricles of the brain that are held together by tight junctions; the CSF is 
secreted across this barrier into the brain ventricular system. The remainder of the brain is 
surrounded in ISF. c) The epithelial cells of the arachnoid membrane, which lies under the 
dura mater, encloses the brain and the CNS from the peripheral system. The meninges-
arachnoid barrier is formed of several layers of epithelial cells creating an effective barrier 
that is avascular in nature and has a small surface area to prevent exchange between the blood 
and the CNS. CSF drains out of the brain via arachnoid villi that project into the sagittal sinus. 
Figure taken from Abbott et al., 2009 (16).  
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1.2 The brain vasculature system 
The brain is one the most perfused organs in the body. The arterial supply to the brain 
consists of two pairs of large arteries - the right and left internal carotid arteries and 
the right and left vertebral arteries. The carotid arteries run along the front of the neck 
to supply the cerebrum whereas the vertebral arteries run along the back, coming 
together to form the basilar artery to supply the cerebellum and the brain stem. At the 
base of the brain, the carotid and basilar arteries join to form an anastomotic ring 
known as the circle of Willis. The circle of Willis gives rise to three further main 
arteries - the anterior, middle, and posterior cerebral arteries. Each of these divides 
progressively into smaller arteries and arterioles that run along the surface of the brain, 
providing blood supply to all regions of the brain (55,56). Figure 1.2 shows the major 
arteries of the brain.  
 
 
Figure 1.2 | The main arterial supply to the brain 
The main arterial supply to the brain is provided by two pairs of arteries – the right and left 
carotid and the right and left vertebral artery. The right and left vertebral artery come together 
to from the basilar artery. Where the basilar and carotid arteries join, at the base of the brain, 
an anastomotic ring is formed known as the circle of Willis. The circle of Willis gives rise to 
three cerebral arteries - anterior, middle, and posterior, to supply the brain (55,56). 
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Arteries enter the brain into two ways; either by running parallel to the surface of the 
cerebral cortex as pial arteries or perpendicularly to the surface of the brain resulting 
in a V-shaped depression in the pia mater (43,57). Parallel pial arteries are surrounded 
by a single layer of pia; pial cells can be identified by the presence of intercellular gap 
junctions and diffuse BMs (43,57). The arteries which enter the brain parenchyma 
perpendicular to the surface also carry a single-layered sheath of pial cells. Unlike 
arteries in the periphery, there are no true perivascular (Virchow-Robin) spaces around 
the arteries in human cerebral cortex (43,58,59). Instead the perivascular compartment 
of the arteries in the cerebral cortex consists of compacted layers of smooth muscle 
cells, endothelial cell BM and pia that associate closely with the BM of astrocyte end-
feet (43,58). Mouse brains show a similar arrangement of arteries (60). Importantly, 
whilst there are no perivascular spaces in the arteries of the cerebral cortex, 
perivascular spaces do exist in the arteries of the cerebral white matter, basal ganglia 
and midbrain (61,62); with the capacity to dilate due to the presence of two 
leptomeningeal layers in these regions versus the one layer of leptomeninges that 
surrounds the arteries in the cerebral cortex (43,58,63). The layers of leptomeningeal 
cells facilitate the entry of CSF into the CNS tissue (60). Additionally, the BMs of the 
arteries and capillaries are also routes for the flow of fluid and solutes into and out of 
the brain (60,64) and is termed the Intramural Peri-Arterial Drainage (IPAD) pathway; 
IPAD has been discussed in Section 1.3.5.  
As the arteries narrow deeper into the brain parenchyma they transition into 
parenchymal arterioles which branch off into capillaries to supply the cells of the NVU 
(56,65). The pial and penetrating arteries are covered by vascular smooth muscles cells 
which remain separated from brain tissue by the parenchymal BM. The descending 
parenchymal arterioles and capillaries on the other hand, become associated with 
astrocytes and inter-neurons (66). The parenchymal arterioles are covered with a 
single layer of smooth muscle cells whereas the capillaries are formed of endothelial 
cells supported by BMs, pericytes and astrocytes (56,66) (described in section 1.2.4). 
The structure of the capillaries gives rise to the BBB (67–71). Figure 1.3 shows the 
transition from pial arteries through to capillaries. 
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From the cerebral capillaries, the blood continues into the post-capillary venules where 
perivenous spaces exist and fill with CSF. There are two groups of valve-less veins 
which allow for the drainage of venous blood from the cerebral hemispheres. One 
group is the superficial cortical veins, which are located in the pia mater and drain the 
cerebral cortex and white matter. The second group is the deep or central veins that 
drain the brain’s interior including the deep white and grey matter that surrounds the 
lateral and third ventricles. These veins drain into the superior sagittal sinus, and 
venous outflow is directed via a confluence of sinuses towards the sigmoid sinuses 
and jugular veins (68).  
 
 
Figure 1.3 | Arteries to capillaries in the brain 
The pial arteries are present on the surface of the brain in contact with the pia. Branching 
arteries penetrating into the brain tissue are termed penetrating arteries. As these penetrating 
arterioles narrow deeper into the brain parenchyma they transition into parenchymal arterioles 
which branch off into capillaries to supply the cells of the NVU. The descending parenchymal 
arterioles and capillaries are associated with astrocytes and neurons. The transition between 
the two can be seen through smooth muscle cell cover, provided at the parenchymal arteries. 
Whereas the capillaries are formed of endothelial cells supported by basement membranes, 
pericytes, astrocytes and neurons, to give rise to the BBB. From the cerebral capillaries, the 
blood continues into the post-capillary venules, which drain into the major veins to be carried 
away from the brain. Figure taken from Yamazaki et al., 2017 (69). 
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1.2.1 Cerebral blood flow 
As an organ, the brain has the highest energy-density demands of all of the organs, 
utilising 20% of the body’s resting metabolic rate (72). Interestingly, the high 
metabolic demand of the brain is not matched by the presence of larger intrinsic energy 
stores within the cells of the NVU. Instead the brain relies on a continuous supply of 
substrates from the peripheral vasculature (73). Consequently, the cerebral blood flow 
(CBF) is critical to ensure proper delivery of oxygen and nutrients and subsequent 
removal of waste products of metabolism (74). The CBF is maintained by the 
coordinated action of the arteries, capillaries and veins, which form a 400-mile long 
vascular network within the brain (75). Changes in blood flow i.e. hypoperfusion 
(insufficient CBF) and hyperperfusion (excessive CBF) can cause ischemic injury or 
BBB breakdown resulting in seizures, encephalopathy and ischemic or haemorrhagic 
strokes.  
In order to maintain regional CBF, the brain has unique mechanisms known as 
functional hyperaemia (increase in CBF occurring in response to brain activity) or 
neurovascular coupling (dynamic functional change in CBF in response to local 
neuronal activity) (76,77). These mechanisms allows for rapid upregulation in CBF in 
activated brain regions. All of the cells within the NVU contribute to neurovascular 
coupling, however the vascular smooth muscle cells are responsible for the contractile 
properties of the vessel to control diameter and blood flow (75–78). Therefore, the 
flow through the capillaries is regulated by the contraction or dilation of vascular 
smooth muscle cells at either the arterial or venous ends resulting in changes in blood 
flow ranging from 0.3mm/s to 3.2mm/s (79,80). There are number of modulators 
which can contribute to the alterations in the vascular tone and thus alter CBF. For 
example, nitric oxide (NO) produced by neurons acts on vascular smooth muscle cells 
leading to hyperpolarisation and relaxation (76,81). The release of ATP or adenosine 
by neurons can cause vascular smooth muscle constriction when bound to purinergic 
receptors P2X and P27 (82,83) or relaxation when bound adenosine A2A receptors 
(78,84). Other modulators include arachidonic acid metabolic products including 
epoxyeicosatetraenoic acids, prostaglandin E2via and cyclooxygenase 1 (81,85,86). 
Impaired myogenic autoregulation, endothelial dysfunction and neurovascular 
uncoupling, can result in a mismatch between CBF, oxygen/nutrient delivery and 
neuronal activity. This disruption in functional connectivity, as a consequence of 
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vascular conditions and aging, is often seen in early stages of a number of neurological 
disorders including AD, stroke and Amyotrophic lateral sclerosis (ALS) and initiates 
the neurodegenerative process (75–77,87).  
 
1.3 The BBB: structure & function 
The BBB is the defining feature of the brain vasculature, limiting the contact of 
peripheral blood and peripheral blood-borne materials with the brain. In order for the 
BBB to provide a specialised protective function, the endothelial cells of the BBB are 
distinctly different in structure from all other endothelial cells in the body (88). Firstly, 
the brain microvascular endothelial cells (BMECs) have an absence of fenestrations, 
which correlates with a high expression of TJs. Secondly there is little pinocytosis and 
paracellular diffusion of hydrophilic compounds; as a result a number of membrane 
receptors and transporters are present on both the luminal and abluminal sides of the 
BMECs (20,89). Due to the high metabolic demands of the BMECs to conduct their 
cellular activities, they are lined with a high number of mitochondria (22,90).  
 
1.3.1 Physical barrier 
The extreme tightness of the BBB, which limits the diffusion of the majority of 
macromolecules, can be attributed to the presence of TJs and adherens junction (AJs) 
that provide cell-cell adhesion contacts. The TJs help to form a continuous blood 
vessel with high electrical resistance in the range of 1500-2000 Ω.cm2 giving rise to 
low paracellular permeability and high transendothelial electrical resistance (TEER) 
(91,92). The role of the AJs on the other hand is to initiate, mature and maintain cell-
cell contacts (93). Within epithelial cells, including the choroid plexus epithelium, TJs 
are the most apical component of the junctional complexes and can clearly be 
distinguished from the AJs however, in the endothelial cells, particularly those of the 
BBB, the complexes appear intermingled (94–97).  
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1.3.1.1 Tight junctions 
TJs are composed of three major transmembrane proteins – occludins, claudins and 
junctional adhesion molecules (JAMs) connected to a series of cytoplasmic proteins 
such as zona-occludens (ZO)-1, ZO-2, ZO-3 and regulatory proteins such as cingulin 
(Figure 1.4). In the brain, claudins-3, -5 and -12 have been identified; these bind 
homotypically to claudins present on adjacent cells thereby forming the TJ seal (98). 
The 65-kDa occludin protein has a much higher expression in brain endothelium 
compared to endothelial barriers in non-neuronal tissues, hence it is key in regulating 
the paracellular permeability through association with ZO proteins (99). All of the 
junctional proteins form a multi-complex junction that links to cytoskeleton 
component actin. Together this maintains the structural and functional integrity of the 
brain endothelium (100–102).  
 
1.3.1.2 Adherens junctions 
The AJs are intermingled with the TJs in the basolateral membrane of BMECs (Figure 
1.4); these AJs help to form a continuous adhesion belt (103). The major 
transmembrane protein of AJs is Ca2+-regulated VE-cadherin, which is linked to 
scaffolding proteins α-, β-, γ- and p120 catenin that couple the entirety of the complex 
to the actin cytoskeleton (104,105). Proteins of the AJs and TJs are known to interact 
(97), for example VE-cadherin engagement through Akt activation and inhibition of 
β-catenin nuclear translocation, causes phosphorylation of the transcription factor 
forkhead box factor 1 (FOX1). FOXO1 induces the transcription of TJ protein claudin-
5 (106). Hence AJs are essential in establishment and maintenance of the endothelial 
cell-cell contact. 
 
1.3.1.3 The cytoskeleton 
The inter-endothelial junctional integrity is provided by the cytoskeleton, consisting 
of actin microfilaments, intermediate filaments and microtubules (107). There are two 
different conformations of actin filaments; globular monomers of G-actin that upon 
polymerisation form helical structures, or asymmetrical filaments of F-actin which 
come together to form contractile bundles. The actin cytoskeleton is essential in 
providing a tension force to BMECs that allows them to retain their shape, driven by 
the interaction of actin with myosin to form stress-fibres. The polymerisation of actin 
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fibres is widely recognised to alter the structure of cells; this is important for normal 
cellular physiological tasks such as cell cytokinesis or endo- and exocytosis (108–
111). Intermediate filaments are 10nm in diameter and are responsible for providing 
tensile strength, the major intermediate filament is vimentin which links to VE-
cadherin (112). Microtubules consist of polymers of α- & β- tubulin involved in the 
rapid assembly of actin filaments and focal adhesions, cellular contraction and 
increased transendothelial migration (113,114).  
 
1.3.1.4 Cell polarity 
TJs and AJs play an important role in providing cell polarity in order to separate the 
apical and the basolateral sides of endothelial cells, this polarity is more pronounced 
in the BBB compared to all other endothelial barriers (115). The lipid and glycoprotein 
composition at plasma membranes is an important mediator of cellular polarity 
(116,117). They aide in the distribution and localisation of transporters which are 
essential for movement of nutrients and ions to meet the metabolic demand of the 
brain. Polarisation is also crucial for the response to stimuli such as cytokines and 
growth factors e.g. VEGF or histamine, as these factors increase BBB permeability 
when administered at the basolateral membrane but not at the apical membrane (49). 
















Figure 1.4 | Molecular composition of BBB endothelial tight junctions 
Cell-cell adhesion in the BBB is provided by the presence of tight junctions (TJs) and adherens 
junctions (AJs), allowing the formation of a continuous vessel. The TJs are composed of 
occludins, claudins and junctional adhesion molecules (JAMs) A, B & C connected to a series 
of scaffolding proteins zona-occludens (ZO)-1, ZO-2 & ZO-3, TJ-associated protein 7H6 and 
Itch (E3 ubiquitin protein ligase). The AJs sit below the TJs; the major component is VE-
cadherin linked to scaffolding proteins α-, β-, γ- and p120 catenin. The platelet–endothelial 
cell adhesion molecule (PECAM) is also part of the AJs and is involved in mediating 
homophilic adhesion. The scaffolding proteins connect with the actin-myosin cytoskeleton to 
retain the cellular shape through interaction with cingulin and junction-associated coiled-coil 
protein (JACOP). A series of secondary adaptor proteins including membrane-associated 
guanylate kinase with inverted orientation of protein–protein interaction domains (MAGI 1-
3), partitioning defective proteins (PAR3/6) and multi-PDZ-protein 1 (MUPP1) help to 
organise regulatory and signalling molecules such as the regulator of G-protein signalling 5 
(RGS5), afadin (AF6), and the transcription regulator ZO-1-associated nucleic acid-binding 
protein (ZONAB) (16,21).  
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1.3.2 Transport barrier 
Molecules can pass across endothelial cells using a paracellular (between adjacent 
cells) or transcellular (through the cell) route (89). Due to the restrictive nature of the 
BBB provided by the junctional complexes, the paracellular pathway is largely 
occluded. Whilst small non-polar molecules such as oxygen and carbon dioxide and 
lipophilic molecules such as ethanol can freely diffuse across the BBB, larger 
hydrophilic molecules require facilitated diffusion in the form of transporters, 
channels or carriers outlined in Figure 1.5 (114). The brain has a high energy 
consumption therefore the transport of nutrients such as glucose and amino acids are 
necessary for metabolism. Consequently the brain is enriched with glucose 
transporter-1 (GLUT1) (20) and the L-type neutral amino acid transporter-1 (LAT1) 
(119,120). The BBB also contains several ATP-binding cassette (ABC) transporters 
required for the efflux of molecules from the brain into the bloodstream to clear waste 
products and prevent the entry of neurotoxic or xenobiotic compounds. The major 
ABC transporters present in the brain are p-glycoprotein (Pgp), multi-drug resistance 
(MDR) proteins 1-6 and breast cancer resistance protein (BCRP) (121–125). Cellular 
polarity is a major determinant on the localisation of all transporters to the luminal or 
abluminal plasma membranes. The BBB endothelium also possesses a number of ion 
channels, required for ionic balance, transport and secretion of signalling molecules 
including Ca2+, nitric oxide (NO) and von Willebrand factor (103).  
On the other hand, the transcellular pathway involves receptor-mediated shuttling 
largely used by hormones and adipokines or by leukocytes. Notably leukocytes are 
also capable of diapedesis through TJs via the paracellular pathway (126).  
 
1.3.2.1 Transport of glucose and insulin across the BBB 
The focus of this thesis is to examine the impact of T2DM on the BBB. In T2DM, the 
role of glucose and insulin in the peripheral system is of paramount of importance, 
with hyperglycaemia and hyperinsulinaemia resulting in T2DM progression as 
discussed later, in Section 1.5. The brain is very metabolically active and utilises 
glucose as its primarily fuel to generate energy (127,128). As a result, the transport of 
glucose and insulin across the BBB are of paramount importance.  
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To date, 14 different GLUTs have been identified with GLUT-1, -2, -4 and -4 being 
the most well characterised. Brain endothelial cells express GLUT-1 on both the apical 
and basolateral membranes, astrocytes express GLUT-1 and GLUT-3, microglia 
express GLUT-5 and neurons express isoforms GLUT-3 and GLUT-4 (129–132).  
Within the peripheral system, insulin is a major regulator of blood glucose levels 
through stimulating uptake of glucose by liver, muscle and adipose tissue (133). 
Insulin is produced within the beta-cells in the islets of Langerhans of the pancreas 
and is immediately released from granular stores upon raises in blood glucose. 
Released insulin acts on insulin specific receptors which signal via intercellular insulin 
receptor substrate-1 (IRS-1). Under basal conditions, the IRS-1 complex is rendered 
inactive through phosphorylation on serine-307. However, upon hyperglycaemic 
conditions, insulin binding to the insulin receptor allows for phosphorylation of 
typrosine-608/638 instead, thereby allowing signal transduction through 
phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) (134). This signalling 
cascade initiated by insulin binding to its receptor facilitates the translocation of 
glucose transporters to cell membranes (135). Insulin crosses the BBB by a saturable 
transport mechanism (133).  
Interestingly, glucose transport in the brain is largely insulin-independent with GLUT-
1 and GLUT-3 not requiring insulin to regulate glucose uptake (136). However, 
GLUT-4 present on neurons does require insulin-mediated glucose uptake (136) for 
neuronal growth, plasticity or neurotransmitters release (137) and thus insulin plays a 
key role in learning, memory and cognition. It has been reported that the highest 
concentration of insulin receptors are found in olfactory bulb, cerebral cortex, 
hypothalamus, hippocampus, and cerebellum; regions associated with learning and 
memory (138–140).  
Aside from cognition, insulin affects feeding behaviour (141). In contrast to the effects 
of peripheral insulin, CNS insulin increases blood glucose levels and decreases 
feeding and body weight (142–144). Other effects of insulin at the BBB include 
enhanced transport of amino acids tyrosine and tryptophan, increased transport of 
adipokine leptin (141) and enhanced expression and function of Pgp (145).  
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1.3.3 Metabolic barrier 
Isolated human brain microvessels reveal the BBB to contain a number of drug 
transporters and drug metabolising enzymes (146) responsible for restricting entry of 
neurotoxic drugs and eliminating foreign compounds from the CNS (Figure 1.5). In 
the human BBB, phase I enzymes such as cytochrome P450 and phase II enzymes 
such as UDP-glucuronosyltransferase and glutathione S-transferase have been 
identified; this strongly impacts the ability of pharmacological agents to target CNS 
diseases (147). The function of these transporters is effected during disease such as 
AD resulting in enhanced exposure of the brain to neurotoxic molecules such as β-
















Figure 1.5 | The transport mechanisms present at the BBB 
As the BBB provides a restricted environment for the free movement of molecules a number 
of transport mechanisms must be present to facilitate entry of enzymes, metabolites and 
leukocytes. These transporters have polarised distribution on either the luminal or abluminal 
surfaces of the BBB endothelium. The BBB is lined with a number of solute carrier (SLC) 
transporters e.g. GLUT1, ion channel pumps to allow entry of metabolites required for ATP 
generation, along with Na+-dependent amino acid and organic acid transporters. In addition, 
there are specific transporters for neuroactive peptides such as arginine-vasopressin (AVP). 
The movement of larger molecules e.g. insulin, transferrin, leptin, β-amyloid is facilitated by 
receptor-mediated transcytosis. Additional protection of the brain is provided by the presence 
of active efflux ABC transporters (Pgp, MDR1, BCRP) which are involved in pumping toxic 
compounds out of the brain. Enzymes are also present at the BBB to metabolise any foreign 
material. Figure adapted from Bennaroch, 2012 (149). 
 
Page | 45  
 
1.3.4 The NVU  
Beyond the BMECs, other components and cells of the NVU also contribute to the 
maintenance and functionality of the BBB. The structure of the NVU is shown in 
Figure 1.6.  
 
1.3.4.1 Basement membranes and the glycocalyx 
The basal lamina is an ECM that is produced by both endothelial cells and the 
surrounding astrocytes to form BMs (150). The different cells are responsible for 
producing different laminin isoforms, with laminin α4 and α5 being derived from 
BMECs and laminin α1 and α2 being derived from astrocytes (151,152). The BMs are 
also composed of various types of collagen, glycoproteins and proteoglycans that are 
termed the glycocalyx (153). The attachment of the endothelial BM to endothelial cells 
is mediated via α-dystroglycan whereas the parenchymal BM attachment to astrocytic 
end-feet is mediated by β-dystroglycan (154). The combination of the parenchymal 
BM and astrocyte foot processes is termed the glia limitans (4). The glia limitans 
covers the entire surface of the brain and spinal cord on the external face towards the 
subarachnoid space and is termed the glia limitans superficialis whereas the glia limits 
that surrounds the vessels is called the glia limitans perivascularis (155). Between the 
endothelial BM and the glia limitans, there is a collagen IV-containing middle layer, 
called the perivascular space (155). In the capillaries, the BMs fuse together to form a 
gliovascular membrane that closes the perivascular space (156). 
The endothelial glycocalyx, present on the luminal side (157), is involved in regulating 
vascular permeability through transmission of physical forces, induced by fluid shear 
stress, to the cytoskeleton of endothelial cells (158,159). The extracellular matrix 
(ECM) of the BBB also contains a number of matrix metalloproteinases (MMPs) and 
their inhibitors, tissue inhibitor of metalloproteinases (TIMPs) which are involved in 
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1.3.4.2 Pericytes 
Pericytes are in close contact with endothelial cells to provide a variety of supportive 
roles. This includes development and maturation of endothelial cells and assistance in 
the metabolic performance of myocytes. The latter helps in the pericyte-aided control 
of capillary diameter and modulation of blood flow in response to neuronal activity 
(161–163). In addition, pericytes secrete growth factors and adhesion molecules as 
well as assisting with angiogenesis and phagocytosis at the BBB (162,163).  
 
1.3.4.3 Glial cells – astrocytes, microglia and oligodendrocytes 
The maintenance of a number of BBB properties, including the formation of TJs and 
polarised expression of transporters relies on the close association of astrocytes with 
the BMECs (164). From an anatomical point of view, neurovascular communication 
takes place through the astrocyte end-foot, which is an extension of the astrocytes that 
encase the endothelial cells and pericytes (165). The astrocyte foot processes provide 
an additional layer of structural support and defence at the BBB. The astrocytes can 
also produce and release substances such as prostaglandins, neurotrophic factor, 
angiopoietin-1 or NO, that contribute to BBB integrity and vascular tone (166). 
Astrocytes also provide simultaneous support to neurons; making them one of the most 
diverse cells in the brain (167). Astrocytes are involved in the regulation and 
maintenance of neuronal synapses through provision of metabolic support, 
neurotransmitter precursors and ion buffering via specialised gap junctions or direct 
contact (168,169). The close association of astrocytes to neurons allows for neuronal 
mediators to affect vessel dynamics and BBB integrity (170).  
 
 
Astrocytes are a type of glial cell, the other glial cells in the brain parenchyma include 
the microglia and oligodendrocytes. Microglia are the resident macrophage of the 
brain and form the first line of immune defence in the brain (171). In a healthy state, 
microglia are involved in surveillance of the CNS, with motile processes that 
constantly monitor the extracellular space (172). Upon activation, microglia become 
activate, proliferate and migrate to the site of injury or inflammation to phagocytose 
bacteria, degenerating cells and neurons to help clear the damage (173). However, 
activated microglia can also release cytokines, chemokines, interleukins and other 
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inflammatory molecules which can contribute to the initiation of a neuroinflammatory 
response (171,173). The activation and role of astrocytes and microglia in 
neuroinflammation has been discussed in Section 1.7. 
With regard to the maintenance of the BBB, early migration of macrophages to 
capillary walls in response to CCL5 release by brain endothelial cells has been 
observed and this results in TJ formation by microglia cells with endothelial cells 
through expression of claudin-5 (174). This additional support helps to maintain BBB 
integrity; indeed, ablation of microglia or blockage of CCL5 signalling early on in 
inflammation increases BBB permeability (174). Sustained inflammation causes 
microglia transformation to a phagocytic phenotype with the ability to release pro-
inflammatory mediators and thus contribute adversely to BBB damage (174,175).  
 
Oligodendrocytes are smaller and have fewer branches than astrocytes (176). The most 
well documented function of oligodendrocytes is myelin formation to produce the 
myelin sheath that insulates neuronal axons for the transmission and propagation of 
action potentials for signal conduction (177). In addition, oligodendrocytes surround 
cerebral blood vessels and help to maintain BBB permeability (178–181). This is via 
trophic communication between oligodendrocyte precursor cells (OPCs) and brain 
endothelial cells (182). Endothelial cells provide fibroblast growth factor-2, brain-
derived neurotrophic factor and vascular endothelial growth factor (VEGF) for 
proliferation, survival and migration of OPCs (182,183). In turn, OPCs secrete 
transforming growth factor β (TGF-β) for maintenance of BBB integrity via the 
MEK/ERK signalling pathway which increases the expression of TJ proteins (184). 
Interestingly, oligodendrocytes can also contribute negatively to BBB permeability 
through the production of ECM degradation proteins, the matrix metalloproteinases 
(MMPs) (185,186). MMPs are expressed by OPCs and are required for the maturation 
into oligodendrocytes and sensitivity to growth factors (185,186). However, MMPs 
increase BBB permeability through degradation of junctional proteins and the BMs 
and can also contribute to neuroinflammation-induced neurotoxicity (187). 
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1.3.4.4 Neurons 
Neurons are the pacemakers of the NVU (188). With the ability to detect small 
variation in nutrient or oxygen supply, they can influence the vessel dynamics and 
BBB integrity through the release of electrical or chemical messengers via astrocytes 
(170). Neuronal functioning is necessary for the co-ordination of sensory and motor 
function. Therefore the precise regulation of the microenvironment is essential for 
signalling (168). The cells and components of the NVU come together to ensure that 
















       





Figure 1.6 | Structural diagram of the neurovascular unit (NVU) 
The NVU is made up of endothelial cells, basement membranes, pericytes (smooth muscle 
cells), astrocytes, neurons, and microglia. Collectively, the NVU is responsible for 
maintaining the homeostasis of the brain microenvironment to allow for optimal CNS 
functioning. The cells of the NVU come together to form the blood-brain barrier (BBB), which 
acts as a protective barrier against potentially cytotoxic agents. As a result, brain capillaries 
have a very distinct structure from general capillaries in the peripheral system. Tight junctions 
between cerebral endothelial cells form a very restrictive seal to block free movement of 
solutes. Instead, a number of transporters localise to the luminal and abluminal sides of the 
cerebral endothelial cells to ensure the delivery of nutrients to meet brain metabolic demand. 
Further support in regulating permeability and cerebral blood flow is provided by the close 
association of pericytes. Astrocytes encase the endothelial cells of the BBB via end-foot 
processes, to provide an additional layer of protection, assist in biochemical maintenance and 
allow for transduction of signals to neurons. Astrocytes and neurons form close associations 
through transmission of metabolites and neurotransmitters, which can control vessel dynamics 
and BBB integrity. Endothelial cells and astrocytes both also secrete laminins to form two 
distinct basement membranes, which are composed of collagen IV, laminins, fibronectins, 
proteoglycans, and glycoproteins to add additional layers of support, protection and BBB 
maintenance. All together these layers ensure a tightly enclosed and regulated system of the 
brain from peripheral blood.  
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1.3.5 The Glymphatic system 
An important aspect of tissue homeostasis is the efficient removal of excess fluid and 
waste products, and the return of soluble materials and proteins back into the 
circulation. In the peripheral tissues, the lymphatic system serves to provide this 
function (190). The lymphatic vascular network is a unidirectional flow system that is 
present in every organ of the body to remove ISF; the major lymphatic systems are the 
cardiopulmonary, hepatic, meningeal, and dermal lymphatic vessels (191). Lymph 
drains into the lymphatic capillary vessels that are present within the interstitial spaces 
of tissues and organs. Lymph is moved into the lymphatic system present within lymph 
nodes and are returned to the blood circulation through the left and right subclavian 
veins and into the vena cava (192). The lymph nodes filter the lymph fluid to remove 
pathogens and other waste products. Importantly, the lymphatic is not only responsible 
for the removal and filtration of ISF from tissues, but it also involved in the transport 
of antigens and immune cells to the lymph nodes, where adaptive immune responses 
are often triggered (190). Thus, the lymphatic system is also implicated in the 
pathogenesis of several diseases such as lymphomas, lymphedema, lymphangitis, 
lymphocytosis and lymphadenitis (193).  
Usually the density of lymph vessels correlates with the rate of tissue metabolism; it 
would therefore be expected that the brain and spinal cord, with the highest metabolic 
rate of the body, would be served by the greatest number of lymphatic vessels 
(194,195). However, the CNS lacks a conventional lymphatic system. Instead the 
brain has a unique clearance system that utilises perivascular tunnels formed by 
astroglial cells, and this is termed the glymphatic system (196). Similar to the 
peripheral lymphatic system, the glymphatic system also serves to facilitate the 
distribution of soluble compounds throughout the brain and spinal cord such as 
glucose, lipids, amino acids, growth factors and neuromodulators through the mixing 
of CSF and ISF (71). 
Given the anatomy of the brain and restrictive environment provided by the 3 brain 
barriers, the glymphatic system can be defined into 3 distinct steps. Firstly, the CSF 
produced by the choroid plexus cells is moved by bulk-flow from the basal cisterns 
into the subarachnoid space that cover the cerebral hemispheres. The CSF enters into 
periarterial spaces (area surrounding pericytes and smooth muscle cells) in a bulk-
flow-driven manner. Next, the CSF moves into the perivascular space surrounding 
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arteries (58) through a combination of arterial pulses, respiration, slow vasomotion 
and CSF pressure gradients. The CSF continues its flow into the perivascular spaces 
around arterioles, capillaries, and venules where the extracellular matrix of the BMs 
provides a continuity of the fluid space and low resistance. The surrounding astrocytic 
end-feet which ensheath these perivascular spaces express aquaporin 4 (AQP4) 
through which CSF can move into the brain parenchyma to enable the mixing of CSF 
and ISF as well as waste product removal (70,197,198). The CSF movement drives 
ISF waste towards perivenous spaces of larger central veins surrounding the meninges 
and cranial nerves, and exiting the skull from where it can drain into the peripheral 
lymphatic system via the cervical lymph nodes (199,200).  
The glymphatic system and clearance mechanism is of significant interest in 
neurodegenerative disorders. In conditions such as AD, the accumulation of β-amyloid 
(A) proteins and tau tangles are central to disease progression. In fact, the first 
pioneering study that lead to the discovery of the glymphatic system was through the 
injection of fluorescent or radiolabelled amyloid-β1-40 into mouse striatum; in which 
it was seen that the protein was transported from the ISF and out of the brain via a 
novel clearance mechanism (197,201). This implicates the glymphatic system as a 
novel therapeutic target for preventing cognitive decline (198,202). The glymphatic 
system is so named, due to its reliance of AQP4 channels located on the astroglial 
cells; with AQP4-/- mice showing 55% reduction in amyloid-β1-40 clearance 
compared to wild-type controls (197,201). The dependence of the AQP4 channels 
located on astrocytic end-feet implicates how damage and BBB breakdown could 
result in the accumulation of waste products and excess fluids that contribute to 
adverse CNS pathology.  
Aside from the glymphatic system formed by perivascular tunnels created by 
astrocytes, fluid and solutes drain from the brain to the cervical lymph nodes along the 
BMs in the walls of cerebral capillaries and arteries (60,64,203). This drainage 
mechanism has been named the IPAD pathway (204). It has been suggested that this 
perivascular lymphatic drainage is dependent on vascular smooth muscle cell 
contractions and biochemical interactions with BMs and therefore reduced 
contractility of the vascular smooth muscle cells with age or vascular dysfunction such 
as atherosclerosis results in reduced efficiency of this lymphatic drainage (205–209). 
Over time this results in the accumulation of Aβ in the IPAD pathways of cerebral 
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arteries and capillaries, known as cerebral amyloid angiopathy (210). The 
accumulation of Aβ and indeed of other waste products or metabolites will affect the 
CNS environment and lead to altered homeostasis. Similar to the glymphatic system, 
targeting the IPAD could provide a novel therapeutic strategy to improve outcomes in 




1.3.6 Disruption to BBB integrity  
A variety of different factors can disrupt the permeability of the BBB. One of the 
biggest group of agents to induce BBB alterations are vasogenic agents such as 
histamine, VEGF, basic fibroblast growth factor and TGF-β (211–214). Inflammatory 
mediators of cytokines (IL-1β, TNF-α & IFN-γ), chemokines (CCL2, CXCL8), matrix 
metalloproteinases (MMP-2 & MMP-9), free radicals (H2O2, OH
- & NOO-) and 
prostaglandins (E2 & F2a) have also largely been implicated in causing BBB 
breakdown (215–219). 
The contractile forces generated by the endothelial cytoskeleton, in combination with 
the adhesive forces of the TJ and AJ proteins, are responsible for maintaining the 
integrity and restrictive nature of the BBB. Increased paracellular permeability and 
low TEER can be associated with alterations in the junctional complex, resulting in 
the formation of intercellular gaps to large plasma proteins, leukocytes and foreign 
molecules (44,63). Changes to the adhesive properties can be correlated to the 
phosphorylation state of the junctional proteins. The TJ and AJ proteins undergo 
phosphorylation and dephosphorylation by protein kinases and phosphatases at serine, 
threonine, or tyrosine residues affecting protein-protein interaction, protein 
localisation and distribution (222–225). In unison, the actin cytoskeleton undergoes 
reorganisation whereby the actin filaments polymerise to form stress fibres. 
Association of the actin with myosin results in the generation of contractile forces that 
‘pull’ apart the endothelial cells to disrupt the junctional complexes hence forming 
small gaps in the barrier (226,227). Downstream effects of changes in the TJs and AJs 
integrity include disruption of cell polarity, subsequently affecting the distribution and 
localisation of transporters and enzymes. Overall a tightly regulated BBB ensures 
limited permeability, aiding in preserving the homeostatic environment of the brain. 
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In order to maintain the correct brain microenvironment, the BBB must function as a 
dynamic system which can sense and response to local changes and requirements, such 
as adjustment of nutrient supply, protection from circulating infections or facilitation 
in local repair (21). However BBB dysfunction has been associated with a large 
number of CNS pathologies including MS, AD, Parkinson’s disease (PD), epilepsy, 
hypoxia and ischemia, tumours, glaucoma and lysosomal storage disease (16). The 
variation in barrier dysfunction can range from mild transient TJ opening to complete 
perturbation and breakdown of the BBB. The loss of BBB integrity can result in altered 
transport, accumulation of toxins such as β-amyloid, activation of microglia cells and 
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1.4 The concept of inflammation: involvement of the immune system 
Inflammation is an evolutionary-conserved response initiated by the innate arm of the 
immune system upon destruction of tissue or against foreign materials (229). The aim 
is to destroy the harmful agent and limit the tissue injury. Inflammation can be 
recognised by its classic signs of heat (calor), redness (rubor), swelling (tumor), pain 
(dolor) and loss of function (function laesa) (230); which correspond to physiological 
changes occurring during the inflammatory process as seen by blood vessel dilation, 
increased blood vessel permeability and leukocyte extravasation (231).  
Inflammation can be categorised as either acute or chronic. Acute inflammation refers 
to the initial response generated by the host organism in order to eliminate the source 
of damage and restore homeostasis (232). The acute phase response causes the release 
of a number of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-α (233). If the 
original source of inflammation is unable to be resolved, long-term chronic 
inflammation can result. This occurs due to persistence of inflammatory mediators and 
activated immune cells that cause on-going tissue damage (229,234). 
Innate immune responses form part of the acute response, whereas chronic 
inflammation also involves the adaptive arm. The innate immune system is composed 
of granulocytes (neutrophils, basophils, eosinophils), mast cells, macrophages, and 
dendritic cells. In contrast, the adaptive immune system is comprised of CD4+ T-
helper (TH) cells, CD8
+ cytotoxic T-cells and B-cells. Natural killer (NK) cells are at 
the interface of the two immune systems, with cytotoxic and antigen-presenting ability 
(235). CD4+ T-helper cells can be divided into different subsets; the pro-inflammatory 
TH1 and TH17 and the anti-inflammatory TH2 and T-regulatory (Treg). TH1 cells are 
responsible for the production of IFN-γ, TNF-α and IL-12 to trigger cell-mediated 
immunity and phagocytic-dependent inflammation as well as inducing macrophage 
switching to a pro-inflammatory M1 phenotype (235). TH2 cells produce IL-4, IL-6, 
IL-10 and IL-13 to regulate antibody responses and TH17 cells predominately secrete 
IL-17 and IL-22 (235,236). Treg cells secrete IL-10 and TGF-β to prevent excessive 
inflammatory responses, including autoimmunity, by regulating the other T-cell 
subsets and innate immune cells (237,238). 
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1.4.2 The immunologically unique CNS: interaction with the peripheral 
immune system 
During the mid-20th century, studies of successful tissue transplantation into the brain 
parenchyma without rejection gave rise to the concept of the CNS as an immune 
privileged site (239,240). However, research in the past 20 years has altered this view 
with an understanding that peripherally-generated inflammatory mediators and 
xenotoxic agents can enter the brain and contribute to neurodegeneration suggesting 
that the CNS cannot be entirely immune-privileged (241,242). The protective barriers 
of the brain establish an interface between the peripheral and central immune systems 
to prevent damage to neurons, through restriction of immune cell entry. Therefore 
immune cell trafficking into the brain, like the movement of all molecules, is strictly 
regulated (4).  
 
1.4.3 Breaching the BBB: leukocyte transmigration  
Transendothelial migration (TEM) is a highly established process, allowing immune 
cells to cross endothelial cell barriers to the site of interest. The classic steps of TEM 
include capture-rolling, activation-adhesion, crawling-arrest and extravasation-
diapedesis (Figure 1.7). Each step requires the involvement of different adhesion or 
signalling molecules on endothelial cells and circulating leukocytes (4,243). There are 
two distinct migration routes, either paracellularly through endothelial junctions or 
transcellularly through the formation of pores. In vitro and in vivo studies implicate 
the paracellular route to be favoured peripherally whereas healthy brain vascular 
endothelium support higher transcellular leukocyte migration, due to the BBB 









Figure 1.7 | Transendothelial migration of leukocytes 
The initial step of TEM is the capture and rolling of leukocytes along the endothelium 
mediated by the selectin family of adhesion molecules (E-, L- and P-selectin), which bind to 
their respective ligands e.g. P-selectin glycoprotein ligand (PSGL-1) (88,89). Tethering and 
firm adhesion is provided by β2-integrins (LFA-1 and VLA-4) present on leukocytes that bind 
the immunoglobulin (Ig) superfamily of adhesion molecules (ICAM-1, ICAM-2, and VCAM-
1). The adhered immune cell can bind a number of chemotactic factors such as CXCL8 via G-
protein coupled receptors to induce conformational changes through inside-out signalling 
allowing for the arrest of immune cells along the vascular endothelium (90). After arrest, 
leukocytes rapidly protrude and translocate through the endothelial barrier at TJs or 
alternatively they use their integrins to crawl along the endothelium in search of exit cues. 
There are two distinct migration routes, either paracellularly through endothelial junctions or 
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Crucially, passage of leukocytes across or through brain endothelial cells is not 
sufficient to reach the brain parenchyma. Instead the migration of leukocytes across 
the BBB is a multi-step process requiring penetration across cells and BMs, a 
mechanism unique to the CNS. Notably, some leukocytes may also enter into the CSF 
via the BCSFB, bypassing this mechanism (247). 
As described in section 1.3.4, the BMECs are surrounded by two distinct BMs (150). 
The first is the endothelial BM composed of laminin α4 and α5 and the second is the 
parenchymal BM composed of lamina α1 and α2 which attaches to the astrocytic end-
feet that ensheath the blood vessel (151,152). The combination of the parenchymal 
BM and astrocyte foot processes is termed the glia limitans, which acts as the second 
supportive barrier in TEM (4). Immune cells must penetrate this second barrier to enter 
into the CNS parenchyma (Figure 1.8) (4,248,249).  
Once leukocytes have crossed the BMECs, they transverse the endothelial BM to enter 
into the perivascular space. T-cells preferentially migrate at sites containing laminin 
α4 and lacking α5 (250). The final challenge for T-cells to invade the CNS parenchyma 
is the glia limitans (4,248,249). T-cells are unable to interact with laminin α1 and α2 
expressed on the parenchymal BM (156), therefore immune cell migration out of the 
perivascular space requires cleavage of the anchoring cell surface receptor β-
dystroglycan present on astrocyte end-feet by MMP-2 and MMP-9 (251).  
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Figure 1.8 | Crossing the BBB 
Immune cells invading the BBB must penetrate through a series of membranes to reach the 
CNS parenchyma. The endothelial cells of the BBB initially deposit an endothelial BM in 
which pericytes are embedded; in order to cross into the perivascular space T-cells 
preferentially migrate at sites containing laminin α4 and lacking laminin α5 (156). Next the 
T-cells must cross the glia limitans, formed by the astrocytic end-feet, by MMP-mediated 
cleavage of cell surface receptor β-dystroglycan (251). It is believed that invading cells must 
already be activated and primed from the periphery to cross the glia limitans, or T-cells must 
interact with the correct antigen presenting cells within the perivascular space to become 
activated. This complex vascular structure prevents damage with the brain parenchyma, 
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In healthy individuals and rodents, T-cells have been detected to cross the BBB, but 
are retained within the CSF-drained perivascular, leptomeningeal or ventricular spaces 
and do not enter the CNS parenchyma (252,253). It is thought that these immune cells 
are present for immunosurveillance, with flow cytometric analysis revealing these 
cells to largely be inactivated CD4+ memory T-cells (254). The glymphatic system 
drains ISF containing CNS antigens into the perivascular spaces or into the CSF of the 
ventricles allowing for immunosurveillance within the CNS (247). Alternatively, the 
glymphatic system drains into the large veins existing the brain and as a result CNS 
antigens can also be detected in cervical lymph nodes (255). The importance of 
drainage of extracellular fluid from the CNS into the cervical lymph nodes for antigen 
detection was shown by Cserr and colleagues. Cserr et al., showed that micro-
injections of antigens into the brain and CSF could elicit both cell and antibody-
mediated immune response in the cervical lymph nodes and spleen (256). Moreover, 
antigens confer greater immune responses when administered into the CNS than into 
conventional extracerebral sites (256). These results implicate that the CNS is far from 
immune-privileged, instead there is highly regulated communication between the 
brain and the immune system response.  
Importantly, opening the BBB alone e.g. during grafting of foreign tissue into the CNS 
is not sufficient to result in leukocyte TEM into the CNS parenchyma (257). Instead 
the loss of BBB integrity must be accompanied by a pro-inflammatory response (258). 
For example, in stroke, following cerebral ischemia and reperfusion (259) there is 
rapid alteration in the BMECs, with the release of oxidants, proteolytic enzymes and 
inflammatory cytokines (260). These mediators contribute to increased BBB 
permeability and result in migration of circulating activated leukocytes towards the 
ischemic lesion (261). The activated leukocytes release MMPs, specifically MMP-9, 
which degrade the laminin of BMs and TJ-associated protein complexes to further 
contribute to brain damage (262,263).  
A number of CNS disorders such as MS, AD, brain tumours and bacterial meningitis, 
have been associated with the disruption of the BBB correlated with enhanced immune 
cell infiltration across the BBB, secondary to changes in systemic levels of molecules 
that are able to disrupt the TJ structure (22). The role of MMPs in BBB breakdown is 
paramount. MMPs levels are controlled by their inhibitors, TIMPs (264,265). In MS 
patients, disruption of the BBB coupled with macrophage infiltration is amongst the 
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earliest indicator of disease (266). Studies have shown MS patients to have higher 
serum levels of MMP-9 than healthy controls, along with higher MMP-9/TIMP-1 
ratios (267). This contributes to decreased expression of TJ proteins occludin and VE-
cadherin in cultured human brain endothelial cells, when stimulated with MS patient 
serum (268,269). Involvement of MMPs/TIMPs in the breakdown of the BBB in other 
CNS disorders implicates its potential to cause disruption in the current study of 
T2DM effects on the brain, particularly as T2DM patients have higher MMP-9 levels 
in their serum (270). 
 
 
1.4.4 Resolution of inflammation 
The purpose of inflammation is to restore tissue homeostasis after tissue damage. 
Uncontrolled and unresolved inflammation can be destructive, with ongoing chronic 
inflammation resulting in loss of tissue or organ function. The host’s natural control 
of inflammation is conducted by switching from pro-inflammatory programmes to 
pro-resolving programmes, involving a shift to anti-inflammatory cytokines (IL4, IL-
10, IL-13 & TGF-β) and cell types (Treg and M2 macrophages). The pro-resolution 
programme involves: 
1. Reversal of vasodilation and vascular permeability. 
2. Switching off signalling pathways associated with pro-inflammatory cytokine 
production responsible for leukocyte infiltration, proliferation, and survival. 
3. Induction of apoptosis and clearance of recruited inflammatory and apoptotic 
cells. 
 
1.4.4.1 Annexin A1: in the peripheral system 
Anti-inflammatory therapies can either focus on neutralising the level of pro-
inflammatory mediators or enhancing pro-resolution programmes (229,271). A well-
established class of anti-inflammatory and immuno-suppressive drugs is the 
glucocorticoids. Annexin A1 (ANXA1), previously known as lipocortin-1, belongs to 
the annexin superfamily of proteins and is one of the molecules upregulated by 
glucocorticoids. ANXA1 is a 37kDa calcium-dependent phospholipid-binding protein 
that binds to the negatively charged phospholipids of cell membrane and the G-protein 
coupled receptor (GPCR) – formyl peptide receptor 2 (FPR2) (272). Binding of 
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ANXA1 to its receptor causes the activation of a number of signalling pathways 
through p38 mitogen-activated protein (MAP) kinase – ERK1/2 stimulation (273). 
During inflammatory reactions, ANXA1 is up-regulated and translocated from the 
cytosol to cell membrane, whereby it prevents the activation of phospholipase A2 
(PLA2) and inhibits subsequent synthesis of eicosanoids (274,275); ANXA1
-/- mice 
show exacerbated inflammation with increased PLA2 activity (276). ANXA1 has also 
been shown to inhibit cyclooxygenase (COX)-2 enzyme production in microglia and 
pro-inflammatory mediators such as histamine whilst inducing anti-inflammatory 
cytokines e.g. IL-10 through the ERK signalling pathway (277) and activating 
caspase-3 signalling to promote apoptosis and chemotaxis of macrophages for 
clearance of immune cells (278).  
One of the most well-documented properties of ANXA1 is its ability to inhibit 
leukocyte TEM. ANXA1 mediates its effect through modulating adhesion molecule-
based leukocyte to endothelium interactions via two mechanisms. Firstly, ANXA1 co-
localises with α4β1 integrin on leukocytes to prevent binding to vascular cell adhesion 
molecule (VCAM-1) on endothelium (279). Secondly, ANXA1 induces L-selectin 
shedding from leukocytes to prevent tethering, rolling and firm adhesion (280). 
Leukocytes mobilise their endogenous ANXA1 to the plasma membrane, upon 
cellular activation by chemokines, to promote leukocyte detachment. In this manner, 
ANXA1 serves as a negative regulator of TEM (166,167).  
ANXA1 also mediates inflammation resolution through accelerating apoptosis 
through activation of caspase-3 (283) and Bcl-2-associated death promoter (Bad) 
activity (284,285). ANXA1 further aids in the removal of apoptotic cells through co-
localising with ‘eat-me’ signal phosphatidylserine, serving as a signalling molecule 
for efferocytosis/phagocytosis (286). 
 
In contrast to the well described effects of ANXA1 in innate immune responses, the 
role of ANXA1 in adaptive immunity, particularly in TH cells, is less clear. ANXA1 is 
expressed in T-cells however the expression levels are almost 100-fold lower than in 
neutrophils and monocytes (287). The effect of ANXA1 on T-cell responses have been 
contrasting. One particular group reported ANXA1 could induce proliferation, 
activation and differentiation of TH cells responses, through promoting TH1 
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development and supressing TH2 development (288,289). In contrast, it has been seen 
across separate studies that T-cell-expressed ANXA1 functions to attenuate pro-
inflammatory TH1 and TH17 responses through limiting T-cell proliferation and 
reducing expression of pro-inflammatory cytokines IL-17, IFN-γ, TNF-α and IL-6 
(290,291). In a mouse model of uveitis, the effect of ANXA1 on TH17 cell 
development was regulated through the  SOCS2/STAT3 pathways (291). Early studies 
in peripheral blood mononuclear cells (PBMCs) from atopic patients reported that 
exogenous peptides of ANXA1 could inhibit T-cell proliferation and differentiation 
(292). Indeed, in our lab we have reported that ANXA1 reduces T-cell activation and 
proliferation secondary to STAT3 hyperactivation. Moreover, it has been observed 
that TH17 cells have reduced ANXA1 production and this can be correlated with an 
increased migratory capacity across an in vitro model of the BBB (293).  
Due to ANXA1’s diverse capacity to resolve inflammation, its role in various different 
diseases and conditions including immune repair (inflammatory bowel disease, 
rheumatoid arthritis), cardiovascular disease, cancers and in the endocrine system 
(HPA axis modulation) has been extensively researched. These have been discussed 
in detail in my published review – “Annexin A1: Uncovering the Many Talents of an 
Old Protein” (294). 
 
 
1.4.4.2 Annexin A1: implications at the BBB 
The presence of ANXA1 can be detected as early as in pre-natal brain development 
(295). During foetal development, the expression of ANXA1 was detected in BMECs 
and microglia-like cells (296). ANXA1 mediates its affect through the FPR2 receptor, 
which is present on BMECs implicating the ability of ANXA1 to bind to the BBB and 
mediate its anti-inflammatory effects through the mechanisms described above. Aside 
from limiting the impact of peripheral challenge on the CNS through blockage of 
TEM, ANXA1 has also shown to be important in maintaining BBB integrity at the 
TJs, through co-localisation with actin microfilaments (297). Evaluation of the BBB 
in ANXA1-/- mice showed disruption in occludin, VE-cadherin and the actin 
cytoskeleton along with loss of cell polarity indicating its importance in regulating 
BBB permeability and receptor distribution, with implications on meeting nutrient 
demand for the brain (296,297).  
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Studies have found a significant role of ANXA1 in the pathological development of 
aging and neurological disorders such as AD, MS, and stroke. In MS patients, there is 
a loss of ANXA1 expression in the brain parenchymal capillaries distant from lesion 
sites suggesting that there is a loss of BBB integrity (297,298). The opening of the 
BBB would allow for enhanced extravasation of activated leukocytes that attack and 
damage the myelin sheaths on neurons. Natalizumab, the current treatment for MS, is 
a humanised monoclonal antibody against α4β1 integrin with the aim to prevent 
leukocyte infiltration (299). Interestingly, this is the mode of action of ANXA1 
thereby suggesting the potential of ANXA1 to be exploited for therapeutic potential, 
particularly as it is an endogenous protein and therefore is likely to induce a lower risk 
of side-effects. The benefit of ANXA1 treatment has also been tested in murine model 
of stroke. ANXA1 Ac2-26 peptide application reduced infarct volume, leukocyte 
adherence and markers of inflammation; neurological scores of treated mice also 
showed improvement versus non-ANXA1-treated mice (300). An alternative analogue 
of ANXA1, peptide 1-188 conferred similar beneficial effects in stroke (301).  
 
Within the brain, microglia are the tissue-resident macrophages which are activated 
upon brain injury or neurological disorders (302,303). Similar to the peripheral system 
where macrophages phagocytose apoptotic cells, microglia remove unwanted cells 
within the brain and this is encouraged by ANXA1 which co-localises with ‘eat-me’ 
signal phosphatidylserine on the cell surface of apoptotic neurons surface thus serving 
as a efferocytosis/phagocytosis signal to microglia (279). In response to Aβ, in AD, 
microglia become constitutively activated. ANXA1 treatments in vivo and in vitro 
reduces Aβ levels by inducing efferocytosis/phagocytosis and enzymatic degradation 
(304). In ischemia-induced injury of neurons, treatment with ANXA1-derived peptide 
Ac2-26 promoted the transition of activated microglia from a pro-inflammatory M1 
phenotype to an anti-inflammatory, pro-resolving M2 phenotype (305), suggesting 
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1.5 An overview of T2DM 
T2DM is a chronic metabolic disorder characterised by the loss of insulin sensitivity 
due to insulin resistance in target organs coupled with reduced production of insulin 
due to pancreatic β-cell dysfunction. Insulin resistance results in reduced uptake of 
glucose into liver, muscle and fat cells thereby raising blood sugar levels, resulting in 
glycated haemoglobin (306) measured as HbA1c levels. 
The development of T2DM is affected by genetic and lifestyle factors. There is a 
strong heritable genetic connection, with approximately 25% of the disease having a 
family history and almost 100% concordance amongst monozygotic twins (307). 
Nevertheless, modifiable lifestyle factors such as  reduced physical activity, increased 
consumption of energy-dense diets, alcohol intake and smoking levels play a 
fundamental role in the onset of the disease (308).  
 
1.5.1 Epidemiology of CVDs & T2DM 
In 2017, 425 million people were living with DM and this number is projected to 
increase to 552 million by 2030 (309); of which 439 million will have T2DM (310). 
People suffering from T2DM are 2.5 times more likely to suffer from a heart attack 
and 2 times more like to have a stroke, compared to those without diabetes (311). 
CVDs represent the greatest cause of mortality and morbidity associated with T2DM 
(312).  
Globally CVDs are the leading cause of death, claiming more than 17 million deaths 
per year which accounts for 31% of all deaths (313). In the UK alone, 7.4 million 
people are living with a CVD and the annual healthcare cost spent on CVDs accounts 
for £9 billion (314). An ageing and growing population are likely to increase these 
numbers further, particularly as obesity and its associated complications of 
hypertension and hypercholesterolaemia are on the rise. In fact, between 1980 and 
2004 the worldwide incidence in obesity, sedentary lifestyle and ageing population 
has quadrupled the prevalence of T2DM (315). Overall, this is placing an increasing 
burden on the economic system therefore highlighting the importance of 
understanding and managing T2DM and its related complications.  
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1.5.2 T2DM – micro and macrovascular complications  
Diabetes and its related complications are associated with vascular disease which can 
lead to long-term damage and failure of organs including the heart, brain, kidney, eyes, 
muscle, and skin. These vascular complications, both at the macrovasculature and 
microvasculature level, are induced via a variety of mechanisms largely attributable 
to endothelial dysfunction and low-grade chronic inflammation. Some specific 
etiological mechanisms involved in causing vascular disease include oxidative stress, 
advanced glycation end products (AGEs) accumulation, haemodynamic 
dysregulation, enhanced platelet aggregation, impaired fibrinolytic ability, ECM 
protein synthesis, capillary BM thickening, smooth muscle dysfunction, 
overproduction of endothelial growth factors and NO response inhibition (316,317).  
Diabetic macrovascular disease involves the aorta and large to medium-sized arteries. 
Atherosclerosis accelerates the progression of macrovascular complications, which 
include cardiovascular, cerebrovascular, and peripheral arterial disease. The 
atherosclerotic plaque build-up is the main factor in contributing to the development 
of these diseases, whereby reduced blood flow along with ruptured plaques and 
subsequent clots can lead to occlusion of arteries in the heart, brain and lower limbs 
resulting in myocardial infarctions, stroke and amputations respectively (318).  
The microvascular complications of diabetes include nephropathy, neuropathy, and 
retinopathy. It is these complications which place an extreme burden on health care 
systems; in the UK the NHS spends approximately 80% of its diabetes-allocated 
budget on managing and treating microvascular complications (311). Worldwide, 
diabetes is response for being the leading cause of end-stage renal disease (>55%), 
neuropathy (60-70%) and non-trauma induced amputations (>60%), as well as being 
the main reason for partial or complete vision loss in individuals over 20 (309,319).  
Given that the BBB serves as the interface between the peripheral and CNS systems, 
for inflammation and immunological integrity, it can be hypothesised that damage at 
the brain microvasculature arising from metabolic disorders, that results in adverse 
brain pathology, is also a secondary complication of T2DM.  
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1.5.3 Endothelial dysfunction in Diabetes 
Endothelial cells serve as a determinant of vascular health. Endothelial cells were once 
thought of a quiescent barrier serving as an interface between vascular smooth muscle 
cells and circulating blood, however decades of research has broken this paradigm. 
Endothelial cells are important in upholding vascular homeostasis which involves 
maintenance of arterial tone (vasodilation and vasoconstriction), maintenance of blood 
fluidity through regulating platelet activity, the clotting cascade and the fibrinolytic 
system, and regulating production of pro-inflammatory and anti-inflammatory 
mediators that regulate inflammatory and regenerative processes. The term endothelial 
cell dysfunction refers to the loss or the impairment of the vascular endothelium to 
uphold these properties (320,321).  
 
1.5.3.1 Vascular tone – maintenance by nitric oxide (NO) 
Endothelial cells regulate vascular tone by balancing the production of vasodilators 
e.g. NO, prostacyclin, and endothelium-derived hyperpolarizing factor and 
vasoconstrictors e.g. endothelin-1 and angiotensin II (322). The balance between the 
production and response to these mediators is essential in maintaining a constant and 
adequate blood supply around the body. Endothelium-derived NO is important in 
maintaining an anti-proliferative and anti-apoptotic environment (323). NO also 
prevents the adhesion of leukocytes (322). In T2DM, the activation of endothelial NO 
synthase (eNOS) and subsequent production of NO is altered.   
Within the peripheral system, insulin is a major regulator of blood glucose levels 
through stimulating uptake of glucose by liver, muscle and adipose tissue (133). Under 
physiological conditions, insulin binding to the insulin transmembrane receptor leads 
to IRS-1 phosphorylation which activates phosphoinositide-3 kinase (PI3K) and Akt. 
Akt phosphorylates eNOS to stimulate NO production (324,325). However, in the 
context of T2DM the increased presence of glucose, lipids (in the form of free fatty 
acids) and diacylglycerol leads to the activation of protein kinase C-β and 
subsequently NF-κB. This blocks insulin signalling via IRS-1 and thus reduces NO 
production via PI3K/Akt (326,327). Interestingly, insulin also activates MAPK via 
small GTPase Ras leading to cellular growth and proliferation. In endothelial cells, 
this leads to the increased expression of endothelin-1 and pro-inflammatory adhesion 
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molecules e.g. ICAM-1. In T2DM, the insulin-mediated Ras/MAPK activation 
remains active (320,328,329).  
 
1.5.3.2 Oxidative Stress 
Increased glucose and free fatty acids (FFAs) result in increased superoxide 
production. The production of reactive oxygen species (ROS) at low concentrations is 
useful to act as regulators of signalling involved in functions such as cell growth, 
however at higher concentration ROS induces cellular injury and death. This oxidative 
stress increases vascular permeability thereby allowing for greater leukocyte 
transmigration. Additionally, superoxides reduce NO bioavailability. Human-based 
studies have found increased markers of oxidative stress e.g. F2 isoprostanes in 
individuals with obesity, insulin resistance and T2DM (330,331). Clinical studies have 
shown improved endothelial function of patients infused with antioxidant ascorbic 
acid (332).  
Importantly, mitochondrial-derived ROS in T2DM activates AMP kinase – a regulator 
of cellular energy status. As with non-mitochondrial ROS, low levels are required 
physiologically however under pathological conditions the mitochondrial-generated 
ROS can have detrimental effects on the lifecycle and function of mitochondria 
leading to impaired ATP production (333,334). Impaired mitochondrial ability 
reduces its ability to metabolise fatty acids thereby resulting in activation of PKC, 
which blocks insulin signalling (335). Antioxidants directed at mitochondria e.g. 
lipoic acid can help to reduce free radical production, improve sensitivity of insulin 
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1.5.4 Inflammation in metabolic disorders 
The first molecular link between inflammation and obesity came from the 
identification of raised levels of TNF-α in adipose tissue of obese mice (337); in 
parallel human adipose tissue was also shown to overexpress TNF-α (338). Over the 
decades this association has been strengthened with identification of large numbers of 
inflammatory markers e.g. IL-1, IL-6, c-reactive protein (CRP), serum amyloid and 
soluble adhesion molecules showing upregulation in metabolic disorders with a graded 
increase with increasing features of MetS/T2DM (339,340). These molecules can 
activate the endothelial cells to become activated, promoting a pro-atherogenic 
phenotype via reduced NO bioavailability and expression of adhesion molecules 
leading to the recruitment of immune cells and their extravasation into tissues 
(231,341–343).  
Under normal conditions, once the trigger of inflammation has been removed, the 
inflammatory mediators are terminated. However in metabolic disorders the trigger 
events such as hyperglycaemia and dyslipidaemia are persistent and therefore the 
aberrant activation of the innate immune system and its signalling cascades in multiple 
tissues such as adipose tissue, liver, heart etc. lead to the failure of inflammatory 
regulation (344). The consumption of carbohydrate-rich and lipid-dense foods also 
disrupts metabolism (345,346). Impaired insulin action results in IRS-1 serine 
phosphorylation consequently switching on p38 MAPK, PKC, JNK, AP-1 and NF-κB 
pathways (347,348). Increased free fatty acid presence places an increased demand on 
mitochondria for the use of the electron transport chain (ETC) for fatty acid oxidation 
(FAO), resulting in overproduction of mitochondrial superoxide. Similarly, 
hyperglycaemia evokes the production of AGEs. The presence of ROS and AGE 
causes oxidative stress and further amplifies the induction of pro-inflammatory 
pathways (340,349–351) such as NF-κB signalling. TNF-α and overexpression of IκB 
kinase-β (IKK-β) can lead to insulin resistance; pharmacological inhibition of IKK-β 
by salicylates prevents this from occurring. In fact, treatment of obese patients with 
salicylates reduces NF-κB activation in isolated endothelial cells, allowing for 
improved insulin sensitivity and endothelial cell-associated vasodilation (352). This 
suggests that control of endothelial cell function via anti-inflammatory drugs may 
improve the outcome of vascular disease.  
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The role of inflammatory events in metabolic disease, can be confirmed using anti-
inflammatory drug aspirin in T2DM patients. After 2 weeks of treatment, aspirin 
lowers fasting blood glucose concentration by 25%, triglycerides by 50%, CRP by 
17% and increases insulin sensitivity by 30% (353). This therefore highlights that 
metabolic disorders are not just characterised by biochemical abnormalities alone, 
such as altered insulin production or secretion; instead they also involve a strong 
inflammatory and immune signalling component (354). It is this long-lasting, low-
grade chronic inflammation that is the distinguishing feature in metabolic disorders 
and CVDs (355), and is often referred to as metaflammation (356,357). 
 
1.5.5 The innate immune system in metabolic disorders 
Of the innate immune system, the role of macrophages is the most well-defined in 
T2DM and CVDs. Macrophages can largely be divided into two subtypes, the pro-
inflammatory M1 phenotype and the anti-inflammatory, pro-resolving M2 phenotype 
(358). In lean adipose tissue, the M2 phenotype are dominant, maintaining the insulin 
sensitivity by the secretion of TGF-β and IL-10 (359). However, upon sustained 
weight gain, adipose tissue becomes hypertrophic, insulin resistant, hypoxic, and 
apoptotic. This causes the macrophages to become metabolically activated due to the 
high glucose, insulin and FFA concentration, causing a switch to the M1 phenotype 
and subsequent release of pro-inflammatory cytokines such as IFN-γ, TNF-α and IL-
1β (360,361). Overall the number of macrophages in obese adipose tissue is 
substantially increased (362). The involvement of the innate immune system and its 
inflammatory effects are clearly identifiably in atherosclerotic plaques. The build-up 
of cholesterol-rich lipid drives macrophage accumulation, foam cell formation and 
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1.5.6 The adaptive immune system in metabolic disorders 
In the adaptive arm of the immune system, the CD4+ T-cells play a large role in obesity 
and insulin resistance (363), with numbers of naïve CD4+ T-cells declining in T2DM 
patients (364). In T2DM patients, the levels of TH1-associted cytokines is increased 
and in contrast, the TH2 cell-mediated immunity is impaired and delayed (365). 
Specifically TH1 along with cytotoxic CD8
+ T-cells are increased in obese adipose 
tissues whereas the numbers of TH2 and Treg cells are decreased (366). The balance 
between the different subsets is important for modulating immune responses. It has 
been reported that both Treg/TH17 and Treg/TH1 ratios are decreased in T2DM 
patients (367,368).  
The innate immune response is fast-acting however does not confer any memory. In 
contrast the adaptive immune response, specifically of CD4+ T-cells are activated to 
induce effector and central memory phenotypes. Upon antigen-presentation, naïve T-
cells become activated, proliferate, and differentiate into effector T-cells (Teff) for 
migration to site of infection/inflammation. These effector subsets are short-lived and 
therefore memory subsets for long-term survival are generated. Memory cells located 
in secondary lymphoid organs are known as central memory T-cells (TCM) and those 
located in tissues are known as effector memory T-cells (TEM). Memory subsets allow 
for quicker and more effective responses upon re-exposure of an antigen (369). A 
study by Mauro et al., found high-fat feeding in rodents primed CD4+ T-cells towards 
an effector memory-like phenotype with no major changes in the size of the central 
memory pool (370). Similarly, there was an increased TEM phenotype in obese 
patients. In another study of T2DM patients with and without CVD, the number of 
TCM and TEM cells were increased in individuals with T2DM regardless of CVD status 
compared to controls; however no changes were seen in the Treg population (371).  
CD8+ T-cells also play a crucial role in adaptive immune response through the 
secretion of IFN-γ, TNF-α and IL-17 and by the release of cytotoxic granules (372). 
Reports in patients with T2DM and high-fat feeding in mice show higher percentages 
of CD8+ T-cells (373,374). B-cell antibody responses are important in the 
development of insulin resistance; with increased numbers of the cells present in 
visceral adipose tissues (375). B-cells can affect TH17 and macrophage activation 
(376).  
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1.6 Dysfunction of the BBB: the role of endothelial cells 
The cells of the NVU together form a dynamic functional unit for signal transduction. 
Thereby any damage occurring to the BMECS can be transduced across the brain and 
affect cellular functions e.g. reduced NO alters synaptic plasticity (377). In addition, 
the changes in the microenvironment have wider implications on the activity of the 
brain and thus its control via the sympathetic and parasympathetic nervous system on 
the entire body. 
Cerebrovascular endothelium-derived NO is responsible for the maintenance of 
cerebral blood flow. Aside from this, cerebrovascular endothelial cell-derived NO 
regulates neurogenesis, axonal outgrowth and synaptic plasticity in the hippocampus 
and cortex which is essential for memory formation and learning (378). Within the 
CNS, eNOS and neuronal NOS (nNOS) are responsible for producing a constitutive 
level of NO to maintain vascular homeostasis. In conditions of inflammation, 
inducible NOS (iNOS) is activated to produce excessive NO, causing neurotoxicity, 
impairment of mitochondrial function and induction of apoptosis through uncoupling 
and free radical generation (378). The lack of available NO in inflammatory conditions 
activates the endothelium and generates oxidative stress. As described previously this 
leads to leukocyte adhesion and has important implications for the transmigration of 
inflammatory cells and toxins to pass through the BBB. 
 
1.6.1 Pathophysiology – MetS to T2DM 
MetS is the cluster of risk factors (obesity, hyperglycaemia, hyperinsulinemia, 
dyslipidaemia, and hypertension) which leads to the development of T2DM and 
subsequent CVD. It is the combined multifactorial nature of the disease which makes 
it hard to medically manage. The stage at which MetS becomes T2DM is not easily 
defined, as the nature of the disease is progressive over a long-term period. However 
usually, the main defining factor between MetS and T2DM is the level of 
hyperglycaemia and hyperinsulinemia correlated with β-cell dysfunction.   
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1.6.1.1 Hyperglycaemia 
Hyperglycaemia arises in MetS and T2DM due to the loss of insulin sensitivity. 
Glucose levels are maintained through cross-talk between insulin-producing β-cells in 
the pancreas and insulin-sensitive tissues. Usually β-cell stimulation releases insulin, 
which stimulates an uptake of glucose, amino acids and fatty acids by muscle and 
adipose tissue and supresses the production of glucose by the liver. The tissues 
feedback to the islets regarding their requirement for insulin, likely mediated by 
neuronal and humoral mechanisms. In conditions such as obesity, in which there is 
accumulation of fat deposition, insulin resistance begins to develop. Initially, β-cells 
try to combat increased glucose levels by producing more insulin however when the 
β-cells cannot maintain this production, impaired glucose tolerance develops. As the 
β-cell dysfunction progresses there is a complete loss of euglycemia eventually 
resulting in T2DM (379). The compensatory hyperinsulinemia is often considered a 
trait of MetS, whereby the fasting glucose levels are maintained to combat insulin 
resistance. It is when the insulin secretion diminishes, that MetS can be differentiated 
from T2DM (380).  
 
1.6.1.2 Hyperinsulinemia 
Hyperinsulinemia not only exists from trying to combat hyperglycaemia, but also in 
response to increased fatty acids. Usually, insulin inhibits the lipolysis of fatty acids 
from triglyceride-rich lipoproteins stores in adipose tissue however when insulin 
resistance develops, there is no brake and uncontrolled lipolysis results in abundant 
levels of circulating FFAs (1). Excessive FFAs alter downstream signalling of the 
PKC pathway and IRS-1 phosphorylation as well as increasing hepatic glucose 
production and lipogenesis (381,382). Taking this into consideration, central obesity 
is a key diagnostic measure of MetS, as excessive subcutaneous and visceral 
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1.6.1.3 Dyslipidaemia 
Dyslipidaemia is a combination of several factors including increased flux of FFAs, 
raised triglyceride levels, reduced high-density lipoprotein (HDL), increased small, 
dense low-density lipoprotein (LDL) and raised apolipoprotein B (apoB). Increased 
FFA presence stimulates hepatic triglyceride synthesis, which in turn results in the 
production of apoB-containing triglyceride-rich very low-density lipoprotein (VLDL). 
When the VLDL is lipolysed, it produces a population of small dense LDL particles 
which fail to efficiently bind to LDL receptors and hence have prolonged circulatory 
time due to reduced clearance. The small dense LDL particles are thus considered pro-
atherogenic. In combination with this, there is reduced production of good HDL 
cholesterol because of reduced triglyceride-cholesterol ester exchange between VLDL 
and HDLs. This results in production of HDL lacking their major apoA component; 
the apoA component is thought to be protective against atherosclerosis (383,384).  
 
1.6.1.4 Hypertension 
The development of high blood pressure is thought to be due to a series of factors 
including central obesity, insulin resistance, sympathetic nervous system overactivity, 
increased inflammatory mediators, oxidative stress, endothelial dysfunction, and 
activated/altered renin-angiotensin system. The combination of these effects can result 
in decreased vasodilation, increased vasoconstriction, and the loss of elasticity in the 
peripheral blood vessels. Lipid accumulation (atherosclerosis), glycated haemoglobin 
(raised HbA1) and hypertension together restrict the delivery of oxygen and nutrients 
to tissues resulting in organ damage and/or failure (385).  
 
All of these risk factors have been discussed in the peripheral system, however the 
potential for damage to the microvasculature of the brain implicates how these risk 
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1.7. From the BBB to neuronal damage: Dementia  
Various models demonstrate that the dysfunction and perturbation of the BMECs 
results in subsequent damage to the brain. This is characterized by astrogliosis, 
microglial activation, white matter damage, impaired synaptic plasticity, neural 
inflammation, and apoptosis leading to cognitive impairment and eventually 
dementias. In fact, BBB damage can be used as a predictor of cognitive impairment in 
elderly patients (386,387).  
Currently there are 50 million individuals worldwide living with dementia and this 
number is projected to triple by 2050 (388). Dementia is the fifth leading cause of 
death worldwide, of which AD constitutes 60-70% of cases (389). Although the 
understanding between the involvement of T2DM and the brain is still being 
understood, hypotheses are starting to arise to describe AD as T3DM (12) due to the 
role played by insulin resistance. In fact, high-fat feeding in an AD transgenic mouse 
model results in T2DM-like peripheral insulin resistance concomitant with decreased 
insulin receptor signalling in the brain, increased β-amyloid and cognitive defects 
(390,391).  
For now, the majority of links of DM are made to the development of VaD, however 
VaD may just be a predecessor to the development of AD (133,392,393). Intriguingly, 
T2DM and transgenic AD mice present with similar vascular dysfunction resulting in 
cognitive decline that can be attributed to increase β-amyloid accumulation in both 
conditions (394,395). It is these similarities which have given rise to the T3DM 
concept (133,396) and implicate the need to understand the role of metabolic disorders 
in causing neurodegenerative disorders. 
 
1.7.1 Astrogliosis 
Astrocytes account for the majority of the cells in the brain with an abundance of 
approximately 50% (397). As astrocytes provide the link between the BMECs and 
neurons, they play a crucial role in providing metabolic support and control of the ion 
and neurotransmitter environment and thus are involved in providing the balance 
between neuroprotection, destruction and regeneration (398). In a rodent brain, a 
single astrocyte covers approximately 140,000 synapses (399); in humans, astrocytes 
are larger and more complex and therefore can link to approximately 2 million 
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synapses highlighting the complexity of glia to neuronal signalling (400). The 
astrocytic end-feet which bind the BMECs are key in mediating the transmission of 
nutrients, neurotransmitters and second messengers from the peripheral side into the 
CNS.   
The close link between astrocytes and neurons therefore underlies that astrocytic 
activation and performance is a key contributor to neuropathological diseases. Acute 
or chronic insults to the brain can trigger glial-specific morpho-functional changes 
resulting in reactive astrocytes known as astrogliosis. Astrogliosis initially serves to 
be protective mechanism, isolating the damaged area and facilitating remodelling of 
brain circuits (401). However, as in all chronic inflammatory conditions, the over-
activation of these cells can release neurotoxic substances, damaging BBB 
permeability and neurons. In animal models of VaD, there is marked astrogliosis and 
astrocytic end-feet swelling (402). Activation of HIF-1α in astrocytes can lead to the 
subsequent elevated expression of MCP-1, MMP-12 and VEGF which are responsible 
for attacking the BBB integrity (403). MCP-1 acts via the Rho signalling pathway to 
induce TJ redistribution altering paracellular permeability (227). MMP-13 can lead to 
the degradation of junctional proteins for example VE-cadherin and ZO-1 (404). 
VEGF secretion from astrocytes can bind to receptors on BMECs and lead to increased 
BBB permeability via activating phospholipase C, thereby down-regulating claudin-5 
expression (405).  
Astrocytes can become activated through several pathways. For example, secretion of 
VEGF by BMECs in inflammation can promote proliferation of astrocytes and result 
in the expression of glial fibrillary acidic protein (GFAP) via the MAPK/ERK and 
PI3K pathways (406). GFAP marks astrocytes for activation, resulting in the 
deposition of chondroitin sulphate proteoglycans and subsequently glial scar 
formation (407). Fibrinogen deposition has been found in patients with brain small 
vessel disease and correlated with the increased risk of dementia development 
(408,409). Moreover, the over-expression of endothelin-1 by BMECs can lead to their 
binding on the endothelin receptor type B on astrocytes, leading to the activation of 
JNK and p38 MAPK signalling pathways causing astrogliosis (410). Notably in 
humans with dementia, there is a marked increase in the number of astrocytes in the 
frontal-temporal lobes in the early stages of the disease (411).  
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1.7.2 Microglia activation 
Microglia are the resident immune cells of the CNS, accounting for approximately 
16% of the total number of cells within the brain. Activation of microglia reduces 
synaptic plasticity and affects the long-term potentiation of the brain thereby leading 
to memory loss and cognitive impairment (412).  
Microglial cells are rapidly activated upon CNS tissues damage. Microglia, as with all 
macrophages, can present with a pro-inflammatory M1 phenotype or an anti-
inflammatory M2 phenotype. M2 microglia secrete protective cytokines in an attempt 
to alleviate the immune response and phagocytose necrotic tissue to promote survival 
and repair of neurons (413). Conversely, excessive M1 microglia activation 
contributes to inflammation within the brain, damaging the BBB, neurons, and 
oligodendrocytes. In VaD, microglia activation has shown to contribute to white 
matter damage and cognitive dysfunction (414).  
Components such as fibrinogen, present during vascular injury, can enter the brain 
parenchyma via a leaky BBB and promote microglia activation and assembly at sites 
of injury (415). Moreover, conditions of hypoxia and sugar deprivation are known to 
activate microglia cells resulting in the expression of TNF-α, IL-1β, IL-16 and MCP-
1. Activated microglia are also the main source of MMP-2, MMP-3, MMP-9 and ROS 
within the brain (416). All these mediators can further degrade the BBB, thereby 
resulting in the loss of protection of the CNS.  
 
1.7.3 White matter lesions, demyelination, and neuronal injury 
White matter constitutes half of the brain volume and is sensitive to changes in blood 
flow and the delivery of nutrients (417). Endothelial cell dysfunction at the BBB, due 
to the risk factors of T2DM is likely to induce the sensitivity of white matter to the 
development of lesions. White matter hyperintensities have been linked to the 
occurrence of cognitive impairment (418) and are characterised by the loss of 
oligodendrocytes and the demyelination of neurons (378).  
 
Page | 77  
 
Oligodendrocytes wrap around axons to form myelin sheaths that are well known to 
be involved in the rapid conduction of nerve impulses. Oligodendrocytes also support 
axonal growth and survival through providing nutrients. Damage to oligodendrocytes 
causes demyelination resulting in axonal degeneration (177,419). In patients with 
VaD, the density of the myelin sheath and number of myelin precursor cells is 
decreased within the white matter (420). The expression of myelin basic protein and 
myelin-associated protein is also significantly reduced in the brain of VaD patients 
(419,421). Disruption to TJs, TNF-α and fibrinogen, amongst others, entering the 
brain can cause demyelination. In these areas, there is notable astrogliosis and 
activated microglia presence, suggesting that these cells contribute to the dysfunction 
of oligodendrocytes (422). Demyelination prevents nerve impulse conduction thereby 
impairing memory and cognition.  Although oligodendrocyte progenitor cells 
proliferate upon tissue injury to induce spontaneous remyelination (423), chemokines, 
cytokines and other factors released during inflammation decrease the remyelination 
ability of these precursor cells (424). Oxidative stress from BBB dysfunction is a 
major factor in causing oligodendrocyte precursor cell dysfunction through free 
radical presence (425) and by reducing expression of genes such as sonic hedgehog 
required for differentiation (426). Activated astrocytes release hyaluronan, which 
further inhibits oligodendrocyte precursor cell maturation (427). Moreover, in an 
inflammatory condition the ability of microglia and macrophages to phagocytose 
myelin fragments is reduced; the presence of these fragments inhibits precursor cells 
from becoming mature (428). 
Astrocyte and microglia activation as a result of BBB dysfunction can directly affect 
synaptic plasticity. Activated microglial cells overexpress iNOS inhibiting long-term 
potentiation formation and impairing cognition (429). In addition, the leakage of the 
BBB results in transmigration of leukocytes into the brain parenchyma. These 
infiltrated leukocytes release a variety of toxic proteins e.g. granzyme-B resulting in 
neuronal injury and death (430). Release of MMPs by the BBB cells can directly 
induce neuronal apoptosis; moreover these MMPs, specifically MMP-9, can enter the 
nucleus of neuronal cells to cause DNA damage resulting in neuronal cell death (431). 
The raise of inflammatory mediators within the brain from astrocytes and microglia 
can result in the accumulation of glutamate that causes cell-death (432). Elevation of 
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TNF-α in elderly patients has shown to initiate the phagocytosis of stressed neurons 
(433).  
The method by which inflammation is induced in the brain can be accounted for by 
BBB disruption, suggesting the dysfunction of BMECs as a major contributing factor. 
Therefore, controlling risk factors which can affect vascular health and cause 
endothelial cell damage, such as those involved in T2DM, is incredibly important in 
preventing dementia development. Studies have found that control of blood pressure 
and a low-fat diet can reduce white matter hyperintensities and dementia risk (87). To 
date there are no drugs that can improve endothelial cell function however traditional 
remedies such as ginseng have well documented anti-inflammatory and anti-oxidant 
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1.8 Metabolic disorders, BBB dysfunction & cognitive decline  
There is a huge array of data focussing on the effect of metabolic disorders in context 
of CVDs however research on the effect of neurodegenerative diseases is still limited. 
So far, research investigating the link between metabolic disorders and brain 
dysfunction has shown significant alterations in the NVU and regions in the brain 
associated with memory and learning, supporting the notion that metabolic overload 
can be causative in development of neurological disorders through loss of BBB 
integrity. 
Obesity and diabetes in rodent models induced by high-fat feeding (approximately 
45% fat) show reduction in pericyte number, activation of astrocytes and microglial 
alongside neuronal loss (435). Together these effects suggest a neuroinflammatory 
response induction, secondary to BBB disruption. BBB permeability studies in these 
rats revealed increased permeability to sodium fluorescein dye particularly in the 
hippocampus region. Several BBB permeability studies have identified decreased 
expression of the TJ proteins claudin-5, claudin-12 and occludin alongside increased 
MMP-2 expression and raised oxidative stress levels (436–439). Furthermore, analysis 
by flow cytometry reveals macrophage infiltration into the perivascular space and 
activation of microglial cells in diabetic mice (440).  
Clinically, neuro-imaging of human brains using a tensor-based morphometry 
technique has revealed obese patients to have atrophy of frontal lobes, hippocampus, 
thalamus, white and grey matter (441–443). In diabetic patients, brain post-mortem 
studies also find reduced grey and white matter in the hippocampus region (444–446) 
suggesting a connection between metabolic disorders and brain deficit.  
Normal brain functioning requires the maintenance of nutrient transport across the 
BBB. Normally when a substrate is in excess the body will down-regulate the receptor 
expression to modulate its supply. The role of hyperglycaemia, hyperlipidaemia and 
hyperinsulinemia could therefore have major effects on transport receptors on the 
BMECs and subsequent neuronal function. Current research shows limited 
understanding of the effect of T2DM on GLUT-1 and lipid uptake. However, there is 
significant interest in understanding the transport of insulin. Insulin transport across 
the BBB is important for regulating tau phosphorylation via inactivation of glycogen 
Page | 80  
 
synthase kinase-3 and β-amyloid, preventing tauopathies and development of AD 
(447,448).  
Western diets have been show to increase peripheral circulating levels of β-amyloid 
that disrupt the BBB and accumulate within the hippocampus (449). The hippocampus 
has a major role in learning and memory. Dementias are characterised by progressive 
memory loss and cognitive decline. Patients with MetS show loss of neurons and brain 
matter in the hippocampus (392,450). In rodents, the association of cognitive decline 
has been tested using spatial memory tests (Morris water maze and arm maze). 
Rodents fed western diets show impaired memory retention in as little as 72 hours of 
feeding in comparison to chow-fed counterparts (451,452), implicating the role of 
metabolic-induced disruption on affecting brain cognition. 
The association of western diets to cognitive decline has raised interest in the role of 
nutritional intake on dementia development. A number of epidemiological and animal 
studies have found particular food groups or individuals nutrients to be important in 
conferring neuroprotective effects; leafy green vegetables provide a good source of 
folate, vitamin E and carotenoids, seafoods provide a source of n-3 fatty acids and 
berries provide a source of polyphenols which reduce oxidative stress (453,454).  
Currently, there is no cure for dementia and therefore preventive strategies are key. It 
is well recognised that nutritional therapy positively influences glycaemic control, 
contributes to weight loss and reduces hypertension and LDL-cholesterol (455,456) in 
the peripheral system, contributing to improved T2DM and CVD outcomes. This 
implicates that dietary changes could also improve cognition and brain disorders; 
however current data is limited. A large systematic review found that adherence to 
Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and 
Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets is 
associated with a reduced cognitive decline and lower risk of AD (457). The majority 
of these studies are observational and there is insufficient evidence to support the 
development of dietary guidelines for dementia. In the first study of its kind, a 
randomised clinical trial is underway to evaluate the MIND diet intervention in AD 
prevention, in 600 participants aged between 65-84 years old. These individuals are 
being tracked over a period of 3 years to assess changes in cognitive score and total 
brain and hippocampal volume (458). The study is due to end in April 2021. Such 
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studies will be influential in healthcare strategies. Nevertheless, comprehensive 
approaches using laboratory and animal models are required to understand how diet 
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2.1 Rationale & Hypotheses 
Over the past twenty years, evidence has been accumulating to indicate that metabolic 
disorders such as MetS and T2DM can strongly affect brain health, leading to 
cognitive decline and AD-like pathology. Given that T2DM can result in 
microvasculature complications of the peripheral system, it is highly plausible that 
brain dysfunction in metabolic disorders arises due to damage at the brain 
microvasculature - the BBB.  
The focus of this project was to investigate how metabolic disorder-induced 
inflammation, termed metaflammation, can disrupt the BBB, with focus on alterations 
to the structural and immunological integrity of the barrier.  
 Hypothesis 1: 
It is hypothesised that metaflammation arising in T2DM will result in a leaky 
BBB phenotype resulting in the infiltration of immune cells from the peripheral 
side into the brain parenchyma to cause neuroinflammation. 
 
Anti-inflammatory drugs have shown to improve T2DM and CVD outcomes. In this 
manner, the effect of using ANXA1 as an anti-inflammatory therapeutic has been 
explored at the BBB. ANXA1 is well-established as a positive regulator of BBB 
structure and it has also been shown to provide neuroprotection, indicating its potential 
to reduce and repair damage at the BBB and beyond.  
 Hypothesis 2: 
It is hypothesised that treatment with human recombinant ANXA1 
(hrANXA1) will restore the leaky BBB phenotype through restoring TJs. 
Improved BBB integrity along with hrANXA1’s effect on leukocytes will 
prevent leukocyte TEM and reduce neuroinflammation.  
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Aside from therapeutic strategies, the simplest method to resolve inflammation is to 
remove the source. In patients, lifestyle modifications are key to reduce the 
progression of T2DM and CVD, with the aim to reduce the inflammation arising from 
hyperglycaemia, hyperinsulinemia, and hyperlipidaemia. Moreover, the 
understanding on dietary intake and brain health is growing. As a result, the effect of 
a dietary intervention has been explored to understand whether preventive measures 
can reinstate the integrity of the BBB and subsequent development of 
neurodegenerative disorders.  
 Hypothesis 3:  
It is hypothesised that reverting to a healthy diet will remove the source of 
metaflammation and therefore improve the integrity of the BBB by reducing 
endothelial dysfunction and subsequently reduce neuroinflammation.  
 
Disruption to the BBB because of metaflammation will also impair its ability as a 
functional, transport and metabolic barrier.  
 Hypothesis 4: 
It is hypothesised that the metabolism of the BBB endothelial cells will be 
disrupted and this together with impaired BBB structure will alter the 
transport of essential nutrients e.g. glucose across the BBB into the brain to 
contribute to neurodegeneration. Treatment with hrANXA1, which is shown 
to repair the BBB TJs, could therefore also repair the metabolic integrity of 
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2.2 Project design  
This study used a diet-induced mouse model of T2DM, fed a combination of high-fat 
and high-sugar (HFHS) for 10 weeks, to investigate the effect of metabolic overload 
on the BBB. Diet-induced diabetic models work through causing obesity from 
imbalanced food intake and low energy expenditure (459). Obesity is the single 
biggest risk factor for developing T2DM, with research suggesting that obese 
individuals are 80 times more likely to develop T2DM than non-obese individuals 
(311). Obesity raises the levels of fatty acids, glucose, pro-inflammatory markers and 
alters hormones and metabolism due to the accumulation of fat deposition, leading to 
the development of insulin resistance (460). The diet-induced models of diabetes are 
used to replicate the westernised lifestyle in humans, with increased intake of foods 
dense in fats and sugars along with a sedentary lifestyle. This was the rationale for 
using a diet that was high in both fats and sugars.  
The comparison of the effects of HFHS-induced T2DM on the BBB was made against 
mice which were fed a standardised chow-based diet. The composition of the two diets 
and further information on the protocol e.g. length of time used to induce and confirm 
T2DM can be found in the Methods Section 3.1.1.1. The effect of HFHS-induced 
T2DM on the BBB has been presented in Chapter 4 and in Chapter 6.   
Pharmacological intervention in this study was delivered by treating mice fed a HFHS-
diet with hrANXA1. Details on the protocol of the treatment provided, e.g. which 
group, length of time, dosage can be found in Methods Section 3.1.1.2. The effect of 
hrANXA1 treatment at the BBB in HFHS-induced T2DM mice has been presented in 
Chapter 5 and Chapter 6.  
Dietary intervention was provided by firstly inducing T2DM by feeding mice a HFHS-
diet for 10 weeks, after which the diet was reversed back to a standard chow diet for a 
further 5 weeks. Details on the dietary intervention protocol can be found in Methods 
Section 3.1.1.3. The effect of dietary intervention on T2DM-induced BBB damage has 
been presented in Chapter 5.  
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2.3 Aims  
The following are the general aims of this entire study, the specific aims/objectives 
have been provided at the beginning of each results chapters.  
 
1. To characterize the early vascular defects occurring in the BBB during HFHS-
feeding in vivo, ex vivo and in vitro. 
o Identify the functional changes occurring to the BBB through 
measuring vascular leakage. 
o Identify structural alterations through immuno-histochemical analysis 
of brain endothelium junctional proteins, BM components and the 
cytoskeleton. 
 
2. To define the pathogenic events leading to cerebrovascular damage at the BBB 
induced by HFHS-feeding.  
o Examine the role of inflammatory mediators and soluble factors 
present in the sera such as cytokines, chemokines, interleukins, 
metabolic factors, extracellular matrix components, on inducing BBB 
permeability and endothelial dysfunction.  
o Define the effect of metabolic disorders on the innate and adaptive 
arms of the peripheral immune system. Determine whether the priming 
of immune cells within the peripheral system can correlate with the 
transmigration across the BBB and subsequently activate the microglia, 
the resident immune cell of the CNS to initiate neuroinflammation in a 
diabetic state. 
 
3. To assess the potential therapeutic effect of hrANXA1 on HFHS-induced BBB 
alterations. 
o hrANXA1 treatment will be given in vivo to animals to examine 
whether the protein has the ability to restore, resolve and revert the 
damage induced to the BBB, to the pre-diabetic state. This will serve 
as a pharmacological intervention. Structural and immunological 
integrity will be assessed as aforementioned in Aims 1 & 2. 
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4. To investigate whether the metabolic stress induced BBB defects are reversible 
upon dietary intervention.  
o In order to assess reversibility of diabetes-induced BBB damage, mice 
fed a HFHS diet for 10 weeks will be re-introduced to a normal chow 
diet for a further 5 weeks Structural and immunological integrity will 
be assessed as aforementioned in Aims 1 & 2. 
 
5. To investigate how nutrient imbalance in T2DM induced by HFHS-feeding 
can affect the BBB endothelium metabolic programming by examining 
cellular metabolism pathways of glycolysis and oxidative phosphorylation. 
The potential of hrANXA1 treatment to restore the metabolic integrity will 





2.4 Outline of Results of Thesis 
The following provides an outline of the arrangement of the results chapters 4-6 of 
this thesis, to clarify where the general aims have been investigated and discussed.  It 
should be noted that all methods of used in thesis have been provided in Chapter 3 and 
a general discussion of the implications of all of the results have been provided in 
Chapter 7.  
 
 
Chapter 4 - The impact of MetS/T2DM at the BBB: structural and 
immunological alterations 
This chapter investigates the effect of a HFHS-induced T2DM at the BBB, by 
examining the functional, structural and immunological alterations. This chapter will 
cover Aims 1 & 2. The results in this chapter will specifically compare the effect of a 
HFHS-fed diet that induces T2DM with a standard chow-based diet.  
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Chapter 5 – Examining the effect of a pharmacological (hrANXA1 treatment) 
and dietary (HFHS – Chow reversion) intervention to restore the BBB to the pre-
diabetic state 
This chapter investigates the effect a pharmacological intervention provided by 
hrANXA1 treatment and a dietary intervention provided by altering diet on restoring 
the BBB to the pre-diabetic state. This chapter will cover Aims 3 and 4. The results in 
this chapter will compare the effects of a pharmacological and dietary intervention 
against the HFHS-diet and chow-diet fed mice, as well as a comparison against each 
other. As a result, there will be 4 experimental groups: 
1. Chow diet-fed mice 
2. HFHS diet-fed mice 
3. HFHS diet-fed mice given hrANXA1 treatment  
4. HFHS – Chow reversion diet-fed mice  
 
 
Chapter 6 – Metabolism at the blood-brain barrier 
This chapter investigates how metabolism of the BBB endothelial cells is altered with 
HFHS-induced T2DM. The effect of hrANXA1 treatment in restoring BBB 
endothelial cell metabolism is also investigated. This chapter covers Aim 5. Therefore, 
the results in this chapter are compared between 3 experimental groups:  
1. Chow diet-fed mice 
2. HFHS diet-fed mice 
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This chapter includes all of the materials and methods used in this thesis. Unless 
otherwise stated, all materials, reagents and solutions were purchased from Sigma-
Aldrich Ltd (Poole, Dorset, UK).  
 
This Chapter has been organised into the following: 
• 3.1 In vivo methods 
This section covers the experimental models and in vivo animal-based 
experiments. These models are relevant to chapters 4, 5 & 6 and the 
methodology covered here is referred to in Chapters 4 & 5. 
• 3.2 In vitro methods 
This section covers all methods that have been conducted in vitro using 
primary cultured cells, cell lines, primary brain microvessels and mouse serum. 
The methodology used here is covered across Chapters 4, 5 and 6. 
• 3.3 Immunofluorescence & Immunophenotyping 
This section details the information on immunohistochemistry conducted on 
mouse brain tissue which is relevant to chapters 4 & 5. The methodology in 
this section also includes the flow cytometry and antibody details relevant to 
Chapters 4, 5 & 6. 
• 3.4 Measuring cellular metabolism 
This section provides the methodology used in Chapter 6.  
• 3.5 Statistical Analysis 
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3.1 In vivo methods         
3.1.1 Animals 
All animal experiments in this study were performed in accordance with the UK 
Animals Scientific Procedures Act 1986 and with approval of the Animal Welfare 
Ethics Review Board (AWERB) of Queen Mary, University of London. The study 
purchased 9-week-old male wild-type C57BL/6 mice from Charles River Laboratories 
UK Ltd., Kent, U.K. Animals were allowed to acclimatise to laboratory settings for a 
period of one week prior to initiation of experimental procedures. All mice were 10-
weeks old at the initiation of study. The mice were housed 6 per cage, in individually 
ventilated cages, in a temperature-controlled room with 12-hour light/dark cycle. All 
mice had free access to food and water, body weight was recorded weekly. The body 
weight of all animals was measured at the same time at the beginning of each week 
using the same balance for the whole experiment for determination of body weight 
gain for measuring obesity. New fresh food (stored at -20℃) was supplied, once 
defrosted, to mice at the beginning of each week and observed every few days during 
the week for colour or consistency changes. High-quality feed is necessary to ensure 
an animal’s nutritional needs are met. Feed and bedding can influence experimental 
outcomes as they can impact an animal’s physiology. Provision of high-quality feed 
is therefore essential to maintain the health and welfare of the animals. Any suspected 
changes in consistency or colour, deviated from the frozen food was removed, if 
necessary. Daily assessments on mouse welfare were conducted by the biological 
services unit technicians on a daily basis. Mice were separated if there was an issue 
with fighting. Mice were identified by ear marking and were house together based on 
diet and treatment received. Mice were assigned to diet and treatment on random, no 
blinding was performed.  
 
3.1.1.1 Induction of T2DM by the use of a HFHS diet 
10-week old male C57BL/6 mice were fed either a standard chow-based diet (5053, 
LabDiet Ltd) or a HFHS diet (58R3, TestDiet Ltd) for 10 weeks. Both chow and 
HFHS-fed mice were 20-weeks old at cull. The compositions and nutritional profile 
of the two diets are shown in Table 3.1. The HFHS diet has been termed ‘high-fat’ and 
‘high-sugar’ due to its high concentration of saturated fats (hydrogenated coconut oil) 
and sucrose.  
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Table 3.1 | Diet composition and nutritional intake of chow and high-fat high-sugar 
(HFHS) diets 
  




(kcal %)  
Protein 24.5 14.9 
Fat 13.1 59.4 









Cholesterol, ppm 142 0 
Linoleic Acid 2.12 1.28 
Linolenic Acid 0.27 0.19 
Arachidonic Acid 0.01 0 
Omega-3 Fatty Acids 0.45 0.19 








Sucrose 3.25 17.5 




In this study, a diet-induced diabetic model was favoured due to its ability to mimic 
the human condition more accurately that genetic models of obesity-induced diabetes 
(461). Diet-induced diabetic models work through causing obesity from imbalanced 
food intake and low energy expenditure (459), therefore the diet-induced models 
replicate the westernised lifestyles in humans, of increased intake of foods dense in 
fats and sugars along with a sedentary lifestyle.  
The use high-fat feeding has been examined in a number of rodent models 
(459,462,463), however the C57BL/6 mouse strain has shown to most closely parallel 
the pathophysiology of T2DM as seen in humans (464). A high-fat (58%) diet in these 
mice has clearly shown to cause weight gain, insulin resistance and hyperglycaemia 
in comparison to mice fed a chow-diet (11% fat) (465). Furthermore studies have 
found male mice to be more prone to the development of diabetes in comparison to 
females (466). Obesity inevitably leads to metabolic syndrome that can progress to 
T2DM and hence the C57BL/6 male diet-induced obese mouse model is highly 
suitable for this study (467,468). 
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It should be noted that there are no ‘gold-standard’ reference values, which are used 
to confirm development of T2DM in an animal model (467). All studies will compare 
the development or induction of T2DM against a control, in this case this will be the 
chow diet mice, and comparison to other studies. The lack of ‘gold-standard’ reference 
values may be due the number of different models that can be used to induce T2DM. 
With regard to diet-induced diabetes, there is no single standard protocol with 
variations in the use of mouse strains, formulations of high fats (fat fractions ranging 
from 20-60%), duration of feeding periods (ranging from a few weeks to more than 
one year) and age of mice at induction of diet (469,470).  
Nevertheless, there are certain clinical measures that are used to confirm T2DM in 
animal models and these are based on the criteria of traits seen in MetS/T2DM in 
humans. Notably, the assessment and definition of these metabolic disorders is still of 
considerable debate in humans, with a number of guidelines available which have 
variations in their diagnostic criteria (471). To confirm the development of T2DM in 
this study, I have used clinical measures that have been previously used by Surwit et 
al., in development of the original high-fat diet-induced model (464) and reversal of 
diet-induced obesity (472) in C57BL/6 mice as well as by others in our group (473–
475). The list of these clinical measures or traits along with the methodology used to 
determine these have been presented in Table 3.2. Further information on each of these 
traits can be found in section 1.6.1. and in the relevant sections of the methods that 
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Table 3.2 | The traits of MetS/T2DM  
The table defines the traits of MetS/T2DM that are often used to confirm 
development of T2DM in mice. The methodology to determine the development of 
these traits or clinical measures has also be listed. OGTT – oral glucose tolerance 
test, ITT – insulin tolerance test.  
 
Clinical Measure Definition (taken from 
WHO) 
Which methodology is 
used to determine the 
measure? 
Obesity Overweight and obesity are 
defined as abnormal or 
excessive fat accumulation 
that presents a risk to health. 
Based on Body Mass Index 
in humans. 
Body weight (taken 
weekly to determine 
weight gain)  & adiposity 
(epididymal and inguinal 




Impaired fasting glucose 
levels and impaired glucose 
tolerance. Often results from 
insulin resistance thereby 
raising blood glucose levels 
Fasted and non-fasted 
blood glucose, OGTT, ITT 
Hyperinsulinemia Occurs in response to high 
glucose and fatty acid levels 
OGTT, ITT and serum 
insulin 
Dyslipdaemia Elevation of blood 
cholesterol, triglycerides, or 
both, or a low HDL 
cholesterol level. 
Serum triglycerides and 













Figure 3.1 | Summary of the experimental model used to establish diet induced T2DM  
10-week old male C57BL/6 mice were fed either a chow or HFHS for 10 weeks. From week 
5, mice were injected with a sham injection of 100µL Hepes/NaCl, 5 times/week via 
intraperitoneal (i.p.) injection for 6 weeks. Assessment for glucose tolerance and insulin 
resistance were conducted via oral glucose tolerance tests (OGTT) and insulin tolerance tests 
(ITT) respectively. Mice were culled at the beginning of week 11. Confirmation of T2DM was 
made by weight and various blood/serum analyses. At cull, blood, brain, lymph nodes and 
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3.1.1.2 Pharmacological intervention: Treatment with human recombinant ANXA1 
(hrANXA1) 
Pharmacological intervention was provided by treating mice fed a HFHS-fed diet with 
hrANXA1. 10-week-old male C57BL/6 mice were fed a HFHS diet for 10 weeks. 
Pharmacological intervention was provided from weeks 5-10, whilst mice remained 
on the HFHS diet. Mice were treated with 1µg hrANXA1 in 100µl of 50mM Hepes 
(hydroxyethyl piperazineethanesulfonic acid) and 140mM NaCl, pH 7.4, daily (5 
times/week) intraperitoneal (i.p.). The daily dose of 1µg was selected based on 
previous report that show the half-life of ANXA1 to be approximately 6 hours through 
i.p. or intravenous (i.v.) injection (476,477). I.p. injection is preferred because 0.5% 
of the injected dose remains in the circulation 24 hours post injection versus almost 
0% through i.v. administration (478). The dose of hrANXA1 remained the same 
throughout the duration of the study and was not changed with increasing weight gain 
in the mice.  
To allow for accurate comparison against the chow-fed and HFHS-fed mice; mice not 
assigned to receive hrANXA1 where treated with vehicle 100µl of 50mM Hepes, 
140mM NaCl, pH 7.4, daily (5 times/week) i.p.  
Assignment to diet and treatment was random and no blinding was performed. All 
groups of mice were 20-weeks old at cull. Summary of the HFHS-fed + hrANXA1 
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Figure 3.2 | Summary of the experimental model used to provide pharmacological 
intervention with hrANXA1 treatment 
10-week old male C57BL/6 mice were fed a HFHS for 10 weeks. From week 5, mice were 
injected with a 1µg hrANXA1 in 100µL Hepes/NaCl, 5 times/week via intraperitoneal (i.p.) 
injection for 6 weeks. Assessment for glucose tolerance and insulin resistance were conducted 
via oral glucose tolerance tests (OGTT) and insulin tolerance tests (ITT) respectively. Mice 
were culled at the beginning of week 11. Confirmation of T2DM was made by weight and 




The hrANXA1 was kindly provided by our collaborator Chris P. M. Reutelingsperger 
(University of Maastricht, The Netherlands) who produced and purified the hrANXA1 
as per procedures described below. The hrANXA1 was provided at a stock 
concentration of 2.1mg/mL in 50mM Hepes, 140mM NaCl pH 7.4. When stored at 
4°C in the Hepes/NaCl buffer, hrANXA1 is stable for at least 1 year. For longer 
periods of time, hrANXA1 can be stored at -80°C. Throughout the study a single 
synthesis/purification of hrANXA1 was used. The hrANXA1 was aliquoted and stored 
in the freezer upon arrival. The required amounts were defrosted and prepared to the 
required concentration prior to use in the mice.  
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hrANXA1 was produced according to previously described procedures (478). Briefly, 
cDNA coding for hrANXA1 was amplified by polymerase chain reaction (PCR) using 
the primers: 5’-GGTATCGAGGGAAGGGCAATGGTATCAGAATTC-3’ and 5’-
GCTCAGCTAATTAAGCTTTAGTTTCCTCCACAAAGAGC-3’. The PCR was 
run for 35 cycles consisting of incubation for 1 minute at 94°C, 1 minute at 55°C, and 
1 minute 20 seconds at 72°C. The primers allowed for the introduction of Stu-I and 
Hind-III restriction sites, which were required for the ligation into the expression 
vector pQE30Xa (Qiagen). This expression vector introduced a His-tag upstream of 
the N-terminal tail. The N-terminal tail of ANXA1 mediates the anti-inflammatory 
activities of the protein and contain protease-sensitive sites. Escherichia coli 
cells (SG13009 pREP4) (Novagen) were transformed with the vector. Cells were 
fermented in Luria-Bertani broth medium supplemented with Ampicillin (50ug/ml, 
Roche), Kanamycin (30ug/ml, Gibco) and 0.5% glycerol. ANXA1 expression was 
induced by incubating sub-confluent culture (optical density of >6) with of 5mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG, Eurogentec). hrANXA1 proteins were 
purified using immobilized metal affinity chromatography. In order to verify that 
procedure yielded full-length recombinant protein, purified hr-anxA1 was subjected 
to structural analyses including Matrix Assisted Laser Desorption/ Ionization (MALDI 
TOF/TOF), silver stained SDS-PAGE and Western blotting and tryptic digestion. The 
analysis confirmed the production and purification of full-length hrANXA1 with a 
purity of >95%. Biological functionality of the N-terminal tail and Ca2+-dependent 
phospho-lipid-binding C-terminal core were assessed by the calcium flux induced in 
FPR-2 transfected HEK-293 cells and ellipsometry, respectively (478).  
Importantly it is not only the full-length ANXA1 molecule which has the ability to 
mediate its widespread effects; ANXA1’s N-terminal derived peptides Ac2-26, Ac2-
12 and Ac2-6 have also been reported to induce activation of FPR1 and FPR2 (479–
481). However treatment is provided by using full length hrANXA1, as the dose 
required to induce biological function is up to 20 times less than that required by the 
peptide Ac2-26 (482) and 14 times less than that needed to induce gene expression 
changes (483). Furthermore, Ac2-26 peptide has a weak ability in reducing leukocyte 
adhesion unlike full-length hrANXA1 (484).  Notably, the sequence homology of 
conserved and variable residues between mouse to human ANXA1 is 87%, making it 
viable for treatment use in mice (485).   
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3.1.1.3 Dietary intervention: Reversion to Chow Diet 
Dietary intervention was provided by reverting mice fed a HFHS diet onto a chow 
diet. 10-week old male C57BL/6 mice were fed a HFHS diet for 10 weeks, after which 
mice were placed back on a chow diet for a further 5 weeks, the total dietary period 
for these mice was 15 weeks. Importantly, comparisons of this group have been made 
to mice given chow or HFHS-diet for 10 weeks and hence there is an element of age, 
which will be a confounder in these results. Chow, HFHS and HFHS + hrANXA1 
mice were 20-weeks old at cull whereas HFHS – Chow reversion mice were 25-weeks 
old at cull.  
Importantly, these mice were also treated with vehicle 100µl of 50mM Hepes, 140mM 
NaCl, pH 7.4, daily (5 times/week) i.p., similar to chow-fed and HFHS-fed mice for 
the first 10 weeks on the intervention. Summary of the HFHS – Chow reversion diet 
mice model is provided in Figure 3.3.  
 
Figure 3.3 | Summary of the experimental model used to provide dietary intervention  
10-week old male C57BL/6 mice were fed a HFHS for 10 weeks. From week 5, mice were 
injected with a sham injection of 100µL Hepes/NaCl, 5 times/week via intraperitoneal (i.p.) 
injection for 6 weeks. From week 10, mice were switched onto a chow diet for 5 weeks. 
Assessment for glucose tolerance and insulin resistance were conducted via oral glucose 
tolerance tests (OGTT) and insulin tolerance tests (ITT) respectively. Mice were culled at the 
beginning of week 16. Effect on T2DM was made by weight and various blood/serum 
analyses. At cull, blood, brain, lymph nodes and bone marrow were collected.  
A summary of the 4 experimental groups has been provided in Table 3.3. 
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Table 3.3 | Experimental groups used to establish a mouse model of diet induced T2DM 
and the models used to provide a pharmacological and dietary intervention.   
Group name 
and age 
Diet and period 
of time 
Treatment and 










from weeks 1 - 10 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 






from weeks 1 - 10 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 







from weeks 1 - 10 
Pharmacological 
intervention of 
1µg hrANXA1 in 
100µl of 50mM 
Hepes, 140mM 
NaCl, pH 7.4,  
5 times/week i.p.  
Given weeks 5-10 
20 weeks 55 






weeks 1 - 10 
Chow from weeks 
11-15 (dietary 
intervention) 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 
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3.1.2 Measuring body weight and feeding behaviour 
The body weight and food and calorie take of mice were measured at the beginning of 
each week to ensure good health and monitor feeding habits. Body weight was 
measured at the beginning of each week at the same time, using the same balance 
throughout the entire study. The body weight gain was calculated at the end of the 
study. 
Fresh food (150 grams/cage) was also supplied at the beginning of each week and was 
regularly monitored through the week for colour or consistency change. The diet from 
each cage was weighed before being changed to measure food (g/mouse/day) and 
calorie intake (kcal/mouse/day) using the following equations (473):  
Food intake 
=
weight of diet at beginning of week − weight of diet at end of week
(number of mice in cage x number of days)
 
Calorie intake = food intake x [protein%, x4 +  fat %, x9, +carb%, x4)] 
Note that energy (kcal/gm) – is the sum of decimal fractions of protein, fat and 
carbohydrate x4, x9, x4 kcal/gm respectively, where a gram of protein and 
carbohydrate give 4 calories and fat gives 9 calories.  
 
 
3.1.3 Collection of blood, brain tissue, lymph nodes and bone marrow 
For chow, HFHS and HFHS + hrANXA1 mice, culls were conducted at the beginning 
of week 11, when a full 10 weeks of diet manipulation had been completed. For HFHS 
– Chow reversion mice, culls were conducted at the beginning of week 16, when 15 
weeks of dietary manipulation had been completed.  
Mice were anaesthetised using a cocktail of xylazine (20mg/mL) and ketamine 
(100mg/mL) in a 1:2 ratio, given i.p. as a dose of 1.5mL/kg. The heart was revealed 
by cutting through both sides of the rib cage and the diaphragm, blood samples were 
collected by cardiac puncture of the left ventricle and the right atrium was cut to allow 
release of blood. Cardiac puncture was performed using a G25 BD hypodermic needle 
(BD Biosciences). Blood was washed out by perfusion of the left ventricle with 12ml 
0.9% saline at 4°C given over 3 minutes. To perform the perfusion, the needle was left 
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in place after the cardiac puncture, and the syringe used to collect blood was removed 
and replaced with a syringe containing saline. An incision was made at both sides of 
the skull to reveal the brain. Brains were removed and placed in ice-cold PBS-/- 
containing 100 units/mL Gentamycin (Gibco) and 2.5µg/mL Amphotericin B (Gibco) 
on ice for endothelial primary culture isolation. For microglial isolation, brains were 
placed in ice-cold PBS-/- containing 1M Hepes, 45% D-Glucose and 10mL/L 
penicillin/streptomycin solution (All reagents from Sigma-Aldrich). Alternatively for 
tissue imaging each hemisphere of the brain was cut into 3 transversal slices, placed 
in 3mL of 2% paraformaldehyde (PFA, pH 7.4) and 0.2% glutaraldehyde (Sigma-
Aldrich) in PBS+/+ for 4 hours at 4°C. Brain slices were then washed several time in 
PBS+/+ at 4°C and stored in 0.002% PFA in PBS+/+. Blood was centrifuged at 9000g 
for 3mins at room temperature (RT) and the serum fraction (supernatant) was obtained. 
Lymph nodes were isolated from the superficial and deep cervical regions (Figure 3.3) 
and stored in ice-cold 0.01M PBS for lymphocyte isolation. Mouse femurs were 
harvested for bone marrow collection and stored in 0.01M PBS. The adiposity of the 
mice was measured, by collecting epididymal and inguinal fats pads. These were 
weighed using the same balance throughout the entire study and presented as a 
percentage of the total body weight of the mouse. The fat pad measurements along 
with the overall body weight helped to determine obesity.  
                         
Figure 3.4 | Figure to show location of lymph nodes in rodent 
Deep cervical lymph nodes were collected. Figure taken from (486). 
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3.1.4 Measurement of glucose, insulin and lipid levels 
T2DM is characterised by hyperglycaemia arising due to the loss of insulin sensitivity. 
Initially, β-cells try to combat increased glucose levels by producing more insulin 
however when the β-cells cannot maintain this production, impaired glucose tolerance 
and insulin resistance develops (379).  
The Oral Glucose tolerance tests (OGTT) is the only means of identifying impaired 
glucose tolerance and is widely used in literature as means of testing for T2DM. It 
should be noted that even a relatively simple procedure such as the OGTT also has 
little consensus on a specific protocol, with variables such as length of fasting period, 
glucose dose and route of administration affecting outcome; making direct 
comparisons between studies complicated (487). Therefore, the protocol per study 
should be carried out in the same procedure. A period of fasting is required before 
glucose administration which can be given either via an oral bolus or i.p.; fasting is 
required to provide a stable baseline blood glucose level. Fasting periods are either 
over night for approximately 16 hours or starting in the morning for approximately 6 
hours (487). Overnight fasting has the advantage of producing a low and stable 
baseline blood glucose however overnight fasting is not often ideal as mice, due to 
their nocturnal nature (488,489). Nocturnal animals consume most of their calories 
overnight, this coupled with a high metabolic rate as seen in mice means an overnight 
fast can often induce a state of starvation rather than fast because of the relatively long 
period in which mice are food deprived (490). Overnight fasting in mice can also 
increase insulin sensitivity (491). Administration of glucose can be via oral gavage or 
a single i.p. injection; both routes are considered appropriate methods for 
administration. Dynamically, peak plasma is reached more quickly in response to oral 
glucose at 15 minutes compared to 30 mins with i.p. injection (490). The dose 
administered for OGTT is typically either 1 or 2g/kg, it should be noted that insulin 
resistance may only be revealed in response to higher glucose loading (490).  
 
Although OGTT tests are often considered to be adequate to monitor glucose tolerance 
and insulin resistance (490), often some form of insulin measurement is also provided 
to complement the measurements of glucose tolerance (487). Similar to the OGTT, an 
insulin tolerance test (ITT) is often used in literature. The ITT involves monitoring 
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blood glucose in response to insulin administration that can only be administered as 
an i.v. or i.p. injection. Typically, a 6 hour fasting is preferential to an overnight fast 
to prevent hypoglycaemia (487).  
 
Taking the above into account, OGTTs and ITTs were conducted prior to termination 
of animals using the following protocol to determine glucose tolerance and insulin 
resistance. The mice were fasted for 6 hours (8am – 2pm) by being moved to clean 
cages with no food but with free access to water. At the end of 6 hour feeding period, 
the body weight of each mouse was measured. A small incision was made to side of 
the tail to obtain blood. Fasting blood glucose was measured, followed by 
administration of an oral bolus of glucose (2g/kg in PBS) or insulin (1unit/kg in PBS). 
Blood glucose was measured via the tail vein puncture at 15-minute intervals for a 
total duration of 120 minutes using a glucometer (Accu-Chek Compact System; Roche 
Diagnostics, Basel, Switzerland), and expressed as a time course of absolute blood 
glucose measurements and area under the curve (AUC). Non-fasting blood glucose 
values were obtained using a glucometer immediately after cardiac exsanguination. 
Non-fasted and fasted blood glucose levels allow for the determination of 
hyperglycaemia. Compensatory hyperinsulinemia often occurs in response to 
hyperglycaemia in an attempt to maintain fasting glucose combat insulin resistance 
(380). ELISA kits were used to measure serum levels of insulin (ThermoFisher 
Scientific), cholesterol (Abcam Plc.) and triglycerides (Abcam Plc.) for the 
determination of hyperinsulinemia and dyslipidaemia.  
 
3.1.5 CD4+ T-cell isolation and expansion 
Isolated lymph nodes were placed on a 70µm cell strainer (Fisher Scientific) placed 
over a 50mL falcon tube. Lymph nodes were kept wet with PBS-/-. The lymph nodes 
were homogenized using a total of 5mL PBS-/-. Isolated lymphocytes were centrifuged 
at 1800rpm for 5 minutes at 4°C, the supernatant was discarded, and the cell pellet 
was re-suspended in 3mL 0.01M PBS. The number of cells were counted and seeded 
on a 24-well plate (Corning) at a density of 1x106 cells/well. For stimulation of CD4+ 
T-cells, plates were previously coated with 1µg/mL of anti-CD3 (E-bioscience) and 
5µg/mL of anti-CD28 (E-bioscience) diluted in 50mM Tris (pH 8.5) in a volume of 
200µl/well for 1 hour at 37°C. The coating solution was removed and the isolated cells 
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were suspended in 1mL of RPMI medium supplemented with 10% fetal bovine serum 
(FBS), 2mM Glutamine, 10mM HEPES, 1mM Sodium Pyruvate, 50µM β-
mercaptoethanol and 100 units/ml Gentamycin containing 10ng/mL IL-2 (Roche, all 
other reagents Gibco). Cells were expanded for 5 days for transmigration assays or for 
flow cytometric analysis. 
 
 
3.1.6 Bone marrow isolation  
Mouse femurs were flushed several times with 1mL 0.001M PBS-/-. To lyse out red 
blood cells, 4mL of 1X cold lysis solution (155mM NH4Cl, 12mM NaHCO3, 0.1mM 
EDTA) was added to 1mL of PBS-cell fraction. The PBS-cell fraction was placed on 
a rocking platform for 10 minutes at RT, followed by centrifugation for 10 minutes at 
250g at 4°C. The supernatant was discarded, and the cells were washed in FACS buffer 
(2% FBS in PBS+/+) for a further 10 minutes at 250g at 4°C. The supernatant was 
discarded, and the cells were re-suspended in 1mL of FACS buffer. The cell solution 




3.1.7 In vivo administration of Evans Blue dye 
Evans blue dye extravasation is an effective technique to analyse permeability changes 
occurring in vivo. This method relies upon small molecules of Evans blue binding to 
serum albumin present in blood; a small proportion remains uncoupled (0.11%-0.31%) 
(492). Evans blue dye has a molecular weight of 961Da and is highly soluble (280g/L), 
it specifically binds to serum albumin both in vivo and in vitro and therefore becomes 
a high molecular weight protein tracer of 69kDa (492–494). When injected, either i.v. 
or i.p., albumin-bound Evans blue dye remains stable in the blood, the dye distributes 
throughout the body and stains the animal with an intense blue colour (495). Under 
normal conditions, the endothelium of the BBB restricts the entry of the dye, however 
under certain stimuli or damage which disrupts the tightness of the BBB, the leakage 
of the dye into the brain parenchyma increases via a paracellular route (496,497). It is 
the increased presence of Evans blue dye into the brain that is a measure of disrupted 
BBB integrity.  
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To measure Evans blue dye leakage in the study, mice were placed in a warming 
chamber for 5 minutes to dilate the tail vein to facilitate i.v. injection of 100µl of 2% 
Evans blue dye in 0.9% saline. The dye was allowed to circulate for 1 hour for 
diffusion from the circulation to tissues, after which mice were anaesthetised. Cardiac 
exsanguination and perfusion were performed, as described in section 3.1.3. Brains 
were isolated, sliced into two hemispheres and stored in 0.01M PBS on ice for 
permeability assessment.  
 
 
3.1.8 Evans blue detection in brain homogenates and serum samples 
The following protocol was adapted from previously published methods (495,498). 
Brain hemispheres collected after in vivo Evans blue dye administration were weighed 
and homogenized through maceration. 2.5mL of 60% tricholoracetic acid (TCA) in 
dH2O was added to each homogenized tissue preparation, samples were mixed and 
incubated on ice for 30 minutes. Samples were centrifuged at 1000g for 30 minutes at 
4°C, 200µL of the supernatant was assessed using a spectrophotometer at 620nm 
(Infinite M200 PRO plate reader, TECAN). The serum was obtained from blood 
samples taken from the mice as described in section 3.1.2. Serum samples were also 
analysed spectrophotometrically in a 1:40 dilution with 0.9% saline in a final volume 
of 200µl. Final values were normalized to tissue weight and expressed as percentage 
of serum dye content. BBB integrity loss is signified by a greater percentage of Evans 
blue dye leakage into the brain.   
 
(µg of dye in brain) / (mg of tissue)
(µg of dye in serum)
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3.1.9 Culturing of primary mouse brain microvascular endothelial cells 
(pMBMECs) 
pMBMECs were cultured from all mice groups – Chow, HFHS, HFHS + hrANXA1 
and HFHS – Chow reversion mice. In addition, pMBMECs were also cultured from 
a group of 6-week old chow-fed mice. This group was compared against the 20-week 
old chow mice group, to assess the effect of age. The results from this experiment 
can be found in Chapter 4.   
The following volumes are calculated for isolation of endothelial cells from a total of 
10 mice brains. Isolated whole brains were placed on sterile chromatography paper. 
The brain stems, cerebellum and thalamus were removed with forceps and the 
meninges were detached by gentle rolling. The remaining brain tissue was cut into 
1mm pieces with a scalpel and transferred to a 50mL falcon containing 12.5ml 
DMEM/F12 (ThermoFisher), 1.5mL 10mg/mL collagenase II (Sigma) and 200µl 
1mg/mL DNase I (Sigma). The brain tissue was mixed thoroughly using a 5mL pipette 
and incubated at 37°C in a shaker (200rpm) for 55mins to generate a milky-looking 
homogenate. Following incubation, 10mL DMEM/F12 was added and the mixture 
was centrifuged at 1000g for 8mins. The supernatant was removed and 10mL 20% 
BSA-DMEM/F12 was added to the cell pellet, mixing thoroughly with a 5mL pipette; 
the mixture was centrifuged at 1000g for 20mins at 4°C. After centrifugation, the 
myelin layer at the top containing neurons, glia and the BSA-DMEM/F12 solution 
was transferred into a 15mL falcon and shaken vigorously before centrifuging again 
at 1000g for 20mins at 4°C. This process was repeated 3-4 times. The cell pellets 
(whitish-red in colour) containing the microvessels were stored on ice.  
For obtaining brain microvessels for proteome analysis (section 3.2.8), the brain 
microvessels pellets were pooled into a single eppendendorf and stored in 1mL of 
radioimmunoprecipitation assay (RIPA) buffer containing inhibitors (1µg/mL 
aprotinin, 1µg/mL leupeptin, 1mM PMSF, 1mM NaF, 1mM Na3VO4). Pellets were 
stored at -80°C until required. Protein quantification was determined before use for 
experiments (described in section 3.2.9). 
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For obtaining pMBMECS for culture, the brain microvessel pellets were pooled into 
a single falcon tube and further digested in 7.5mL DMEM/F12, 833µl 10mg/mL 
collagenase-dispase (Roche) and 83µl 1mg/mL DNase I. The brain vessels were mixed 
with a 1mL pipette and incubated at 37°C in a shaker (200rpm) for 35mins to generate 
a reddish-pink fluid. Following incubation, 10mL DMEM/F12 was added to the 
mixture and centrifuged at 700g for 6mins, the washing step was repeated, and the 
cells were ready to plate. pMBMECs were plated in 35mm culture dishes (Falcon); 1 
dish was used for every 2-3 mice. The surface of the culture dishes were coated with 
500µl of 0.2% Rat Tail Collagen I (Corning) in PBS-/-, the coating was pipetted up & 
down 10 times to ensure whole surface coverage and the solution was transferred to 
the next dish. The plates were allowed to dry in a 5% CO2 incubator for approximately 
3 hours prior to plating cells.   
pMBMECs were initially cultured in DMEM/F12 supplemented with 15% FBS, 
1ng/mL basic fibroblast growth factor (bFGF, Roche), 100µg/mL heparin (Sigma), 1 
x Insulin-Transferrin-Selenium (ITS, Gibco), 4µg/mL puromycin (Sigma) and 100 
units/ml Gentamycin. Cells are grown at 37°C in a 5% CO2 incubator. Fresh medium 
was added on day 3 containing only 10% FBS and from day 4, medium was prepared 
without puromycin. Puromycin is initially supplemented into the medium in order to 
obtain a pure monoculture. Cells reach confluency between days 5-7, however cells 
are used for experiments or passaged at 75% confluency (around day 4). For 
passaging, cells were washed twice with PBS-/- followed by incubation with 
200µl/dish 0.25% Trypsin at 37°C for 2-3 minutes. Growth medium was added in a 
1:4 ratio to trypsin to inhibit the action of trypsin, cells were counted using a 
disposable haemocytometer (Kova International). Further passages were plated at a 
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3.1.10 Culturing of primary mouse microglia cells 
The following volumes are calculated for isolation of microglia cells from a total of 
10 mice brains. Isolated brains were placed into a sterile petri dish; brain tissue was 
cut into 1mm pieces with a scalpel and transferred to a 50mL falcon containing ice-
cold PBS-/-. Tissue fragments were centrifuged at 300g for 2 minutes at 4°C and the 
supernatant discarded. The fragments were mixed thoroughly using a 5mL glass 
pipette in 20mL of enzyme buffer (PBS-/-, 10ml/L penicillin/streptomycin solution, 
1M Hepes, 30% BSA, 0.5mg/ml DNAse1, 5mM L-Cysteine (Sigma-Aldrich) and 1.5 
units/mL papain and incubated at 37°C in a shaker (200rpm) for 30 minutes. After 
incubation, the cell suspension was passed through a 40µm strainer (Fisherbrand 
Scientific) rinsing with warm PBS-/-. The cell suspension was centrifuged at 300g for 
10 minutes at 20°C, the supernatant was discarded and the pellet re-suspended in 
20mL of myelin removal buffer (0.9M sucrose in PBS+/+), followed by further 
centrifugation at 300g for 10 minutes at RT. Stock isotonic percoll (SIP) was used to 
separate microglial cells using density dependent centrifugation; SIP was prepared at 
30% and 70% gradients in Hanks balanced salt solution (HBSS,). The cells were 
washed in PBS-/- and re-suspended in ice-cold 70% SIP (3.5mL/brain) and distributed 
across 15mL falcons (one/brain). An overlay was created, first using 5mL ice-cold 
30% SIP and then 3mL ice-cold PBS. The cells were centrifuged at 800g for 30 
minutes at 4°C, removing the brake to avoid disruption of the interphase containing 
microglia. The microglia cells were collected using pasteur pipettes at the 25/75 
interphase and diluted with 3X ice-cold PBS, followed by centrifugation at 1000g for 
10 minutes at RT. The pellet was suspended in warm medium (1mL/brain) and plated 
at a density of 3 x 105 cells/well in 24 well plates. Microglia cells were cultured in 
DMEM with L-glutamine, 20% FBS, 100units/mL gentamycin and 50ng/mL M-CSF 
(Gibco) and maintained at 37˚C in 5% CO2. Microglia were allowed to adhere for 3 
hours, after which fresh medium was given. Medium was changed every 2-3 days 
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3.2 In vitro methods 
3.2.1 Origin of bEnd3 cell line 
All in vitro studies examining the effect of mice sera on the BBB have used the mouse 
brain-derived endothelial cell line – bEnd3. The cell line was established by W. Risau 
(Max-Planck Institute) through transformation of primary brain endothelial cultures 
obtained from BALB/c mice with the NTKmT retrovirus vector expressing 
polyomavirus middle T antigen coding for the Polyoma virus middle T oncogene 
(499). bEnd3 cells are commercially available and were purchased from The European 
Collection of Authenticated Cell Cultures (ECACC), Public Health, England.  
 
3.2.2 Routine cell culture of bEnd3 cell line 
bEnd3 cells were cultured in DMEM 1g/L D-glucose culture medium (Gibco) 
supplemented with 10% FBS, 4mM Glutamax, 100 units/mL Gentamycin, 50µM β-
Mercaptoethanol, 1mM Na-Pyruvate and 1x non-essential amino acids. Expansion of 
cells was carried out in T75 flasks at a plating density of 4 x 106 cells, in a 5% CO2 
incubator at 37°C; previously coated with gelatin solution (Gibco), diluted 1:20 in 
PBS-/. Cells were checked daily for confluency and passaged approximately every 4-
5 days when they had reached the log phase of their division. bEnd3 passages 24-34 
were used throughout the study. 
 
3.2.3 Thawing, Passaging & Cryopreservation of cell lines 
Frozen stock vials were stored in liquid nitrogen. Cells were thawed using warmed 
culture medium and centrifuged at 1800rpm for 5 minutes to remove the dimethyl 
sulfoxide (DMSO). The supernatant was aspirated, and fresh medium was added to 
resuspend the pellet, which was transferred to a T75 flask. Fresh medium was replaced 
24 hours after thawing and every 2-3 days after. 
For passaging, cells were first washed in PBS-/- followed by incubation with 1.5ml 
0.25% Trypsin at 37°C for 2-3 minutes. Growth medium was added in a 1:4 ratio to 
trypsin to inhibit the action of trypsin, cells were counted using a disposable 
haemocytometer and harvested at 1800rpm at RT for 5 minutes. The pellet was 
resuspended in fresh medium and transferred into a T75 flask. Any cells not required 
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for experiments or for culturing, were cryopreserved using 10% DMSO in FBS. Cells 
were stored in cryovials (Nalgene) in a freezing container at -80°C for 24 hours after 
which vials were transferred to -196°C liquid nitrogen tank.  
 
3.2.4 Stimulation of cell lines with serum or inflammatory mediators 
Any experimental studies using bEnd3 cells were stimulated overnight with 
decomplemented 10% mouse serum in place of FBS in the culture medium. Serum 
stimulation was used to model the effect of peripheral mediators on the BBB. All 
serum was decomplemented for 20 minutes in a 56°C water bath prior to use. 
 
3.2.5 Paracellular permeability assay 
The paracellular permeability of pMBMECs and bEnd3 serum-stimulated cells was 
assessed using the fluorescent marker protein fluorescein isothiocyanate (FITC)-
dextran, MW 55-77kDA (Sigma-Aldrich).  
The assay was conducted using transwell polyester membrane inserts (Corning, pore 
size 0.4 μm, membrane diameter 12 mm) coated with 200μL of laminin (50ug/mL, 
Sigma) diluted in PBS-/- for 30 minutes in a 5% CO2 humidifier at 37°C. Cells were 
harvested and seeded on the top compartment of the transwells in 500μL culture 
medium; 700μL culture medium was added to the bottom compartment of each 
transwell. Cells were allowed to reach confluency (3-4 days) after which the medium 
was changed. The cells were left for another 3-4 days to allow full tight junction 
formation. Fresh medium was only replaced every few days to prevent shear stress.  
Prior to assessment using FITC-dextran, cell lines were stimulated overnight with 
500µL medium containing 10% mouse serum. Cell-free transwells were served to 
measure the resistance of the plastic filter alone to paracellular movement of 
molecules.  
After 24 hour stimulation, the medium from the top compartment was aspirated and 
replaced with 500μL FITC-dextran (3mg/mL) dissolved in transport buffer (2% FBS 
in DMEM 4.5g/L glucose without phenol red). Each set of transwells were transferred 
to a new 12-well plate (Corning) containing 1.5mL of transport buffer and incubated 
in a 5% CO2 incubator at 37°C. Every 10 minutes, the insert was moved to the next 
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row of wells, containing 1.5mL transport buffer for a total duration of 60 minutes. At 
the end of the 60 minutes the filters were removed and the fluorescence of each well 
measured to determine the amount of diffused FITC-dextran. Refer to Figure 3.4 for 
a schematic representation of the assay.  Fluorescence was measured using a 
spectrophotometer (Tecan Infinite M200 Pro, Tecan, Austria) at excitation wavelength 
485nm and emission wavelength 535nm. The endothelial permeability coefficient (Pe) 
was calculated in cm/min as previously described (297,500,501). Briefly, the 
clearance principle was used to define the concentration-dependent transport 






Where [C]u represents the fluorophore concentration on the upper chamber, while 
[V]l and [C]l represents the volume and the fluorophore concentration in the lower 
chamber, respectively. The concentration values of the lower chamber were 
calculated by plotting a standard curve of known amounts of FITC-dextran. An 
increment of cleared volumes was plotted against time of measurement (60 minutes). 
The slope of the linear curve the proportionally represents the permeability 
properties of the monolayer and defines PS, the permeability surface area. The PS 
indicates the resistance opposed to the clearance: 
PS (permeability surface area) = slope 
The total resistance opposed to the passage of the dye is the sum of the resistance 
offered by the monolayer and the resistance offered by the filter:  
Total resistance of PS (PS TOT) = PS monolayer +  PS filter 
Therefore, PS monolayer can be calculated by subtracting PS filter from PS TOT. 
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The permeability coefficient (also called conductance) is defined as the inverse of 
the resistance, the permeability coefficient of the endothelium (Pe) can be calculated 
as follows: 
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3.2.6 Transendothelial electrical resistance (TEER) 
The TEER is another measure of permeability, it provides an indication on the 
tightness of the endothelium barrier. TEER measurements were performed on the 
same transwells as described in the paracellular permeability experiments. The TEER 
was measured 3 hours prior to the paracellular permeability assays to allow the 
monolayers to resettle. TEER was measured using the Epithelial Volt/Ohm (EVOM2) 
Meter (World Precision Instruments, USA) consisting of two electrodes. One 
electrode is place in the upper chamber of the transwell and the other electrode is place 
in the lower chamber allowing the two electrodes to be separated by the endothelial 
layer. Electrical resistance was expressed as Ohms/cm2 (Ω/cm2). Collagen-coated cell-
free resistance values were subtracted from the values of obtained in the presence of 
endothelial cells.  
 
3.2.7 Transmigration assays 
Polycarbonate transwell inserts (24-well, 0.33cm2 surface area, pore size 5µm; Sigma-
Aldrich, UK) were coated with 50µg/mL laminin. Cells were seeded on the top 
compartment of the transwells and cultured in 200µL medium for 72 hours to allow 
confluent monolayers to form; no medium was added to the bottom compartment. On 
the day of the assay, 600µl of complete medium was added to the bottom compartment 
of the transwells. 1 x 106 mouse leukocytes were added per tranwells were added to 
the top compartment and incubated for 4 hours at 37°C in 5% CO2. After 4 hours, 
inserts were removed, and the entire volume of the bottom compartment was collected 
to assess the transmigrated lymphocyte population. Lymphocytes adhered to 
monolayers were collected by washing inserts with 100µl PBS-/- to remove non-bound 
cells, followed by 50µL 5mM EDTA for 5 minutes. Cells recovered in the EDTA 
washing step were considered the adherent cell population.  Adherent and migrated 
cells were stained with mouse antibodies as shown in Table 3.7 and analysed via flow 
cytometry. To standardise the result collection, all samples were run at the flow 
cytometer for a period of 2 minutes as oppose to setting an x number of events to be 
collected.   
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3.2.8 Proteome analysis – cytokine analysis 
The Mouse Cytokine Array XL Kit (R&D Systems) was used to analyse 111 different 
cytokines, chemokines and acute phase proteins using mouse serum or mouse brain 
microvessels. The kit is a membrane-based sandwich immunoassay. The kit contains 
nitrocellulose membranes onto which capture, and control antibodies have been 
spotted in duplicate. Each membrane was blocked for 1 hour on a rocking platform at 
RT with blocking buffer. After 1 hour, the block buffer was removed and replaced 
with the different samples. For serum 200µL/sample was used and for tissue lysates 
200µg/sample was used; the final volumes of the samples/membrane were made up to 
1.5mL in blocking buffer. Samples were incubated overnight at 4°C on a rocking 
platform. Following overnight incubation, the membranes were washed 3 times in 
wash buffer for 10 minutes each. For each membrane, 30µL of detection antibody 
cocktail was added to 1.5mL of 1X Array buffer 4/6 (provided in kit). The detection 
antibody was incubated for 1 hour on a rocking platform at RT followed by a series of 
3 washes. Next 2mL of 1X Streptavidin-HRP was added to each membrane followed 
by a series of 3 washes. For detection, the Chemi Reagent mix was prepared and 1mL 
of the mix was added to each membrane for 1 minute. Membranes were exposed to x-
ray film for multiple exposure times between 1-15 minutes. Signal was produced at 
the different capture sports which corresponded to the amount of protein bound. 
Negative control spots were used for background subtraction. Image Studio™ Lite 
(LI-COR Biosciences, USA) software was used to analyse the data. 
Mouse serum analysis of TIMP-1 was additionally measured using a quantikine 
ELISA kit (R&D systems). 
 
3.2.9 Protein extraction and quantification 
Protein concentration was determined by homogenising cells or brain microvessels 
with RIPA buffer containing inhibitors. Plated cells were homogenised using a 
multichannel pipette, vortexed for 1 minute on a plate shaker at 200rpm followed by 
centrifugation at 2500rpm for 15 minutes at 4°C and the supernatant collected. Brain 
microvessels stored at -80°C in RIPA buffer were thawed, and homogenised using a 
homogeniser (Omni Int, USA), centrifuged and the supernatant was collected. 
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To determine the protein concentration the bicinchoninic acid method (BCA) was 
applied, using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific). The assay 
is based on the principle that under alkaline conditions copper Cu2+ ions form a 
complex with peptide bonds of proteins and are reduced to Cu+. The BCA reagent is 
highly stable and specific for this purpose and forms a purple compound when reduced 
whose intensity is proportional to the amount of protein present in the sample.  
A calibration curve was constructed using albumin standard samples containing 
2mg/ml of bovine serum albumin (BSA). Concentrations of 1mg/mL, 0.8mg/mL, 
0.6mg/mL, 0.4mg/mL and 0.2mg/mL were made up with RIPA buffer. In a 96-well 
ELISA plate (Nunc MaxiSorp, ThermoScientific, UK), 20µL of the standard curve or 
20µL or each sample were plated. BCA Reagent A and BCA Reagent B were mixed 
in a 1:50 ratio and 200µL of the reagent solution was added to each well containing 
the standard curve or samples. The plate was placed in 37°C incubator for 10 minutes 
after which the values were read using a spectrophotometer at 562nm. The 
concentration value was extrapolated using the standard curve. 
 
3.2.10 Zymography 
Zymography is an electrophoretic technique used for measuring proteolytic activity. 
Gelatin zymography was used for the detection of gelatinases MMP-2 and MMP-9 in 
brain microvessels. For each sample, 1µg/lane was loaded for separation by non-
reducing gel electrophoresis on a 7.5% acrylamide gel containing 1mg/mL porcine 
skin gelatin (Sigma). After electrophoresis, the gel was washed extensively with 
50mM Tris-HCL containing 2.5% Triton X-100, 5mM CaCl2 and 1µM ZnCl2 to 
remove SDS. During this step, the enzymes partially renature and recover their 
activity. Subsequently the gel was incubated overnight in activation buffer (50mM 
Tris-HCl containing 1% Triton X-100, 5mM CaCl2 and 1µM ZnCl2) at 37°C. During 
this incubation, the concentrated renatured MMPs will digest the substrate. After 
incubation, the gel is stained in Coomassie brilliant blue, the MMPs are detected as 
clear bands against a blue background of undegraded substrate. Images were acquired 
with a ChemidocMP imaging system (Bio-Rad) and analysed using ImageJ (NIH).  
Page | 117  
 
3.3 Immunofluorescence & Immunophenotyping  
3.3.1 Immunofluorescence on tissues 
Brains were collected from mice, fixed and stored (described in section 3.1.2) until 
ready for staining. Fixed brain tissue was cut using a vibratome (Leica Microsystems) 
into 30-35µm thick sagittal sections at 200µM internals. Brain slices were stored in 
0.002% PFA in PBS at 4°C. Approximately 60-120 sections/hemisphere were cut 
using the vibratome. Staining was carried out in an IF chamber that was kept moist at 
all times. First, tissue slices were permeabilised using 0.5% Triton X-100 in PBS+/+ 
for 40 minutes at RT followed by 3 washes using PBS+/+. Next tissue slices were 
blocked with immunofluorescence buffer (1% BSA & 2% FBS in PBS+/+ for 40 
minutes at RT. Primary antibody staining was carried out using 200µL 
immunofluorescence buffer overnight at 4°C, tissues sections were washed 3 times 
using PBS+/+ and the secondary antibody was added in 200µL immunofluorescence 
buffer for 40 minutes at RT.  Following a further 3 washes using PBS+/+, sections were 
counterstained for nuclei using TO-PRO3. Finally, the sections were mounted on 
SuperFrost slides (Menzel). Vectashield coverslips were applied using mounting 
medium (Vector Laboratories). Slides were allowed to cure overnight at RT, for long-
term storage, slides were stored at 4°C. Antibodies used are shown in Table 3.4 and 
Table 3.5.  
Sections were examined using a confocal laser scanning microscope Leica TCS SP5 
(Leica Microsystems) using a sequential scan procedure. Confocal images were taken 
at 0.35µm intervals through the x-, y-, and z- axes of the section with 40x and 63x oil 
lenses. Fluorescence intensity analysis was performed by two independent observers 
on ten randomly selected fields at the 63x magnification using Cell F image analysis 
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Claudin-5 Mouse  1:100 Invitrogen 35-2500 
Occludin Mouse  1:100 Invitrogen 33-1500 
Pan-
laminin 
Rabbit 1:100 Sigma-Aldrich L9393 
Laminin α4 Mouse  1:1000 Novus Biologicals NBP-42393 
Laminin α1 Rabbit 1:1000 LifeSpan 
BioSciences 
LS-C119557 
GFAP Rat 1:100 Invitrogen I3-0300 
ICAM-1 Rat 1:100 Novus Biologicals NBP2-12360 
P-selectin Rabbit 1:100 LifeSpan 
BioSciences 
LS-B3578 
CD45 Rat 1:100 Bio-Rad MCA 
Iba1 Goat 1:100 Abcam ab5076 


















AF488 1:500 Invitrogen A11001 Claudin-5, 
Occludin, 




AF488 1:500 Invitrogen A11070 P-selectin 
Goat anti-
rat IgG 
AF488 1:500 Invitrogen A11006 ICAM-1 
Goat anti-
rabbit IgG 




AF568 1:500 Invitrogen A11057 Iba1 
Goat anti-
rat IgG 
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3.3.2 Flow Cytometry - Fluorescence-activated cell sorting (FACS)  
Collected cells were placed in FACS tubes and washed using FACS buffer (2% BSA 
in PBS+/+); samples were vortexed and centrifuged at 1800rpm for 5 minutes at 4°C. 
The supernatant was discarded, and the cells were fixed using 100µL of 2% PFA for 
10 minutes at RT. Cells which required live-imaging e.g. for metabolism monitoring 
were not fixed, but instead staining was carried out on ice. Fractions were topped up 
200µL of FACS buffer vortexed and centrifuged at 1800rpm for 5 minutes at 4°C. The 
supernatant was discarded, and antibody staining was conducted.  
 
3.3.2.1 Cell surface staining  
Samples which were being stained for cell surface markers were stained using a 
primary antibody in 100µL of FACS buffer/tube; cells were incubated in the dark at 
RT for 20-30 minutes. After 20-30 minutes, each of the tubes was topped up with 
300µL FACS buffer and centrifuged as before. Any primary antibodies that were not 
conjugated, required secondary antibody staining. This was carried out in 100µL of 
FACS buffer/tube; cells were incubated in the dark at RT for 20-30 minutes. After 20-
30 minutes, each of the tubes was topped up with 200µL FACS buffer and centrifuged 
as before. Antibodies used are shown in Table 3.6 and Table 3.7.  
 
3.3.2.2 Intracellular staining 
Cells that were stained for intracellular markers required permeabilisation to open up 
the cellular membrane. Any cell surface marker staining was conducted prior to 
permeabilisation. 
The BD Bioscience Mouse FoxP3 buffer kit was used for permeabilisation. The 
permeabilisation buffer was diluted 1:5 in PBS-/- and 200µL of permeabilisation buffer 
was added to each tube, vortexed and incubated for 30 minutes in the dark at RT. After 
30 minutes, 2mL of FACS buffer was added to each tube, vortexed and centrifuged at 
1800rpm for 5 minutes at 4°C. The supernatant was discarded, and antibodies were 
added in 100µl of FACS buffer/tube; cells were incubated in the dark at RT for 20-30 
minutes. After 20-30 minutes, each of the tubes was topped up with 200µL FACS 
buffer and centrifuged as before.  
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Once all staining was conducted, cell pellets was re-suspended in 200µL of PBS+/+ 
ready for FACS analysis; tubes were stored at 4°C. Analysis of flow cytometry was 
performed using a BD LSR Fortessa (BD, Biosciences). Compensation was conducted 
and applied to panels to ensure there was minimal spectral overlap. In general, 
approximately 100,000 viable cells were collected from all samples, after which a 
gating strategy was applied. FlowJo (BD Biosciences, UK) was used to analyse data. 
Data was presented as median intensity of fluorescence (MFI), as cell percentages or 
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Ly6G FITC 1:200 Abcam ab25024 
F4/80 PE-Cy7 1:200 Biolegend 123114 
CD11c APC-Cy7 1:200 Biolegend 117311  
CD11b PE-Cy7 1:200 Biolegend 101208 
NK1.1 BV421 1:200 Biolegend 108731 
CD45 APC-Cy7 1:200 Biolegend 103116  
CD3 - 1:200 eBioscience 10-0032-85 
CD4 PE-Cy7 1:200 Biolegend 552775 
CD8 BV450 1:200 Biolegend 100741 
CD19 APC 1:200 eBioscience 17-0193-82 
CD25 BB515 1:200 BD Horizon 564424 
CD44  BV421 1:200 BD Horizon 563970 
LFA1 PE 1:200 eBioscience 12-0111-82 
CXCR31 PE 1:200 Biolegend 126505  
CD62L BB515 1:200 BD Horizon 565261 
CCR7 AF647 1:200 BD 
Pharmingen 
560766 
CX3CR1 BV711 1:200 Biolegend 149031 
MHC II BV421 1:200 Biolegend 107631 
CD86  PE-Cy7 1:200 Biolegend 105116 
CD206 BV785 1:200 Biolegend 141729 
ICAM-1 APC 1:100 Biolegend 116119 
VCAM-1 Pacific blue 1:100 Biolegend 105722 
Occludin AF488 1:100 ThemoFisher 
Scientific 
33-1500 
PECAM-1 AF488 1:100 eBioscience 11-0311-81 
VE-
Cadherin 
- 1:100 Abcam ab33168 
CD220 APC 1:100 R&D Systems FAB1544A 
GLUT-1 - 1:100 Abcam ab653 
Pgp 
transporter 
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1:100 Invitrogen p31585 CD3 
Goat anti-
rabbit IgG 





























FoxP3 AF647 1:100 BD 
Pharmingen 
560401 
RoRγt BV421 1:100 BD Horizon 562894 
Phalloidin 
 (F-actin) 
AF568 1:40 ThermoFisher A12380 
DNase1  
(G-actin) 
AF488 1:1800 ThermoFisher A11096 
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3.4 Measuring cellular metabolism 
Metabolism is a critical component of all cells playing a role in activation, 
proliferation, differentiation, apoptosis, and disease. Using Agilent Seahorse XF 
technology, the glycolytic and mitochondrial function (oxidative phosphorylation, 
OxPhos) of bEnd3 cells stimulated with mouse serum was investigated. 
Briefly, a 96-well Seahorse culture plate was coated with 50µL 0.1% gelatin/well 
(1:20 dilution in PBS-/-) and incubated for 30 minutes in 10% CO2, the plate was 
washed with PBS-/- prior to the addition of cells. bEnd3 cells were harvested and plated 
in a density of 15,000 cells/well in 200µL of bEnd3 medium. Wells A1, A8, L1 and 
L8 did not have cells seeded as these wells are used by the Seahorse XFe96 Analyzer 
(Agilent Technologies) to calculate the background.  
bEnd3 cells were left to grow for 3 days to ensure an even and confluent monolayer 
was formed, after which cells were serum stimulated. pMBMECs were left to grow 
for 4 days. The day before the assay, a Seahorse utility plate was filled with 
180µL/well of calibrant solution (Seahorse, Agilent Technologies). A sensor cartridge 
was lowered onto the utility plate to submerge the sensors in calibrant. The cartridge 
plate was placed at 37°C in a non-CO2 incubator overnight. The following day, the 
medium was aspirated from the cell culture plate and replaced with 180µL/well of 
assay medium, the plate was transferred to the non-CO2 incubator to stabilize the 
conditions of the cells with the medium and absence of CO2 for 1-2 hours.  
The assay medium was prepared by supplementing the Seahorse XF Base Medium 
with the requirements for each kit: 
• For glycolytic function - 1mM of glutamine was added 
• For mitochondrial function -1 mM sodium pyruvate, 2 mM glutamine and 10 
mM glucose were added 
The assay medium for each kit was adjusted to pH 7.4 and filter sterilized before use.  
In the meantime, the drugs for each kit were prepared and loaded into the cartridge. 
Each vial of drug was diluted with 3mL of the respective assay medium for the assay. 
All drugs were protected from light and stored at 4°C once prepared. The drugs were 
loaded into the cartridge using the ports provided in the kit, and the cartridge was 
Page | 124  
 
returned to the CO2-free incubator for a further 30 minutes. Table 3.9 shows the port 
and volume of drugs loaded per assay. 
After 30 minutes, the calibration of the Seahorse XFe Analyzer was initiated, the cells 
were placed into the machine when prompted and the experiment was allowed to run. 
After running the assay, the data was normalized to protein concentration. Analysis 
was conducted using Wave Software 2.3 (Agilent Technologies) and Microsoft Excel.  
 
Table 3.9 | Name, concentration and volume of the drugs used in the glycolysis and 
oxidative phosphorylation metabolism assay 
Glycolysis - ECAR 
Port Drug Final 
Concentration 
Volume added to 
port 
A Glucose 10mM 20 
B Oligomycin 1µM 20 
C 2DG 50mM 25 
 
Mitochondrial respiration (OxPhos) - OCR 
Port Drug Final 
Concentration 
Volume added to 
port 
A Oligomycin 1µM 20 
B FCCP 0.5µM 22 







3.4.1 Glycolytic Function 
The glycolytic function of cells was determined by measuring the extracellular 
acidification rate (ECAR), which is the extrusion of protons, produced by glucose 
conversion to pyruvate and lactate, into the extracellular medium. A Seahorse XF 
Glycolysis Stress Test Kit (Agilent Technologies) was used to assess the parameters 
of glycolytic flux including basal glycolysis, glycolytic capacity, glycolytic reserve, 
and the non-glycolytic acidification (Figure 3.5). 
The assay works by initially incubating the cells in glycolysis stress test assay medium 
that lacks glucose or pyruvate to determine the non-glycolytic acidification, which is 
caused by processes other than glycolysis. The first injection given is a saturating 
concentration of glucose to determine glycolysis of the cells under basal conditions. 
The second injection given is oligomycin, an ATP synthase inhibitor that blocks 
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mitochondrial ATP production thereby shifting all energy production to glycolysis. 
This determines the maximum glycolytic capacity of the cells. The glycolytic reserve 
is the difference between the cells maximum capacity and the basal rate of glycolysis; 
it serves to indicate if the cells are capable to respond to an energetic demand and also 
how close the basal rate of glycolysis is to the theoretical maximum. The third 
injection given is 2-deoxyglucose (2-DG), a glucose analogue that inhibits glycolysis 
by binding to the first enzyme in the glycolytic pathway – hexokinase. The subsequent 
decrease after 2-DG serves to confirm that ECAR production in the experiment was 
due to glycolysis.  
 
 
                             
Figure 3.6 | Glycolytic Function Stress Test 
The graph shows the expected profile to be obtained when conducting the Glycolysis 
Stress Test. Injections are added sequentially to determine basal glycolysis, glycolytic 
capacity, glycolytic reserve, and non-glycolytic acidification. Figure taken from 
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After running the assay, the ECAR data was normalized to protein concentration 
which could be used to calculate each parameter by using the equation in Table 3.10. 
 
Table 3.10 | Equations used to calculate the different parameters for assessing glycolytic 
function 
Parameter value Equation 
Glycolysis ECAR value after glucose injection – ECAR value 
after 2DG injection 
Glycolytic capacity ECAR value after oligomycin injection – ECAR 
value after 2DG injection 
Glycolytic reserve ECAR value after oligomycin injection – ECAR 
value after glucose injection 
Non-glycolytic 
acidification 




3.4.2 Mitochondrial function 
The mitochondrial function of cells was determined by measuring the oxygen 
consumption rate (OCR). A Seahorse XF Cell Mito Stress Test (Agilent Technologies) 
was used to assess the parameters of metabolic function including basal respiration, 
ATP production, proton leak, maximal respiration, spare respiratory capacity, and 
non-mitochondrial respiration (Figure 11). The assay works by initially incubating the 
cells in mito stress test assay medium supplemented with sodium pyruvate, glutamine, 
and glucose to determine basal respiration. The kit uses different compounds, which 
target various points of the ETC to modulate respiration. The first injection given is 
oligomycin that inhibits ATP synthase (complex V of the ETC), the resultant decrease 
in the OCR relates to the mitochondrial respiration that is used to drive cellular ATP 
production. The second injection is carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP), an uncoupling agent that collapses the proton gradient to 
disrupt the mitochondrial membrane production. The resultant increase in OCR is due 
to uncontrolled electron flow through the ETC, this serves to provide the maximal 
respiration or O2 consumption by complex IV. Maximal respiration is achieved by 
causing rapid oxidation of substrates such as sugars, fats & amino acids to meet an 
increased metabolic demand.  The third injection is a combination of rotenone and 
antimycin A that inhibit complexes I and III respectively, effectively shutting down 
mitochondrial respiration to determine non-mitochondrial associated respiration rate. 
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The proton leak is measure of any mitochondrial damage and the spare respiratory 
capacity is an indicator of a cell’s flexibility to respond to an increased energetic 
demand as well as showcasing how close the basal rate of respiration is to the 
theoretical maximum.      
 
 
                           
 
Figure 3.7 | Mitochondrial (Oxidative Phosphorylation) Stress Test 
The graph shows the expected profile to be obtained when conducting the Mito Stress 
Test. Injections are added sequentially to determine basal respiration, ATP production, 
proton leak, maximal respiration, spare respiratory capacity, and non-mitochondrial 
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After running the assay, the OCR data was normalized to protein concentration, which 
could be used to calculate each parameter by using the equations in Table 3.11.  
 
Table 3.11 | Equations used to calculate the different parameters for assessing 
mitochondrial function in the Mito Stress Test  
 
Parameter value Equation 
Basal respiration OCR value prior to oligomycin injection – OCR value 
after Rotenone/Antimycin A injection 
ATP production OCR value prior to oligomycin injection – OCR value 
after oligomycin injection 
Proton leak OCR value after oligomycin injection – OCR value after 
Rotenone/Antimycin A injection 
Maximal respiration OCR value after FCCP injection – OCR value after 
Rotenone/Antimycin injection 
Spare capacity OCR value after FCCP – OCR value prior to oligomycin 
Non-mitochondrial 
respiration 






3.4.3 Glucose uptake 
bEnd3 cells were cultured in 24 well plates for 72 hours to form confluent monolayers. 
Once confluency had been reached, cells were stimulated overnight with 200µL of 
mouse serum. The following day, cells were washed with 200µL PBS-/- and collected 
in FACS tubes using 5mM EDTA. Cells were washed with FACS buffer and 
resuspended in 200µL/tube of glucose-free culture medium for 1 hour at 37°C in a 5% 
CO2 incubator. Glucose uptake was measured using 6-NBDG (a fluorescent 
nonhydrolyzable glucose analogue) at a final concentration of 20µM made in FACS 
buffer. Cells were incubated with 6-NBDG for 20 minutes at 37°C. After staining, 
cells were washed with FACS buffer, centrifuged for 5 minutes at 1800rpm and 
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3.4.4 ATP production 
ATP is a marker of cell viability; it is present in all metabolically active cells. The 
ATPLite Detection Assay kit (Perkin Elmer) was used to measure ATP production. 
Briefly, a 96-well black-bottom plate was coated with 50µL 0.1% gelatin/well (1:20 
dilution in PBS-/-) and incubated for 30 minutes in 10% CO2, the plate was washed 
with PBS-/- prior to the addition of cells. bEnd3 cells were harvested and plated in a 
density of 15,000 cells/well in 200µL of bEnd3 medium and grown for 72 hours. The 
cells were stimulated overnight with 100µL medium containing 10% mouse serum. 
On the day of the assay, reagents were equilibrated to RT. Lyophilised substrate 
solution was reconstituted, as per manufacturers instruction, by adding 5mL of 
substrate buffer to one vial. A standard was constructed using the ATP stock solution 
(10mM); concentration of 0.1µM to 5µM were made up in dH2O. To all wells, 
50µL/well of mammalian cells lysis solution was added, the plate was placed on an 
orbital shaker for 5 minutes at 700rpm. In the standard wells, 10µL of the ATP 
standard dilution series was added, the plate was placed on an orbital shaker for 5 
minutes at 700rpm. To all wells, 50µL/well of substrate cells lysis solution was added, 
the plate was placed on an orbital shaker for 5 minutes at 700rpm. The plate was dark-
adapted for 10 minutes, the luminescence was read (1 sec/well) on a plate reader 
(Infinite M200 PRO plate reader, TECAN). The concentration value was extrapolated 
using the standard curve. 
 
 
3.4.5 DCFDA – cellular ROS 
Cellular ROS was measured using the DCFDA kit (Abcam). The kit uses the cell 
permeant reagent 2’, 7’ – dichlorofluorescin diacetate (DCFDA), a fluorogenic dye 
that measure the hydroxyl, peroxyl and other ROS species activity within the cell. 
Briefly, a 96-well black-bottom plate was coated with 50µL 0.1% gelatin/well (1:20 
dilution in PBS-/-) and incubated for 30 minutes in 10% CO2, the plate was washed 
with PBS-/- prior to the addition of cells. bEnd3 cells were harvested and plated in a 
density of 15,000 cells/well in 200µL of bEnd3 medium and grown for 72 hours. On 
the 3rd day, cells were serum starved overnight in medium without phenol-red. The 
following day, cells were washed in 100µL 1X buffer. The cells were stained with 
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25µM DCFDA (100µL/well), prepared in 1X buffer for 45 minutes at 37°C. Following 
incubation with DCFDA, the cells were washed and replaced with fresh medium 
containing 10% mouse serum; cells were stimulated for 6 hours. The production of 
ROS was measured using a plate reader at 37°C, Ex/Em = 485nm/535nm. 
 
 
3.4.6 MitoSOX Red – mitochondrial superoxide indicator  
MitoSOX Red permeates live cells and selectively targets mitochondria. It is rapidly 
oxidised by superoxide but not by other ROS or reactive nitrogen species (RNS). The 
oxidised product is highly fluorescent upon binding to nucleic acid; therefore, the 
accumulation of dye positively correlates with increased mitochondrial superoxide 
production and is a marker of oxidative stress.  
Briefly, a 96-well black-bottom plate was coated with 50µL 0.1% gelatin/well (1:20 
dilution in PBS-/-) and incubated for 30 minutes in 10% CO2, the plate was washed 
with PBS-/- prior to the addition of cells. bEnd3 cells were harvested and plated in a 
density of 15,000 cells/well in 200µL of bEnd3 medium and grown for 72 hours. On 
the 3rd day, cells were serum starved overnight in medium without phenol-red. The 
following day, cells were incubated with 2µM of MitoSOX in phenol red-free medium 
at 37°C. The mitochondrial respiratory chain complex I inhibitor rotenone was used 
as a positive control, used at a concentration of 2.5µM. The medium was aspirated and 
replaced with fresh medium containing 10% serum; cells were stimulated for 6 hours. 
The production of mitochondrial superoxide was measured using a plate reader at 
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3.5 Statistical Analysis 
All data are presented as mean ± standard error of mean (SEM) of n observations, 
where n denotes the number of animals studied. The numbers of animals used, repeats 
per carried out per experimental procedure and/or technical replicates have been 
reported in each figure legend. Outliers were identified on Microsoft Excel using the 
Interquartile Range (IQR). Briefly, data is divided into quartiles: 
• 1st quartile, Q1 – 25% of the data are less than or equal to this value 
• 3rd quartile, Q3 – 25% of the data are greater than or equal to this value 
• IQR – 50% of the data, calculated as the difference between Q3 – Q1 
Outliers are defined as any values that fall outside of the range of the following 
equations: 
• Q1 – (1.5 x IQR) or Q3 + (1.5 x IQR) 
All statistical analysis was conducted using GraphPad Prism 8 (GraphPad Software, 
San Diego, California, USA). All data was tested for normality and analysed by a 
student’s t-test, Mann-Whitney U test or one-way ANOVA for multiple comparisons 
with post-hoc analysis using Bonferonni's. Significance is indicated as *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 vs chow or $p<0.05, $$p<0.01, $$$p<0.001, 
$$$$p<0.0001 vs HFHS or #p<0.05, ##p<0.01, ###p<0.001, ####p<0.0001 vs HFHS 



































Chapter 4 – The impact of MetS/T2DM at the BBB: 
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4.1 Introduction  
Animal models are regularly used to investigate T2DM pathophysiology and its 
secondary complications, as a well as evaluate potential therapeutic treatments and 
preventive strategies (504). In order for an animal model to be relevant in the study of 
T2DM in humans, the animal model should mirror the aetiology and pathophysiology 
of T2DM seen in the human condition. T2DM is closely linked to obesity and therefore 
the majority of animal models of T2DM are obese. Obesity is the single biggest risk 
factor for developing T2DM, with research suggesting that obese individuals are 80 
times more likely to develop T2DM than non-obese individuals (311). Obesity raises 
the levels of fatty acids, glucose, pro-inflammatory markers and alters hormones and 
metabolism due to the accumulation of fat deposition, leading to the development of 
insulin resistance (460). Insulin resistance presents with an impairment in β-cell 
function; the continued decline of β-cell function with inadequate insulin production 
causes a loss of glucose control resulting in T2DM (379). Due to this continuum 
between obesity, insulin resistance and T2DM, research into metabolic disorders is 
based across the spectrum of these stages. Of course, in humans it is far easier to assess 
the stage of the disease, as this is progressive and long-term. Weight loss and reducing 
BMI are therefore key in preventing T2DM development (347). In comparison, in 
rodents the definition of each stage is not as easily determined. 
 
The major ways to induce development of T2DM in rodents is via genetic 
manipulation (monogenic or polygenic) or through diet by feeding on primarily high 
fat (505) which causes obesity and insulin resistance (468). 
The most common monogenic models of T2DM are defective in leptin signalling. 
Leptin is  a satiety hormone and therefore lack of functional leptin removes the 
‘hunger’ control mechanism to induce excessive food consumption that ultimately 
results in obesity (506). These models include the Leptin ob/ob mouse which are 
deficient in leptin or the Leptin db/db mice and Zucker Diabetic Fatty rats which are 
deficient in the leptin receptor (506).  
Notably, obesity in human is rarely caused by a monogenic mutation and therefore 
polygenic models of obesity, glucose intolerance and T2DM may provide a more 
accurate model of the human condition in which a more varied approach is used. These 
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polygenic models include KK mice, OLETF rat, NZO mice, TallyHo/Ing mice and 
NoncNZO10/LtJ mice (504). Nonetheless polygenic models are still unable to mimic 
the multifaceted nature of the disease in humans, in which over 50 genes have been 
identified to play a role in inducing T2DM (507). Moreover, the polygenic models do 
not have a true wild-type control and the male sex bias is more extreme (508).  
 
In this study, we used a diet-induced mouse model of T2DM, fed a combination of 
high-fat and high-sugar. Diet-induced diabetic models work through causing obesity 
from imbalanced food intake and low energy expenditure (459). The diet-induced 
models of diabetes are used to replicate the westernised lifestyle in humans, with 
increased intake of foods dense in fats and sugars along with a sedentary lifestyle. 
Since the obesity is induced by environmental manipulation rather than genes, diet-
induced models are thought to mimic the human condition more accurately that 
genetic models of obesity-induced diabetes (461).  
Numerous studies have examined the effect of high-fat feeding in rodent models 
(459,462,463); of the strains tested the C57BL/6 mouse progression of metabolic 
abnormalities parallels the dysfunction seen in humans. The model of high-fat feeding 
in C56BL/6J mice was first described in 1988 (464). A high-fat (58%) diet in these 
mice has clearly shown to cause weight gain, insulin resistance and hyperglycaemia 
in comparison to mice fed a chow-diet (11% fat) (465). Furthermore studies have 
found male mice to be more prone to the development of diabetes in comparison to 
females (466). Obesity inevitably leads to metabolic syndrome that can progress to 
T2DM and hence the C57BL/6 male diet-induced obese mouse model is highly 
suitable for our investigations (467,468) 
Importantly, to date, no single standard protocol of high fat induced T2DM has been 
established. Within the literature, there are a vast variety of protocols with variations 
in mouse strains, formulation of high fats (fat fractions ranging from 20-60%), 
duration of feeding periods (ranging from a few weeks to more than one year) and age 
of mice at induction of diet (469,470). Importantly, it is not just the percentage of fat 
but the origin and exact composition of fat which can induce different biological 
responses, for example animal-derived fat or saturated fatty acids are more obesogenic 
compared to plant-derived (e.g. coconut oil) or unsaturated fatty acids (509,510).  
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In this particular study, a combination of high-fat and high-sugar (fat 59.4%, 
carbohydrate 25.7 %, protein 14.9%) was used (see Table 3.1 for full composition) 
compared to a standard chow diet (fat 13.2%, carbohydrate 62.3 %, protein 24.5%). 
This HFHS diet was used to closely mimic consumption of a high-fat, high-sugar and 
energy dense diet seen in modern day society. The C57BL/6 strain was used as the B6 
mouse has been shown to be a good model for mimicking the multi-factorial nature 
and progression of MetS/T2DM as seen in humans, through the development of 
obesity, hyperglycaemia, hyperinsulinemia and hypertension when fed a HF diet ad 
libitum. In comparison, when fed a chow diet ad libitum, the B6 mouse model remains 
lean (467,511).   
Moreover, we have previously established this particular mouse model of HFHS in 
our lab for inducing T2DM related secondary complications and cardiomyopathy with 
a feeding period between 10-16 weeks (473–475). In particular, using the same 10-
week feeding model used in the current study, previously results have shown HFHS-
feeding caused hepatosteatosis resulting in liver injury, seen through lipid deposition 
and accumulation in the liver  (512). Additionally, HFHS-feeding induced renal 
dysfunction as seen through decreased creatinine clearance resulting in proteinuria and 
vacuolar degeneration in the kidney (512). The ability of HFHS-feeding to induce 
microvascular complications in the peripheral systems suggests that this model is 
efficient in producing a low-grade chronic inflammatory state, as seen in conditions 
of MetS/T2DM, thereby making it viable to use for the aims of this thesis.   
 
4.1.1 Aims and objectives 
The focus of this chapter was to investigate how metabolic disorder-induced 
inflammation, termed metaflammation, can disrupt the BBB, with focus on alterations 
to the structural and immunological integrity of the barrier.  
The chapter addresses the first hypothesis mentioned in Chapter 2, this is as follows: 
 Hypothesis 1:  
It is hypothesised that metaflammation arising in T2DM will result in a leaky 
BBB phenotype resulting in the infiltration of immune cells from the 
peripheral side into the brain parenchyma to cause neuroinflammation. 
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This chapter addresses Aims 1 & 2 mentioned in Chapter 2, these are as follows:  
 
1. To characterize the early vascular defects occurring in the BBB during HFHS-
feeding in vivo, ex vivo and in vitro. 
o Identify the functional changes occurring to the BBB through 
measuring vascular leakage. 
o Identify structural alterations through immuno-histochemical analysis 
of brain endothelium junctional proteins, BM components and the 
cytoskeleton. 
 
2. To define the pathogenic events leading to cerebrovascular damage at the BBB 
induced by HFHS-feeding.  
o Examine the role of inflammatory mediators and soluble factors 
present in the sera such as cytokines, chemokines, interleukins, 
metabolic factors, extracellular matrix components, on inducing BBB 
permeability and endothelial dysfunction.  
o Define the effect of metabolic disorders on the innate and adaptive 
arms of the peripheral immune system. Determine whether the priming 
of immune cells within the peripheral system can correlate with the 
transmigration across the BBB and subsequently activate the microglia, 
the resident immune cell of the CNS to initiate neuroinflammation in a 
diabetic state. 
 
The following objectives were covered in this chapter to address these aims: 
• To induce T2DM in mice via diet by feeding mice on a HFHS-diet for 10-
weeks 
• To measure disruption of BBB integrity (vascular leakage) using in vivo Evans 
blue dye and ex vivo/in vitro via measuring the paracellular permeability 
coefficient and TEER.  
• To imaging structural alterations occurring at the BBB via confocal 
microscopy of cerebral cortical mouse brain sections for expression of 
junctional proteins occludin and claudin-5 and endothelial and astrocytic BM 
laminins, α4 and α5.  
Page | 137  
 
• To determine the role played by MMPs and their inhibitor, TIMP-1 in BBB 
degradation through measurement of expression and activity.  
• To compare the inflammatory profile in chow and HFHS-fed mice via 
examination of cytokines, interleukins and chemokines. 
• To determine whether the endothelial cells become activated by 
metaflammation and expression adhesion molecules. 
• To phenotype the activation of the innate and adaptive immune cells in bone 
marrow and cervical lymph nodes. 
• To characterise, using FACS, the effect of HFHS-induced T2DM on CD4+ Teff, 
TCM, TEM, TH17 and Treg cells present in cervical lymph nodes.  
• To image the infiltration of CD45+ leukocytes cells into the brain parenchyma, 
and classify the different CD4+ T-cell phenotypes migrating across the BBB 
using an in vitro model.  
• To characterise the effect of HFHS-induced T2DM on microglia cell activation 
and microglia M1 or M2 phenotype via FACS analysis of primary microglia 
cultures and imaging cerebral cortical brain sections.  
• To characterise the initiation of neuroinflammation through measuring 
expression of iNOS in the brain parenchyma using confocal microscopy.  
 
In order to study these aims, 10-week old male C57BL/6 mice were fed either a 
standard chow-based diet (5053, LabDiet Ltd) or a HFHS diet (58R3, TestDiet Ltd) 
for 10 weeks. The latter was used to induce diet induced T2DM. Both chow and 
HFHS-fed mice were 20-weeks old at cull. A summary of the experimental groups, 
experimental plan and the methods used to quantify each measure have been provided 
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Table 4.1 | Experimental groups used to establish a mouse model of diet induced T2DM  
Group name 
and age 
Diet and period 
of time 
Treatment and 










from weeks 1 - 10 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 






from weeks 1 - 10 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 






Figure 4.1 | Summary of the experimental plan used to establish diet induced T2DM  
10-week old male C57BL/6 mice were fed either a chow or HFHS for 10 weeks. From week 
5, mice were injected with a sham injection of 100µL Hepes/NaCl, 5 times/week via 
intraperitoneal (i.p.) injection for 6 weeks. Assessment for glucose tolerance and insulin 
resistance were conducted via oral glucose tolerance tests (OGTT) and insulin tolerance tests 
(ITT) respectively. Mice were culled at the beginning of week 11. Confirmation of T2DM was 
made by weight and various blood/serum analyses. At cull, blood, brain, lymph nodes and 
bone marrow were collected.  
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Table 4.2 | Summary of the central and individual measures used to evaluate the aims 
and objectives of Chapter 4, with reference to the respective methodology used to 
conduct these experiments. 





Obesity - weight gain and fat pads  3.1.1.1, 3.1.2 
& 3.1.3 




Hyperinsulinaemia - ITT, serum insulin 3.1.1.1, 3.1.2 
& 3.1.4 






Evans blue dye leakage in vivo 3.1.7 & 3.1.8 
Paracellular permeability in vitro 3.1.9 & 3.2.5 
TEER 3.1.9 & 3.2.6 
BBB structure 
Imaging junctional proteins occludin and 
claudin-5 
3.1.3 & 3.3.1 
Imaging BM laminins α4 and α2 3.1.3 & 3.3.1 
MMP 
involvement 
MMP-2, -3, -9 expression at brain 
microvessels via cytokine array 
3.1.9 & 3.2.8 




TIMP-1 ELISA 3.2.8 
Inflammatory 
profile 
Cytokine array for interleukins, chemokines, 
cytokines in serum and brain microvessels 
3.2.8 
Imaging and characterising adhesion 
molecule expression at BBB 
3.2.8 & 3.4.3 
Immuno- 
phenotyping 
Cell frequency of innate and adaptive 
immune cells in bone marrow and deep 
cervical lymph nodes 
3.1.3, 3.1.5, 
3.1.6, 3.4.3 
CD4+ T-cell activation for Teff 3.1.3 & 3.4.3 
TCM vs TEM  3.1.3 & 3.4.3 
TH17 vs Treg 3.1.3 & 3.4.3 
Leukocyte TEM 
across BBB 
Imaging CD45 infiltration into brain 
parenchyma 
3.1.3 & 3.3.1 









Imaging IBA1 activated microglia cells  3.1.3 & 3.3.1 
Imaging for iNOS expression 3.1.3 & 3.3.1 
Page | 140  
 
4.2 Results: In vivo & ex vivo 
4.2.1 Induction of MetS/T2DM in a mouse model 
Confirmation of metabolic disruption (obesity, hyperglycaemia, dyslipidaemia and 
insulin resistance) in this mouse model was conducted by measurements of weight 
gain, fat mass (epididymal & inguinal), fasting and non-fasting blood glucose, OGTT 
and ITT as well as serum insulin, cholesterol and triglyceride levels (Figure 4.2). At 
the end of the 10-week feeding period, mice fed a HFHS diet presented with 
significantly increased body weight (Figure 4.2A,D) and fat mass (Figure 4.2E,F) in 
comparison to mice fed a chow diet. All mice fed a HFHS diet had lower food intake 
than chow-fed mice, however the calorific intake of the HFHS diet was substantially 
higher than the chow diet (Fig 4.2B,C) 
Tests for hyperglycaemia found raised non-fasted and fasted blood glucose levels in 
HFHS-fed mice when compared to chow-fed mice (Figure 4.2G,J). Insulin resistance 
was confirmed using OGTT and ITT; measurement of the area under the curve (AUC) 
in both tests found HFHS-fed mice to have an impaired insulin response compared to 
chow-fed mice (Figure 4.2H-L). Although notably, the ITT in HFHS-fed mice was not 
significant, which may have been due to small n numbers of 6 vs 48 in OGTT. 
Similarly, serum insulin levels were also elevated in HFHS-fed mice compared to 
chow-fed mice (Figure 4.2M).  HFHS-fed mice were also found to have 
hyperlipidaemia, as seen by elevated serum cholesterol and triglyceride levels 
compared to chow-fed mice (Figure 4.2N,O).  
Conclusively the HFHS diet induced obesity and contributed to the development of 
MetS/T2DM as noted by hyperglycaemia, hyperinsulinemia, hypercholesterolemia, 
and hypertriglyceridemia.  
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Figure 4.2 | Characteristics of mice fed a chow or HFHS diet for 10 weeks 
C57BL/6 male mice were fed either a chow or HFHS diet for 10 weeks; n=55/group. Food 
(B) and calorific intake (C) was recorded (n=10/group). Weekly body weight measurements 
(A), final body weight gain (D) and epididymal (E) & inguinal fat mass (F) was recorded to 
confirm obesity onset; n=54-55/group. Non-fasting (G; n=38/group) and fasting (J; n=39-
40/group) blood glucose was measured to confirm hyperglycaemia. Serum insulin levels (M; 
n=22-23/group), glucose (H, I; n=38/group) and insulin tolerance testing (K, L; n=6) was 
conducted to confirm insulin resistance. Serum cholesterol (N) and serum triglycerides (O) 
levels were measured to confirm hypercholesterolemia and hypertriglyceridemia (n=11-
16/group). Statistical analysis was performed by either an Independent Student’s T-test or 
Mann-Whitney U test. Data is expressed as mean ± SEM., *p< 0.05, **p<0.01, ***p<0.001, 
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4.2.2 Effect of metabolic overload on the integrity of the BBB  
A central function of the BBB is to restrict and control the entry and exit of molecules 
such as nutrients, enzymes, hormones, and waste products. The endothelial TJs 
maintain strict control of paracellular permeability movement; instead the plasma 
membranes of brain endothelial cells are lined with transporters, carriers and ion 
channels (513). The contractile and adhesive forces produced by the endothelial 
cytoskeleton and cell-cell junctions respectively maintain the paracellular 
permeability of the BBB (220,514). The first assessment in this study therefore 
required investigating whether metabolic overload could perturb the adhesive 
properties of the junctions to create intracellular gaps, thereby increasing the 
permeability of the BBB and altering its integrity as a barrier. 
 
4.2.2.1 Measuring permeability in vivo using Evans blue dye 
Evans blue dye was used to assess the permeability of the BBB in vivo. The dye was 
injected into the tail vein of all mice and allowed to circulate for 1 hour. 
Spectrophotometer analysis of the brain dye content revealed a significantly greater 
leakage of the BBB by almost 3-fold in HFHS-fed mice in comparison to chow-fed 
mice (Figure 4.3A). 
 
4.2.2.2 Ex vivo analysis of paracellular permeability & TEER 
To further investigate the abnormal permeability observed in vivo and depict any 
molecular change at the endothelium level, pMBMECs were isolated and cultured 
from the two different experimental mice groups, as well as from an additional group 
of 6-week old male mice fed a chow diet. These 6-week old mice vs 20-week old mice 
represented a young vs aged phenotype to determine the change in BBB integrity as a 
factor of time (age). When comparing the effects of age, young chow-fed mice had the 
lowest permeability coefficient, and this was statistically significant when compared 
to older chow-fed mice (Figure 4.3B). The young chow fed-mice had the highest 
TEER, which was significant when compared to older chow-fed mice (Figure 4.3C).   
When comparing the HFHS-fed mice to their age-matched chow-fed counterparts, it 
was seen that a diabetic phenotype further increased paracellular permeability (Figure 
4.3B) and further reduced the TEER (Figure 4.3C). 
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Figure 4.3 | Measuring permeability in vivo & ex vivo  
Assessment of BBB permeability in vivo was conducted using Evans blue dye extravasation 
into the brain (A). 100µl of 2% Evans blue dye was given i.v. to mice (n=6/group) and allowed 
to circulate for 1 hour. The dye content was analysed spectrophotometrically at an absorbance 
of 620nm, values were normalized to brain tissue weight and are expressed as percentage of 
serum dye content. Isolated and cultured pMBMECs from 20-week old chow-fed and 20-week 
old HFHS-fed  mice were grown on transwell inserts for 7 days to measure ex vivo paracellular 
permeability (B) and transendothelial electrical resistance (TEER) (C) using 70kDA FITC-
dextran and the Epithelial Volt/Ohm (EVOM2) Meter (World Precision Instruments, USA), 
respectively (n=10 pooled/group per experiment, two technical replicates, performed as three 
independent experiments with a total of n=30 per/group). pMBMECs were also isolated and 
cultured from young 6-week old male chow-fed mice against 20-week old chow-fed and 
HFHS-fed mice for a comparison of age-effect. Statistical analysis was performed by either 
an Independent Student’s T-test or One-Way ANOVA followed by a Bonferonni post-hoc 
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4.2.3 Imaging the structural changes occurring to the brain endothelial 
cells 
Increased BBB permeability results due to changes in the structural arrangement and 
interaction of the TJ and AJ proteins. It has been observed that these proteins undergo 
phosphorylation or modifications, resulting in their redistribution and reorganisation 
(225,515–517). As the results of this study highlighted that there was increase in the 
BBB permeability upon metabolic overload, the next part of the study aimed to 
examine whether this could be correlated to changes in the junctional proteins within 
the endothelial cells. Additionally, for immune cells and other cells or molecules to 
enter the brain parenchyma, there must be degradation of key components of BBB 
structure including the BM components and surrounding cells of the NVU. As 
described in section 1.3.4, the BMECs are surrounded by two distinct BMs (150). The 
first is the endothelial BM composed of laminin α4 and α5 and the second is the 
parenchymal BM composed of lamina α1 and α2 which attaches to the astrocytic end-
feet that ensheath the blood vessel (151,152). Therefore, in order to assess the impact 
of HFHS-induced T2DM on the BMs, staining was conducted for laminin forms 
present on both endothelial cells (laminin α4) and astrocytes (laminin α2). In order for 
immune cells, toxins or other molecules to enter into the CNS parenchyma, they must 
be able to transverse both BMs (4,248,249).  
 
 
4.2.3.1 Changes occurring to the junctional proteins of brain endothelium 
Immuno-histochemical analysis of TJ proteins claudin-5, occludin and vessel basal 
lamina (VBL) component pan-laminin was conducted on cerebral cortex microvessels 
of mice. Confocal microscopy analysis showed claudin-5 and occludin in chow-fed 
mice had a regular, linear and continuous pattern of staining along the microvessel 
along with intense VBL reactivity for pan-laminin (Figure 4.4A,B). In comparison, in 
HFHS-fed mice claudin-5 and occludin showed thinner linear TJ strands and reduced 
VBL pan-laminin reactivity (Figure 4.4A,B). The differences in junctional proteins 
and laminin staining was confirmed by quantification of fluorescence intensity, in 
which HFHS-fed mice has significantly lower amounts of claudin-5, occludin and 
laminin when compared to chow-fed mice.  
 





Figure 4.4 | Immuno-histochemical analysis of brain endothelium junctional proteins 
and flow cytometrical analysis of actin cytoskeleton 
Confocal microscopy of cerebral cortical sections of mouse brains double immune-labelled 
with claudin-5/pan-laminin (A) and occludin/pan-laminin (B). Nuclear counterstain with TO-
PRO3. Confocal images are representative images from n=4 mice/group, 35 section/animal 
(scale bar: 25µm). Quantification of staining shown as mean fluorescence intensity (arbitrary 
units) of markers on ten randomly selected fields. Flow cytometric analysis of G/F actin ratio 
in pMBMECs (C). Statistical analysis was performed by an Independent Student’s T-test. Data 
is expressed as mean ± SEM., **p<0.01, ***p<0.001.    
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4.2.3.2 Changes occurring to the basement membranes of endothelial cells & 
astrocytes 
The BM forms an integral part of BBB, therefore immuno-histochemical analysis of 
the BMs on endothelial cells of capillaries and astrocytes were conducted in cerebral 
cortical brain sections. Firstly, VBL component pan-laminin and endothelial laminin 
α4 was examined (Figure 4.5A). Chow-fed mice showed an intense expression of both 
laminin forms; however, it was noticeable that pan-laminin immunoreactivity 
prevailed on the outer VBL layer and showed limited co-localization with laminin α4. 
Laminin α4 staining was localised at the basal and the inter-endothelial sides 
suggestive of junctional-like immunostaining and diffused in the endothelial 
cytoplasm. In comparison, staining in HFHS-fed mice revealed substantive loss of 
immune-reactivity of both pan-laminin and laminin α4, which was confirmed by 
quantification. Importantly there was no change in the general distribution of the 
laminins.  
Astrocytes form close associations with endothelial cells of the BBB, ensheathing the 
cerebrovasculature to provide an added layer of protection. Hence double immune-
staining was conducted for the distribution and localisation of laminin α2 present on 
astrocyte end-feet and for laminin α4 on the endothelial cells (Figure 4.5B). In chow-
fed mice it can be seen that the astrocytic laminin α2 was localised on the outer vessel 
surface whereas the endothelial laminin α4 was present within the vessel, surrounding 
and between the cells. In chow-fed mice, the two laminins never co-localised however 
there was clear noticeable linear tract of both laminins suggesting an intact vessel 
morphology. In comparison, in HFHS-fed mice, both laminin α2 and α4 immuno-
reactivity was significantly reduced when compared to chow-fed counterparts, as 
quantified using mean fluorescence intensity.  
To further elucidate whether a HFHS diet induced structural changes to the BBB, 
staining for the presence and distribution of astrocytes was conducted using astrocytic 
marker GFAP in conjunction with the astrocytic laminin α2 (Figure 4.5C). In chow-
fed mice laminin α2 and GFAP showed clear co-localization, suggestive of astrocytic 
end-feet embracing the microvessel structure, forming an intact vessel. Astrocytes 
protruded from the vessel structure outward into the brain parenchyma. In contrast, in 
HFHS-fed mice where there was a loss of laminin α2, the astrocyte end-feet lost 
contact with the endothelial cells of the microvessel, indicative of loss of the BBB 
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structure and hence barrier properties. It is important to note, that whilst the mean 
fluorescence intensity of laminin α2 was significantly lower in HFHS-fed mice, the 






















Figure 4.5 | Immuno-histochemical analysis of basement membranes & astrocytes  
Confocal microscopy of cerebral cortical sections of mouse brains double immune-labelled 
with endothelial laminin α4/vascular basement membrane pan-laminin (A), endothelial 
laminin α4/astrocytic laminin α2 (B) and endothelial laminin α4/astrocytic marker glial 
fibrillary acidic protein (GFAP) (C). Nuclear counterstain with TO-PRO3. Confocal images 
are representative images from n=4 mice/group, 35 section/animal (scale bar: 25µm). 
Quantification of staining shown as mean fluorescence intensity (arbitrary units) of markers 
on ten randomly selected fields. Statistical analysis was performed by an Independent 
Student’s T-test. Data is expressed as mean ± SEM., **p<0.01, ***p<0.001.    
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4.2.3.3 The role of MMPs in BBB disruption 
The breakdown of the BBB structure in HFHS diet-fed mice led to the investigation 
of MMPs in the brain microvessels, which could be responsible for the degradation of 
junctional proteins and BMs. Proteomic analysis of brain microvessels using a 
membrane-based sandwich immuno-assay showed significantly increased levels of 
MMP-2, MMP-3 and MMP-9 in brain microvessels extracts of mice fed a HFHS diet 
in comparison to mice fed a chow diet (Figure 4.6A). In conjunction, the endogenous 
regulator of MMP activity - tissue inhibitor of metalloproteinases (TIMPs) 
concentration was reduced in the serum of HFHS-fed mice compared to chow-fed 
mice by 1.5-fold (Figure 4.6B).   
The proteomic analysis of brain microvessels only revealed the presence of the MMPs 
through expression, therefore, to evaluate the proteolytic activity of these enzymes, a 
zymography of MMP-2 and MMP-9 was conducted (Figure 4.6C). Zymography 
resolves the gelatinases by molecular mass, thereby allowing detection of the active 
and latent forms of the enzymes. The inactive pro-peptide domain must be cleaved to 
allow enzymatic activity of the MMPs. Quantification of the zymogram showed 
increased pro-MMP-2 and active MMP-2 forms (Figure 4.6D) along with increased 
pro-MMP-9 and active MMP-9 forms (Figure 4.6E) in the brain microvessels of 
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Figure 4.6 | The role of MMPs in BBB disruption 
Expression of MMP-2, MMP-3, MMP-9 was analysed in brain microvessel extracts of chow 
and HFHS-fed mice using a Mouse Proteome Profiler (R&D Systems). The membrane-
antibody array was loaded with 500ng of protein/group overnight (n=10 pooled/group, two 
technical replicates per experiment, performed as two independent experiments total 
n=20/group). Membranes were exposed to x-ray film and the signal produced at the different 
capture spots was used to quantify the amount of protein bound using ImageStudio Lite (LI-
COR Biosciences) and expressed as arbitrary units (A). Serum levels of tissue inhibitor of 
metalloproteinases (TIMP-1) were measured using a quantikine ELISA kit (R&D Systems) 
(B; n=11/group). Proteolytic activity of MMP-2 and MMP-9 in brain microvessel extracts was 
determined via zymography, based on separation of proteins by non-reducing sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS–PAGE). Molecular weight markers were 
used to estimate the molecular masses of inactive ‘pro’ and active/cleaved forms of MMP-2 
and MMP-9 (C). Blots were scanned (BioRad Imager) and densitometry analysis was 
performed using ImageJ software (C,D). Each lane was loaded with 100ng of protein (n=10 
pooled/group, representative of two independent experiments total n=20). Statistical analysis 
was performed by an Independent Student’s T-test. Data is expressed as mean ± SEM., *p< 
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4.2.4 The inflammatory state: measuring inflammatory molecules in 
circulating serum and in the brain microvessels 
It is well documented that T2DM induces a low-grade chronic inflammatory state 
within the peripheral vasculature and is damaging to peripheral blood vessels over 
time. To measure if there is a raised state of inflammation within the HFHS-fed mice 
compared to chow-fed mice, cytokines, chemokines and other inflammatory proteins 
in the serum (Figure 4.7A) were simultaneously measured using the R&D Mouse 
Cytokine Array Panel A Kit (R&D Systems). Within the serum of HFHS-fed, there 
were raised levels of chemokines CXCL1 and CXCL12, sICAM-1 and pro-
inflammatory interleukins IL-1a, IL-16 and TNF-α. There was also a noticeable 
reduction in the anti-inflammatory IL-13 levels, chemokine CXCL13 and TIMP-1 in 
HFHS-fed mice compared to chow-fed mice. There appeared to be no major 
differences in the C5a and CXCL13 levels between the two groups, within the serum 
(Figure 4.7A).  
Further analysis of the presence and potential impact of inflammatory mediators at the 
brain microvasculature was detected by conducting a similar proteome profile of the 
cytokines, chemokines, and other acute phase proteins in isolated brain microvessels 
protein extract of chow and HFHS-fed mice. Review of general inflammatory markers 
revealed HFHS-fed mice to have raised C5a, Chitinase 3-like 1, IFN-γ, TNF-α, 
receptor for advanced glycation end products (RAGE) and VEGF compared to chow-
fed mice. HFHS-fed mice had reduced levels of periostin when compared to chow-fed 
mice and no difference was seen in CRP levels. Review of pro- vs anti-inflammatory 
interleukins found all listed pro-inflammatory interleukins to be raised in HFHS-fed 
mice compared to chow-fed mice with the exception of IL-1β and IL-7, whose levels 
remained similar between the two groups (Figure 4.7D). Similarly, the levels of all 
listed anti-inflammatory interleukins were also increased in HFHS-fed mice compared 
to chow-fed  mice with the exception of IL-1ra and IL-5, whose levels were decreased 
with HFHS-feeding (Figure 4.7E). The interleukins that showed the greatest 
abundance were IL-1a, IL-7, IL-15, IL-27 p28 and IL-11. Likewise, chemokines that 
induced both neutrophil/monocyte and T/B-cells were markedly raised on the whole 
in mice fed a HFHS-compared to mice fed a chow diet (Figure 4.7C). Overall, the 
results indicate a raised inflammatory profile in the HFHS-fed mice. 
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Figure 4.7 | Evaluation of inflammation in mouse serum and at the brain 
microvasculature through measuring inflammatory markers, interleukins & 
chemokines 
Simultaneous measurement of multiple cytokines, chemokines, interleukins and other 
inflammatory markers in both serum and protein extract from brain microvessels of chow and 
HFHS-fed mice using Mouse Cytokine Array Kits (R&D Systems). Membrane-based 
immunoassays detected the relative expression levels of analytes detected as arbitrary units. 
Analytes were measured in serum (A; n=10 pooled/group, two technical replicates per 
experiment, performed as two independent experiments total n=20/group) or in brain 
microvessels (C-E, n=10 pooled/group, performed in duplicate) and categorised as 
inflammatory factors (B), chemokines (C), pro-inflammatory interleukins (D) or anti-
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4.2.5 Activation of endothelial cells of the BBB 
It is widely acknowledged that an inflammatory state causes the activation and 
extravasation of leukocytes particularly in atherosclerosis and coronary heart disease, 
for which obesity and MetS are risk factors (518). In order for leukocytes to 
transmigrate, the endothelium must be primed and activated to allow immune cells to 
roll, tether and adhere. Both in vitro and in vivo studies have linked hyperglycaemia 
and hyperlipidaemia in T2DM to cause endothelium activation with enhanced 
expression of activation markers such as ICAM-1 (519). In parallel, research has 
indicated glucose and lipid presence to also activate lymphocytes (520–522).  
To observe if an enhanced metabolic state induces the BBB endothelial in the same 
manner, the expression of ICAM-1 and P-selectin on microvessels in the cerebral 
cortex of the brain was examined using immunofluorescence. Confocal microscopy 
illustrates major differences in ICAM-1 (Figure 4.8A) and P-selectin (Figure 4.8B) 
expression on the microvessels between chow-fed and HFHS-fed mice, whereby both 
cell adhesion molecules have a higher constitutive expression in HFHS-fed mice; 
statistically confirmed via mean fluorescence intensity (Figure 4.8A,B). Moreover, 
transversely cut sections of the microvessels of HFHS-fed mice showed the 
localisation of ICAM-1 and P-selectin prevalently at the luminal side of the vessel, to 
allow TEM into the brain parenchyma. 
Proteomic analysis of isolated brain microvessel tissue (Figure 4.8C) confirmed the 
confocal imaging results. HFHS-fed mice had raised ICAM-1, P-selectin and VCAM-
1 compared to chow-fed mice. HFHS-fed mice also showed a trend of increased co-
stimulatory molecule CD40 compared to chow-fed mice however, however no 
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Figure 4.8 | Activation of the BBB endothelium to a pro-inflammatory state - cell 
adhesion molecule expression on brain microvessels  
Cerebral cortical sections of the brain were immunofluorescently stained for endothelial cell 
adhesion molecules ICAM-1 (A) and P-selectin (B); nuclei were labelled with TO-PRO3. 
Typical images from n=4 animals, 35 section/animals (scale bar: 25µm). Quantification of 
staining shown as mean fluorescence intensity (arbitrary units) of markers on ten randomly 
selected fields. Proteomic analysis of adhesion molecules on brain microvessel extracts from 
chow and HFHS-fed mice using a membrane-based immunoassay (Mouse Cytokine Array XL 
Kit, R&D Systems) to detect the relative presence of E-selectin, ICAM-1, P-selection and 
VCAM-1 and co-stimulatory molecule CD40 by x-ray film exposure (C, n=10 pooled/group, 
two technical replicates per experiment, performed as two independent experiments total 
n=20/group); quantified using ImageStudio Lite (LI-COR Biosciences). Statistical analysis 
was performed by an Independent Student’s T-test. Data is expressed as mean ± SEM., *p< 
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4.2.6 Induction of the immune system in metabolic overload 
The pathogenesis of T2DM is considered to involve both the innate and adaptive 
immune systems. The progressive tissue damage occurring to the heart, liver, kidney, 
and adipose tissue are characterised by abnormal immune cell function. It is therefore 
likely that the damage occurring at the BBB and subsequently within the brain 
parenchyma would involve peripherally activated and primed immune cells. 
 
 
4.2.6.1 Examining the innate and adaptive arms of the immune system in the 
peripheral system 
In order to evaluate whether the immune system is primed and activated in this mouse 
model, the frequency of different immune cells types from the innate and adaptive 
arms was assessed.  
Bone marrow was isolated and stained for cells of the innate (neutrophils, 
macrophages & dendritic cells) and adaptive (NK cells, T-cells, and B-cells) immune 
system (Figure 4.9A).  Percentage cell frequency of all innate immune cell types were 
higher in the HFHS-fed mice when compared to chow-fed mice. In the adaptive 
immune cells, only CD8+ T-cells had a higher frequency in HFHS-fed mice when 
compared to chow-fed mice. In comparison, NK cells and B-cells had a reduced 
frequency in HFHS-fed mice when compared to chow-fed mice and no differences 
were seen with CD4+ T-cells.  
The T- and B-cell frequency was also analysed from the cervical lymph nodes of mice, 
the main lymph drainage points from the brain (Figure 4.9B). Again no differences 
were seen in CD4+ T-cells however opposite to the bone marrow, in the cervical lymph 
nodes HFHS-fed mice showed a reduced frequency of CD8+ T-cells and higher 


























Page | 162  
 
Figure 4.9 | Activation of the innate and adaptive arms of the immune system 
Bone marrow and deep cervical lymph nodes were collected from chow and HFHS-fed mice. 
Bone marrow was flushed with PBS-/- to obtain white blood cells, red blood cells were lysed 
using lysis buffer. Cells were stained using fluorescently conjugated antibodies for cell-
surface markers on cells of the innate – neutrophils (Ly6G), macrophages (CD11b), dendritic 
cells (F4/80, CD11c), and adaptive – NK cells (NK 1.1), T-cells (CD4, CD8), B-cells (CD19) 
immune system and underwent flow cytometric analysis (n=19-23/group). Deep cervical 
lymph nodes were homogenised to obtain lymphocytes and underwent flow cytometric 
analysis after staining to obtain percentage frequency of T-cell subsets CD4+ and CD8+ and 
B-cells (CD19+) (n=12-16/group). Statistical analysis was performed by either an 
Independent Student’s T-test or Mann-Whitney U Test. Data is expressed as mean ± SEM., 
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4.2.6.2 Examining the activation of CD4+ T-cells in T2DM 
CD4+ T-cells are also known as T-helper (TH) cells and play an important role in 
shaping the response of the adaptive immune system by releasing cytokines to enhance 
or supress immune responses. Mature TH cells express the cell surface protein CD4. 
The CD4+ cells are vital in B-cell antibody class switching, activation of cytotoxic T-
cells and in maximising the phagocytic activity of macrophages. In this part of project, 
we investigated the role of this specific subset of T-cells in more detail. Lymphocytes 
were always isolated from deep cervical lymph nodes. 
HFHS-feeding enhanced activation of CD4+ T-cells, as represented by immune-
staining with activation marker CD44, which is typically upregulated after activation 
of naïve T lymphocytes during immune response. Results showed that when compared 
to chow-fed mice, HFHS-fed mice had a greater percentage of CD4+ CD44+-
expressing T-cells, however this was not statistically significant (Figure 4.10A).  
In order for immune cells to illicit immune response and combat microbes or infection, 
they must be able to reach the site of target by passing across endothelial cell barriers 
from bloodstream to tissue. Transmigration not only requires the expression of 
adhesion molecules on endothelial cells but also co-receptors on the leukocytes to 
allow for firm arrest. CD44 itself can regulate the tethering and rolling interaction. 
Nonetheless within the CD4+ CD44+-expressing T-cells the expression of adhesion 
molecule lymphocyte function-associated antigen 1 (LFA-1) that binds to ICAM-1 on 
endothelial cells was assessed (Figure 4.10B). Results showed a significant increase 
in percentage of CD4+, CD44+, LFA-1+-expressing T-cells by 1.5-fold in HFHS-fed 
mice when compared to chow-fed mice. 
T-cells which respond to immune cues in the short-term can be named as effector T-
cells (Teff). Chemokine receptor, CXCR3 is highly expressed on these Teff cells and is 
key in the trafficking and function of these cell types in response to chemokines. 
Within the CD4+ CD44+-expressing T-cells, the expression of CXCR3 was also 
measured (Figure 4.10C). Results showed a significant increase in the percentage of 
CD4+, CD44+, CXCR3+-expressing Teff cells by 2-fold in HFHS-fed mice when 
compared to chow-fed mice. 




Figure 4.10 | T-effector cell activation in T2DM 
Deep cervical lymph nodes were collected from chow and HFHS-fed mice. Lymph nodes 
were homogenised to obtain lymphocytes. All T-cells were stained for CD4, within this subset 
of T-cells staining was conducted for activation marker CD44 (A). On CD4+ CD44+-
expressing T-cells, the expression of lymphocytic adhesion molecule LFA-1 (B) and 
chemokine receptor CXCR3 (C) was evaluated (n=5-11/group). Statistical analysis was 
performed by either an Independent Student’s T-test or Mann-Whitney U Test. Data is 
expressed as mean ± SEM., **p<0.01, ****p< 0.0001. 
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4.2.6.3 Involvement of central memory vs effector memory T-cells 
Memory T-cells are often termed antigen-experienced T-cells due to their 
characteristic to have encountered and responded to their antigen previously. Such 
memory T-cells can reproduce faster and stronger responses upon re-encounters to 
their cognate antigens. Memory T-cells can be divided into several subsets, of which 
central memory (TCM) and effector memory (TEM) are the two major groups. TCM have 
a self-renewal ability and confer powerful responses against viruses, bacteria, and 
cancer cells. In comparison TEM cells are responsible for cytotoxic action.  
As MetS and T2DM confers a low-grade chronic inflammatory state whereby the same 
antigens will be encountered by the immune cells, the relative numbers of TCM and 
TEM in the HFHS model was investigated. The expression of CD44 is retained on 
memory T-cells, therefore cells were initially defined as CD4+ CD44+-expressing T-
cells. Within this population, the expression of chemokine receptor CCR7 (Figure 
4.11A) and L-selectin CD62L was analysed (Figure 4.11B). It is the differential 
expression of these ligands as high (hi) or low (lo) which defines whether, these cells 
are central or effector memory. TCM
 cells are defined as CD44hi CD62Lhi CCR7hi 
whereas TEM cells are defined as CD4hi CD62Llo CCR7lo.  
In HFHS-fed mice there is a significantly greater percentage of CD44hi CCR7hi cells 
when compared with chow-fed mice. The HFHS-fed mice have a slightly increased 
percentage of CD44hi CD62Lhi-expressing cells when compared to chow-fed mice, 
however this is not statistically significant. Overall, the results implicate HFHS-fed 
mice to have a greater proportion of TCM cells when compared with chow-fed mice.   
Similarly, in HFHS-fed mice there is a significantly greater percentage of CD44hi 
CCR7lo and CD44hi CD62Llo-expressing cells when compared with chow-fed. 
Overall the results implicate HFHS-fed mice to have greater numbers of TEM cells 
when compared with chow-fed.  
Given the differences in percentages and statistically significance, it appears as though 
HFHS-fed mice have a greater proportion of TEM to TCM
 cells ratio. 






Figure 4.11 | Effector Memory vs Central Memory T-cells 
Deep cervical lymph nodes were collected from chow and HFHS-fed mice. Lymph nodes 
were homogenised to obtain lymphocytes. All T-cells were stained for CD4 antigen, within 
this subset of T-cells staining was conducted for high (hi) or low (lo) expression of activation 
antigen marker CD44 (A). On CD4+ CD44+-expressing T-cells, the high and low expression 
of L-selectin CD62L (A) and chemokine receptor CCR7 (B) was evaluated (n=5-11/group) to 
characterise the presence of central memory (CD44hi, CD62Lhi, CCR7lo) or effector memory 
(CD44hi, CD62Llo, CCR7lo) T-cells. Statistical analysis was performed by either an 
Independent Student’s T-test or Mann-Whitney U Test. Data is expressed as mean ± SEM., 
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4.2.6.4 Pro vs Anti-inflammatory T-cells: Treg vs Th17 cells 
CD4+ T-helper subsets can be categorised into different effector subsets including the 
pro-inflammatory TH1, TH2 and TH17 and the anti-inflammatory Treg. A combination 
of different cytokine signals determines the fate and production of the TH cells. The 
different subsets orchestrate varied responses and conduct specific functions 
dependent on their cytokine production.  
TH17 cells are RAR-related orphan receptor gamma (RoRγt)-expressing cells involved 
in inflammation and autoimmune responses. In contrast, the Treg cells are vital in 
supressing excessive inflammatory responses and to limit tissue damage. Treg cells 
are characterised by the expression of fork head/winged-helix transcription factor, 
Foxp3.  
The involvement of T-cells in T2DM has been widely reported in mice and humans; 
with a skew towards the pro-inflammatory TH1 and TH17 subsets and a decrease in 
Treg; culminating in inflammation, insulin tolerance and T2DM progression (523–
526). Importantly, the TH17 cells were negatively correlated to plasma levels of HDL 
and Treg were positively correlated to IL-6 levels; suggesting the relationship between 
CD4+ T-cells subsets and dyslipidaemia and hyperglycaemia (368). Therefore, the 
presence and ratio of TH17 to Treg was investigated in the experimental mice to see if 
there was an imbalance in their proportion (Figure 4.12).  
Flow cytometric analysis of lymphocytes isolated from deep cervical lymph nodes 
found that in HFHS-fed mice the percentage of RoRγt-expressing TH17 cells was 
significantly upregulated (Figure 4.12A) compared to chow-fed mice. The percentage 
of Foxp3-expressing Treg cells (Figure 4.12B) showed a trend towards 
downregulation in HFHS-fed mice compared to chow-fed mice, but this was not 
significant. However, in the HFHS-fed mice there was a higher TH17/Treg ratio 
compared to chow-fed mice (Figure 4.12C), thereby highlighting a skew towards a 










Figure 4.12 | Pro vs Anti-inflammatory T-cells: TH17 vs Treg cells 
Deep cervical lymph nodes were collected from chow and HFHS-fed mice. Lymph nodes 
were homogenised to obtain lymphocytes. All T-cells were stained for CD4, within this subset 
T-cells were categorised as pro-inflammatory T-helper (TH17) cells based on their expression 
of RoRγt (A) or as anti-inflammatory regulatory T-cells (Treg) based on their expression of 
Foxp3 (B) The skew towards a pro- or anti-inflammatory phenotype was determined by the 
ratio of TH17/Treg cells (C) (n=9=11/group). Statistical analysis was performed by either an 
Independent Student’s T-test or Mann-Whitney U Test. Data is expressed as mean ± SEM., 
**p<0.01 
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4.2.6.5 Transmigration of peripherally activated leukocytes across the BBB 
Having previously shown that the HFHS diet damages the BBB and its barrier 
properties, and activates T-cells, we measured the migratory activity of T-cells 
through the endothelium into the brain parenchyma. 
Confocal microscopy of cortical brain sections double-stained with CD45 and pan-
laminin (Figure 4.13A) revealed numerous CD45+ cells in the vessel lumen of HFHS-
fed mouse brains, which appeared trapped between the VBL layers. In comparison, in 
chow-fed mice brains, CD45+ cells were rarely detected and there was absence of 
perivascular leukocytes infiltrates.  
To further dissect the mechanism of action of T-cell migration, in vitro 
adhesion/migration experiments were performed using lymphocytes isolated from 
deep cervical lymph nodes. Isolated lymphocytes from chow-fed and HFHS-fed mice 
were activated and expanded for 4 days using CD3 and CD28, after which they were 
placed in contact for 4 hours with an in vitro model of the BBB; using bEnd3 cells 
plated on transwells to conduct a transmigration assay (see Figure 4.13B). The 
migrated cells represented those which had crossed the BBB, whereas the adhered 
cells were equivalent to the immune cells which had arrested on the endothelium but 
had not crossed the BBB (Figure 4.13B).   
FACS analysis of double immune-stained CD4+ CD45+ T-cells from lymph nodes 
(Figure 4.13D) showed that the numbers of adhered and migrated cells were higher in 
the HFHS-fed mice when compared to chow-fed mice, however this was only 
significant in the migrated population.  
T-cells expanded from lymph nodes were also stained for pro-inflammatory TH17 and 
anti-inflammatory Treg cells (Figure 4.13E,F). Results showed a greater number of 
adhered and migrated TH17 and Treg cells in the HFHS-fed mice when compared to 
chow-fed mice, all results were significant.  
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Figure 4.13 | Transmigration of peripherally activated leukocytes across the BBB  
Cerebral cortical sections of the brain were immunofluorescently stained for antigen CD45, 
present on all activated leukocytes, to examine the transmigration of immune cells across the 
BBB (A); nuclei were labelled with TO-PRO3. Typical images from n=4 animals, 35 
section/animals (scale bar: 25µm). Quantification of staining shown as mean fluorescence 
intensity (arbitrary units) of markers on ten randomly selected fields. Further assessment of 
T-cell migration was conducted using deep cervical lymph nodes, collected from chow and 
HFHS-fed mice (B-E). Lymph nodes were homogenised to obtain lymphocytes and expanded 
for 4 days in the presence of CD3 and CD28. On day 4, a transmigration assay was conducted, 
with 1 x 106 cells placed in contact with bEnd3 cells grown on transwell inserts. T-cells were 
placed in contact with the in vitro BBB model for a period of 4 hours, after which the cells 
collected from the top compartment of the transwell served as the adhered component and the 
cells collected from the bottom compartment served as the migrated component (B). All 
collected cells were stained for CD4; within this subset cells were stained for activation marker 
CD45 (C), RoRγt-expressing TH17 cells (D) or Foxp3-expressing Treg (E) (n=5-9/group). 
Statistical analysis was performed by either an Independent Student’s T-test or Mann-Whitney 
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4.2.7 Activating the brain-tissue resident immune cells: The microglia 
The data provided until now have proved that a HFHS diet causes inflammation and 
activates the peripheral immune system; together these factors disrupt the structural 
and immunological integrity of the BBB. The next step was to investigate how the 
brain innate response and functionality was affected. A protagonist at the centre of 
brain immunity is the microglia cells; and hence their activation and behaviour were 
investigated.   
 
4.2.7.1 M1 vs M2 Microglia 
Microglial cells were identified from macrophages by gating on the CD45lo CD11b+ 
population (Figure 4.14A). Results showed a higher percentage of microglial cells in 
the HFHS-fed mice when compared to chow-fed mice. Microglial cells also highly 
express the fracktaline receptor CX3CR1+ which responds to the fracktaline 
(chemokine) CX3CL1 produced by neurons. Interestingly the expression of 
CX3CR1+, as measured by MFI, was reduced in HFHS-fed mice when compared to 
chow-fed mice (Figure 4.14B). Activated microglial cells were identified by the 
markers CD11c+  and MHCII+ on CD45lo CD11b+-expressing cells (Figure 4.14C); 
the results showed HFHS-fed mice to have a higher percentage of activated microglial 
cells compared to chow-fed mice. These activated cells were further differentiated as 
a pro-inflammatory M1 phenotype (CD86+-expressing cells) or as an anti-
inflammatory/resolving M2 phenotype (CD206+-expressing cells, Figure 4.14D). 
Notably HFHS-fed mice had more than double the percentage of M1 CD86+ cells 
compared to chow-fed mice; this correlated with a decrease of M2 CD206+ cells by 
more than 50%. In summary, the HFHS-fed mice had a greater ratio of M1:M2 
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Figure 4.14 | Activation of brain tissue resident macrophages – the microglia cells  
Microglia cells were isolated and cultured from chow and HFHS-fed mice (n=6-12/group, 
pooled in pairs). Microglia cells were identified by gating on CD45lo CD11b+ cells to 
differentiate from macrophages (A). Expression of fracktaline receptor CX3CR1+ in CD45lo 
CD11b+-expressing cells (B), as median intensity of fluorescence (MFI). Percentage of 
activated microglial cells identified as CD11c+ MHCII+-expressing cells (C) differentiated 
into pro-inflammatory M1 (CD86+-expressing) and anti-inflammatory M2 (CD206+-
expressing cells) phenotypes (D) and presented as a ratio of M1/M2 (E). Statistical analysis 
was performed by an Independent Student’s T-test. Data is expressed as mean ± SEM., *p< 
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4.2.7.2 Oxidative damage in the diabetic brain 
NO is key in modulating physiological responses such as vasomotor tone and neuronal 
function. The production of ROS and RNS forms a part of innate defence mechanism; 
however, their overproduction can cause apoptosis and promote tissue damage. 
Endothelial cells, macrophages/microglia and neurons are the main producers of NO 
(527).  
Immune staining of IBA1, a microglia activation marker, showed activated microglia 
of a pro-inflammatory phenotype in the HFHS-fed mice, which are known to be source 
of iNOS production (Figure 4.15A). In comparison, in the chow-fed mice there is low 
expression of microglia activation marker IBA1. Confocal imaging of cortical brain 
sections reveals HFHS-fed mice to have a higher constitutive expression of iNOS 
when compared to chow-fed mice (Figure 4.15B). The localisation of iNOS is 
consistent with the formation of a vessel, suggesting that the endothelial cells are 
producing iNOS. This is confirmed in through the co-localisation of iNOS with 
endothelial cells via nuclei staining of TO-PRO3 (Figure 4.15B). iNOS presence 
outside of the vessel formation in the brain tissue suggests production by brain 











Figure 4.15 | Oxidative stress in the brain 
Cerebral cortical sections of the brain were immunofluorescently stained for IBA1 (A) and 
iNOS (B) expression; nuclei were labelled with TO-PRO3. Typical images from n=4 animals, 
35 section/animals (scale bar: 25µm). Quantification of staining shown as mean fluorescence 
intensity (arbitrary units) of markers on ten randomly selected fields.  Statistical analysis was 
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4.3 Discussion  
This chapter investigates the use of a combination of high-fat and high-sugar feeding 
to serve as a diet-induced model of MetS/T2DM. As mentioned previously, there are 
no gold-standard reference values for confirmation of T2DM in mice (467), therefore 
results have been compared to previous literature and studies.  
Feeding on a HFHS diet for 10 weeks resulted in progressive increase in body weight 
compared to chow-fed mice. Previous studies using C57BL/6 mice indicate that an 
increase in body weight is noticeable as early as 2 weeks and becomes clearly apparent 
after 4 weeks (505), which parallels the results in this HFHS model. Literature reports 
that after 16-12 weeks of high-fat feeding, mice will exhibit a 20-30% increase in body 
weight compared to chow-fed mice (505); in the results of our study it can be seen that 
HFHS feeding results in approximately a 40% weight gain in comparison to chow-fed 
counterparts. These results are similar to those reported previously in our group using 
the same HFHS diet for a period of 10-12 weeks (473,474,512). According to Surwit 
et al., this increase in body weight gain in chow-fed versus high fat-fed mice can be 
termed as obesity (464,472). We also similarly report an increase in the percentage of 
epididymal and inguinal fat in HFHS-fed mice compared to chow-fed mice, as 
measures of adiposity and thus obesity (472).  
 
The HFHS-fed mice in this study also show a significant impairment in oral glucose 
tolerance at week 8. Similar results have also been shown by Andrikopoulos et al., at 
8 weeks of high-fat feeding in C57BL/6 mice (490) and have also been shown by our 
group using the same HFHS diet for a period of 10, 12, 14 or 16 weeks (473–475). In 
fact, it has been reported that an impairment in glucose tolerance can be seen as early 
as 1 week after dietary manipulation (528).  
According to the initial establishment of the T2DM using a high-fat diet model in 
C57BL/6 mice, fasting blood glucose and serum insulin levels are sufficient to confirm 
glucose in tolerance and insulin resistance, respectively (464,472). Based on these 
criteria alone, it would be sufficient to suggest that the HFHS-fed mice in this study 
have impaired glucose tolerance and insulin resistance due to high fasted and non-
fasted blood glucose and high serum insulin levels compared to controls; this criteria 
has been used by other studies too (490). Nevertheless, the advancement in obesity 
and diabetes research has led to more in-depth measures of insulin resistance of which 
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insulin tolerance testing in the most popular. The results in the HFHS-fed mice 
indicate that there is an impaired insulin response, but this is not significant. This may 
simply be due to a small n number of 6 animals, however other studies that have 
reported impaired insulin response, as measured by ITT in mice place on a high-fat 
diet for 12-16 weeks or more (473,528–530). Therefore, it is plausible to say that the 
HFHS-fed mice in this study have moderate insulin resistance as opposed to overt 
insulin resistance. In fact, it is well known that compensatory hyperinsulinemia is 
often considered a trait of MetS or mild diabetes, whereby the fasting glucose levels 
are maintained to combat insulin resistance (380). In this manner, the high serum 
insulin levels are an attempt to combat the hyperglycaemia and therefore the insulin 
resistance is not fully established. Indeed, in mice it is more difficult to assess the stage 
of disease and there is significant continuum between obesity, MetS, insulin resistance 
and T2DM (379). 
 
Dyslipidaemia with high cholesterol and high triglyceride levels is significantly 
apparent in the HFHS-fed mice compared to chow-fed mice. This parallels previous 
reports by our group and others (474,512,529–532).   
 
Therefore initially the results of this chapter showcase that the use of a combination 
of high-fat and high-sugar feeding appropriately serves as a diet-induced model of 
MetS/T2DM through the development of obesity, hyperglycaemia, hyperinsulinemia, 
mild insulin resistance  and dyslipidaemia compared to a normal chow diet. 
Furthermore, the HFHS diet impairs the structural, functional, and immunological 
integrity of the brain through a rise in pro-inflammatory mediators including IL-1, IL-
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4.3.1 Disruption of BBB integrity & permeability: the role of MMPs and 
TIMPs 
Endothelial cells serve as a key interface between the blood and organs; therefore, 
vascular health is a key determinant in disease progression. Here, we show that 
metabolic disorders also disrupt the endothelial cells of the BBB. The important barrier 
function of these endothelial cells is perturbed with consumption of a HFHS diet, as 
seen by increased paracellular permeability and decreased TEER; which can be 
attributed to the loss of TJ proteins occludin and claudin-5 and loss of fibrillar actin. 
Loss of cell-cell contact through reduced TJ and AJ proteins hinders the correct 
association with the cell cytoskeleton resulting in loss of cell shape and reduced 
tension (100–102), which is further reduced upon actin depolymerisation (108–111). 
Loss of tensile strength hinders the ability of the brain endothelial cells to maintain 
their properties as a strict barrier.   
BMs add an additional supportive layer to the BBB structure. Research by Sorokin 
and team has shown that different laminins transverse the BM dependent on layers in 
the brain and regions within the vascular beds, as well as stage of development 
(151,152). Within the capillaries of the CNS parenchyma, endothelial BMs 
ubiquitously express laminin α4 and laminin α5 and astroglial BMs express laminin 
α1 and α2 (152,533).   
In this study, confocal imaging was conducted on brain capillaries and the relevant 
BM markers were utilised. Staining revealed loss of lamina components in both 
endothelial cells and astrocytes in HFHS-fed mice thereby preventing the association 
of astrocytic end-feet, suggesting a complete breakdown of the BBB. Under normal 
conditions, model systems have shown BMs to exclude macromolecules the size of 
albumin (hydrodynamic diameter 7nm) and limit transport of molecules in size from 
40kDa (534,535,535–537). With a complete breakdown of the brain microvessel 
structure, molecules can readily pass through into the brain parenchyma and this 
correlated with enhanced albumin-bound Evans blue dye leakage in the brains of 
HFHS-fed mice compared to chow-fed mice. Other rodent studies using high-fat 
feeding also report increased BBB permeability using Evans blue dye (538), sodium 
fluorescein dye (539) or antibodies against endothelial barrier antigen (540), 
specifically in the hippocampal region of the brain. Notably, cerebral cortical brain 
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imaging in our study has not differentiated between brain regions. Future studies 
would benefit from determining whether the loss of TJs and BMs of the BBB occur 
within specific regions of the brain and the correlation of these brain regions with 
motor and neuronal function. 
Breakdown of junctional proteins and BMs involves digestion by MMPs. 
Physiologically MMPs are required for normal tissue homeostasis. Specifically within 
the brain, the degradation of the ECM allows for tissue remodelling, cell migration, 
axonal elongation, angiogenesis and breakdown of Aβ peptides (Aβ40 and Aβ42) 
(187,541). However, MMPs are also involved in adverse pathophysiological 
processes. A number of CNS diseases including MS, AD, gliomas and stroke have 
implicated MMPs to be involved with undesirable effects including BBB breakdown, 
demyelination, tumour invasion, metastasis and promotion of leukocyte migration 
(187,542). A number of studies have also reported increased MMP-2 and MMP-9 
concentrations in the serum (543), plasma (544), kidney arteries (545) and eyes (546) 
of diabetic patients. To our knowledge, our study is the first to correlate MMPs with 
BBB breakdown in a T2DM model, shown through increased expression of MMP-2, 
MMP-3 and MMP-9 within the brain microvessels of HFHS-fed mice, and enhanced 
activity of MMP-2 and MMP-9 via gel zymography.  
MMP activity is regulated transcriptionally by cytokines, growth factors, ROS and 
hormones (187,547,548); this correlates with the inflammatory profile witnessed in 
the HFHS-fed mice with increased cytokines, interleukins, chemokines and iNOS. 
Inhibition of MMPs on the other hand, is mediated by TIMPs; through their binding 
to MMP domains (264,265). Therefore, to maintain a favourable balance of tissue 
homeostasis and neuroprotective events vs pathological events, a balance is required 
between the MMP and TIMP ratio. In the HFHS-fed mice, TIMP-1 activity was 
significantly reduced when compared to chow-fed mice in combination with raised 
MMP-2, MMP-3, and MMP-9 activity, indicating a disruption in the balance and 
control of MMP activity. Notably, it would be beneficial to also examine the serum 
levels of TIMP-2, TIMP-3 and TIMP-4, as the TIMPs interact with the MMPs with 
varying degrees of affinity (264). TIMP-2 has a higher affinity for MMP-2 whereas 
TIMP-1 forms strong interactions with MMP-9; TIMP-3 possess the broadest range 
of inhibition through targeting all family members of the MMPs (264). 
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Numerous studies have reported pro-inflammatory IL-1 and TNF-α to upregulate 
TIMP-1 levels in both endothelial cells and astrocytes (549,550). In mouse models of  
Experimental Autoimmune Encephalomyelitis (EAE), a widely-accepted model of 
demyelinating diseases such as MS, GFAP-expressing astrocytes increase TIMP-1 
expression to aid remodelling of the brain ECM (551). Similarly, in human T-
lymphotropic virus, TH1 cells interact with astrocytes causing them to become 
reactive; reactive astrocytes secrete pro-inflammatory cytokines and express TIMP-1 
and TIMP-3 (552). Additionally, in CNS morbillivirus infection of mouse, TIMP-1 
mRNA is up-regulated in affected brain areas which can be correlated with increased 
TH1 cytokines, IFN-γ, TNF-α and IL-6 (553). Although in our diabetic model, there is 
a substantial increase in the presence of T-cell inducing chemokines, the serum and 
brain microvessel protein levels of TIMP-1 are decreased. This contrast, between our 
results and other studies showing upregulated TIMP-1 may in fact represent the switch 
between a protective vs detrimental effect of MMPs/TIMPs.  
For example, reports have shown differential expression of TIMP-1 in human 
immunodeficiency virus (HIV)-1-associated dementia (HAD). In HAD, IL-1 
produced by mononuclear phagocytes induces acute activation of astrocytes resulting 
in significantly increased TIMP-1 mRNA and protein, despite astrocytes being rarely 
infected (550). In contrast, CSF and brain tissue examination from HAD patients at 
the end-stage of the neurological disease shows significant downregulation of TIMP-
1 (554). Studies by Ghorpade and team propose differential regulation of TIMP-1, 
specifically in astrocytes of HAD or AD patients, to correlate with acute vs chronic 
inflammatory state of the disease (542,550,554). In inflammation, astrocytes initially 
become activated to serve as a protective mechanism, isolating the damaged area and 
facilitating brain circuit remodelling (401). As such, acute activation of astrocytes 
along with microglial activation may enhance the levels of TIMP-1 in the brain 
microenvironment to allow positive remodelling. However, under sustained 
inflammation, the levels of TIMP-1 cannot be maintained and therefore decline 
significantly. In a similar manner, in the diabetic mouse model where there is 
underlying chronic inflammation, the results show an imbalance of TIMP-1 and 
MMPs.  In fact, a study of T2DM patients found serum concentrations of MMP-2 and 
MMP-9 to be lower in diabetic patients vs non-diabetic controls during short-lasting 
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hyperglycaemia induced by OGTT whereas chronic hyperglycaemia, reflected by 
HbA1c levels, correlated with higher MMP-9 levels in T2DM patients (270). 
To fully consolidate the theory of acute vs chronic inflammatory MMP/TIMP balance, 
evaluation of brain tissue before 10 weeks of HFHS-feeding would be necessary or 
equivalently an acute dose of inflammation e.g. via LPS could be administered in the 
HFHS-fed mice before sacrificing and collecting brain tissue. Nevertheless, in this 
study the MMP/TIMP levels have been observed in the brain microvessels, which 
represents a better overall understanding of the impact at the BBB. Even so, culturing 
brain endothelial cells and astrocytes individually will provide a clear picture of the 
activity levels in each cell type. Particularly as results in models of stroke and middle 
cerebral artery occlusion have shown release of MMP-2, MMP-3 and MMP-9 in the 
acute phase (2-24 hours), by endothelial cells and infiltrating leukocytes to correlate 
with BBB dysfunction through degradation of the BMs; this predisposed the brain 
capillaries to rupture and impacted the extent of the infarct (555–560). In contrast, 7 
days post-stroke when the BBB is presumably restored, the astrocytes and microglia 
produce MMPs which may contribute positively to the ECM remodelling (561,562). 
With this in mind, it is plausible that long-term presence of circulating inflammatory 
factors cause endothelial dysfunction inducing BBB degradation via loss of the 
feedback mechanism that maintains proportional levels of MMPs to TIMPs. Whilst 
the roles of astrocytes have not been investigated in this study, it was noted that 
intensity of GFAP-expressing astrocytes was not altered between chow and HFHS-
fed groups despite the loss of astrocytic end-feet attachment to the endothelial cells in 
the HFHS-fed mice. Instead the astrocytes may respond to these inflammatory cues 
by becoming reactive in HFHS-fed mice. Future studies would benefit from exploring 
astrogliosis in a diabetic condition to understand the protective vs detrimental effect 
of this response, as no studies have done this to date.  
It should also be noted, that TIMPs may have several diverse roles that can be either 
positive or negative in the brain. For instance, TIMP-3 can inhibit ADAM17 to reduce 
TNF-α production; ADAM17, also known as TNF-α-converting enzyme (TACE), 
regulates the cleavage of pro-TNF-α to its active form (563,564) to limit inflammation. 
On the other hand, TIMP-3 inhibition of ADAM10 and ADAM17 results in Aβ-
peptide accumulation and thus plaque formation involved in AD pathogenesis (565). 
Indeed, increased TIMP-3 levels have been reported in AD brains of humans and 
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mouse models, where it associates with neurofibrillary tangles and neuritic senile 
plaques (566). However, this upregulation of TIMP-3 in these plaques has also been 
proposed as a potential compensatory mechanism to reduce inflammation through 
controlling TNF-α levels (567). The differential positive and negative effects of 
TIMP-3 in AD suggest a more complex nature of MMP/TIMP regulation.  
Interestingly, increased TIMP-3 in the brain has not been reported in any other 
neuropathologies, suggesting a specific role in AD and β-amyloid build up (567). 
Studies have shown that T2DM results in cognitive decline that can be attributed to 
increase Aβ accumulation, similar to the pathology seen in transgenic AD mice 
(394,395); thus the role of TIMP-3 requires particular attention in the future, in the 
HFHS-fed mice.  
 
 
4.3.2 The inflammatory state at the BBB: impact of metaflammation  
A critical component of T2DM is the low-grade chronic inflammation that is 
characterised by cytokine expression and immune cell infiltration that remains 
unresolved over time (344). In metabolic disorders, the excessive nutrient 
consumption leading to hyperglycaemia and dyslipidaemia is accompanied by a 
plethora of inflammatory and metabolic responses in multiple cell types, and is termed 
metaflammation i.e. metabolism-induced inflammation (356,357).  
Chronic hyperglycaemia and hyperlipidaemia induce the production of pro-
inflammatory cytokines from various cells and tissues including the liver, pancreas, 
kidney, heart, adipose tissue and immune cells; a distinct signature of cytokines 
includes raised TNF-α, IL-1, IL-6, IL-8, CRP and MCP-1 (337,339,340,568). The 
excessive production of these peripheral pro-inflammatory mediators contributes to 
molecular alterations that lead to the development of T2DM-related secondary 
conditions such as nephropathy, neuropathy, retinopathy, ischemic heart disease and 
peripheral vasculopathy (316,317).  
In the HFHS-fed mice, there is a rise in TNF-α, IL-1α, IL-6 and MCP-1 in the serum 
and brain microvessels; along with a rise in a range of other inflammatory mediators 
e.g. C5a and IFN-γ, receptors e.g. RAGE, interleukins e.g. IL-12p40 and IL-23 and 
chemokines e.g. CCL5 and CXCL12 (Figure 4.7).  A number of these mediators have 
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been implicated to induce BBB damage. For example, complement activation and 
generation of C5a in systemic lupus erythematosus (SLE) damages brain endothelial 
cells and astrocytes. The loss of BBB integrity in SLE has been attributed to the 
activation of NF-κB signalling by C5a, resulting in loss of claudin-5 and ZO-1 at the 
TJs and rearrangement of actin fibres at the cytoskeleton (569). Similarly, RAGE 
alters the cell cytoskeleton through increasing β-catenin levels resulting in decreased 
F-actin stress fibres, with implications for loss of BBB structure (570). In the HFHS-
fed model, there is disruption to the brain endothelial junctional proteins and 
cytoskeleton, which can be attributed to the up-regulation of these inflammatory 
mediators.   
Moreover, a number of studies have reported correlations between high peripheral 
inflammation and risk of neurodegenerative diseases such as AD, PD, HD, ALS and 
MS (392,571). For example, a meta-analysis of forty studies showed AD development 
to be linked to higher peripheral blood cytokine concentrations of TNF-α, IL-1β, IL-
6, IL-8, IL-12 and TGF-β (572), as well as the activation of circulating peripheral 
immune cells (573).  
What then, is the mechanism by which peripheral immune system activation results in 
brain pathology? One particular study has shown that stimulation of the mouse 
immune system results in AD pathology, with increased deposition of amyloid 
precursor protein (APP) and it’s proteolytic fragments, build-up of Aβ, tau 
aggregation, microglia activation and reactive gliosis (574). The activation of 
astrocytes and microglia contributes to disease progression and neurodegeneration 
through subsequent release of acute-phase proteins, complement components, 
prostaglandins, cytokines and ROS/RNS that promote neuronal cell death (575,576). 
Moreover the release of MMPs by the BBB cells can directly induce neuronal 
apoptosis; MMP-9 can enter the nucleus of neuronal cells to cause DNA damage 
resulting in neuronal cell death (431). These studies demonstrate a clear link between 
peripheral inflammation and neuroinflammatory response that leads to 
neurodegeneration (577). In conditions such as MetS/T2DM where peripheral 
inflammation is chronic and sustained, the pro-inflammatory microenvironment is 
likely to propagate a vicious cycle of self-propelling inflammation from endothelial 
cells, astrocytes, microglia and neurons that ultimately leads to chronic 
neuroinflammation and neurodegeneration (578).  
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In the HFHS-fed mice there is an initiation of a neuroinflammatory response as seen 
by the activation of CD11c+ MHCII+ CD86+ IBA1-expressing microglia cells. 
Importantly, the intact BBB in the chow-fed mice vs the damaged BBB in the HFHS-
fed mice along with greater M1 phenotype microglia cells consolidates the theory that 
peripheral inflammation arising as a result of metabolic disorders plays a significant 
role in causing disruption to the brain microvasculature resulting in 
neuroinflammation. In our diabetic model, investigation into neuronal loss is beyond 
the scope of this study; however future studies would benefit to review the effect on 
neurons to confirm that metaflammation-triggered neuroinflammation leads to 
neurodegeneration.  
Furthermore, the evidence for the role of peripheral inflammation in contributing to 
neurodegeneration has been evidenced via blocking this inflammation (575). For 
example, IL-12 and IL-23 influence the development of TH1 and TH17 cells and have 
been shown to be upregulated in the microglia of AD mice (579). Targeting IL-12p40, 
the common subunit of IL-12 and IL-23, reduced Aβ burden and improved cognition 
(580). Both IL-12p40 and IL-23 levels are increased in the HFHS-fed mice, indicating 
the potential for these cytokines to induce adverse microglial responses. Indeed, within 
mouse models of MS it has been demonstrated that IL-12p40 produced by microglia 
plays a critical role in the encephalitogenicity during the effector phase of the disease 
(581). 
 
Aside from the rise in pro-inflammatory mediators in the HFHS-fed mice, there is also 
an increase in the anti-inflammatory cytokines e.g. IL-4, IL-10 and IL-13. These 
classical anti-inflammatory cytokines have been previously associated with obesity 
and insulin resistance (582–586) and have been suggested to offer a degree of 
protection through recruiting eosinophils and TH2 cells (587). In MS, IL-4 and IL-10 
help modulate the balance between TH1/TH2/TH17/Treg cells which is crucial for 
determining disease progression (588). Anti-inflammatory cytokines have also shown 
to reduce neuronal damage, for example IL-10 represses sepsis-associated 
hippocampal neuronal damage (589) and IL-1ra significant reduces the extent of 
neuronal cell death through binding to IL-1 receptors in ischemia, trauma and 
excitotoxicity (590).  
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The rise in these anti-inflammatory interleukins in the HFHS-fed mice could perhaps 
represent an attempt to balance and resolve the ongoing inflammation. In fact, in 
T2DM, adipose tissue is also a key producer of anti-inflammatory interleukins such as 
IL-4 and IL-10 (582,583). Nevertheless, other reports suggest hypo-responsiveness or 
a ‘resistance’ to IL-10 in T2DM (591) and the increased production may be a 
mechanistic response to overcome this issue. Importantly, within the brain, different 
mediators have differential effects dependent on disease. In EAE or PD mice, IL-10 
ameliorates the disease phenotype (592,593). However in AD mice, IL-10 
administration leads to Aβ accumulation through impaired microglia phagocytosis 
(594). Further contrasting studies find hippocampal targeted expression of IL-10 and 
IL-4 to decrease gliosis and improve spatial memory in AD mice (595,596). 
Importantly, the administration of IL-10 in EAE mice is largely only beneficial when 
provided at disease onset (597) and through intracranial administration (598).  
These studies highlight the complex nature of chronic inflammation as well as the 
brain microenvironment. The simultaneous rise of pro- and anti-inflammatory 
mediators activate and alter multiple signalling cascades (340,349–351) and perhaps 
it is this disarray that results in the self-perpetuating inflammatory environment that 
contributes to overall disease progression.  Rebalancing the immune response, is 
therefore not as simple as blocking inflammation but rewiring the immune response 
in a spatial and temporal manner (599). In depth studies are required to understand the 
role played by pro- and anti-inflammatory mediators arising from metaflammation, 
and the signalling pathways involved in inducing BBB damage, reactive gliosis, and 
microglial activation. In doing so, useful targets to help alleviate or decelerate the 
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4.3.3 Immune imbalance  
CD4+ TH subsets play a crucial role in modulating immune response. Of the subsets, 
the TH1 and TH2 subsets have been well studied in relation to T2DM and contribute to 
chronic inflammation and insulin resistance. TH1 cells are responsible for the 
production of IFN-γ, TNF-α and IL-12 to trigger cell-mediated immunity and 
phagocytic-dependent inflammation (236). TH2 produces a variety of cytokines 
including IL-4, IL-6, IL-10 and IL-13 to regulate antibody responses (600). In our 
diabetic model of HFHS-feeding, although the percentage of the TH1 and TH2 subsets 
were not evaluated, all of the above mentioned cytokines were increased at the brain 
microvasculature in the HFHS-fed mice compared to chow-fed mice thereby 
suggesting that these cytokine-producing cells are likely to have been present to try 
and combat the disease and reduce inflammation.  
Another T-cell subset of importance are the Treg cells which maintain immune 
homeostasis by preventing excessive inflammatory response; this is achieved through 
regulating the response of other T-cell subtypes and by influencing the activities of 
innate immune cells (601,602). TH1 and Treg cells in visceral adipose tissue play a 
key role in regulating body weight, insulin resistance, glucose tolerance and thus 
T2DM progression, in both mice and humans (525,526). Generally, the skew of CD4+ 
T-cell subsets in T2DM patients are towards the pro-inflammatory subsets (368). 
However a study by Zeng et al., have demonstrated that it is not only the balance 
between TH1/TH2 but also the balance of TH17/Treg that influences pathogenesis of 
T2DM (368). TH17 are reported to be increased in obese and T2DM patients and have 
been linked to altered lipid metabolism (603–605). TH17 cells produce IL-17, which 
stimulates the production of TNF-α and correlates to obesity (606), with IL-17-/- mice 
on a high-fat diet showing improved insulin sensitivity despite being overweight 
(607). In the HFHS-fed mice there is an increase in IL-17 and TNF-α levels compared 
to chow-fed mice, that are likely to contribute to the increase weight gain. 
Additionally within the gut, TH17 cells induce anti-microbial peptides (AMPs) which 
increase intestinal permeability within mice fed a high-fat diet (603,608). AMPs are 
part of the innate immune response, and within the brain, Aβ itself is recognised as an 
AMP when it forms aggregates under inflammatory response (609). These aggregates 
cause CNS inflammation, inducing microglial cells and promote further Aβ 
production resulting, over time, in AD. The enhanced presence of TH17 cells in a 
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diabetic inflammatory state may therefore induce AMPs at the BBB and further 
contribute to the development of negative immune responses within the brain, 
enhancing the rate of neurodegenerative disease development.  
The involvement of TH17 cells in the brain has been most well studied in MS. TH17 
cells and IL-17 is increased in peripheral blood, the brain parenchyma, CSF and 
lesions of MS patients or EAE rodents; with the numbers of TH17 cells linked to 
disease severity (610–612). The contribution of TH17 to MS progression is confirmed 
by IL-17-/- mice which are protected against EAE development (613). The role of TH17 
cells have also been of interest in AD, with studies reporting elevated TH17 cells in 
AD brains (614), that can be correlated to the degree of amyloidopathy (615). The 
infiltration of TH17 cells into the brain parenchyma of AD mice contribute to 
neuroinflammation and neurodegeneration either indirectly through increasing the 
release of pro-inflammatory cytokines IL-17 and IL-22 or directly by the Fas/FasL 
apoptotic pathway (616). These studies implicate the potential of TH17 cells to 
contribute to neuroinflammation/neurodegeneration in the HFHS-fed model, in which 
numbers of migrated RoRγt+ cells are elevated.  
Furthermore, TH17 cells have largely been implicated in the microvascular diabetic 
complication of diabetic nephropathy. In patients with diabetic nephropathy the TH17 
counts increased along with the ratio of TH17/Treg cells (367). Similarly, in our 
diabetic model of HFHS-feeding within the cervical lymph nodes, the percentage of 
TH17 cells are increased along with the ratio of TH17/Treg cells in the HFHS-fed mice 
compared to chow-fed mice. Moreover, in the same study of diabetic nephropathy 
patients, it was seen that the ratio of TH17/Treg increased over disease duration, 
whereas there was no change in the ratio of TH1/TH2 cells over disease duration (367) 
suggesting therefore that TH17 and Treg cells may have stronger roles to play in the 
pathology of metabolic disorders and its associated complications. Indeed, in the brain, 
Treg confer neuroprotection and have shown to attenuate TH17-mediated 
neurodegeneration in PD brains (617). In contrast, the levels of Treg and their role is 
in AD is still under debate. Some studies have shown Treg to be reduced and thus 
linked to cognitive impairment; the administration of Treg into mouse models have 
thus shown to have suppressive activity, slow down disease progression and restore 
cognition (618,619). On the other hand, other studies report increased Treg numbers 
in AD which positively correlate to the level of tau protein in AD brains (614,615). 
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Interestingly, there was also increased migration of Treg cells along with TH17 cells 
in a BBB model, this could be an attempt to provide neuroprotection. 
Overall lack of Treg in the peripheral systems results in reduced immunosuppression 
of monocytes/macrophages, which are strong contributors to the inflammatory process 
and development of secondary complications (238). Within the HFHS-fed mice, it was 
seen that percentages of neutrophils, macrophages and dendritic cells are all increased 
in the bone marrow compared to chow-fed mice, further implicating the loss of Treg 
to dampen immune response and thus loss of immune balance control within metabolic 
disorders.  
 
CD8+ T-cells are also key in inducing the recruitment and differentiation of 
macrophages in obese adipose tissues, with studies showing early infiltration of CD8+ 
T-cells into adipose tissue with high-fat feeding (372). In the present study, the 
percentage of CD8+ T-cells is increased in the bone marrow of HFHS-fed mice 
compared to chow-fed mice however, surprisingly the percentage of CD8+ T-cells in 
draining cervical lymph nodes of HFHS-fed mice is decreased. In traumatic brain 
injury mouse models, it has been seen that CD8+ T-cells are increased in the brain 
preceding increased CD4+ RoRγt+ T-cells; and a pharmacological or genetic depletion 
of CD8+ T-cells improved neurological outcomes through providing a TH17/TH2 
immunological shift (620). In addition, B-cells can also impact the proliferation of 
TH17 cells with depletion of B-cells in T2DM patient resulting in reduced TH17 cell 
proliferation (621). Within the HFHS-fed mice, in the bone marrow there was a 
reduction of B-cells compared to chow-fed mice. The reduction of B-cells may be an 
attempt to improve glucose tolerance, through inactivating Teff cell response. Mice 
which are unable to produce mature B-cells and are fed a high-fat diet have improved 
glucose levels compared to wild-type controls on high-fat diet (375). Therefore 
overall, it can be assumed that increases in levels of particular anti-inflammatory 
cytokines or alteration in cell types in the diabetic state are likely to be a compensatory 
mechanism induced by the immune system in an attempt to attain back control. To 
gain clarity, further work would be required to look at the infiltration and differential 
subset ratios within the brain parenchyma of these mice to determine exact 
neurological impact with metabolic disorders.  
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On the other hand, the reduction of NK cells in HFHS-fed mice compared to chow-
fed mice is not unexpected, with a large majority of studies reporting decreased NK 
cells and function in obese individuals compared to healthy controls (363,622). In fact, 
NK cell-deficient mice have worse metabolic disorders and enhanced weight gain 
(622–625). Injections of Galactosylceramide (𝛼GalCer), a potent lipid ligand that 
induces NK cells, in obese mice increased NK cell activity resulting in weight loss, 
reversal of glucose and insulin insensitivity along with differentiation of macrophages 
to an anti-inflammatory phenotype (626–628).  
Crucially, the assessment of the innate and adaptive immune cells has been conducted 
in the bone marrow and cervical lymph nodes of these mice, and adhesion/migratory 
capacity of these cells across the BBB into the brain parenchyma has only been 
assessed in CD4+ T-cells. Without doubt, future work is required to understand the 
migration of other immune cells into the brain parenchyma, and the regional 
distribution between parenchymal and leptomeningeal compartments.  
 
 
4.3.4 Immune cell recruitment to the BBB 
BBB breakdown is considered a significant event in the start of neuroinflammatory 
and neurodegenerative disorders. Notably, models of EAE clearly showcase that 
symptoms of disease do not occur until leukocytes have migrated across the BBB; thus 
suggesting that leukocyte migration is a rate-limiting step in disease onset (156,251). 
Damage to the structural and functional integrity of the BBB therefore allows for an 
easier passage of immune cells, amongst other molecules, from the peripheral system 
into the brain either transcellularly or paracellularly.  
Importantly, opening the BBB alone is not sufficient to result in leukocyte TEM into 
the CNS parenchyma (257). Instead the loss of BBB integrity must be accompanied 
by a pro-inflammatory response (258). There are several conditions which are required 
to allow for the optimal migration of leukocytes across an endothelium barrier. First 
and foremost, chemokine signals must induce the chemotaxis of immune cells. Review 
of the chemokines at the brain microvasculature in HFHS-fed mice revealed a raised 
presence of chemokines that induce monocytes, neutrophils, and T-cells. Examination 
of CD45+ leukocytes staining is indicative of chemotaxis in the HFHS-fed mice. In 
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viral models of lymphocytic choriomeningitis virus and mouse hepatitis virus, the 
generation of CXCL10 in the CNS precedes leukocyte infiltration and development of 
disease (629–631). This suggests that brain cells in the parenchyma are also 
responsible for production of chemokines; and in fact astrocytes, microglia and 
neurons were confirmed to produce CXCL10 in these particular viral models (253). 
Moreover, a transgenic mouse with astrocyte-targeted CXCL10 gene found that 
despite the ability of CXCL10 to recruit leukocytes into the CNS, the leukocytes were 
not fully activated until additional pro-inflammatory cytokines provided by a 
peripheral immune challenge was given (253). In the HFHS-fed mouse model, this 
latter condition has been met by the sustained metaflammation and indeed we see 
increased CXCL10 and increased migration of leukocytes across the BBB in vivo and 
in vitro. Without doubt, there are several chemokines which work by similar 
mechanisms to induce chemotaxis that will be relevant in the HFHS-fed model. It 
would be interesting to evaluate the chemokines produced by the different cell types 
in future studies, particularly as the ability of brain parenchymal cells to produce 
chemokines and thus induce leukocyte infiltration suggests that these cells can detect 
perturbations in the brain or blood milieu very early on and thus contribute to the 
disease pathology.    
 
Whilst there is a higher level of the majority of chemokines noted in the brain 
microvessels and serum of the HFHS-fed mice compared to chow-fed mice, it should 
be noted that a number of chemokines are also categorised as homeostatic. The 
constitutive expression of chemokines CCL19, CCL20, CCL21, CXCL12 and 
CX3CL1 are also detected in uninflamed brain tissue (632,633); as seen in the chow-
fed mice. For example, the presence of CXCL12 protein at the BBB under normal 
conditions is found to be located on the abluminal surface of the endothelium. During 
EAE or MS in mouse and humans respectively, CXCL12 relocates to the luminal 
surface thereby increasing the entry of immune cells, which express the co-receptor 
CXCR4, into the brain (633,634). Localisation of CXCL12 therefore represents a 
method of homeostatic protection in the brain to limit immune cell extravasation. 
Whilst the levels of CXCL12 have not been measured at the brain microvessels in our 
model using the cytokine kit, there are increased levels of this chemokine in the serum 
of HFHS-fed mice suggesting increased production and therefore chemotactic 
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properties. Again, there are likely to be several chemokines which function within the 
same manner and examining the differential location of chemokines under 
inflammation could be an interesting line of work to pursue to determine the particular 
subsets of immune cells that migrate across the BBB.  
 
Moreover activated or memory T-cells are known to be favoured for migration from 
blood to tissues (635,636). Interestingly, Kivisäkk et al., characterised the phenotype 
of T-cells in the CSF of normal humans and found activated TCM cells with high 
expression levels of CCR7, CXCR3 and L-selectin (637,638). It is therefore not 
surprising that in the draining cervical lymph nodes of HFHS-fed mice there is a higher 
percentage of CD4+ T-cells expressing CD44, LFA1 and CXCR3 compared to chow-
fed mice. In addition, the HFHS-fed mice also had a higher percentage of both TCM 
CD44hi CD62Lhi CCR7hi-expressing cells and TEM CD44hi CD62Llo CCR7lo-
expressing cells in cervical lymph nodes, compared to chow-fed mice. The activation 
and memory status of CD4+ T-cells, along with cytokine presence and antigen-
presentation therefore may account for the significantly larger number of both adhered 
and migrated CD4+ CD45+, RoRγt+ and Foxp3+ cells in the HFHS-fed mice compared 
to the chow-fed mice. Indeed work by Marelli-Berg and colleagues in a high-fat model 
of western diet, have shown TEM cells (CD44hi-CCR7lo-CD62Llo-CXCR3
+-LFA1+) 
to preferentially migrate to non-lymphoid inflammatory sites (370) and Shirakawa et 
al., showed an increase of these TEM cells in the visceral adipose tissue of obese mice 
(639). Furthermore in a human cohort study of 1172 subjects, defined as lean (BMI 
<25), overweight (BMI <25-<30) and obese (BMI >30), flow cytometric analysis of 
CD4+ T-cell subsets found obesity to be strongly associated with reduced naïve T-cells 
and increased TEM cells (CD4
+RA+ RO-CCR7+HLA-DR+CXCR3+) (370). More 
research is required into looking at human patient samples in BBB models to 
determine the migratory profiles. 
 
Although an inflammatory cytokine environment is required as a contributing factor 
to activation and thus migration of leukocytes across the BBB, the underlying presence 
of chemokines in normal chow-fed mice suggests that immune cells must be present 
in normal conditions too. In fact, studies have shown presence of peripherally-derived 
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T-cells, macrophages and dendritic cells localised in the perivascular compartments 
outside the parenchyma acting as immune-surveillance; importantly the number of 
these cells is relatively small compared to peripheral organs (171,640). One key role 
during immune surveillance is to act as an antigen-presenting cell; some reports 
suggest the ability of dendritic cells to present antigens detected in the CNS to T-cells 
in the periphery. Nonetheless, dendritic cells injected into the CSF of patients have 
been detected in B-cell follicles of cervical lymph nodes (641). Although the cell 
frequency of dendritic cells in cervical lymph nodes was not evaluated in chow or 
HFHS-fed mice, it was noted that there was a significantly greater B-cell frequency in 
the HFHS-fed mice suggesting that B-cells had been stimulated to proliferate, perhaps 
by antigen-presentation from the CNS. Without antigen presentation, the T-cells will 
simply not become activated despite the inflammatory environment.  
 
One other factor preceding TEM, is the requirement of the endothelium to become 
activated to express adhesion molecules thus allowing for the initiation of the 
transmigration cascade (capture, rolling, tethering, firm adhesion & diapedesis) (642). 
In the HFHS-fed mice, the serum contains higher levels of sICAM-1 and the 
endothelium clearly expresses higher levels of ICAM-1, VCAM-1 and P-selectin with 
confocal imaging confirming presence on the luminal side. Increased adhesion 
molecule presence on endothelial cells along with increased expression of co-receptors 
on T-cells allows for enhanced adhesion, as confirmed by greater numbers of adhered 
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4.3.5 Leukocyte TEM across the BBB  
In peripheral tissues, transmigration allows cells to directly enter the tissue 
parenchyma. However due to the tightly controlled nature of the brain, the 
transmigration of leukocytes across the BBB into the brain parenchyma is in fact a 
two-step process (643–645). Invading leukocytes must initially pass across the 
endothelial cells whereby they become trapped in specialised compartments termed 
the perivascular space; defined by the inner endothelial BM and the outer astrocytic 
BM. To cross into the brain parenchyma, the invading cells must be able to transverse 
both BMs. In models of EAE, it has been seen that leukocytes can accumulate within 
this region and this accumulation of leukocytes is dubbed as the perivascular cuff 
(156,251). In the HFHS-fed mice, double immunostaining with pan-laminin (a marker 
for both endothelial and astrocytic BM) and general leukocyte marker CD45 shows 
clear entrapment of CD45+ leukocytes between the two BM layers or perivascular 
space and some infiltration into the brain parenchyma. Staining in the chow-fed mice 
does not show this type of perivascular cuffing. Although migration studies with 
isolated and activated leukocytes in transwells confirmed far greater numbers of 
migrated CD4+ CD45+ leukocytes in the diabetic model of HFHS-feeding compared 
to control chow-fed mice, it must be noted that in vitro modelling did not use co-
culture methods with endothelial cells and astrocytes. This would be a true indicator 
of the passage of activated leukocytes across both BMs.  
Initial passage across the endothelial cells requires a β1-integrin-mediated process. 
Research by Sixt et al., demonstrated that upon approaching the endothelial BM, T-
cells preferentially infiltrate across regions containing only laminin α4 due to the high 
expression of α6β1-integrin located here (156). As noted, the number of migrated 
leukocytes was far greater in the HFHS-fed model indicating that these cells were 
interacting via integrins to allow the TEM cascade. Electron microscopy studies could 
help to reveal the pores through which leukocyte migration occurs and identify if these 
are at laminin α4 regions.  Importantly the ability of some cells to adhere and migrate 
in the chow-fed model is indicative of immune surveillance. Studies in healthy patients 
and rodents have shown the presence of inactivated CD4+ T-cells to reside in the 
perivascular region for this purpose (254). The astrocytic BM lacks α6 and therefore 
in order for leukocytes to pass from the perivascular space into the brain parenchyma 
β-dystroglycan, a transmembrane receptor, that anchors astrocyte end-feet to the 
Page | 195  
 
parenchyma must be cleaved (156,646). In vivo studies in EAE models have shown 
that MMP-2 and MMP-9 selecting cleave β-dystroglycan, with double MMP-/- mice 
conferring resistance to leukocyte infiltration through inhibiting this cleavage (251). 
Within the HFHS-fed mice, the increased activity of the gelatinases implicates the 
ability of β-dystroglycan to be cleaved; corresponding with loss of the astrocytic end-
feet association to the microvessels in the HFHS-fed mice compared to chow-fed mice. 
Additionally, activated leukocytes also release MMPs to aid in passage across the 
BBB (262,263).  
 
The production of MMPs by tissue and immune-cell sources have been implicated to 
be strongly affected by cytokine levels. Work by Agrawal and colleagues show that 
the balance of TNF-α vs IFN-γ regulates activation of astrocytes and secretion of 
MMP-9 (647). TNF-α-/- mice show enlarged perivascular cuffs due to the 
accumulation of leukocytes that are unable to breach the astrocytic BM barrier due to 
lack of MMP production thereby delaying disease onset in EAE models (647,648). On 
the contrary, IFN-γ acts a negative regulator of secretion, activation and subsequent 
transmigration (649,650). Interestingly, in the HFHS-model there is an increase of 
both TNF-α and IFN-γ at the brain microvessels; notably the relative expression of 
TNF-α to IFN-γ is much higher. Moreover, the balance of TNF-α/IFN-γ production is 
controlled by the TH17/TH1 cell populations. TH1 cells are characterized by secretion 
of TNF-α and IFN-γ whereas TH17 cells produce TNF-α and IL-17 (651) suggesting 
that the ratio of the cells at the BBB and the perivascular space have important roles 
to play in MMP secretion and subsequent astrocyte induction (647). In this regard, the 
increased percentage of CD4+ RoRγt+ cells in the cervical lymph nodes and in the 
adhesion/migration model in the HFHS-fed mice versus the chow-fed mice implicate 
that cells of the TH17 lineage are a likely contributor to the source of increased TNF-
α, IL-17a and MMPs detected in the brain microvessels. Nevertheless, as eluded to 
previously the exact ratio of different T-cell subsets within the cervical lymph nodes, 
at the perivascular space, and in the CNS parenchyma requires further investigation. 
It should be noted that in the HFHS-fed model, there is also an equally large proportion 
of adhered and migrated cells of the Treg subpopulation, again perhaps representing a 
compensatory mechanism by the brain to combat the enhanced inflammation at the 
BBB.  
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The work of this project has focused on leukocyte TEM across the BBB, however it 
is should be acknowledged that some leukocytes may also enter the brain parenchyma 
in the CSF via the BCSFB (247). In MS patients, the number of T-cells, B-cells and 
macrophages in the CSF correlates with the number of CNS lesions (652). Although 
the BCSFB does not have the two-step process of leukocyte TEM, with leukocytes 
held in the perivascular space due to the glia limitans, the BCSFB epithelial cells are 
also interconnected with TJs (653). Disruption of the TJ molecule claudin-3 in choroid 
plexus cells in EAE models coincides with enhanced levels of infiltrating leukocytes 
in the CSF of these mice (653). It has been proposed that leukocytes passing across 
the BCSFB produce large amounts of inflammatory mediators and cytokines that 
activate the endothelial cells of the brain vasculature to induce adhesion molecule 
expression. Thus, this facilitates an influx of immune cells across the BBB (654). 
Increased permeability of the BCSFB has also been noted in mild cognitive 
impairment and AD accompanied by the passage of interleukins such as IL-17 and IL-
4 (655). Future studies would benefit in examining the extent to which the disruption 
of the BCSFB contributes to the immune cell passage in HFHS-fed mice.  
 
Moreover, this study has largely focused on the correlation of BM degradation with 
leukocyte TEM. However, it is important to note that degradation of the BM also has 
wider implications in disrupting the CNS environment; through impacting the 
drainage of ISF. Fluid and solutes from the brain drain to the cervical lymph along the 
BMs in the walls of capillaries and arteries (60,64,203). This drainage mechanism has 
been named the IPAD pathway (204). Reduced lymphatic drainage via IPAD can 
result in the accumulation of Aβ and results in cerebral amyloid angiopathy, which 
appears as white matter hyperintensities during scans of the brain (210). The 
accumulation of Aβ and indeed of other waste products or metabolites will affect the 
CNS environment and lead to altered homeostasis. Indeed, this could be one potential 
mechanism by which T2DM results in T3DM. It would be interesting to explore the 
IPAD in these HFHS-fed mice, to determine whether degradation of the BMs in 
endothelial cells and astrocytes also correlates with the loss of ISF drainage, and Aβ 
accumulation.  
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4.3.6 Metaflammation induced microglial activation 
To understand if the metabolic disruption at the BBB has implications within the brain 
parenchyma, the status of the microglia cells was investigated. Microglia cells are the 
primary resident immune cells of the brain. Typically, microglia are described to be in 
either their resting or activated state. However, microglia are not truly ‘resting’ even 
in a healthy CNS. Instead microglia form close associations with neurons, contacting 
synapses with their processes in order to monitor synapse function, state and stability 
by providing trophic support (171) and engaging in environmental surveillance to 
maintain homeostasis. Once microglia sense harm or encounter an antigen that is 
foreign, they enter into an ‘activated’ state; inducing changes in morphology, 
proliferation, phagocytic activity and immunoreactivity with increased expression of 
pro- and anti-inflammatory mediators (656). Within the activated state, microglia can 
be categorised into two broad states, which are the pro-inflammatory M1 phenotype 
or the anti-inflammatory, pro-resolving M2 phenotype. Activation of microglia, aims 
to resolve, retain and limit the infection and/or tissue damage (657). Dysfunction and 
uncontrolled activation or skew towards the M1 phenotype therefore has huge 
implications for vascular breakdown, neuronal death and synaptic plasticity, and forms 
the neuroinflammatory response (412). Reactive gliosis has been implicated in a 
number of brain disorders including AD, PD, ALS, traumatic brain injury (TBI), 
Stroke and Epilepsy amongst others. In AD, there is an increase in proliferation of 
activated microglia of the M1 phenotype, with impaired ability of microglia to take up 
Aβ for phagocytosis, resulting in its accumulation (658,659). Confocal images in the 
HFHS-fed mice showed activated microglia through the expression of IBA1+ staining 
and in primary culture cells there was an upregulation of activation markers MHCII 
and CD11c compared to the chow-fed mice, indicating that an immune response was 
being elicited within the brain. In line with this, in HFHS-fed mice there is a significant 
rise in the M1 phenotype accompanied with a decrease in the resolving M2 phenotype. 
The initiation of neuroinflammation with a skew towards the M1 phenotype in HFHS-
mice implicates how the altered brain responses may lead to the development of AD 
pathology (660–663). In diabetic retinopathy patients, activation of microglia cells 
leads to nerve fibre thinning, apoptosis of neurons and visual loss (656); it is possible 
that similar effects may be occur in diabetic brains.  
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Of particular interest in the HFHS-fed mice was the loss of the CX3CR1 receptor 
expression compared to chow-fed mice. Under both normal and pathological 
conditions, the CX3CR1 receptor present on microglia interacts with neuronally-
derived CX3CL1 to mediate cross-talk for controlling functions such an intracellular 
calcium mobilisation, chemotaxis and Fas-mediated apoptosis (664,665). In mouse 
models of T1DM, loss of CX3CR1 signalling increased systemic inflammation 
through increased IL-1β production by proliferating microglia. Further studies found 
the deletion of CX3CR1 in T1DM sped up diabetic retinopathy onset through 
increased apoptosis in the retina (666). This implicates, that the loss of CX3CR1 
expression in the microglia of HFHS-fed mice could potentially have detrimental 
effects on neurons within the brain parenchyma; particularly as CX3CR1-/- mice have 
aberrant IL-1β expression, loss of long-term potentiation and loss of synapse 
plasticity/activity resulting in impaired cognition (667,668). Nevertheless, knockout 
of CX3CR1 in mouse models of AD (APP/PS1 transgenics) found CX3CR1 
deficiency to reduce amyloid plaque aggregation and microglia-mediated neuronal 
death despite microglia hyperactivation (669–671). However in vitro, microglia 
treated with β-amyloid show downregulation of CX3CR1 with increased expression 
of IL-6 and TNF-α (672). Patients with AD also exhibit lower levels of CX3CR1 and 
CX3CL1 (672). In summary, this suggests that reduced CX3CR1-CX3CL1 can induce 
both negative and beneficial effects. Further work is required to substantiate the true 
role of CX3CR1-CX3CL1 in T2DM, as studies in other models of disease including 
ALS, PD and stroke show differential signs of benefit vs harm (673). 
Overall, a low grade chronic inflammatory state within the peripheral system because 
of MetS/T2DM has major implications in inducing and causing sustained 
neuroinflammatory responses. As a consequence of sustained BBB breakdown 
through inflammatory mediators there will be constant activated leukocyte 
transmigration and therefore subsequent astrocyte and microglial activation. The 
sustained neuroinflammatory response, like the immune response within the 
peripheral system, will have negative and destructive effects on the neurons within the 
brain. In the HFHS-fed mice, the loss of astrocyte association to the brain endothelial 
cells will impact the transmission of nutrients, neurotransmitters and second 
messengers to neurons (400). Moreover, iNOS production by microglial cells, as seen 
in the HFHS-fed mice, is known to inhibit long-term potentiation formation thereby 
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impairing cognition (429). The blindness induced by microglial activation in diabetic 
retinopathy, highlights the potential impact of widespread degeneration within the 
brain. Although further research is required on the impact on the neurons in the HFHS-
fed mice, research has shown that diabetes induces a loss of memory or impaired 
cognition in both patients (392,450) and rodents (451,452) with T2DM. In C56BL/6J 
mice fed a high-fat high-fructose diet for 24 weeks there is a significant deterioration 
in cognitive function as assessed by the Morris Water Maze test compared to control 
on a normal diet (451,452). In line with cognitive decline, staining for astrocytes and 
degenerating neurons using GFAP and Fluro-Jade C respectively in diabetic rats, 




In summary, this chapter shows that the development of MetS/T2DM induces an 
inflammatory state both at the serum level and at the brain microvasculature. The 
increased presence of interleukins and chemokines has an impact at both an immune 
system level but also at the BBB by inducing breakdown and thus enhancing 
permeability. The complete breakdown of the BBB, resulting from loss of TJs, 
cytoskeleton and BMs as a result of dysregulated MMPs/TIMPs ratio allows for the 
passage of CD45+ leukocytes to transverse the BBB and enter into the brain 
parenchyma. The peripherally activated Teff, TCM, TEM and TH17/Treg imbalance along 
with chemokine/cytokine disruption induce activation of the brain resident immune 
cell - the microglia. The disbalance of M1/M2 microglia phenotype could have a huge 
impact on causing further inflammation within the CNS parenchyma and affecting the 
astrocytes and neuronal cells.  In conclusion, a diabetic phenotype has a negative 
impact on the brain and begins to initiate an inflammatory response which could have 
detrimental effects for neuroinflammatory and neurodegenerative disorder 
development.   
It should be noted that this study is examining the effect of peripherally derived 
inflammation arising from a HFHS-diet on the BBB and the NVU.  There is a vast 
amount of research detailing the pathophysiology and development of T2DM in the 
peripheral system. Although, the brain is no longer considered immune-privileged, the 
BBB and the other central barriers described in Section 1.1 indicates the unique and 
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enclosed structure of the brain. Therefore, manifestation and development of disease 
at the BBB and within the brain arising from T2DM may differ from the atypical 
pathology seen in the peripheral system. Equally, as the T2DM is a disease of the 
peripheral system, it is also likely to differ from the pathology of atypical CNS 
disorders. Therefore, when examining the development of neuroinflammation or 
neurodegeneration arising from T2DM, the interplay of the two system must be 
considered in greater depth. This has huge implications for not only understanding the 
development and progression of the disease but also when considering treatments to 
combat the disease.  
 
Of final note, this chapter studies the differences in chow vs HFHS fed mice and does 
not look at the effects of aging, which formulates a study within itself. However, a 
simple evaluation of permeability and TEER of young vs aged pMBMECs showcases 
that there is a significant degree of damage to the BBB overtime with age; this is 
perhaps not unexpected as it is well documented that health and immune response 
declines with age (675,676). The natural inflammatory state is raised with age, and is 
referred to as inflammaging (677). However, the ability of a HFHS-fed diet to further 
enhance permeability and reduce TEER significantly against age matched chow-fed 
counterparts is indicative of how metaflammation can accelerate brain 
microvasculature damage and thus initiate detrimental pathology within the brain. 
This is a cause for concern, given that the worldwide incidence for obesity, sedentary 
lifestyle and ageing population is on the rise (315); suggesting that not only will CVDs 
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5.1 Introduction  
The findings from Chapter 4 showed how metabolic disorders disrupt the BBB and 
can lead to adverse immune events both peripherally and within the brain parenchyma. 
These results implicate that controlling metabolic disease is not just essential for 
prevention of typical diabetes-related peripheral secondary complications and 
cardiovascular disease but also for secondary complications of the brain (initiation of 
neuroinflammation and development of potential neurovascular/neurodegenerative 
disorders).  
Management of T2DM in patients is achieved through medications and lifestyle 
changes such as dietary intake, physical activity levels and behavioural therapy. 
Medical management of T2DM requires the control of hyperglycaemia, 
dyslipidaemia, and high blood pressure to reduce chronic inflammation and its 
associated tissue damage. Therefore, the identification of drugs or molecules that 
combat the underlying low-grade chronic inflammatory state, alongside medications 
specifically for glucose, lipid or blood-pressure lowering could have huge implications 
in preventing or slowing the progression of macrovascular and/or microvascular 
complications.  
Annexin A1 (ANXA1) is an endogenous anti-inflammatory molecule that is 
upregulated by glucocorticoids. ANXA1 reduces inflammation by preventing the 
activation of PLA2 (274,275)., inhibiting COX-2 and inducing anti-inflammatory 
cytokines such as IL-10 (277). At the immune system, ANXA1 prevents leukocyte 
TEM through inducing L-selectin shedding and co-localising with α4β1 integrin to 
prevent leukocyte-endothelial interactions (279). In addition, ANXA1 promotes 
clearance of apoptotic cells through inducing efferocytosis by macrophages (278). 
ANXA1 levels are modulated in a number of different diseases and hrANXA1 or it’s 
n-terminal peptide Ac2-26 have been shown to produce therapeutic benefits in many 
diseases, including rheumatoid arthritis, MS and atherosclerosis, amongst others 
(294).  
Previous studies undertaken in our lab, have investigated the potential of hrANXA1 
to act as a therapeutic agent in modulating T1DM and T2DM-related microvascular 
disease. The results from these studies found that prophylactic hrANXA1 treatment 
had the ability to prevent development of microvascular complications (nephropathy 
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and cardiomyopathy) in STZ-induced T1DM mice (678). Similarly, therapeutic 
hrANXA1 treated in STZ-induced T1DM mice, in which microvascular complications 
had already developed, prevented further decline in cardiac and renal function (678). 
Likewise, in a T2DM model of high-fat high-sugar feeding treatment with hrANXA1 
prevented further deterioration of T2DM through restoring insulin sensitivity (512). 
Moreover, hrANXA1 treatment reduced the development of microvascular 
complications specifically renal nephropathy and lipid accumulation within the liver 
of T2DM mice.  
ANXA1 signals through the GPCR - FPR2, which is present on brain endothelial cells 
thus implicating its potential for limiting microvascular complications of the brain. In 
fact, studies from our lab have shown that ANXA1 is pivotal in maintaining cellular 
polarity, cytoskeleton integrity and consequently tightness of the BBB through the 
inhibition of the small G protein RhoA (297). Other cells of the NVU including 
astrocytes, microglia and neurons also express ANXA1 (679), further implicating its 
potential as neuromodulating agent.  
In this study, mice fed a HFHS-diet are treated with hrANXA1 as a pharmacological 
intervention. Treatment is provided by using full length hrANXA1, as the dose 
required to induce biological function is up to 20 times less than that required by the 
peptide Ac2-26 (482) and 14 times less than that needed to induce gene expression 
changes (483). Furthermore, Ac2-26 peptide has a weak ability in reducing leukocyte 
adhesion unlike full-length hrANXA1 (484). The daily dose of 1µg was selected based 
on previous report that show the half-life of ANXA1 to be approximately 6 hours 
through i.p. or i.v. injection. I.p. injection is preferred because 0.5% of the injected 
dose remains in the circulation 24 hours post injection versus almost 0% through i.v. 
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Lifestyle modifications are essential in managing T2DM development and 
progression. A meta-analysis of 89 studies indicates that nutritional therapy alone has 
the largest impact on producing weight loss and improving metabolic control (680). A 
number of nutritional guidelines are available from NICE (681), International 
Diabetes Federation (682), American Diabetes Association (683) and Joint British 
Societies (684). These guidelines provide recommendations for reference intake of 
food groups and nutrients (e.g. protein 0.75g/kg of ideal body weight, saturated fat 
<10% of daily intake, salt<6g/day) as well as proposed targets to reduce risk factors 
of MetS/T2DM (e.g. blood pressure <130/80mmHg, LDL cholesterol <2mmol/L, 
HbA1c levels <6.5%). These guidelines are for proposed for both patients that are at 
high risk of developing T2DM and CVDs or patients already diagnosed with T2DM 
with or without CVD complications.  
The majority of dietary recommendations are based on the consumption of a 
Mediterranean-style diet which is high in monounsaturated fats and fish oils with 
abundance of fruits, vegetables, legumes, and grains. Together these food groups help 
combat inflammation due to the high presence of omega-3 fatty acids, antioxidants 
and polyphenols that reduce free radical and cytokine production. This limits the 
activation of pro-inflammatory signalling pathways and helps to alleviate a chronic 
inflammatory state (685).  
Dietary recommendations form a crucial part of chronic disease management for a 
number of other diseases too, such as cancer, osteoporosis and dental disease.  
Consequently, the role of a paleo diet has also been investigated for the prevention of 
brain disorders, specifically dementias. Reports from large systematic reviews, made 
up of largely observational-based longitudinal studies, propose Mediterranean diets to 
improve cognitive function, decrease risk of cognitive impairment and lower risk of 
dementia development (686,687).  
As previously shown in Chapter 4, a diet high in fat and sugar causes inflammation 
which is damaging to the brain microvasculature and can start to initiate a 
neuroinflammatory response. In this study, mice fed a HFHS-fed diet for 10 weeks 
have been reverted to a normal chow diet for a following 5 weeks to review whether 
dietary intervention can also help to alleviate metabolic disorder-induced damage at 
the BBB.  
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5.1.1 Aims and objectives 
The chapter addresses Hypotheses 2 and 3 mentioned in Chapter 2, this is as follows: 
Anti-inflammatory drugs have shown to improve T2DM and CVD outcomes. In this 
manner, the effect of using ANXA1 as an anti-inflammatory therapeutic has been 
explored at the BBB. ANXA1 is well-established as a positive regulator of BBB 
structure and it has also been shown to provide neuroprotection, indicating its potential 
to reduce and repair damage at the BBB and beyond.  
 Hypothesis 2: 
It is hypothesised that treatment with human recombinant ANXA1 
(hrANXA1) will restore the leaky BBB phenotype through restoring tight 
junctions. Improved BBB integrity along with hrANXA1’s effect on 
leukocytes will prevent leukocyte TEM and reduce neuroinflammation.  
 
Aside from therapeutic strategies, the simplest method to resolve inflammation is to 
remove the source. In patients, lifestyle modifications are key to reduce the 
progression of T2DM and CVD, with the aim to reduce the inflammation arising from 
hyperglycaemia, hyperinsulinemia, and hyperlipidaemia. Moreover, the 
understanding on dietary intake and brain health is growing. As a result, the effect of 
a dietary intervention has been explored to understand whether preventive measures 
can reinstate the integrity of the BBB and subsequent development of 
neurodegenerative disorders.  
 Hypothesis 3:  
It is hypothesised that changing to a chow diet will remove the source of 
metaflammation and therefore improve the integrity of the BBB by reducing 
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This chapter addresses Aims 3 & 4 mentioned in Chapter 2, these are as follows:  
3. To assess the potential therapeutic effect of hrANXA1 on HFHS-induced BBB 
alterations. 
o hrANXA1 treatment will be given in vivo to animals to examine 
whether the protein has the ability to restore, resolve and revert the 
damage induced to the BBB, to the pre-diabetic state. This will serve 
as a pharmacological intervention.  
 
4. To investigate whether the metabolic stress induced BBB defects are reversible 
upon dietary intervention.  
o In order to assess reversibility of diabetes-induced BBB damage, mice 
fed a HFHS diet for 10 weeks will be re-introduced to a normal chow 
diet for a further 5 weeks.  
 
The following objectives were covered in this chapter to address these aims, the 
relevant methodology section has been referenced in brackets: 
• To determine whether pharmacological intervention provided by hrANXA1 
for 6 weeks and dietary intervention provided for 5 weeks can revert HFHS-
induced T2DM in mice.  
• To determine whether both interventions can restore BBB integrity (vascular 
leakage). Measurement will be conducted using in vivo Evans blue dye and ex 
vivo/in vitro via measuring the paracellular permeability coefficient and TEER.  
• To determine whether both interventions can restore the junctional proteins 
and BMs laminins. Expression of junctional proteins occludin and claudin-5 
and endothelial and astrocytic BM laminins, α4 and α5 to be imaged using 
confocal microscopy.  
• To determine whether both interventions can restore the expression and 
activity of MMPs and its inhibitor TIMP-1 to baseline, as seen in chow-fed 
mice.  
• To determine whether both interventions can resolve the inflammatory profile 
seen in HFHS-fed mice via examination of cytokines, interleukins and 
chemokines. 
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• To determine whether both interventions can reduce metaflammation-induced 
activation and expression adhesion molecules on endothelial cells. 
• To determine the effect of both interventions on the phenotype the of the innate 
and adaptive immune cells in bone marrow and cervical lymph nodes. 
• To determine the effect of both interventions, restore the activation status and 
ratio of CD4+ Teff, TCM, TEM, TH17 and Treg cells present in cervical lymph 
nodes.  
• To determine whether both interventions can reduce the infiltration/migration 
of leukocytes into the brain parenchyma.  
• To determine whether both interventions can reduce microglia cell activation 
and restore microglia M1 or M2 phenotype via FACS analysis of primary 
microglia cultures and imaging cerebral cortical brain sections.  
• To determine whether hrANXA1 can reduce neuroinflammation through 




In order to study these aims and objectives, interventions were provided in the 
following manner: 
❖ Pharmacological intervention was provided by treating mice fed a HFHS-fed 
diet with hrANXA1. 10-week old male C57BL/6 mice were fed a HFHS diet 
for 10 weeks. Pharmacological intervention was provided from weeks 5-10, 
whilst mice remained on the HFHS diet. Mice were treated with 1µg 
hrANXA1 in 100µl of 50mM Hepes and 140mM NaCl, pH 7.4, daily (5 
times/week) intraperitoneal (i.p.). The dose of hrANXA1 remained the same 
throughout the duration of the study and was not changed with increasing 
weight gain in the mice. To allow for accurate comparison against the chow-
fed and HFHS-fed mice; mice not assigned to receive hrANXA1 where treated 
with vehicle 100µl of 50mM Hepes, 140mM NaCl, pH 7.4, daily (5 
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❖ Dietary intervention was provided by reverting mice fed a HFHS diet onto a 
chow diet. 10-week old male C57BL/6 mice were fed a HFHS diet for 10 
weeks, after which mice were placed back on a chow diet for a further 5 weeks, 
the total dietary period for these mice was 15 weeks. Importantly, comparisons 
of this group have been made to mice given chow or HFHS-diet for 10 weeks 
and hence there is an element of age, which will be a confounder in these 
results. Chow, HFHS and HFHS + hrANXA1 mice were 20-weeks old at cull 
whereas HFHS – Chow reversion mice were 25-weeks old at cull.  
Importantly, this group of mice were also treated with vehicle 100µl of 50mM 
Hepes, 140mM NaCl, pH 7.4, daily (5 times/week) i.p. similar to chow-fed 
and HFHS-fed mice for the first 10 weeks on the intervention.   
 
Comparisons of both interventions have been made to mice fed a HFHS-diet or chow-
diet for 10 weeks. A summary of the experimental groups, experimental plan and the 
methods used to quantify each measure have been provided in Table 5.1, Figure 5.1 
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Table 5.1 | Experimental groups used to establish a mouse model of diet induced T2DM 
and the models used to provide a pharmacological and dietary intervention.   
Group name 
and age 
Diet and period 
of time 
Treatment and 










from weeks 1 - 10 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 






from weeks 1 - 10 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 







from weeks 1 - 10 
Pharmacological 
intervention of 
1µg hrANXA1 in 
100µl of 50mM 
Hepes, 140mM 
NaCl, pH 7.4,  
5 times/week i.p.  
Given weeks 5-10 
20 weeks 55 






weeks 1 - 10 
Chow from weeks 
11-15 (dietary 
intervention) 
Vehicle of 100µl 
of 50mM Hepes, 
140mM NaCl, pH 
7.4,  
5 times/week i.p.  
Given weeks 5-10 












Figure 5.1 | Summary of the experimental plan used to induce T2DM and provide 
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Table 5.2 | Summary of the central and individual measures used to evaluate the aims 
and objectives of Chapter 5, with reference to the respective methodology used to 
conduct these experiments. 





Obesity - weight gain and fat pads  3.1.1.1, 3.1.2 
& 3.1.3 




Hyperinsulinaemia - ITT, serum insulin 3.1.1.1, 3.1.2 
& 3.1.4 






Evans blue dye leakage in vivo 3.1.7 & 3.1.8 
Paracellular permeability in vitro 3.1.9 & 3.2.5 
TEER 3.1.9 & 3.2.6 
BBB structure 
Imaging junctional proteins occludin and 
claudin-5 
3.1.3 & 3.3.1 
Imaging BM laminins α4 and α2 3.1.3 & 3.3.1 
MMP 
involvement 
MMP-2, -3, -9 expression at brain 
microvessels via cytokine array 
3.1.9 & 3.2.8 




TIMP-1 ELISA 3.2.8 
Inflammatory 
profile 
Cytokine array for interleukins, chemokines, 
cytokines in serum and brain microvessels 
3.2.8 
Imaging and characterising adhesion 
molecule expression at BBB 
3.2.8 & 3.4.3 
Immuno- 
phenotyping 
Cell frequency of innate and adaptive 
immune cells in bone marrow and deep 
cervical lymph nodes 
3.1.3, 3.1.5, 
3.1.6, 3.4.3 
CD4+ T-cell activation for Teff 3.1.3 & 3.4.3 
TCM vs TEM  3.1.3 & 3.4.3 
TH17 vs Treg 3.1.3 & 3.4.3 
Leukocyte TEM 
across BBB 
Imaging CD45 infiltration into brain 
parenchyma 
3.1.3 & 3.3.1 









Imaging IBA1 activated microglia cells  3.1.3 & 3.3.1 
Imaging for iNOS expression 3.1.3 & 3.3.1 
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5.2 Results 
5.2.1 Effect of pharmacological and dietary intervention on the 
development of MetS 
Confirmation of metabolic disruption (obesity, hyperglycaemia, dyslipidaemia and 
insulin resistance) in this mouse model was conducted by measurements of weight 
gain, fat mass (epididymal & inguinal), fasting and non-fasting blood glucose, OGTT 
and ITT as well as serum insulin, cholesterol and triglyceride levels (Figure 5.2). Mice 
fed a chow diet, HFHS diet or HFHS diet + hrANXA1 treatment were culled at 10 
weeks, a total of 55 mice/group were used. Mice placed on a reversion diet were fed a 
HFHS diet for 10 weeks followed by reversion to a chow diet for 5 weeks; these mice 
were culled at 15 weeks; a total of 15 mice were used.  
At the end of the 10-week feeding period, HFHS-fed + hrANXA1 treated mice had 
significantly increased body weight and fat mass compared to chow-fed mice (Figure 
5.2A,D-F). Interestingly, treatment with hrANXA1 significantly reduced the overall 
weight gain and epididymal fat mass compared to HFHS-fed mice (Figure 5.2D,E). In 
the HFHS – Chow diet reversion group, the switch to a chow diet led to a decrease of 
body weight, with final body weight at 15 weeks significantly lower than the HFHS-
fed and HFHS-fed + hrANXA1 treated mice (Figure 5.2A,D) . In the HFHS – Chow 
reversion diet mice, there was a trend towards decreased percentage of fat mass 
however this was only statistically significant for percentage of epididymal fat 
compared HFHS-fed mice (Figure 5.2E,F).  
Food and calorific intake were only measured for chow-fed, HFHS-fed and HFHS + 
ANXA1 treated mice. The food intake of mice on HFHS diet was substantially lower 
than the chow diet however calorific intake was substantially higher (Figure 5.2B,C). 
Treatment with hrANXA1 in HFHS-fed had no effect on feeding patterns when 
compared to HFHS-fed, suggestive that hrANXA1 does not affect eating habits e.g. 
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Treatment with hrANXA1 and reversion diet significantly reduced the non-fasted 
blood glucose levels when compared to HFHS-fed diet mice, however no changes 
were seen in the fasted blood glucose levels, with concentrations significantly higher 
across all HFHS-fed groups when compared to chow-fed mice (Figure 5.2G,J).  
Insulin resistance was confirmed using OGTT and ITT. HFHS-fed + hrANXA1 
treated mice had improved glucose tolerance when compared to HFHS-fed mice 
although the tolerance remained worse than chow-fed mice (Figure 5.2H,I). HFHS – 
Chow reversion diet mice had impaired glucose tolerance when compared to chow-
fed and HFHS-fed + hrANXA1 treated mice; and were similar to HFHS-fed mice. In 
the ITT, treatment with hrANXA1 did not alter the insulin tolerance when compared 
to HFHS-fed mice (Figure 5.2K,L). Nevertheless, treatment with hrANXA1 did 
significantly lower serum insulin levels compared to HFHS-fed mice, comparable to 
concentrations seen in chow-fed mice (Figure 5.1M). Dietary reversion showed a trend 
towards improved insulin tolerance, similar to the tolerance seen in chow-fed mice. 
Dietary reversion lowered serum insulin levels when compared to HFHS-fed mice 
however the concentration of serum insulin remained higher than in concentrations in 
chow-fed and HFHS-fed + hrANXA1 mice (Figure 5.1M).  
Correspondingly, serum cholesterol and triglyceride levels were significantly reduced 
with hrANXA1 treatment; the serum cholesterol levels were comparable to chow-fed 
mice whereas the serum triglyceride levels were non-significantly higher (Figure 
5.2N,O). Similarly, HFHS – Chow reversion diet mice also had reduced serum 
cholesterol and triglyceride levels compared to HFHS-fed mice. The concentrations 
were comparable to those in chow-fed and HFHS-fed + hrANXA1 treated mice; 
however, these results were not statistically significant.  
In summary, it was seen that the HFHS-diet induced obesity and contributed to the 
development of MetS as noted by hyperglycaemia, hyperinsulinemia, 
hypercholesterolemia, and hypertriglyceridemia. Treatment with hrANXA1 in HFHS-
fed mice attenuated the development of MetS as seen through reduced weight gain 
(independent of affecting satiety), lower non-fasted blood glucose levels, improved 
OGTT and lower serum insulin, serum cholesterol and serum triglyceride levels. 
Likewise, reversion from a HFHS diet to a chow diet also resulted in a reduction in 
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weight gain, lower non-fasted blood-glucose levels, improved ITT and lower serum 
insulin, serum cholesterol and serum triglyceride levels.  
Generally, whilst both pharmacological and dietary interventions attenuate MetS 
development, treatment with hrANXA1 showed greater improvement across the 
majority of measures when compared to HFHS-fed mice, with particular effect on 
improving serum levels and glucose tolerance. Furthermore, results showed the 
levels/concentrations in HFHS-fed + hrANXA1 treated mice were largely similar to 
those in chow-fed mice, with the exception of weight gain. The reduction of weight 
gain, in comparison, was the strongest indicator of improvement in HFHS – Chow 
reversion diet group suggestive that diet has a huge impact on obesity.  
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Figure 5.2 | Characteristics of mice fed a chow diet, HFHS diet, HFHS diet + hrANXA1 
treatment or HFHS-diet for 10 weeks + 5 weeks of chow diet (HFHS – Chow reversion) 
C57BL/6 mice were fed either a standard diet (Chow) or a high-fat high-sugar diet (HFHS) 
for 10 weeks. Pharmacological intervention was given with either vehicle or human 
recombinant (hr) ANXA1 (1µg/100µl, i.p.) five times/week from weeks 5 to 10 (n=55). 
Dietary intervention was provided by placing mice on a HFHS for 10 weeks, followed by a 
chow diet for 5 weeks (HFHS – Chow reversion; n=15). Food (B) and calorific intake (C) was 
recorded for chow, HFHS and HFHS + hrANXA1 mice (n=10/group). Weekly body weight 
measurements (A), final body weight gain (D) and epididymal (E) & inguinal fat mass (F) was 
recorded to confirm obesity onset (n=15-55/group). Non-fasting (G; n=15-44/group) and 
fasting (J; n=15-39/group) blood glucose levels were measured to confirm hyperglycaemia. 
Serum insulin levels (M; n=8-27/group), glucose (H, I; n=15-38/group) and insulin tolerance 
testing (K,L; n=6-15) was conducted to confirm insulin resistance. Serum cholesterol (N) and 
serum triglycerides (O) levels were measured to confirm hypercholesterolemia and 
hypertriglyceridemia (n=9-23/group). Statistical analysis was performed by one-way ANOVA 
followed by a Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, 
**p<0.01, ***p<0.001, ****p< 0.0001 vs. Chow; $p<0.05, $$p<0.01, $$$p<0.001, 
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5.2.2 Treatment with hrANXA1 and healthy dietary changes reduces the vascular 
leakage of the BBB  
The first measure to determine whether the interventions could improve BBB integrity 
was to measure the in vivo permeability (Figure 5.3A). Both treatment with hrANXA1 
and dietary changes reduced the BBB leaky phenotype, as seen by a reduction in the 
Evans blue dye leakage. However, the reduction in leakage when compared to HFHS-
fed mice was slightly better in the HFHS-fed + hrANXA1 treated mice with 
approximately a 65% reduction compared to 50% reduction in HFHS – Chow 
reversion diet mice. Levels of Evans blue brain content in HFHS-fed + hrANXA1 
mice were comparable to levels of Evans blue in chow-fed mice.  
Further measurements for BBB integrity assessment were conducted ex vivo using 
cultured pMBMECs. Both intervention arms significantly decreased the paracellular 
permeability when compared to HFHS-fed mice (Figure 5.3B). Interestingly, the 
reduction in the in vitro paracellular permeability was significantly greater in the 
HFHS – Chow reversion diet mice with a 4-fold decrease compared to a 3-fold 
decrease in HFHS-fed + hrANXA1 mice and was in fact even better than the chow-
fed mice by 1.5-fold, suggesting a tighter restriction of paracellular flow. In 
combination with reduced permeability, both intervention arms showed a significant 
increase in the TEER which was better in the HFHS-fed + hrANXA1 treated mice, 
suggesting a tighter restriction in the ionic conductance (Figure 5.2C).  
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Figure 5.3 | In vivo and in vitro vascular permeability measurements  
Assessment of BBB permeability in vivo was conducted using Evans blue dye extravasation 
into the brain (A). 100µl of 2% Evans blue dye was given i.v. to mice (n=6/group) and allowed 
to circulate for 1 hour. The dye content was analysed spectrophotometrically at an absorbance 
of 620nm, values were normalized to brain tissue weight and are expressed as percentage of 
serum dye content. Isolated and cultured pMBMECs from mice were grown on transwell 
inserts for 7 days to measure ex vivo paracellular permeability (B) and transendothelial 
electrical resistance (TEER) (C) using 70kDA FITC-dextran and the Epithelial Volt/Ohm 
(EVOM2) Meter (World Precision Instruments, USA), respectively (For chow, HFHS, HFHS 
+ hrANXA1 n=10 pooled/group per experiment, two technical replicates, performed as three 
independent experiments with a total of n=30 per/group. For HFHS – Chow reversion 
n=6pooled/group, with two technical replicates, performed as two independent experiments 
with a total of n=12). Statistical analysis was performed by one-way ANOVA followed by a 
Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, ***p<0.001 vs. Chow; 
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5.2.3 Treatment with hrANXA1 restores the BBB integrity through 
restoring tight junctions and the basement membranes. Dietary 
intervention begins to improve BBB morphology. 
 
5.2.3.1 Changes occurring to the junctional proteins of brain endothelial cells  
The impaired BBB integrity in the HFHS-fed mice could be correlated to the 
disruption of TJs and BMs of endothelial cells and astrocytes. The significantly 
reduced leakage of the BBB in the HFHS-fed + hrANXA1 and HFHS – Chow 
reversion diet mice, therefore proposed an improvement in the cell-cell contacts and 
vascular structure of the brain microvessel.  
Confocal imaging of cerebral cortical brain sections revealed treatment with 
hrANXA1 restored TJ protein, claudin-5 and occludin and BM, pan-laminin (Figure 
5.4A,B) distribution, with staining showing a regular and continuous pattern. Further 
re-instatement of the cell-cell contacts was correlated to the actin cytoskeleton, with 
results showing HFHS-fed + hrANXA1 mice to have restored F-actin fibre formation, 
as seen with a reduction in the G/F actin ratio compared to HFHS-fed mice (Figure 
5.4B). 
Intriguingly, in the HFHS – Chow reversion diet mice there was a trend towards 
improved occludin deposition when compared to HFHS-fed mice, though this was not 
statistically significant. The reverse diet mice also retained weak laminin reactivity 
similar to the HFHS-fed mice (Figure 5.4C). Both occludin and pan-laminin reactivity 
















Figure 5.4 | Immuno-histochemical analysis of brain endothelium junctional proteins and flow cytometrical analysis of cytoskeleton 
Confocal microscopy of cerebral cortical sections of mouse brains double immune-labelled with claudin-5/pan-laminin (A) and occludin/pan-laminin (C). 
Nuclear counterstain with TO-PRO3. Confocal images are representative images from n=4 mice/group, 35 section/animal (scale bar: 25µm). Quantification of 
staining shown as mean fluorescence intensity (arbitrary units) of markers on ten randomly selected fields. Flow cytometric analysis of G/F actin ratio in primary 
brain endothelial cells (B). Statistical analysis was performed by one-way ANOVA followed by a Bonferroni post-hoc test. Data is expressed as mean ± SEM., 
*p< 0.05, **p<0.01, ***p<0.001, vs. Chow; $p<0.05, $$p<0.01, vs. HFHS. #p< 0.05, vs. HFHS + hrANXA1 
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5.2.3.2 Changes occurring to the BMs of brain endothelial cells & astrocytes 
Treatment with hrANXA1 also recovered the presence of BMs that were disrupted 
with HFHS-feeding, with both laminin α2 and α4 showing a regular and continuous 
staining pattern, as was observed in chow-fed mice brains (Figure 5.5A,B). The pan-
laminin immunoreactivity was also restored, prevailing on the outer VBL layer (Figure 
5.5A). Importantly, the recovery of laminin α2 allowed for re-association of co-
localised astrocytic end-feet (labelled with GFAP) back to the vessel, reforming an 
intact-looking BBB (Figure 5.5C).  
In contrast, in the HFHS – Chow reversion diet mice the laminin α2 presence on 
astrocytic end-feet was not fully restored like the HFHS-fed + hrANXA1 treated mice, 
and thus prevented the reattachment of the astrocytes to the vessel (Figure 5.5C). 
Interestingly there was no difference in the overall intensity of GFAP between with 
groups, with the exception of HFHS – Chow reversion diet mice, in which there 
appeared to be significantly fewer astrocytes compared to chow-fed mice.   
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Figure 5.5 | Imaging the basement membrane in hrANXA1 treated and dietary reversion 
mice 
Confocal microscopy of cerebral cortical sections of mouse brains double immune-labelled 
with endothelial laminin α4/vascular basement membrane pan-laminin (A), endothelial 
laminin α4/astrocytic laminin α1 (B) and endothelial laminin α4/astrocytic marker glial 
fibrillary acidic protein (GFAP) (C). Nuclear counterstain with TO-PRO3. Confocal images 
are representative images from n=4 mice/group, 35 section/animal (scale bar: 25µm). 
Quantification of staining shown as mean fluorescence intensity (arbitrary units) of markers 
on ten randomly selected fields. Statistical analysis was performed by one-way ANOVA 
followed by a Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 vs. Chow; $p<0.05, $$p<0.01, vs. HFHS. #p< 0.05, 
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5.2.3.3 Effect of hrANXA1 treatment and dietary intervention on MMPs at the BBB 
In chapter 4, the loss of the TJs and BMs in the HFHS-fed mice was associated to the 
rise in MMPs that degrade the junctional and ECM proteins. Similarly the restoration 
of the TJs and BMs in the HFHS-fed + hrANXA1 mice could be correlated to a 
reduction in MMP-2-, MMP-3 and MMP-9 expression at the brain microvessels 
compared to HFHS-fed mice; however this was only statistically significant when 
examining MMP-9 (Figure 5.6A). In HFHS – Chow reversion diet mice, the levels of 
MMP-3 and MMP-9 decreased when compared to HFHS-fed mice comparable with 
levels in HFHS-fed + hrANXA1 treated mice. Interestingly, the levels of MMP-2 in 
the reversion diet mice remained the same as the levels observed in the HFHS-fed 
mice.  
Confirmation of reduced MMP proteolytic activity was conducted via a zymography 
of MMP-2 and MMP-9 (Figure 5.6C). Results showed treatment with hrANXA1 in 
HFHS-fed mice reduced pro-MMP-9, MMP-9, pro-MMP-2 and MMP-2 when 
compared to HFHS-fed mice however these results were not statistically significant 
(Figure 5.6D,E). In the HFHS – Chow reversion diet mice, the levels of all MMPs 
were dramatically reduced, which were statistically significant when compared to 
HFHS-fed mice; levels of proteolytic activity in the reversion mice were similar to 
those seen in chow-fed mice (Figure 5.6D,E). 
MMPs levels are kept in check by their inhibitors - TIMPs. In the HFHS-fed mice, the 
increased MMP expression at the brain microvessels was marked by a significant 
reduction in the TIMP-1 serum concentration. In the HFHS-fed + hrANXA1 mice, 
where the MMP levels were shown to decrease, the concentration of TIMP-1 in the 
serum increased but the levels were still lower than in chow-fed mice, albeit not 
significantly (Figure 5.6B). Similarly, the HFHS – Chow reversion diet mice also 
showed restored TIMP-1 levels in the serum when compared to HFHS-fed mice, 
however this was not significant; and concentrations remained lower than those seen 
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Figure 5.6 | Effect of hrANXA1 treatment and dietary intervention on MMPs at the BBB 
Expression of MMP-2, MMP-3, MMP-9 was analysed in brain microvessel extracts of mice 
using a Mouse Proteome Profiler (R&D Systems). The membrane-antibody array was loaded 
with 500ng of protein/group overnight (n=10 pooled/group, two technical replicates per 
experiment, for chow, HFHS and HFHS + hrANXA1 performed as two independent 
experiments total n=20/group). Membranes were exposed to x-ray film and the signal 
produced at the different capture spots were used to quantify the amount of protein bound 
using ImageStudio Lite (LI-COR Biosciences), expressed as arbitrary units (A). Serum levels 
of tissue inhibitor of metalloproteinases (TIMP-1) were measured using a quantikine ELISA 
kit (R&D Systems) (B; n=11/group). Proteolytic activity of MMP-2 and MMP-9 in brain 
microvessel extracts was determined via zymography, based on separation of proteins by non-
reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS–PAGE). 
Molecular weight markers were used to estimate the molecular masses of active “pro” and 
inactive forms of MMP-2 and MMP-9 (C). Blots were scanned (BioRad Imager) and 
densitometry analysis was performed using ImageJ software (C,D). Each lane was loaded with 
100ng of protein (n=10 pooled/group for chow HFHS, HFHS + hrANXA1, total n=20 and 
n=6 pooled for HFHS – Chow-reversion, total n=12, this gel is representative of two 
independent experiment). Statistical analysis was performed by one-way ANOVA followed 
by a Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, **p<0.01, 
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5.2.4 Treatment with hrANXA1 and dietary changes reduce the 
inflammatory profile seen in diabetic mice 
Results from Chapter 4 clearly demonstrated an enhanced pro-inflammatory profile in 
the HFHS-fed mice, both in the serum and at the brain microvasculature.  
Within the serum, treatment with hrANXA1 in HFHS-fed mice resulted in a reduction 
in inflammation, with restoration in the levels of CXCL1, CXCL12, IL-1a, IL-16, s-
ICAM-1 and TNF-α (Figure 5.7) when compared to HFHS-fed mice. However, the 
levels of anti-inflammatory IL-13 were further decreased when compared to HFHS-
fed mice and there was no change in the C5a expression. Notably, hrANXA1 appeared 
to have a potent effect on reducing the interleukins; with levels reduced beyond those 
seen in control chow-fed mice. 
 
Further in-depth analysis of mediators, interleukins, cytokines, chemokines, and acute 
phase proteins at the brain microvessels was conducted across all animal groups.  
Figure 5.8A reviews general inflammatory markers. Results show that hrANXA1 
treatment restored levels of IFN-γ, chitinase 3-like 1 and C5a (in contrast to serum 
values) when compared to HFHS-fed mice. On the other hand, hrANXA1 treatment 
exacerbated the levels of TNF-α and VEGF, beyond those seen in HFHS-fed mice and 
in comparison, the levels of CRP and periostin were improved beyond those seen in 
chow-fed mice; there was no change in expression of RAGE. Comparatively, HFHS 
– Chow reversion diet mice improved a larger proportion of these mediators, with 
reduction in C5a, IFN-γ, TNF-α, RAGE and VEGF levels when compared to HFHS-
fed mice; notably the levels of IFN-γ were considerably higher than in HFHS-fed + 
hrANXA1 treated mice. The HFHS – Chow reversion diet mice also worsened the 
periostin and CRP levels beyond those seen in chow-fed mice (Figure 5.8A). 
Review of pro- vs anti-inflammatory interleukins found all listed pro-inflammatory 
interleukins to be raised in HFHS-fed mice compared to chow-fed (Figure 5.8B). 
Treatment with hrANXA1 in HFHS-fed mice further increased the levels of IL-1α, 
IL-1β, IL-7, IL-22 and IL-23 when compared to HFHS-fed mice; levels of IL-2, IL-6, 
IL-12 p40 and IL-27 p28 where improved whilst there was no large differences in IL-
15 and IL-17A. In the HFHS – Chow reversion diet group there was reduction in the 
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levels of IL-15, IL-17A, IL-23 and IL-27 p28 when compared to HFHS-fed mice. 
Notably in the reversion group, there was also a reduction in the levels of IL-1α, IL-6, 
IL-7 and IL-22 when compared to HFHS-fed mice and chow-fed mice. However, the 
reversion diet increased levels of IL-1β and IL-2 when compared to HFHS-fed mice 
(Figure 5.8B).   
When examining the anti-inflammatory interleukins (Figure 5.8D), treatment with 
hrANXA1 in HFHS-fed mice reduced the levels of IL-1ra, IL-4, IL-5 and IL-13, whilst 
levels of IL-10 and IL-11 did not change compared to HFHS-fed mice. The levels of 
IL-33 did not differ across the groups. Dietary intervention managed to lower the 
levels of all anti-inflammatory cytokines when compared to HFHS-fed mice, except 
for IL-5.  
Review of chemokines (Figure 5.8C) found the large majority of chemokines to be 
increased in the HFHS-fed mice. Treatment with hrANXA1 in HFHS-fed mice further 
increased the levels of all chemokines when compared to a HFHS-fed diet with the 
exception of CX3CL1 which was further decreased. On the whole, HFHS – Chow 
reversion diet mice had reduced levels of all chemokines when compared to HFHS-
fed mice with the exception of CCL5, CXCL1 and CX3CL1.  
In summary, the results showed both pharmacological and dietary intervention to have 
anti-inflammatory effects. Nevertheless, the reversion of diet was more potent at 
reducing the overall inflammatory phenotype. 
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Figure 5.7 | Cytokine measurements in the serum 
Inflammatory mediator analysis was conducted to reveal the relative level of inflammation 
occurring within the serum of chow, HFHS or HFHS + hrANXA1 mice. The Mouse Cytokine 
Array Panel A kit (R&D Systems) was used to analyse the presence of acute phase proteins, 
interleukins and chemokines using a membrane-based sandwich immunoassay; results are 
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Figure 5.8 | Profiling the inflammation at the brain microvasculature  
Simultaneous measurement of multiple cytokines, chemokines, interleukins and other 
inflammatory markers in protein extracts from brain microvessels using Mouse Cytokine 
Array Kits (R&D Systems). Membrane-based immunoassays detected the relative expression 
levels of analytes detected as arbitrary units (n=10 pooled/group, two technical replicates per 
experiment, for chow, HFHS and HFHS + hrANXA1 performed as two independent 
experiments total n=20/group) and categorised as inflammatory factors (A), chemokines (C), 
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5.2.5 Both pharmacological and dietary intervention reduce the activation 
and expression of adhesion molecules at the BBB 
In line with a reduced inflammatory phenotype, histological analysis of ex vivo cortical 
brain sections showed treatment with hrANXA1 in HFHS-fed mice to downregulate 
the expression of ICAM-1 and P-selectin when compared to HFHS-fed mice (Figure 
5.9A,B). Nevertheless, the expression levels were still significantly higher when 
compared to chow-fed mice.  
Proteomic analysis of isolated brain microvessel tissue (Figure 5.9C) confirmed the 
confocal imaging results, with hrANXA1 treatment significantly decreasing 
expression of ICAM-1 and VCAM-1. Interestingly, treatment with hrANXA1 showed 
no change in P-selectin expression and trend towards increased CD40 and E-selectin 
expression when compared to HFHS-fed. Dietary reversion, on the other hand, 
decreased expression of all adhesion molecules when compared to HFHS-fed and 
chow-fed mice, however this was only statistically significant for ICAM-1 and 
VCAM-1 levels.  
 
Page | 234  
 
Page | 235  
 
 
Figure 5.9 | Changes in the expression of adhesion molecules on the BBB with hrANXA1 
treatment and dietary intervention 
Cerebral cortical sections of the brain were immunofluorescently stained for endothelial cell 
adhesion molecules ICAM-1 (A) and P-selectin (B); nuclei were labelled with TO-PRO3. 
Typical images from n=4 animals 35 section/animals (scale bar: 25µm). Quantification of 
staining shown as mean fluorescence intensity (arbitrary units) of markers on ten randomly 
selected fields. Proteomic analysis of brain microvessel extracts using a membrane-based 
immunoassay (Mouse Cytokine Array XL Kit, R&D Systems, Minneapolis, USA) to detect 
the relative presence of adhesion molecules E-selectin, ICAM-1, P-selection and VCAM-1 
and co-stimulatory molecule CD40 by x-ray film exposure (n=10 pooled/group, two technical 
replicates per experiment, for chow, HFHS and HFHS + hrANXA1 performed as two 
independent experiments total n=20/group); quantified using ImageStudio Lite (LI-COR 
Biosciences). Statistical analysis was performed by one-way ANOVA followed by a 
Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, **p<0.01, ***p<0.001 
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5.2.6 The effect of pharmacological and dietary intervention on the 
immune system   
 
5.2.6.1 The innate and adaptive arms of the immune system 
As previously described in Chapter 4, the HFHS-fed mice increased both innate and 
adaptive immune cells. Assessments have been carried out using bone marrow and 
cervical lymph nodes. 
The percentage of macrophages and neutrophils remained significantly high in the 
HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet mice (Figure 5.10A). 
Interestingly, the percentage of macrophages was significantly higher in the reversion 
group compared to hrANXA1 treated group and this was also the same for dendritic 
cells. The percentage of dendritic cells however was decreased in the HFHS-fed + 
hrANXA1 treated mice when compared to HFHS-fed mice. Remarkably the 
percentage of NK cells in the HFHS-fed mice where further depleted with hrANXA1 
treatment, and no change was seen with dietary modification (Figure 5.10A).  
In the other adaptive immune cells (Figure 5.10B), both HFHS-fed + hrANXA1 
treated and HFHS – Chow reversion diet mice had significantly depleted CD4+ and 
CD8+ T-cells in the bone marrow when compared to HFHS-fed mice. The percentage 
of T-cells in HFHS – Chow reversion diet mice was in fact lower than both the HFHS-
fed + hrANXA1 treated mice and the chow-fed mice, however only significantly in 
CD4+ cells. Furthermore, hrANXA1 treatment reverted the inhibitor effect of the 
HFHS-diet on the percentage of CD19+ B-cells. In contrast, no changes were seen with 
HFHS – Chow reversion diet mice (Figure 5.10B).  
Interestingly, hrANXA1 treatment did not have any effect on the percentage of CD4+ 
T-cells or CD8+ T-cells in the cervical lymph nodes when compared to HFHS-fed 
mice (Figure 5.10C). However, hrANXA1 slightly reduced the percentage of CD19+ 
B-cells compared to HFHS-fed mice, but this was not significant. Similarly, the 
reversion diet had no effect on the CD8+ T-cells or the CD19+ B-cells in cervical 
lymph nodes when compared to HFHS-fed mice. However, the reverse diet depleted 
the percentage of CD4+ T-cells, to percentages lower than in the chow-fed mice. 
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Figure 5.10 | Effect of hrANXA1 and diet on the activation of the innate and adaptive 
arms of the immune system  
Bone marrow and deep cervical lymph nodes were collected from mice. Bone marrow was 
flushed with PBS-/- to obtain white blood cells, red blood cells were lysed using lysis buffer. 
Cells were stained using fluorescently conjugated antibodies for cell-surface markers on cells 
of the innate – neutrophils (Ly6G), macrophages (CD11b), dendritic cells (F4/80, CD11c), 
and adaptive – NK cells (NK 1.1), T-cells (CD4, CD8), B-cells (CD19) immune system and 
underwent flow cytometric analysis (n=13-23/group). Deep cervical lymph nodes were 
homogenised to obtain lymphocytes and underwent flow cytometric analysis after staining to 
obtain percentage frequency of T-cell subsets CD4+ and CD8+ and B-cells (CD19+) (n=11-
16/group). Statistical analysis was performed by one-way ANOVA followed by a Bonferroni 
post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, **p<0.01, ***p<0.001, 
****p<0.0001 vs. Chow; $p<0.05, $$p<0.01, $$$p<0.001, $$$$p<0.0001 vs. HFHS; 
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5.2.6.2 Treatment with hrANXA1 reduces the activation of CD4+ T-cells   
Pharmacological and dietary intervention had no effect on the activated CD4+ CD44+-
expressing T-cells with percentages similar to those seen in the HFHS-fed mice 
(Figure 5.11A). Despite this, treatment with hrANXA1 did reduce the percentages of 
CD4+ CD44+ LFA-1+ and CD4+ CD44+ CXCR3+-expressing T-cells compared to 
HFHS-fed mice (Figure 5.11B,C). In contrast, the reversion diet significantly 
increased the percentages of CD4+ CD44+ LFA-1+ and CD4
+ CD44+ CXCR3+-
expressing T-cells; and these percentages were even higher than those seen in the 
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Figure 5.11 | Effect of hrANXA1 and diet on CD4+ T-cell activation   
Deep cervical lymph nodes were collected and homogenised to obtain lymphocytes. All T-
cells were stained for CD4, within this subset of T-cells staining was conducted for activation 
marker CD44 (A). On CD4+ CD44+-expressing T-cells, the expression of lymphocytic 
adhesion molecule LFA-1 (B) and chemokine receptor CXCR3 (C) was evaluated (n=5-
11/group). Statistical analysis was performed by one-way ANOVA followed by a Bonferroni 
post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, **p<0.01, ***p<0.001, 
****p<0.0001 vs. Chow; $p<0.05, $$p<0.01, $$$p<0.001, $$$$p<0.0001 vs. HFHS; 
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5.2.6.2 Both pharmacological and dietary intervention show greater presence of TCM 
vs TEM cells 
The memory status of the CD4+ T-cells found HFHS-fed mice to have increased 
percentages of TCM and TEM cells compared to chow-fed mice, and with slightly higher 
TEM percentages. TCM
 cells are defined as CD44hi CD62Lhi CCR7hi whereas TEM 
cells are defined as CD44hi CD62Llo CCR7lo.  
Treatment with hrANXA1 did not change the percentage of CD44hi CCR7hi cells 
when compared to HFHS-fed mice (Figure 5.12A). However, the percentage of 
CD44hi CD62Lhi cells was lower compared to HFHS-fed mice, and similar to chow-
fed mice percentages (Figure 5.12B), although this was not significant. In contrast, in 
the HFHS – Chow reversion diet mice, the percentage of CD44hi CCR7hi cells was 
further elevated when compared to all other groups, whereas the percentage of CD44hi 
CD62Lhi cells was depleted when compared to all other groups. In summary, both 
hrANXA1 and diet reversion induced loss in the high expression of CD62L (Figure 
5.12B). 
Both pharmacological and dietary intervention caused a significant loss of CD44hi 
CCR7lo expressing cells when compared to HFHS-fed mice (Figure 5.12A). The 
percentage of CD44hi CC62Llo cells in both intervention arms remained elevated, 
with percentages equal to HFHS-fed mice (Figure 5.12B). This suggests that 
hrANXA1 treatment and dietary intervention cause the loss of CCR7lo expression. 
Given the differences in percentages and statistically significance, it appears as though 
HFHS-fed + hrANXA1 mice have a greater ratio of TCM vs TEM cells. In the HFHS – 
Chow reversion mice, there appears to be more disarray in the expression levels of 
receptors, with perhaps an equal balance of TCM and TEM
 cells. 
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Figure 5.12 | Effect of hrANXA1 and diet on Effector vs Central Memory T-cells 
Deep cervical lymph nodes were collected and homogenised to obtain lymphocytes. All T-
cells were stained for CD4, within this subset of T-cells staining was conducted for high (hi) 
or low (lo) expression of activation marker CD44 (A). On CD4+ CD44+-expressing T-cells, 
the high and low expression of L-selectin CD62L (A) and chemokine receptor CCR7 (B) was 
evaluated (n=5-11/group) to characterise the presence of central memory (CD44hi, CD62Lhi, 
CCR7lo) or effector memory (CD44hi, CD62Llo, CCR7lo) T-cells. Statistical analysis was 
performed by one-way ANOVA followed by a Bonferroni post-hoc test. Data is expressed as 
mean ± SEM., *p< 0.05, ****p<0.0001 vs. Chow; $p<0.05, $$$$p<0.0001 vs. HFHS; 
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5.2.6.3 Both pharmacological and dietary intervention reduce the TH17/Treg ratio 
Treatment with hrANXA1 and dietary reversion significantly reduced the percentage 
RoRγt-expressing TH17 cells when compared with the HFHS-fed mice (Figure 
5.13A). Although there were no changes in the Foxp3-expressing Treg cells in the 
intervention arms when compared to HFHS-fed mice (Figure 5.13B), the drop in TH17 
cells resulted in a large reduction in the TH17/Treg ratio in these intervention strategies 
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Figure 5.13 | Effect of hrANXA1 and diet on Th17 vs Treg cells 
Deep cervical lymph nodes were collected from chow and mice. Lymph nodes were 
homogenised to obtain lymphocytes. All T-cells were stained for CD4, within this subset T-
cells were categorised as pro-inflammatory T-helper (TH17) cells based on their expression of 
RoRγt (A) or as anti-inflammatory regulatory T-cells (Treg) based on their expression of 
Foxp3 (B). Ratio between TH17/Treg cells (C) (n=9=11/group). Statistical analysis was 
performed by one-way ANOVA followed by a Bonferroni post-hoc test. Data is expressed as 
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5.2.6.4 Treatment with hrANXA1 reduces the transmigration of peripherally activated 
leukocytes across the BBB. Dietary modifications reduce TH17 TEM across the BBB. 
In the HFHS-fed mice, the loss of BBB integrity coupled with a pro-inflammatory 
status and increased immune cell numbers resulted in increased TEM of leukocytes 
across the BBB. In contrast, treatment with hrANXA1 showed no or rare CD45+ cells 
infiltration into the brain parenchyma (Figure 5.14A). However, diet reversion did not 
have any apparent differences in the CD45+ infiltration when compared to HFHS-fed 
mice, with confocal imaging showing entrapped CD45+ cells within the VBL layers.  
In vitro transmigration assays found similar results, with hrANXA1 treatment 
significantly reducing the number of CD4+ CD45+ of adhered and migrated T-cells 
when compared to the HFHS-fed mice (Figure 5.14B). Intriguingly, the reversion diet 
did not abolish the higher adhered or migratory numbers of CD4+ CD45+ T-cells. 
Although, a more detailed analysis on the TH17 and Treg cells showed that dietary 
reversion significantly reduced the adhered and migrated RoRγt+-expressing TH17 
cells compared to HFHS-fed mice (Figure 5.14C) but did not affect the Foxp3+-
expressing Treg cells adherence or migration (Figure 5.14C,D). In contrast, treatment 
with hrANXA1 affected both the TH17 and Treg numbers, causing significant 
reduction in the adherence and migratory capacity of these T-cells when compared to 
HFHS-fed mice (Figure 5.14C,D).  
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Figure 5.14 | Transmigration of peripherally activated leukocytes across the BBB  
Cerebral cortical sections of the brain were immunofluorescently stained for activation marker 
CD45, present on all leukocytes, to examine the transmigration of immune cells across the 
BBB (A); nuclei were labelled with TO-PRO3. Typical images from n=4 animals, 35 
section/animals (scale bar: 25µm). Quantification of staining shown as mean fluorescence 
intensity (arbitrary units) of markers on ten randomly selected fields. Deep cervical lymph 
nodes were collected from chow and HFHS-fed mice. Lymph nodes were homogenised to 
obtain lymphocytes and expanded for 4 days in the presence of CD3 and CD28. On day 4, a 
transmigration assay was conducted, with 1 x 106 cells placed in contact with bEnd3 cells 
grown on transwell inserts. T-cells were placed in contact with the in vitro BBB model for a 
period of 4 hours, after which the cells collected from the top compartment of the transwell 
served as the adhered component and the cells collected from the bottom compartment served 
as the migrated component. All collected cells were stained for CD4; within this subset cells 
were stained for activation marker CD45 (B), RoRγt-expressing Th17 cells (C) or Foxp3-
expressing Treg (D) (n=5-9/group).  Statistical analysis was performed by one-way ANOVA 
followed by a Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 vs. Chow; $p<0.05, $$$p<0.001 vs. HFHS; #p<0.05, 
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5.2.7 Pharmacological and dietary interventions restore the M1/M2 
microglia phenotypic balance. 
 
5.2.7.1 M1 vs M2 Microglia 
Results show treatment with hrANXA1 reduces the percentage of microglia cells 
(CD45lo CD11b+) when compared to HFHS-fed mice (Figure 5.15A). On the 
contrary, dietary reversion further increases the percentage of microglial cells when 
compared to all groups. In microglia cells, the expression of fracktaline receptor 
CX3CR1+ expression was restored with pharmacological and dietary intervention 
when compared to HFHS-fed mice; however, results were only significant for the 
HFHS-fed + hrANXA1 treated mice (Figure 5.15B). 
Interestingly, although HFHS-fed + hrANXA1 treated mice had a reduced percentage 
of microglia cells, an equivalent percentage of these cells were activated (CD11c+ 
MHCII+-expressing) as in HFHS-fed mice (Figure 5.15C). In contrast, the percentage 
of activated microglia cells was significantly lower with dietary reversion, with 
percentages even lower than those seen in chow-fed mice. These activated cells were 
further differentiated as a pro-inflammatory M1 phenotype (CD86+-expressing cells, 
Figure 5.15D) or as an anti-inflammatory/resolving M2 phenotype (CD206+-
expressing cells, Figure 5.15D). In the HFHS-fed + hrANXA1 treated mice, the 
percentage of M1 cells remained equivalently elevated as the HFHS-fed mice however 
there was an increase in the M2 phenotype of cells resulting in a restoration of the 
M1/M2 phenotypic balance (Figure 5.15E). In the HFHS – Chow reversion diet mice, 
there was a trend towards reducing M1 phenotypic cells and a trend towards an 
increased M2 phenotype balance when compared to HFHS-fed mice. Like hrANXA1 
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Figure 5.15 | Changes in the phenotype of microglia cells with hrANXA1 treatment and 
dietary modifications 
Microglia cells were isolated and cultured from chow, HFHS, HFHS + hrANXA1 and HFHS 
– Chow reversion mice (n=6-12/group, pooled in pairs). Microglia cells were identified by 
gating on CD45lo CD11b+ cells to differentiate from macrophages (A). Expression of 
fracktaline receptor CX3CR1+ in CD45lo CD11b+-expressing cells (B), as median intensity 
of fluorescence (MFI). Percentage of activated microglial cells identified as CD11c+ MHCII+-
expressing cells (C) differentiated into pro-inflammatory M1 (CD86+-expressing) and anti-
inflammatory M2 (CD206+-expressing cells) phenotypes and ratio of M1/M2 cells (D). 
Statistical analysis was performed by one-way ANOVA followed by a Bonferroni post-hoc 
test. Data is expressed as mean ± SEM., *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs. 
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5.2.7.2 Oxidative damage in the diabetic brain 
In addition, confocal imaging confirmed reduced microglia cell activation in the 
HFHS-fed + hrANXA1 treated mice, as seen by reduced IBA1+-expressing cells 
compared to HFHS-fed mice (Figure 5.16A). Treatment with hrANXA1 lowered the 
production of iNOS by both endothelial cells and by microglial cells (Figure 5.16B) 
when compared to HFHS-fed mice. Notably, the levels of IBA1 and iNOS were 
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Figure 5.16 | Effect of hrANXA1 on IBA1 and iNOS expression in endothelial cells and 
microglia 
Cerebral cortical sections of the brain were immunofluorescently stained for IBA1 (A) and 
iNOS (B) expression; nuclei were labelled with TO-PRO3. Typical images from n=4 animals 
35 section/animals (scale bar: 25µm). Quantification of staining shown as mean fluorescence 
intensity (arbitrary units) of markers on ten randomly selected fields. Statistical analysis was 
performed by one-way ANOVA followed by a Bonferroni post-hoc test. Data is expressed as 
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5.2.8 Summary and comparison of results 
Overall, this chapter has evaluated the effect of two interventions – pharmacological 
and dietary on improving HFHS-feeding induced T2DM. As there are multiple 
different effects measured, a summary table has been provided (Table 5.3). HFHS-
fed mice data is compared to chow-fed mice data, which serves as the ‘control’. The 
effects of pharmacological treatment and dietary intervention have been compared to 
HFHS-fed mice. The table also compares which intervention fared better against 
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Table 5.3 | Summary and comparison of results from HFHS-induced T2DM mice and 
pharmacological and dietary intervention 
A summary of the main effects measured in this study has been provided. HFHS-fed 
mice data is compared to chow-fed mice, which serves as a ‘control’. The effects of 
pharmacological treatment and dietary intervention have been compared to HFHS-
fed mice. The table also provides information on which intervention served better 











































































Restored F-actin Not measured N/A 
Claudin-5 
expression 
Decreased  Restored Not measured N/A 
Occludin 
expression 





Decreased Restored, similar 
to chow diet 




Decreased Restored, similar 
to chow diet 
Decreased hrANXA1 
treatment 
Pan-laminin Decreased Restored, similar 
to chow diet 
Restored hrANXA1 
treatment 
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5.3 Discussion 
The focus of this chapter was to evaluate how the damage induced by metabolic 
disorders, both immunologically and at the BBB, can potentially be reversed using 
either pharmacological or dietary intervention. Data in this chapter provides evidence 
that treatment with hrANXA1 and switch to a diet low in fat and sugars reduces 
metaflammation and attenuates T2DM development to restore the damage to the BBB. 
These interventions could have huge implications on future treatments and healthcare 
guidance for managing metabolic disorders.  
 
 
5.3.1 The use of ANXA1 as a pharmacological agent to reduce, revert and 
restore the damage to the BBB in metabolic disorders 
 
5.3.1.1 The role of ANXA1 in attenuating T2DM development  
First and foremost, the findings of this chapter reveal the administration of hrANXA1 
in HFHS-fed mice to attenuate MetS/T2DM development; as seen by lower serum 
insulin, cholesterol and triglycerides along with lower blood glucose levels and 
improved OGTT. Previous work in our lab found the therapeutic administration of 
hrANXA1 in a HFHS-fed mouse model to improve insulin resistance by attenuating 
hepatosteatosis (lipid accumulation in the liver) and renal dysfunction (proteinuria) 
(512). Purvis et al., showed that the impaired glucose tolerance in HFHS-fed mice was 
mediated by the IRS-1/Akt/GSK-3β signalling cascade which is involved in energy 
metabolism (glycolysis) (688). Treatment with hrANXA1 restored this signalling 
cascade to allow for GSK-3β-dependent enzymatic conversion of glucose to glycogen 
thus lowering blood glucose levels (689,690).  
The beneficial role of ANXA1 as a therapeutic agent in diabetes has been further 
confirmed by our team’s previous studies using ANXA-/- mice fed a HFHS diet. These 
ANXA1-/- mice have a more severe diabetic phenotype compared to wild-type HFHS-
fed mice, with severe dyslipidaemia, hepatic steatosis and renal dysfunction (512). 
Treatment with hrANXA1 also halts microvascular disease development in a mouse 
model of T1DM through restoring Akt signalling (678); notably these STZ-induced 
mice also have improved cardiac function. Studies using LDLR-/- mice have shown 
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hrANXA1 treatment to reduce atherosclerotic plaque burden and improve plaque 
stability through reduced lipid accumulation (691), demonstrating the therapeutic 
benefit of ANXA1 in treating metabolic disease and its associated peripheral co-
morbidities. These studies already implicate the potential for ANXA1 in improving 
diabetes-induced brain microvascular disease. 
 
5.3.1.2 ANXA1 and BBB integrity  
In the BBB community, the role of endogenous ANXA1 in maintaining BBB integrity 
has long been recognised. Work by Cristante and colleagues showed ANXA-/- mice to 
have constitutively elevated BBB permeability compared to wild-type controls (297). 
The leaky BBB phenotype in ANXA1-/- mice can be attributed to loss of occludin and 
VE-cadherin at sites of cell-cell contact; in contrast wild-type mice show high 
abundance of ANXA1 at junctional sites. The role of ANXA1 in tight junction stability 
has been clearly demonstrated through use of hCMEC/D3 ANXA1 knock-down cells, 
in which rescue experiments using hrANXA1 restored F-actin organisation via co-
localisation with β-actin (297). Similarly, the disrupted tightness of the brain 
microvasculature as a loss of claudin-5, occludin and F-actin in the HFHS-fed mice 
was restored with hrANXA1 treatment. This reinstatement of the TJs and cytoskeleton 
can be correlated with reduced paracellular permeability measures and increased 
TEER compared to HFHS-fed mice. The ability of hrANXA1 to re-establish cell-cell 
contacts suggests a depletion of endogenous ANXA1 at the brain microvasculature 
that impacts the BBB tightness. In fact, ANXA1-/- mice have a similar leaky BBB 
phenotype to HFHS-fed mice, and rescue experiment with hrANXA1 in these 
ANXA1-/- mice also improves BBB tightness (297). Together, these data strongly 
support the therapeutic effect of hrANXA1, which remains to date, the best 
endogenous molecule exploitable as a therapeutic target in the neuroinflammatory 
pathology of a leaky BBB.  
Moreover, in this chapter we extend our findings of the therapeutic effect of hrANXA1 
treatment also on the essential components of the BM; with clear restoration of 
endothelial and astrocytic laminin α4 and laminin α2, respectively. This allowed for 
the re-attachment of astrocytic end-feet to the brain endothelial cells to restore the full 
structure of the BBB in HFHS-fed + hrANXA1 treated mice. In the HFHS-fed mice, 
the breakdown of the BBB was linked to digestion by MMPs namely MMP-2 and 
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MMP-9, as discussed in depth in Chapter 4.3.1. Treatment with hrANXA1 in HFHS-
fed mice down-regulated the presence/activity of MMP-2, MMP-3, and MMP-9. The 
reduced permeability measures and clear confocal imaging of brain microvessels in 
the HFHS-fed + hrANXA1 treated mice overrides the lack of statistical significance 
seen in the MMP studies which is likely a factor of small n numbers and repeats.  
Previous studies investigating the link of ANXA1 and MMPs have largely been 
carried out in the cancer field however results find differential expression and effect 
depending on cancer type. For example in breast cancer cells, the ablation or silencing 
of ANXA1 leads to decreased MMP-9 expression that is associated with reduced 
migration and invasion (692). In comparison, the decrease of ANXA1 in pancreatic 
ductal adenocarcinoma (PDAC) was associated with worse disease progression, as 
seen by lymph node metastasis and advanced TNM stage (693). Indeed extensive 
research of the literature implicates that ANXA1 can act as both a tumour suppressor 
and oncogene (694,695), suggesting that the role of ANXA1 may be dependent on 
tissue type and disease phenotype.  
Furthermore, in conjunction with reduced MMPs, there is a significant increase in 
TIMP-1 concentrations in the serum with hrANXA1 treatment. The restoration of 
TIMPs/MMPs is a key contributor in the remodelling and restoration of the BBB 
(187,542). In Chapter 4, the expression and ratio MMPs/TIMPs have been discussed 
regarding changes in acute to chronic inflammation. In HFHS-fed + hrANXA1 treated 
mice, there is a reduction in the pro-inflammatory profile and therefore hrANXA1 may 
aid the restoration of MMPs/TIMPs balance through reduction of chronic 
metaflammation. The role of ANXA1 to restore the TIMP ratios is confirmed in 
ANXA1 knockout cells. Knockout of ANXA1 in PDAC results in the disbalance of 
MMP/TIMP, with increased MMP-9 activity to be correlated with a decreased TIMP-
1 expression (693).   
In diabetes, MMPs have been associated with microvascular complications. Altered 
MMP expression in diabetic nephropathy contributes to glomerular hypertrophy (696). 
Likewise, increased plasma MMP-2 and MMP-9 in peripheral arterial disease has been 
associated with disease progression and severity (697). In diabetes, it appears that 
increased MMP expression is associated with a negative outcome and this appears to 
be the case at the brain microvasculature in our HFHS-fed model, with ANXA1 
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treatment positively restoring MMPs/TIMPs levels and thus preventing BBB 
degradation.  
 
5.3.1.3 ANXA1 and its role in preventing TEM  
The most well-documented property of ANXA1 is its ability to inhibit leukocyte TEM. 
ANXA1 mediates its effect through modulating adhesion molecule-based leukocyte 
to endothelium interactions. Firstly, ANXA1 co-localises with α4β1 integrin on 
leukocytes to prevent binding to VCAM-1 on endothelium (482). Usually leukocytes, 
upon cellular activation by particular chemokines, mobilise and release their 
endogenous ANXA1 to promote leukocyte detachment (281). Treatment with 
exogenous hrANXA1 will further promote this detachment by increasing ANXA1 
levels; indeed HFHS-fed + hrANXA1 treated mice have a significant reduction in both 
adhesion and TEM of CD4+ leukocytes across the BBB compared to HFHS-fed mice 
and akin to numbers seen in chow-fed mice. Moreover, we have previously shown that 
ANXA1 expression (total and surface) is reduced in TH17 and Treg cells of MS 
patients and this was connected to an increase migratory potential of TH17 cells across 
an in vitro model of the BBB (293). Given the inflammatory nature of T2DM, we can 
hypothesise that ANXA1 is likely to be reduced within these T-cell subsets in the 
HFHS-fed model, thus accounting for the increased TH17 cell migration in HFHS-fed 
mice which is reduced upon hrANXA1 treatment. Future studies should examine the 
expression of ANXA1 in these T-cells subsets to elucidate whether treatment with 
exogenous ANXA1 restores the intracellular stores of ANXA1 in the leukocytes to 
contribute to reduce TEM.  
Notably, previous work in our lab has shown that exogenous ANXA1 increases 
endogenous ANXA1 in the human brain endothelial cell line hCMEC/D3 to restore 
the actin cytoskeleton (297). Moreover, in the HFHS-fed model we have shown that 
endogenous ANXA1 is depleted in the kidney, liver and skeletal muscle (512). 
Treatment with hrANXA1 restored the intracellular stores of ANXA1 contributing to 
attenuation of T2DM development in the HFHS-fed + hrANXA1 treated mice (512). 
In this manner, we can hypothesise that treatment with hrANXA1 will restore 
endogenous ANXA1 at the brain endothelial cells of the BBB in the HFHS-fed + 
hrANXA1 treated mice, which will further contribute to the reduced leukocyte TEM 
through mobilisation of ANXA1 and restored tightness of the BBB. In vivo 
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inflammatory models show increased endothelial ANXA1 mobilisation post 
neutrophil diapedesis (measured over 4hours) (698) to support this theory. Here, we 
have also shown ANXA1’s ability to reinstate the TJ and BMs, therefore future studies 
would also benefit from examining the ANXA1 localisation in accordance with actin 
and laminin isoforms. 
 
ANXA1 also inhibits leukocyte TEM through inducing L-selectin shedding from 
leukocytes to prevent tethering, rolling and firm adhesion (280). In the HFHS-fed + 
hrANXA1 treated mice, there is a reduction in the percentage of CD4+ CD44+ 
CD62Lhi-expressing cells compared to HFHS-fed mice, and hence reduced adhesion 
of CD4+ cells. Notably there was also a marked reduction in the number of CD4+ 
CD44+ LFA-1+-expressing cells. Importantly, whilst glucocorticoid treatment has 
shown to reduce LFA-1 expression (699), this effect is not attributed to ANXA1 (700). 
Results also showed a significant reduction in several adhesion molecules including 
ICAM-1, P-selectin, and VCAM-1. Although ANXA1 does not modulate the 
expression of CAM molecules it has been proposed that ANXA1 induces 
functional/conformation changes on the surface of CAM molecules contributing to 
diminished adhesion and TEM (700).  
During inflammation resolution, β2 integrins can themselves act as efferocytic 
receptors; for example ICAM-3 is known to serve as an “eat-me” signal through 
binding to CD14 on apoptotic cells (701). In fact, ANXA1 can be recruited to the cell 
surface of apoptotic cells to co-localise with the “eat-me” signal phosphatidylserine 
thus regulating cell removal. Although further studies are required to determine 
whether integrin/ANXA1 co-localise, the combination of these efferocytic integrins 
and ANXA1 serving as apoptotic markers suggests a potential mechanism by which 
leukocyte-endothelial cell interaction is reduced during the resolution phase of 
inflammation (286). Undeniably, in the HFHS-fed + hrANXA1 treated mice the 
overall inflammatory profile is improved when compared to HFHS-fed mice. In the 
literature, ANXA1 is documented to reduce IL-6, TNF-α, IL-1β, IL-12p40 levels 
whilst increasing IL-10 (702). In the HFHS-fed + hrANXA1 treated mice, there is 
reduced expression of IL-6 and IL-12p40 at the brain microvessels with increased IL-
10 levels; TNF-α levels increased at the brain microvessels however were decreased 
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within the serum. Without doubt there is a large degree in variation in the levels of 
inflammatory mediators expressed in the serum and brain microvessels of ANXA1 
treated mice, nevertheless the alteration and differentiation in the markers compared 
to HFHS-fed mice suggest that inflammation resolution is being undertaken. Taking 
all the above into consideration, the reduction of adhesion and TEM at the BBB in the 
hrANXA1 treated mice can be attributed to both direct and indirect effects of ANXA1.  
Nonetheless, it is noteworthy that all the chemokines measured at the brain 
microvasculature, except CX3CL1, increased in the HFHS-fed + hrANXA1 treated 
mice when compared to HFHS-fed mice suggestive that chemotaxis of leukocytes is 
still occurring in these mice and the adhesion is the rate limiting factor. Besides it is 
documented that upregulated ANXA1 in circulating leukocytes, after glucocorticoid 
treatment, are responsible for the prolonged diapedesis time (703). This serves to 
explain why in the HFHS-fed + hrANXA1 treated mice the number of adhered CD4+ 
cells are far greater than the number migrated, whereas the proportion of 
adhered/migrated cells in each of the other experimental groups are roughly 
equivalent.  
 
5.3.1.4 ANXA1 and its effect on adaptive immunity 
Whilst the role of ANXA1 on innate immunity has thoroughly been investigated, the 
function of ANXA1 in adaptive immunity remains largely undiscovered. 
Nevertheless, T-cells express ANXA1 and its deficiency has been associated with 
autoimmune diseases. For example, PBMCs isolated from MS patients show reduced 
ANXA1 expression in T-cell subsets CD4+ CD25+, CD4+ CD25-, CD4+ RoRγt+ and 
CD4+ Foxp3+ compared to healthy patients and this was associated with an increased 
migratory capacity of CD4+ CD25- and TH17 cells across an in vitro model of the BBB 
(293). In a mouse model of uveitis, in which there is reduced ANXA1 expression, 
hrANXA1 administration rescues the severity of the disease through restricting TH17 
development (291). Although we have not measured the expression of ANXA1 in T-
cells in the HFHS-fed mice, it is evident that metabolic disorders cause a shift in the 
TH17/Treg ratio with increase in the percentage of TH17 cells in HFHS-fed mice 
compared to chow-fed mice, in line with other studies (367,368). hrANXA1 treatment 
corrected this shift and reduced the TH17/Treg ratio, with TH17 percentages lower than 
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those in chow-fed counterparts; suggestive that hrANXA1 treatment is affecting TH17 
development concomitant with reduced IL-17 production. In addition, the number of 
TH17 cells migrating in the HFHS-fed + hrANXA1 treated mice was reduced.  
Some studies have eluded to the role of ANXA1 in modulating the differentiation of 
naïve T-cells into TH cells, with ANXA1 promoting development of the TH1 subset 
and supressing TH2 subsets (288). Another study found ANXA1-derived peptide Ac2-
26 to inhibit the proliferation and cytokine production of both TH1 and TH2 cells via 
interfering with T-cell activation through antigen presentation (292). To date, the role 
of ANXA1 in modulating TH differentiation largely remains disputed. Nevertheless, 
studies in human PBMCs show ANXA1 reduces T-cell proliferation and activation 
due to altered T-cell priming by the reduction of co-stimulatory molecules CD80, 
CD86 and CD83 on monocytes (293). Interestingly in the HFHS-fed + hrANXA1 
treated mice, the cell frequency of macrophages and neutrophils remained similar to 
HFHS-fed mice; both were significantly higher than chow-fed mice. However, the cell 
frequency of dendritic cells was reduced in HFHS-fed + hrANXA1 treated mice 
compared to HFHS-fed mice. Although this was not statistically significant, it perhaps 
represents a reduction in antigen presentation by dendritic cells involved in the 
reduced T-cell activation seen in HFHS-fed + hrANXA1 treated mice as seen by 
reduced CD4+ CD44+ CXCR3+-expressing Teff cells. Studies in a rodent models of 
high feeding have shown increased TEM cells (CD44hi-CCR7lo-CD62Llo-CXCR3
+-
LFA1+) compared to control mice (370). Interestingly in the HFHS-fed + hrANXA1 
treated model there appears to be a greater ratio of TCM/TEM cells indicative of a 
resolving inflammation phenotype with reduced circulating TEM cells. 
 
5.3.1.5 ANXA1 and its involvement in conferring neuroprotective 
Overall, treatment with hrANXA1 has a profound effect on restoring the BBB 
integrity; ANXA1 also reduces inflammatory mediators resulting in fewer Teff cells 
and is key in preventing leukocyte attachment to the brain endothelial cells. Together 
these properties help to reduce the migration of peripherally-activated immune cells 
into the brain parenchyma thereby limiting the potential for inflammation within the 
brain. This is clearly apparent by the lower percentage of microglia cells (CD45lo 
CD11b+) within the HFHS-fed + hrANXA1 treated mice compared to the HFHS-fed 
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mice whereby microglia cells had proliferated in response to inflammation. 
Interestingly, flow cytometrical analysis revealed that despite the fewer microglia 
cells, a similar percentage of these CD45lo CD11b+ microglia cells were activated in 
the HFHS-fed + hrANXA1 treated mice as in the HFHS-fed mice. Of these activated 
microglia cells, HFHS-fed mice had a higher M1/M2 phenotype ratio whereas 
treatment with hrANXA1 balanced the ratio of M1/M2 phenotype with a prominent 
increase in the percentage of M2 cells. Intriguingly, confocal imaging reveals lower 
IBA1 expression in HFHS-fed + hrANXA1 treated mice compared to HFHS-fed mice 
and reduced iNOS expression by endothelial cells and microglia. iNOS is largely 
produced by activated M1 phenotypic microglia cells and is responsible for causing 
neurotoxicity and neuronal apoptosis (378), decreased M1 cells will contribute to the 
reduction in iNOS production. 
In macrophages, presence of ANXA1 drives a phenotypic switch from pro-
inflammatory M1 to pro-resolving M2 (704–706). Furthermore in ischemic-injured 
neurons, treatment with ANXA1 peptide Ac2-26 promoted the transition of activated 
microglia from an M1 to M2 phenotype through peptide-FPR engagement (305). The 
importance of this phenotypic switch is highlighted in studies conducted by McArthur 
and colleagues; in which they illustrate the role of ANXA1 in contributing to microglia 
surveillance and maintenance of brain homeostasis. Under inflammatory conditions, 
induced by LPS or Aβ in vitro, BV2 microglia cells had aberrant upregulation of 
efferocytosis/phagocytosis of both apoptotic and non-apoptotic neurons, accompanied 
by surges in pro-inflammatory cytokines TNF-α and IL-6 (279). Treatment with 
ANXA1 reduced the phagocytosis of non-apoptotic neurons by LPS-stimulated BV2 
cells, highlighting that ANXA1 is key in regulating microglia activity to limit 
uncontrolled neuronal damage. In fact, it was noted that ANXA1 reduced the 
production of NO in these LPS-stimulated BV2 cells. Microglia-derived NO and its 
associated RNS are neurotoxic thereby highlighting the role of ANXA1 in conferring 
neuroprotection (279). In the diabetic model of HFHS-feeding, it was noted that iNOS 
production was reduced upon treatment with hrANXA1.  
It is noteworthy that endogenous production and release of ANXA1 by microglia 
occurs under basal conditions, this is to enable the removal of damaged neurons 
through binding with phosphatidylserine that signals to microglia via the FPR2 
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receptor for engulfment (279); serving to explain the high percentage of M2 cells seen 
in chow-fed mice. McArthur et al., demonstrated that in early phases of AD, ANXA1 
expression is upregulated in human microglia and this may serve to control microglia 
response to amyloid plaques and subsequent neurodegeneration (279). Further studies 
by Ries et al, however found microglia become constitutively activated under 
inflammatory conditions (304). The secretion of endogenous ANXA1 is not enough 
to maintain control and therefore treatment with ANXA1, in vitro and in vivo, 
stimulated Aβ phagocytosis by microglia through inducing endocytosis of the 
Aβ/FPRL1 complex, thus reducing plaque burden (304). It is well documented that 
Aβ1-42 peptide binds to FPRL1/FPR2 and is rapidly internalised by phagocytic cells 
(707). ANXA1 which co-localises with F-actin in the cell cytoskeleton facilitates the 
interaction of F-actin and phagosomes in macrophages and therefore facilitates 
endocytosis (708).  
Microglial upregulation of ANXA1 has also been detected in mouse models of 
excitotoxic neuronal injury and transmissible spongiform encephalopathies 
particularly around lesional sites indicative of mechanisms to restore brain 
homeostasis (709–711). Without doubt, these studies implicate the neuroprotective 
effects of ANXA1; and the loss of ANXA1-dependent microglia regulation appears to 
occur under conditions where inflammation changes from acute to chronic. Future 
research would benefit from examining the ability of metabolic disorders to damage 
neurons and the role played by ANXA1 in conferring protection against 
neurodegeneration with particular focus on the point at which endogenous ANXA1 
loses control. However, for now, it is clear treatment with ANXA1 in metabolic 
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5.3.2 Can the switch to a healthy diet reduce, revert and restore the 
damage to the BBB caused by metabolic overload? 
 
5.3.2.1 Effect of dietary modifications on T2DM development & BBB integrity 
Initial observation of results from this chapter clearly highlight the switch of diet from 
HFHS-feeding to chow-feeding reduces obesity; a key risk factor in the development 
of MetS/T2DM (148) . Whilst HFHS – Chow reversion diet mice had lower non-fasted 
blood glucose levels, the glucose tolerance as measured by OGTT did not improve 
compared to HFHS-fed mice, however the HFHS – Chow reversion mice did show an 
improvement in the ITT. Nonetheless, reversion mice showed a decrease in 
concentrations of serum insulin, serum cholesterol and serum triglyceride compared 
to HFHS-fed mice. Excessive subcutaneous and visceral abdominal tissue can 
contribute to raised levels of circulating FFAs (1), therefore the weight loss in these 
mice is central to the reduction in lipid levels. Lack of statistical significance here may 
in part be reflective of smaller n numbers in the HFHS – Chow reversion diet mice 
group 
It is well recognised that an improved diet can help control and manage T2DM and 
the development of CVDs (712–716) and there is growing evidence of the role of 
Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets in 
reducing cognitive decline and lowering AD risk (457). However, the majority of these 
studies are large longitudinal observation studies or meta-analyses. To our knowledge, 
our study is the first to examine the effect of diet on the structural and functional 
changes of the brain microvasculature in a diabetic model induced by HFHS-feeding.  
From the results, it is clearly noticeable that dietary changes have a huge impact on 
BBB integrity with significantly reduced Evans blue dye extravasation, reduced 
paracellular permeability of FITC-dextran and increased TEER compared to HFHS-
fed mice. Reduced leakage can be accounted for by restoration of junctional proteins; 
although whilst occludin presence at junctional sites is beginning to be re-established, 
the laminin reactivity remains low preventing the ensheathment of astrocytes. When 
examining the MMP levels, there is a significant reduction in the expression and 
activity of MMP-2 and MMP-9 in HFHS – Chow reversion diet mice compared to 
HFHS-fed mice, comparable to levels in chow-fed mice which can be accounted for 
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by decreased inflammatory mediators such as TNF-α and IFN-γ; therefore the lack of 
BBB vessel restoration is of surprise. Notably, the TIMP-1 levels are not increased in 
the HFHS – Chow reversion diet mice and perhaps it is this balance which is required 
to prevent MMP-induced degradation.  
As a result of the lack of complete BBB restoration, in the HFHS – Chow reversion 
diet mice CD45+ leukocytes are still present within the VBL layers and appear to show 
migration outwards into the brain parenchyma. These results together illustrate that 
brain endothelial cells contacts are repaired with dietary changes however the BBB 
vasculature in its entirety, is not restored. The endothelial cells are the first cells of the 
BBB structure and therefore it is logical that the most immediate improvement is 
apparent at this cellular level. It would be interesting to assess the role of ANXA1 in 
improving BBB integrity in the HFHS – Chow reversion diet mice, thus future studies 
should examine the endogenous levels of ANXA1 in the BBB and T-cells in these 
mice.    
Importantly, this study has only placed mice back onto a chow diet for a period of 5 
weeks, which may not be sufficient to re-instate the conformational changes of the TJs 
and BM required for a tight BBB. Studies which have investigated dietary changes in 
diabetic rodents by food or calorie restriction (717–719), ketogenic diets (720), herbal 
formulas (721), reduced glycoxidation products (722) or addition of extra virgin olive 
oil (723) report improved insulin sensitivity with feeding over a duration of 8 – 24 
weeks on intervention. In our study, a 5-week intervention begins to improve insulin 
and lipid levels however optimal glycaemic control has not been achieved. It would 
without doubt be beneficial to examine a longer intervention period, as well as 
comparing to chow-fed or HFHS-fed mice that have been on their respective diets for 
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5.3.2.2 Diet and the immune system: metaflammation 
In the HFHS – Chow reversion diet mice, remarkably there is a significant reduction 
in the percentage of activated microglia cells compared to chow-fed and HFHS-fed 
mice, despite the larger population of microglia cells (CD45lo CD11b+). Of these 
activated microglia cells, there is a restoration in the M1 to M2 phenotype balance, 
compared to HFHS-fed mice which are skewed towards M1. The reduced activation 
status and movement towards a resolving phenotype is indicative of less triggering of 
microglial response (724). A closer look at the effect of diet intervention on immune 
cells however reveals that there are still highly activated percentages of CD4+ CD44+ 
LFA1+ CXCR3+ cells within the cervical lymph nodes of the HFHS – Chow reversion 
diet mice, even higher than those seen in HFHS-fed mice. These two sets of results 
appear to be contradictory. Conversely, upon further examination of the activation 
status of the brain microvessels of HFHS – Chow reversion diet mice, there is reduced 
expression of adhesion molecules (CD40, E-selectin, P-selectin, ICAM-1 and VCAM-
1) to levels lower than those even in chow-fed mice. Reduced adhesion molecule 
expression would prevent the TEM cascade (642). Therefore, despite the higher 
percentage of activated T-cells, fewer passage would reduce the activation of 
microglia from this source. Interestingly, the cell frequency of dendritic cells in the 
HFHS – Chow reversion diet mice was particularly high, which may account for the 
large number of activated CD4+ T-cells; however overall the frequency of CD4+ cells 
in the bone marrow and cervical lymph nodes was considerably reduced, even when 
compared to chow-fed mice.  
Nevertheless, review of CD4+ T-cell subsets finds a significantly lower percentage of 
TH17 cells in the HFHS – Chow reversion diet mice compared to both HFHS-fed and 
chow-fed mice thereby reducing the ratio of TH17/Treg cells. The ratio of TH17/Treg 
cells have been suggested to play a key role in the pathology of metabolic disorders 
and its secondary complications (367). In line with this, in vitro experiments show a 
significant reduction of the adhered and migrated TH17 cell subset across the BBB 
compared to HFHS-fed mice whereas the numbers of adhered and migrated Treg and 
CD4+ CD45+ leukocytes remain the same as HFHS-fed mice. Here, we have not 
evaluated the proportion of the TH1 subset; TH1 cells are known to play a substantial 
role in regulating body weight, insulin resistance, glucose tolerance in visceral adipose 
tissue (368) and may account for high presence of CD4+ cells at the BBB.  
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Furthermore, TH1 cells presence may aid in explaining the lack of insulin sensitivity 
restoration within the HFHS – Chow reversion diet mice. Future studies would benefit 
from examining the role played by other subsets under dietary changes. 
   
Generally, it is documented that individuals with T2DM are more prone to infectious 
disease and cancer as a result of the hyperglycaemic environment that favours immune 
dysfunction (725–728). An important concept of inflammation is to remember than 
intact inflammatory pathways are required for maintenance of tissue health and 
response to acute triggers. Therefore disruption of immune state results in tissue 
damage (357). As described in Chapter 4, in the HFHS-fed mice there is a large 
disruption in the inflammatory mediator profile (pro- and anti-inflammatory 
interleukins, cytokines and chemokines). In the HFHS-fed – Chow reversion mice, the 
inflammatory profile is greatly improved with reduction in cytokines TNF-α and IFN-
γ, interleukins e.g. IL-1α, IL-6, IL-1ra, IL-4, IL-10 and IL-1 and chemokine e.g. 
CCL2, amongst many others (Figure 4.7). Studies report improved diabetic outcomes 
in rodents which have been treated with IL-1 inhibitors (729). Therefore, the improved 
inflammatory mediator profile in HFHS – Chow reversion diet mice plays a strong 
role in the overall improvement seen in these mice both immunologically and at the 
BBB. Indeed, the benefit of Mediterranean diets, rich in polyunsaturated fats, 
flavonoids, vitamins and minerals (calcium, iron, zinc etc), are associated to the high 
presence of omega-3 fatty acids, antioxidants and polyphenols that reduce free radical 
generation and cytokine production, thereby inhibiting pro-inflammatory signalling 
pathways (685,730). Similarly, the use of these diets in humans have been associated 
with improved cognition and learning by facilitating synaptic plasticity and/or 
enhancing synaptic membrane fluidity through reduction of inflammation and 
oxidative stress (730–732). Support of the role of diet in cognition, has been seen 
through rodent studies. Rodents fed on diets high in saturated fats and sucrose show 
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Metaflammation involves a number of signalling pathways that affect both 
metabolism and the immune system (357). Ingestion of foods rich in lipids, can 
activate toll-like receptor 4 (TLR4) subsequently initiating the inflammasome to 
trigger immune response (734,735). TLR4 activation by fatty acids is thought to be 
due the LPS component. Certainly, diabetes and obesity have been associated with 
high LPS levels which are negatively correlated to insulin sensitivity (736,737). LPS 
in the intestine increases the gut-barrier leakiness (738). Mice with loss of TLR4 
function, under high fat diets are protected from insulin resistance (739). Additionally, 
deletion of TLR adaptor molecule MyD88 in the CNS also protects mice from diet-
induced insulin-resistance (740). Alternatively, nutrients such as long-chain omega-3 
polyunsaturated fatty acids can also interfere with the TLR4 activation to prevent its 
signalling pathway (741). A healthy diet is associated with lower levels of 
endotoxemia in the gut (742) and this has been linked to not only improving the gut 
health but also to improving neuroinflammation in conditions such as PD (743). This 
has led to a vast amount of research in the area of the gut-brain axis. These concepts 
highlight a possible mechanism through which BBB leakage has been reduced in 
HFHS – Chow reversion diet mice. Although insulin sensitivity is not entirely re-
established, the serum cholesterol and triglycerides are considerably lower than in 
HFHS-fed mice and overall, this leads to a reduction in metaflammation with 
beneficial effects on improving brain microvasculature health.  It is likely that a longer 
duration of a chow-diet would provide considerable improvements across all 
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5.3.3 Pharmacological intervention vs dietary intervention 
All current existing anti-diabetic medications such as metformin, incretin agonists, 
thiazolidinediones  and DPP4 inhibitors have an anti-inflammatory component (744). 
Essentially the use of ANXA1 as a pharmacological intervention or dietary changes 
to a healthier intake aim to reduce metaflammation and thereby limit the primary 
macrovascular and secondary microvascular complications. In this chapter, it is seen 
that both a therapeutic treatment delivered by ANXA1 and dietary intervention from 
a HFHS diet to a chow diet have the ability to slow the progression of T2DM.  
In summary, treatment with hrANXA1 clearly attenuates the development of T2DM, 
by restoring insulin sensitivity and preventing hepatosteatosis and proteinuria (512). 
At the level of the BBB, treatment with hrANXA1 in the HFHS model has profound 
effects on restoring the BBB integrity through restoration of TJs (actin-mediated) and 
BM laminins to allow a resealing of the BBB vasculature through astrocytic end-feet 
association, resulting in reduced permeability and TEM. At the immunological level, 
hrANXA1 treatment limits T-cell activation, reducing Teff cells and reduces the 
TH17/Treg ratio, which can be accounted for by alterations in the interleukins and 
cytokines. Reduced T-cell activation accompanied by prevention of leukocyte 
adhesion via L-selectin shedding, amongst possible other mechanisms such as 
endothelial cell ANXA1 shedding, significantly reduces the migration of peripherally 
activated immune cells into the brain parenchyma. Within the brain, hrANXA1 
reduces the number of microglia cells, restores the expression of CX3CR1 and induces 
a shift from the pro-inflammatory M1 to the pro-resolving M2 phenotype, this can 
have a huge impact on improving cross-talk and preventing damage to neurons 
through reduced iNOS production and controlled apoptosis.  
To sum up, dietary intervention of HFHS – Chow reversion diet causes significant 
weight loss and reduces obesity. Changes in nutritional intake affects a number of 
metabolic and immune signalling pathways to reduce inflammation. Most notably, 
HFHS – Chow reversion diet mice have significant improvement in their 
inflammatory profile. After 5 weeks of diet intervention, brain endothelial cells show 
improvement in TJs, and reduced activation via adhesion molecules accounting for 
improved permeability. Overall dietary changes do not reduce the activation of all T-
cells; nevertheless, there is a reduction in the TH17/Treg ratio which are implicated in 
diabetes. Along with this, TEM studies show presence of CD45+ leukocytes at the 
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BBB. Whilst there is a reduction in adhesion/migration of TH17 cells, the Treg cells 
still transmigrate implicating that T-cells have not lost their ability to migrate however 
there are changes being made immunological to restore the disease status. In 
particular, Treg cells are known to be present to allow for brain surveillance; migration 
of CD4+ CD45+ T-cells and CD4+ Foxp3+ cells perhaps represents T-cells required for 
immune surveillance, inflammation resolution and immune suppression to slow down 
disease progression and restore cognition (617–619). In fact, within the brain 
parenchyma there is considerably reduced microglia activation suggesting that less 
damaging cells or molecules are passing through. Microglia also show a restoration of 
balance between M1/M2 phenotype and the CX3CR1 receptor. In can be concluded 
that dietary changes begin to show changes in diabetes and its associated brain 
microvascular complications however a longer duration of diet may be required to 
allow for the complete reversal of diabetes-induced damage.  
Taking the results of this chapter into consideration, what then is a better treatment for 
diabetes-induced BBB damage and neuroinflammation inflammation – 
pharmacological intervention by hrANXA1 or dietary changes? Without doubt, 
hrANXA1 therapeutic treatment appears to have a much more significant effect on 
reducing the overall diabetic phenotype compared to dietary change. Nonetheless, 
when examining permeability and TEER, both hrANXA1 and dietary change show 
equivalent improvement highlighting that both are beneficial in restoring BBB 
integrity. It appears that ANXA1 has more direct effects on the BBB restoration 
through its links with the actin cytoskeleton, BMs and TEM prevention. On the other 
hand, the attributes of a healthy diet are through reduced inflammatory mediators, 
downstream this would result in the altering of signalling pathways associated with 
T2DM. Both interventions also show significantly better microglia outcomes 
indicative of reduced neuroinflammation.  
Importantly, the HFHS – Chow reversion mice are 5 weeks older compared to the 
chow-fed, HFHS-fed and HFHS-fed + hrANXA1 mice, and as shown in Figure 4.2, 
there is an effect of age that can contribute to BBB leakage. Therefore, it is likely that 
beneficial effects of a dietary change are likely to be even greater than those shown 
here by our HFHS – Chow reversion mice in this preliminary study. Confirmation is 
required by comparing mice all at the same age at cull. Nevertheless, our results 
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provide a baseline for the potential of diet in improving BBB integrity and 
neurovascular health.  
It is well-documented that a multi-factorial approach of lifestyle, drug and behavioural 
therapy produces greater improvements in HbA1c, blood pressure, total cholesterol 
and triglycerides than conventional drug therapy alone (716). Therefore, in the future, 
it would be beneficial to combine HFHS – Chow reversion diet mice with treatment 
of hrANXA1, both prophylactically from week 5 in HFHS-feeding through to the end 
of chow-feeding and therapeutically from week 11 when dietary intervention is 
implemented.  
 
In conclusion, this chapter highlights that both a pharmacological and dietary 
intervention can have huge potential for improving brain health that has been impaired 
as a result of metabolic disorders. Research is being undertaken for using hrANXA1 
as a therapeutic treatment in human disease as its benefits have been documented in a 
variety of conditions including heart disease, MS and rheumatoid arthritis (294). In 
fact, the ability of hrANXA1 to prevent α4β1 integrin-VCAM1 interaction is the main 
mechanism of action of the MS drug, Natalizumab. As ANXA1 is an endogenous 
protein it has the potential of reducing side effects and could be highly beneficial in 
conditions of T2DM whereby patients are already prescribed a number of other 
medications.  
The ability of dietary changes to reduce BBB leakage suggests that MetS/T2DM 
effects are not only limited to the peripheral system but also the brain. In fact, large 
clinical trials are underway to assess the role of diet in conditions of dementia and MS, 
with a focus on foods high in poly-unsaturated fatty acids, antioxidants and 
polyphenols and a reduction of saturated fats, refined sugars and salt content. Taking 
these results into consideration, whereby it is clear that reduced peripheral 
inflammation benefits the brain, it would be valuable to educate individuals on the 
effect of diet not just on causing T2DM and heart disease but also on causing brain 
disorders. The role of diet in improving brain health, has huge implications in national 
and international strategies of preventing and lowering the burden of 
neuroinflammatory and neurodegenerative disorders.  
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6.1 Introduction  
Maintenance of healthy cellular and systemic function requires the constant supply of 
metabolites for cellular energy metabolism in order to generate ATP. It is widely 
recognised that the brain has the highest energy consumption of all organs in the body, 
utilising 20% of the body’s resting metabolic rate (72). Of this, neurons consume 70-
80% of the total energy for neuronal functions such as restoration of membrane 
potential, vesicle recycling and neurotransmitter transport (745–748). However the 
high metabolic demand of the brain is not matched by the presence of large intrinsic 
energy stores within cells of the NVU, instead the brain depends on a continuous influx 
of substrates from the peripheral vasculature (73). Therefore the BBB, along with the 
BCSFB, is integral in providing transport of essential nutrients, ions and signalling 
molecules from the peripheral blood into the brain parenchyma (21,749).  
The BBB controls the influx of metabolites such as glucose, amino acids and ketones 
whilst limiting the entry of unwanted toxic molecules or immune cells (16,749). 
Results from the previous chapters have clearly demonstrated the loss of BBB integrity 
in T2DM. As previously shown in Chapters 4 & 5, the BBB endothelial cells of HFHS-
fed mice become activated through increased expression of inflammatory mediators 
such as cytokines, chemokines, interleukins, adhesion molecules and MMPs. This 
results in enhanced leukocyte TEM and subsequently leads to microglia activation. 
All these processes confer increased energetic demands.  Moreover, loss of the BBB 
will impact the transport functionality, altering the energy availability and supply to 
the brain (750) impacting neuronal function and thus leaving the brain susceptible to 
neurodegeneration and cognitive impairment.  
Indeed, disruption in glucose and oxygen metabolism and mitochondrial function have 
been attributed to the pathology of a number of neurodegenerative diseases including 
AD, MS, PD and Huntington’s Disease (73,751). However to date, research has 
primarily focused on understanding the metabolism of neurons and astrocytes in health 
and disease (73,751). To our knowledge the only other study reporting metabolic 
status of the BBB endothelial cells was conducted by our own lab which was 
investigating the effect of MS patient’s serum on brain endothelial cells. We reported 
that factors in the serum of MS patients reduced the glycolytic and mitochondrial 
activity of BBB endothelial cells (269).  
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6.1.1 Aims and objectives 
Since BBB endothelial cells are sensing for metabolic-related factors, disruption to the 
BBB because of metaflammation will also impair its ability as a functional, transport 
and metabolic barrier.  This is likely to be crucial to the downstream effects occurring 
in microglia, astrocytes, and neurons.  
 
The chapter addresses Hypothesis 4 mentioned in Chapter 2, this is as follows: 
 Hypothesis 4: 
It is hypothesised that the metabolism of the BBB endothelial cells will be 
disrupted and this together with impaired BBB structure will alter the 
transport of essential nutrients e.g. glucose across the BBB into the brain to 
contribute to neurodegeneration. Treatment with hrANXA1, which is shown 
to repair the BBB TJs, could therefore also repair the metabolic integrity of 
the BBB endothelial cells.  
 
This chapter addresses Aim 5 mentioned in Chapter 2, this are as follows: 
5. To investigate how nutrient imbalance in T2DM induced by HFHS-feeding 
can affect the BBB endothelium metabolic programming by examining 
cellular metabolism pathways of glycolysis and oxidative phosphorylation. 
The potential of hrANXA1 treatment to restore the metabolic integrity will 
also be assessed. 
 
In order to study this aim, the mouse brain endothelial cell line, bEnd3 was used and 
stimulated with serum collect from the three experimental mice groups: chow-fed diet, 
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The following objectives were covered in this chapter to address this aim: 
• To determine whether serum stimulation with mouse serum on the mouse brain 
endothelial cell line, bEnd3 serves as a relevant in vitro model. Serum from 
chow-fed diet, HFHS-fed diet, HFHS-fed diet + hrANXA1 treatment and 
HFHS – Chow reversion diet mice was used to stimulate bEnd3 cells. 
Confirmation of the model was determined by measuring BBB integrity via in 
vitro paracellular permeability, TEER, junctional proteins and adhesion 
molecules expression.  
• To investigate the effect of HFHS-induced T2DM and hrANXA1 treatment in 
HFHS-feeding on the glycolytic activity of BBB endothelial cells. 
• To investigate the effect of HFHS-induced T2DM and hrANXA1 treatment in 
HFHS-feeding on glucose uptake and transport.  
• To investigate the effect of HFHS-induced T2DM and hrANXA1 treatment in 
HFHS-feeding on the mitochondrial respiration of BBB endothelial cells. 
• To investigate the effect of HFHS-induced T2DM and hrANXA1 treatment in 
HFHS-feeding on ATP production of BBB endothelial cells. 
• To investigate the effect of HFHS-induced T2DM and hrANXA1 treatment in 
HFHS-feeding on ROS production by BBB endothelial cells.  
• To investigate the effect of HFHS-induced T2DM and hrANXA1 treatment in 
HFHS-feeding and dietary intervention on lipid and adipokine expression at 
the BBB.  
 
A summary of the experimental plan and the methods used to quantify each measure 
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Table 6.1 | Summary of the central and individual measures used to evaluate the aims 
and objectives of Chapter 6, with reference to the respective methodology used to 
conduct these experiments. 
Central measure Individual measures 
Method 
section 
Confirmation of in 
vitro model - mouse 
serum stimulation of 
bEnd3 cells 
Cell culture & serum stimulation 3.2.1-3.2.4 
Paracellular permeability & TEER 3.2.5 & 
3.2.6 
FACS analysis of junctional proteins and 
cytoskeleton  
3.4.3 
FACS analysis of adhesion molecules  3.4.3 
Glycolytic activity 




Glucose uptake (6NBDG) and glucose 
transport (GLUT1 expression) 
3.4.3 & 
3.4.3 
Insulin receptor expression 3.4.3 
Mitochondrial 
respiration 
Seahorse assay for oxidative 
phosphorylation of bEnd3 cells 
3.4.2 & 
3.2.9 
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6.2 Results 
The results from the previous chapters clearly demonstrate that metabolic disorders 
impact the brain microvasculature, causing the BBB to lose its inherent properties as 
a barrier interface between the central and peripheral systems. The leaky phenotype of 
the BBB predisposes the brain to a neuroinflammatory response. Therapeutic 
treatment with hrANXA1 or dietary intervention from a HFHS diet to a chow diet 
dampened the pro-immuno-inflammatory status thus improving the structural, 
functional, and immunological integrity of the BBB, which will thereby reduce the 
neuroinflammatory status.  
The anti-inflammatory effect of ANXA1 or a healthy diet versus HFHS-feeding mice 
implicates that damage to the BBB occurs due to peripheral pro-inflammatory 
mediators attacking and damaging the brain microvasculature. To replicate such 
effects in vitro, serum collected from chow-fed, HFHS-fed, HFHS-fed + hrANXA1 
treated and HFHS – Chow reversion-fed mice was used to stimulate an immortalised 
cell line of mouse brain endothelial cells - bEnd3. The benefit of using an in vitro 
model is to replace, reduce and refine the number of rodents used; particularly as 
primary brain endothelial or microglial cultures require several mice per each culture 
which only remain viable for a few passages.  
 
 
6.2.1 Effect of serum stimulation on BBB integrity  
Firstly, the integrity of the BBB was measured through assessing the permeability and 
electrical resistance of bEnd3 cells stimulated with mouse serum from chow-fed, 
HFHS-fed, HFHS-fed + hrANXA1 treated and HFHS – Chow reversion-fed mice. 
Serum stimulation was provided by switching the FBS in complete bEnd3 medium 
with mouse serum. The serum was decomplemented before use, to ensure the effects 
seen were not due to the interference of the complement system. The cells were also 
left unstimulated e.g. in normal complete medium with FBS to ensure that the effect 
seen was due to factors present in the mouse serum. Additionally, cells were also 
stimulated with 100ng/mL TNF-α overnight to mimic an inflammatory state, as means 
of confirmation that this is the trigger for BBB damage.  
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The permeability of the BBB was tested using an in vitro system whereby bEnd3 cells 
were cultured on transwell inserts until confluent. Cells were either left unstimulated, 
stimulated with 100ng/mL TNF-α or stimulated with 10% mouse serum in culture 
medium for 16 hours. The permeability of the tight junctions to 55-77kDa FITC-
dextran was assessed (Figure 6.1A). The results showed a 2.5-fold increase in 
paracellular permeability of cells stimulated with HFHS-fed mice serum when 
compared to chow-fed mice serum-stimulated cells. Stimulation of bEnd3 cells with 
serum from HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet mice 
reduced the permeability compared to HFHS-fed mice serum-stimulated cells; 
comparable to the permeability seen with chow-fed mice serum stimulation. Results 
from the permeability assay reveal unstimulated cells to have a similar coefficient to 
chow-fed mice serum-stimulated cells. TNFα-stimulated cells had increased 
permeability compared to unstimulated cells, which was similar to the HFHS-fed mice 
serum-stimulated cells, confirming that pro-inflammatory interleukins and other 
mediators are indeed present in the serum to induce increased permeability and these 
are reduced in the pharmacological and dietary intervention arms (also confirmed by 
the serum analytes analysis on chow-fed, HFHS-fed and HFHS-fed + hrANXA1 
treated mice in Figure 5.7).  
The TEER was also tested in the transwells as another measure of BBB tightness 
(Figure 6.1B). Cells stimulated with HFHS-fed mice serum had reduced electrical 
resistance compared to cells stimulated with chow-fed mice serum. Serum from 
HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet mice significantly 
increased the TEER when compared to HFHS-fed mice serum-stimulated cells and 
the TEER was in fact higher that in chow-fed mice serum-stimulated cells, albeit not 
significantly. Unstimulated cells had a similar TEER to cells stimulated with chow-
fed mice serum, and TNF-α, like the HFHS-fed mice serum, reduced the TEER.  
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Figure 6.1 | Measuring the permeability and TEER of bEnd3 cells stimulated with mouse 
serum 
FITC-dextran (55-77kDa) was used to assess the in vitro paracellular permeability of bEnd3 
cells grown on transwell inserts. Cells were stimulated overnight (16 hours) with 10% serum 
collected from chow, HFHS, HFHS + hrANXA1 or HFHS – Chow reversion mice (A). The 
TEER of bEnd3 cells with serum stimulation was also measured using the Epithelial 
Volt/Ohm (EVOM2) Meter (World Precision Instruments, USA) (B); cells were also left 
unstimulated in complete culture medium with FBS or stimulated with 100ng/mL of TNF-α 
(n=30/group, 10 mice pooled/group, per 3 independent experiments, two technical replicates 
per experiment). Statistical analysis was performed by one-way ANOVA followed by a 
Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, **p<0.01 vs. Chow; 
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Previously, the changes in permeability and TEER could be correlated to the 
alterations in the structure and alignment of TJs, AJs and cytoskeleton. To confirm 
that the in vitro results were replicable to the in vivo and ex vivo results, the effect of 
serum stimulation of on junctional proteins, the actin cytoskeleton and adhesion 
molecules was also assessed using flow cytometry (Figure 6.2).  
Stimulation with HFHS-fed mice serum reduced the expression of occludin and VE-
cadherin compared to chow-fed mice serum-stimulated cells (Figure 6.2A). Serum 
from HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet mice restored 
the expression of occludin and VE-cadherin when compared to HFHS-fed mice serum, 
comparable to chow-fed mice serum-stimulated cells. Interestingly, there was no 
change in the expression of PECAM-1 across all groups.  
Figure 6.2B showed HFHS-fed mice serum stimulation to disrupt the actin 
cytoskeleton arrangement, with a 2-fold increase in the G/F actin ratio compared to 
chow-fed mice serum-stimulated cells. Both HFHS-fed + hrANXA1 treated and 
HFHS – Chow reversion diet mice serum-stimulated cells restored the G/F actin ratio 
when compared to HFHS-fed mice serum-stimulated cells.  
The expression of ABC transporter, Pgp was also measured via flow cytometry. Pgp 
is an efflux pump and is important in protecting the brain from the accumulation of 
toxic substances (752). Figure 6.2C shows a decrease in the expression of the Pgp 
transporter in HFHS-fed mice serum-stimulated cells compared to chow-fed mice 
serum-stimulated cells. HFHS-fed + hrANXA1 treated and HFHS – Chow reversion 
diet mice serum-stimulated cells show increased Pgp expression compared to HFHS-
fed mice serum-stimulated cells. Although there was a trend, there was no statistical 
significance in these results.  
Review of the activation status of the endothelium upon serum stimulation (Figure 
6.2D), revealed that HFHS-fed mice serum significantly increased expression of 
ICAM-1 compared to chow-fed mice serum, this was reduced upon serum stimulation 
from HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet mice. 
Interestingly there was no change in expression of VCAM-1 across all groups. 
  
 
Page | 286  
 
Another marker used to measure the activation of the BBB endothelium, was the co-
stimulatory molecule CD86. CD86, is normally presented by antigen presenting cells 
an accessory signal for optimal T-cell activation and proliferation. Previous studies 
using human brain microvascular endothelial cells have found CD86 to be upregulated 
after TNF-α or IFN-γ stimulation, suggesting that endothelial cells may act as an 
antigen presenting cell themselves to trigger T-cell activation (753,754).  Using the 
bEnd3 model, it was seen that stimulation with HFHS-fed mice serum resulted in 
upregulation of CD86 compared to chow-fed mice serum. HFHS-fed + hrANXA1 
treated mice serum reduced the expression of CD86 on bEnd3 cells, whereas the 
expression of CD86 remained high in cells stimulated with HFHS – Chow reversion 
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Figure 6.2 | Effect of mouse serum on junction proteins and the adhesion molecules 
bEnd3 cells were stimulated overnight (16 hours) with 10% mouse from chow, HFHS, HFHS 
+ hrANXA1 and HFHS – Chow reversion mice. Cells were collected and stained for junctional 
proteins, G/F-actin and adhesion molecules. The expression (median fluorescence intensity, 
MFI) of junctional proteins occludin, PECAM-1 and VE-cadherin (A), G/F actin ratio pool 
(B), P-glycoprotein (Pgp) transporter (C) and adhesion molecules ICAM-1, VCAM-1 and co-
stimulatory molecule CD86 (D) was analysed flow cytometrically (n=6-26/group, mouse 
serum pooled in pairs, conducted as at least 3 independent experiments). Statistical analysis 
was performed by one-way ANOVA followed by a Bonferroni post-hoc test. Data is expressed 
as mean ± SEM., *p< 0.05, **p<0.01 vs. Chow; $p<0.05, $$p<0.01, vs. HFHS, #p<0.05 vs 
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6.2.2 HFHS-feeding alters the metabolism of BBB endothelium cells   
Brain endothelial cells primarily use glucose and lipid-derived fatty acids as energy 
sources (346), which are metabolised to produce ATP via a series of metabolic 
pathways.  
Briefly, glucose is metabolised via glycolysis to produce pyruvate, which is further 
oxidised to Acetyl-CoA. Fatty acids are metabolised via β-oxidation to also produce 
Acetyl-CoA. Acetyl-CoA from glycolysis and β-oxidation enters the citric acid cycle 
(TCA). The conversion of glucose to pyruvate, pyruvate to Acetyl-CoA, fatty acid to 
Acetyl-CoA and oxidation of Acetyl-CoA results in the production of electrons and 
H+ ions which are transferred via NADH or FADH2 to the ETC for oxidative 
phosphorylation. Oxidative phosphorylation involves the reduction of O2 to H2O with 
electrons donated by NADH and FADH2, through a series of electron carries (Figure 
6.3). All of these metabolic pathways are ATP yielding (755,756).   
Using the Seahorse metabolic assays (Agilent, UK), the glycolytic pathway and 
downstream metabolic respiration at the ETC was assessed in brain endothelial cells 
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Figure 6.3 | Linking glycolysis & β-oxidation to mitochondrial respiration of the TCA 
cycle and ETC 
Different metabolic pathways are used to metabolise different nutrients for production of ATP. 
Glucose is metabolised via glycolysis to produce pyruvate in the cytosol. Pyruvate is taken up 
by the mitochondria and further metabolised to Acetyl-CoA. Fatty acids are metabolised by 
co-enzymes to fatty acyl-CoA, which undergo β-oxidation to produce Acetyl-CoA. Acetyl-
CoA from glucose and fatty acids enters into the TCA cycle for oxidation. In each of these 
conversion steps - glucose to pyruvate, pyruvate to Acetyl-CoA, fatty acid to Acetyl-CoA and 
oxidation of Acetyl-CoA, electrons and H+ ions are produced. These are transferred via NADH 
or FADH2 to the electron transport chain for oxidative phosphorylation. Oxidative 
phosphorylation involves the reduction of O2 to H2O with the donated electrons. The TCA and 
oxidative phosphorylation pathways collectively are termed as mitochondrial respiration. 
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The Glycolytic Stress Kit was used to measure glycolytic function and thus assess the 
use of glycolysis in brain endothelial cells. In glycolysis, the conversion of glucose to 
pyruvate and subsequently lactate results in the production and extrusion of protons 
into the extracellular medium. The extrusion of protons causes acidification of the 
medium and hence the extracellular acidification rate (ECAR) is used to determine the 
glycolytic function of the cells.  
The ECAR profile (Figure 6.4A) shows HFHS-fed mice serum-stimulated cells have 
a higher ECAR than the chow-fed mice serum-stimulated cells, indicative of greater 
glycolysis taking place in these cells. This can be seen through all parameters of 
glycolytic rate, glycolytic capacity and glycolytic reserve (Figure 6.4 B-D) whereby 
HFHS-fed mice serum-stimulated cells have a higher ECAR compared to chow-fed 
mice serum-stimulated cells. Cells stimulated with serum from HFHS-fed + 
hrANXA1 treated mice have a lower ECAR profile when compared to HFHS-fed mice 
serum-stimulated cells, with a statistically significant reduction only seen in the 
glycolytic capacity. The non-glycolytic acidification rate does not differ between the 
groups suggesting that only glycolysis is the source of extracellular acidification in 
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Figure 6.4 | Effect of chow, HFHS, HFHS + hrANXA1 mouse serum on the glycolytic 
activity of brain endothelial cells 
bEnd3 cells were stimulated for 16 hours with 10% mouse serum from chow, HFHS, HFHS 
+ hrANXA1 mice. Using the Glycolysis Stress Test (Seahorse, Agilent, UK) sequential 
injections of glucose, oligomycin and 2-deoxy-glucose (DG) were added to measure 
glycolytic function (extracellular acidification rate, ECAR, mpH/min). The kinetic profile of 
glycolytic function (A) was used to quantify the glycolytic rate (B), maximum glycolytic 
capacity (C), glycolytic reserve (D) and non-glycolytic acidification (E) (n=12/group, three 
replicates per mouse). Statistical analysis was performed by one-way ANOVA followed by a 
Bonferroni post-hoc test. Data is expressed as mean ± SEM., *p< 0.05, **p<0.01 vs. Chow; 
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To gain a better understanding of glucose as a fuel for these cells as well as the 
transport of glucose across the BBB, the expression of glucose receptor - glucose 
transporter-1 (GLUT-1), and the uptake of glucose was measured using flow 
cytometry (Figure 6.5). When measuring glucose uptake by the cells using 6NBDG, a 
fluorescent nonhydrolyzable glucose analogue, there was a trend towards increased 
uptake by HFHS-fed mice serum-stimulated cells compared to chow-fed mice serum-
stimulated cells, and a trend towards reduced uptake by HFHS-fed + hrANXA1 treated 
mice serum-stimulated cells. There was no change in the expression of GLUT-1 
between HFHS-fed and chow-fed mice serum-stimulated cells however there was a 
decrease in the expression of GLUT-1 expression in HFHS-fed + hrANXA1 treated 
mice serum-stimulated cells, to levels lower than in chow-fed mice serum-stimulated 














Figure 6.5 | Glucose uptake and transport 
The expression (median fluorescence intensity, MFI) of receptors involved in glucose 
transport in brain endothelial cells were assessed using flow cytometry (n=4-8/group, 
duplicates per mouse). bEnd3 cells were stimulated for 16 hours with 10% mouse serum from 
chow, HFHS, HFHS + hrANXA1 mice after which cells were stained for glucose transporter-
1 (GLUT-1). To measure glucose uptake, cells were first incubated in glucose free medium 
for 1 hour followed by the addition of 200µM 6NBDG, a glucose analogue; cells were 
analysed live at the flow cytometer. Statistical analysis was performed by one-way ANOVA 
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In addition, as metabolic disorders cause hyperinsulinemia and subsequent insulin 
resistance, the expression of the insulin receptor by bEnd3 cells was also measured 
(Figure 6.6). There was no stark change in the expression of insulin receptor across all 
3 groups, however there appeared to be a trend towards decreased expression in the 






Figure 6.6 | Expression of insulin receptor on brain endothelial cells 
The expression (median fluorescence intensity, MFI) of the insulin receptor in brain 
endothelial cells were assessed using flow cytometry (n=4-8/group, duplicates per mouse). 
bEnd3 cells were stimulated for 16 hours with 10% mouse serum from chow, HFHS, HFHS 
+ hrANXA1 mice after which cells were stained and were passed by the flow cytometer. 
Statistical analysis was performed by one-way ANOVA followed by a Bonferroni post-hoc 
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The Mito Stress test was used to measure mitochondrial respiration at the ETC 
(oxidative phosphorylation) and thus assess the mitochondrial function (Figure 6.7). 
Mitochondrial respiration was measured by oxygen consumption rate (OCR). Cells 
stimulated with serum from HFHS-fed mice had a significantly higher OCR profile 
compared to chow-fed mice serum-stimulated cells (Figure 6.7A), indicative of higher 
mitochondrial respiration. The OCR of all parameters - basal respiration, ATP 
production, proton-leak, maximal respiration and spare capacity (Figure 6.6 B-G) is 
higher in HFHS-fed mice serum-stimulated cells compared to chow-fed mice serum-
stimulated cells; indicative of increased oxidative phosphorylation taking place within 
these cells. Overall, cells stimulated with serum from HFHS-fed + hrANXA1 treated 
mice have a lower OCR profile when compared to HFHS-fed mice serum-stimulated 
cells. Although the basal respiration and proton leak remain high in the HFHS-fed + 
hrANXA1 treated mice, there is a significant reduction in the maximal respiration and 
spare capacity of these cells when compared to HFHS-fed mice serum-stimulated 
cells; the latter two measurements are similar to chow-fed mice serum-stimulated 
cells. The high basal respiration rate in HFHS + hrANXA1 accounts for the high ATP 
production via the ETC. Importantly the non-mitochondrial oxygen consumption does 
not differ between the groups suggesting that this test is an accurate measure for 
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Figure 6.7 | Effect of chow, HFHS, HFHS + hrANXA1 mouse serum on the 
mitochondrial respiration of brain endothelial cells 
bEnd3 cells were stimulated for 16 hours with 10% mouse serum from chow, HFHS, HFHS 
+ hrANXA1 mice. Using the Mito stress kit (Seahorse, Agilent, UK) sequential injections of 
oligomycin, FCCP, Antimycin A & Rotenone were added to measure mitochondrial 
respiration (oxygen consumption rate, OCR, pmoles/min) by inhibiting different complexes 
of the electron transport chain. The kinetic profile to quantify mitochondrial respiration (A) 
was used to quantify the other indices of mitochondrial function – basal respiration (B), ATP 
production (C), proton leak (D), maximal respiration (E), spare capacity (F), non-
mitochondrial respiration (G) (n=6/group, three replicates per mouse). Statistical analysis was 
performed by one-way ANOVA followed by a Bonferroni post-hoc test. Data is expressed as 
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To measure the production of all ATP generated by the cell, an ATP luminescence 
detection kit (Perkin-Elmer, USA) was used (Figure 6.8). Results reveal there to be an 
increase in the production of ATP by HFHS-fed mice serum-stimulated cells 
compared to chow-fed mice serum-stimulated cells, however the production of ATP 
is further increased in HFHS-fed + hrANXA1 treated mice serum-stimulated cell. 





Figure 6.8 | ATP production by bEnd3 cells stimulated with mouse serum 
ATP production by bEnd3 cells stimulated with mouse serum (n=5/group, five replicates per 
mouse) was measured using the ATP luminescence detection kit (Perkin Elmer, USA). 
Luminescence was read (1 sec/well) on a plate reader (Infinite M200 PRO plate reader, 
TECAN). Statistical analysis was performed by one-way ANOVA followed by a Bonferroni 
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The combination of hyperglycaemia and insulin resistance causes oxidative stress 
through disruption of NO release; coupled with increased AGE and ROS production 
thereby enhancing activation of inflammatory pathways (758).  
Firstly cellular and mitochondrial ROS production was measured using DCFDA and 
MitoSOX respectively (Figure 6.9A,B). Fluorescence assays showed stimulation with 
HFHS-fed mice serum induced a greater production of both cellular and mitochondrial 
ROS when compared to chow-fed mice serum stimulation, as seen by higher 
fluorescence emission (relative fluorescence unit, RFU). Cells stimulated with serum 
from HFHS-fed + hrANXA1 treated mice had significantly reduced cellular and 





Figure 6.9 | Measurement of cellular and mitochondrial ROS production in bEnd3 cells 
stimulated with mouse serum  
ROS production, cellular and mitochondrial was measured using fluorescence assays. bEnd3 
cells were grown in 96-well plates until confluent; cells were stained using 25µM DCFDA 
(cellular ROS, Ex/Em 485/535nm; A) or 2.5µM of MitoSOX (mitochondrial ROS, Ex/Em 
510/580nm; B) followed by stimulation with 10% serum from chow, HFHS or HFHS + 
hrANXA1 mice. Using a plate reader, the accumulation of ROS was measured by fluorescence 
emission and the relative fluorescence unit (RFU) taken as a readout for ROS production. 
(n=12/group, pooled in pairs, three replicates per pair).   
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6.2.3 The role of lipids and adipokines in metabolism at the BBB 
Aside from glycolysis and oxidative phosphorylation there are several other cellular 
metabolism pathways that could be impacted by T2DM. Aside from hyperglycaemia, 
T2DM also causes hyperlipidaemia, as seen by raised levels of cholesterol and 
triglycerides in the HFHS-fed mice (Figure 4.2). Here, we briefly investigated how 
lipid metabolism may be altered by briefly investigating the expression of LDL 
receptor (LDL-R) and PCSK9, a protein that can bind to LDL-R, in primary brain 
microvessels of chow-fed, HFHS-fed, HFHS-fed + hrANXA1 treated and HFHS – 
Chow reversion mice (Figure 6.10A).  
The results showed that the expression of LDL-R is significantly decreased in HFHS-
fed mice compared to chow-fed mice. The expression of LDL-R is restored in HFHS-
fed + hrANXA1 treated and HFHS – Chow reversion diet mice. PCSK9 is a protein 
that competes with lipids to bind to the LDL receptor and prevent lipid uptake; results 
show significantly increased PCSK9 protein expression in HFSH-fed mice compared 
to chow-fed mice, the expression is reduced in HFHS-fed + hrANXA1 treated and 
HFHS – Chow reversion diet mice. 
 
In addition, research in recent years has suggested that expression of adipose-derived 
factors called adipokines, that act has hormones, may disrupt CNS homeostasis and 
thereby play a role in the development of neuroinflammatory disorders. Four 
adipokines have been measured at the brain microvessels of the mice, these include 
adiponectin, chemerin, leptin and resistin (Figure 6.10B).  
Adiponectin is involved in regulating glucose levels; results show that its expression 
is decreased in HFHS-fed mice compared to chow-fed mice and levels are improved 
in HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet mice.  
Chemerin regulates adipocyte development and glucose metabolism; results show that 
its expression is significantly increased in HFHS-fed mice compared to chow-fed mice 
and levels are restored in HFHS-fed + hrANXA1 treated and HFHS – Chow reversion 
diet mice.  
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Leptin is a satiety hormone, there are no significant differences across the groups 
however there appears to be a slight trend towards increased leptin expression in 
HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet mice compared to 
chow-fed and HFHS-fed mice.  
Resistin has been shown to induce inflammation; results at the brain microvessels 
indicate an increased expression of resistin in HFHS-fed mice compared to chow-fed 










Page | 304  
 
                
 
Figure 6.10 | Expression of metabolic factors in primary brain microvessels  
Simultaneous measurement of adipokines and lipid mediators in protein extracts from primary 
brain microvessels of chow, HFHS, HFHS + hrANXA1 and HFHS – Chow reversion mice, 
using Mouse Cytokine Array Kits (R&D Systems, Minneapolis, USA). Membrane-based 
immunoassays detected the relative expression levels of analytes detected as arbitrary units 
by x-ray film exposure (n=10 pooled/group, two technical replicates per experiment, for chow, 
HFHS and HFHS + hrANXA1 performed as two independent experiments total n=20/group); 
quantified using ImageStudio Lite (LI-COR Biosciences).  
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6.3 Discussion 
The results from the first part of this chapter using serum stimulation, show stimulation 
with HFHS-fed mice serum increases the leakage of the brain endothelial cells with 
heightened permeability and reduced TEER compared with chow-fed mice serum-
stimulated cells, which can be accounted for by the reduction of junctional proteins 
such as occludin and VE-cadherin as well as loss of the actin filamentous fibres. 
Moreover, the HFHS-fed mice serum activates the bEnd3 cells to upregulate adhesion 
molecule expression. In addition, cells stimulated with HFHS-fed mice serum show 
an upregulation of co-stimulatory molecule CD86, indicating that the brain endothelial 
cells themselves act as antigen presenting cells under inflammatory stimuli, as 
previously reported (753,754). This coincides with the increased adhesion and 
migratory profile of TH17 and Treg cells seen in the HFHS-fed mice (Figure 5.14) 
Stimulation with HFHS-fed + hrANXA1 treated and HFHS – Chow reversion diet 
mice serum retains the cellular integrity as seen in chow serum-stimulated cells.  
All of these results are comparable to the in vivo and ex vivo data shown in Chapters 
4 & 5, measuring the same parameters. It can therefore be concluded, that pro-
inflammatory mediators (interleukins, chemokines, cytokines, acute phase proteins 
etc.) are present in the serum collected from the mice and these induce the same 
phenotypic changes seen in the primary brain endothelial cells or microvessels. The 
restoration of the parameters with both an anti-inflammatory agent (ANXA1) and 
dietary switch implicates the role played by chronic inflammation in causing 
endothelial dysfunction and vascular damage induced by the traits of MetS (obesity, 
hyperglycaemia and dyslipidaemia).  
Primarily, these results demonstrate that an in vitro BBB model stimulated with mouse 
serum serves as a comparable model to ex vivo primary cultures. This has major 
implications for the 3Rs (reduction, replacement, and refinement) of research. It would 
therefore seem viable to use cell lines of astrocytes or microglia, that are stimulated 
with serum in vitro to assess the affects occurring to these cells too. Notably, the most 
robust way to model the BBB in vitro would be to use a 3D co-culture model.  
Secondly, these results are integral in confirming that peripherally-induced 
inflammation arising as a result of metabolic disorders is detrimental to the brain 
microvasculature. It is this metaflammation that triggers BBB malfunction. No doubt, 
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the other cells of the NVU also contribute to the sustained and long-term damage seen 
at the BBB and in the brain, however it is the metaflammation and immuno-metabolic 
disturbance that initiates this sequence of events.  
It has long been established that T2DM can cause microvessel damage in the 
peripheral system resulting in secondary complications such as retinopathy, 
neuropathy and nephropathy. The results from the previous chapters in context with 
the results from serum stimulation, reveal that neuroinflammation/neurovascular 
disorders are also a secondary complication of T2DM.  
 
 
6.3.1 Altered metabolism of brain endothelial cells in MetS/T2DM 
Accumulating evidence has indicated that T2DM changes the metabolic signatures in 
the liver, pancreas, adipose tissue and immune cells, with reports of altered glucose, 
amino acid, fatty acid, glycerophospholipid and sphingomyelin metabolism (759–
763). The altered metabolic state contributes to the progression of T2DM. Given the 
fundamental role played by the brain endothelial cells as a physical, transport and 
metabolic barrier; and the disruption incurred to these cells, we hypothesised that 
changes in metabolism will also contribute to the progressive loss of the BBB and its 
functionality. This chapters of the thesis begins to explore and describe the differences 
in different metabolic pathways or metabolic factors seen with HFHS-feeding.  
 
6.3.1.1 The role of glucose at the BBB and in the brain 
The brain is very metabolically active and utilises glucose as its primarily fuel to 
generate energy (127,128). On the whole, fatty acids are not considered to contribute 
to normal brain energy metabolism however this view had been challenged with 
reports that up to 20% of energy in the brain can be derived from fatty acid oxidation 
(764–766). In endothelial cells, there are still mixed reports on whether glycolysis or 
oxidative phosphorylation is the preferred energy-yielding pathway. Peripheral 
endothelial cells have low mitochondrial content (767) and therefore it is thought these 
endothelial cells rely heavily on glycolysis for ATP generation (768–770). In contrast, 
the cells of the NVU, including the endothelial cells, are densely packed with 
mitochondria to meet the brain’s energetic demand (771). In fact, reports suggest that 
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glycolysis is the main energy production mechanism in the developing brain with a 
switch to oxidative phosphorylation in the mature brain (772). Nevertheless, it is well 
documented that glycolysis is enhanced in cerebral endothelial cells when they acquire 
tip cell phenotype for angiogenesis (769) or during hypoxic events (773). This has led 
some to believe that mitochondrial activity is preferentially used in resting cells 
whereas glycolysis is intensified in activated cells (774). Interestingly, in bEnd3 cells 
stimulated with serum from HFHS-fed mice, both the use of glycolysis and oxidative 
phosphorylation is significantly enhanced. 
When reviewing glycolysis, HFHS-fed mice serum-stimulated cells have an increased 
rate of basal glycolysis correlating with increased glucose uptake. The cells are further 
able to maximise the use of the glycolytic pathway when oxidative phosphorylation 
was shut down by addition of oligomycin. Results from this chapter and previous 
chapters clearly demonstrate an increased activation of brain endothelial cells in a 
diabetic phenotype; therefore the increased glycolytic reserve amount in HFHS-fed 
mice serum-stimulated cells indicates that brain endothelial cells are able to respond 
to the energetic demand induced by inflammation and hyperglycaemia. Although the 
ATP generated by glycolysis has not been calculated, the measurement of all ATP 
produced by the cells shows an increase in ATP generation by all sources in HFHS-
fed mice serum-stimulated cells compared to chow-fed mice serum-stimulated cells.  
For normal brain function and energy metabolism, the brain relies on a continuous 
supply of glucose across the BBB. Usually substrate excess results in the 
downregulation of its corresponding receptor in order to balance supply and demand. 
Here, we see no apparent differences in the expression of GLUT-1 between chow-fed 
and HFHS-fed mice serum-stimulated cells. However other studies using diabetic 
mice models have reported decreased GLUT-1 and GLUT-3 expression at the BBB 
(775,776). On the other hand, in AD patients no change is seen in GLUT-1 expression 
but GLUT-3 expression is decreased (129–131). GLUT-1 is present on both the apical 
and basolateral membranes of brain endothelial cells (132), GLUT-1 and GLUT-3 are 
present on astrocytes and GLUT-3 and GLUT-4 are present on neurons. It is therefore 
possible to hypothesise, that glucose transport across the brain endothelial cells is not 
impacted by reduction in transporter expression. Instead, astrocytes and neurons have 
reduced glucose uptake and this contributes to the cognitive impairment seen in 
neurodegenerative disorders such as AD (129–131). In support of this, human studies 
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report no change in the concentration of glucose in the brain of diabetic patients vs 
healthy controls (777–779). This implies that glucose transport across the brain 
endothelial cells remains intact, but it is the differential uptake and utilisation by the 
other NVU cells that contributes to brain dysfunction.  
To better understand the glucose uptake and utilisation in brain endothelial cells vs. 
the transport of glucose into the brain for use by other cells, alternative strategies need 
to be employed such as in vivo monitoring or 3D co-culture models. The use of 3D co-
culture models will allow for the communication of different cell types and thus impact 
transporter or receptor expression in a dynamic environment, which is missing in the 
current bEnd3 model. 
 
6.3.1.2 Insulin in the brain 
Within the peripheral system, insulin is a major regulator of blood glucose levels 
through stimulating uptake of glucose by liver, muscle and adipose tissue (133). In 
contrast, glucose transport in the brain is largely insulin-independent with GLUT-1 
and GLUT-3 not requiring insulin to regulate glucose uptake (136). However the brain 
is not an insulin-insensitive tissue, with insulin receptors distributed throughout the 
brain; GLUT-4 present on neurons does require insulin-mediated glucose uptake (136) 
for neuronal growth, plasticity or neurotransmitters release (137). Therefore, insulin 
is highly involved in memory and cognition. Evaluation of insulin receptor expression 
in bEnd3 cells treated with mouse serum, revealed a trend towards insulin receptor 
downregulation in HFHS-fed mice serum-stimulated cells. Other studies using obese 
animals, have reported decreased insulin transport across the BBB resulting in reduced 
CNS insulin levels (780–783). 
Additionally, deficiency in insulin and insulin receptors have been reported in patients 
with AD (396,784,785). A phase III clinical trial in which insulin was administered 
nasally, improved cognitive function in AD patients (393). Subsequent studies have 
shown that insulin administration improves AD pathology through restoring metabolic 
function of neurons. Impaired neuronal insulin signalling is seen in mice with 
apolipoprotein E (APOE) ε4 allele - the strongest genetic risk factor for AD (786). 
APOE4 traps the insulin receptor in endosomes preventing its trafficking, thereby 
causing a reduction in mitochondrial respiration and glycolysis in the neurons (786). 
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Interestingly, a high fat diet was seen to accelerate the results seen in the APOE4 mice 
with impaired insulin signalling (786). Epidemiological studies report diabetic patients 
to have an increased risk of developing AD (787). High fat-feeding in an AD 
transgenic mouse model results in T2DM-like peripheral insulin resistance 
concomitant with decreased insulin receptor signalling in the brain, increased Aβ 
burden and cognitive defects (390,391). In fact, T2DM and transgenic AD mice 
present with similar vascular dysfunction resulting in cognitive decline that can be 
attributed to increase Aβ accumulation in both conditions (394,395). The similarities 
in the T2DM and AD mice linked with insulin sensitivity has therefore lead to the 
concept that AD is in fact a continuum of DM, termed T3DM (133,396). 
Interestingly, insulin therapy was also reported to restore Pgp levels in diabetic rats 
(145). Pgp has been shown to be involved in the clearance of Aβ (788–791). In serum 
stimulation of bEnd3 cells with HFHS-fed mice serum, the insulin receptor and Pgp 
expression showed a downwards trend compared to chow-fed mice serum-stimulated 
cells. Together, these results implicate how insulin receptor deficiency or insensitivity 
at the level of brain endothelial cells in diabetes, could subsequently lead to reduced 
insulin in the brain and therefore induce AD pathology. 
 
6.3.1.3 Mitochondrial respiration in the brain endothelial cells 
Upon review of mitochondrial respiration, HFHS-fed mice serum-stimulated cells also 
increased oxidative phosphorylation compared to chow serum-stimulated cells; this is 
likely due to the hyperglycaemia and hyperlipidaemia in the HFHS-fed mice (Figure 
5.2). In the HFHS-fed mice serum-stimulated cells there is an increase in the basal 
respiration and ATP production compared to chow-fed mice serum-stimulated cells; 
the increase in maximal respiration confirms that the cells have the ability to rapidly 
oxide substrates such as sugars, fats and amino acids, which are augmented in HFHS-
feeding. Importantly, the HFHS-fed mice serum-stimulated cells also have a large 
increase in their spare respiratory capacity suggesting that the bEnd3 cells have the 
flexibility and fitness to respond to the need of an increased energetic demand. Despite 
this however, there is increased proton leak, indicative of mitochondrial damage.  
Mitochondrial damage has been implicated in diabetes, with reports of altered 
morphology (reduced size (792) and cristae (793)) and defects in biogenesis and 
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mitophagy (794) resulting in mitochondrial fragmentation, impaired function and 
increased ROS production (795). In addition, metabolomic studies in rodents have 
found that high fat-feeding overloads mitochondria resulting in incomplete β-
oxidation and impaired activity (796). Studies conducted in our lab using MS serum 
on hCMEC/D3 cells showed decreased glycolysis and oxidative phosphorylation, 
accompanied by mitochondrial hyperpolarisation that could be correlated to an 
increase in mitochondrial superoxide and NO production (269). Similar experiments 
are required to be conducted in the HFHS-fed model, to measure how metabolic 
overload can affect the mitochondrial mass, membrane potential and subsequent 
function in brain endothelial cells.   
 
 
6.3.2 Oxidative stress at the BBB 
ROS (superoxide anion O2
-, hydrogen peroxide H2O2 and hydroxyl radio HO) are 
present in all living cells, being produced either endogenously or exogenously. 
Endogenously, ROS is generated from mitochondria during oxidative phosphorylation 
and by oxygen metabolising enzymatic reactions (797). Provided redox signalling 
mechanisms, which control the balance between generation and elimination of ROS 
remain in intact, the homeostatic levels of ROS are maintained; however an imbalance 
between pro-oxidants and anti-oxidants and impairment of anti-oxidant defence 
mechanisms can lead to oxidative stress (798–800). Oxidative stress is damaging to 
lipids, proteins and nucleic acids of cells and has been implicated in cancers, diabetes, 
atherosclerosis, aging and neurodegenerative disease (801,802).  
In the HFHS-fed mice, both production of cellular ROS and mitochondrial ROS was 
measured in bEnd3 cells. Results found serum stimulation from mice fed a HFHS-diet 
induced a greater production of cellular and mitochondrial ROS in comparison to their 
chow-fed counterparts. This is not surprising, as research has shown diabetes to 
increase production of free radicals due to chronic hyperglycaemia and 
hyperlipidaemia (349,350). Metabolic by-products of glycolysis and fatty acids are 
shunted into the citric acid cycle and ETC for subsequent oxidation (803,804), driving 
up ROS generation. Additionally, hyperglycaemia hinders the transport of other 
nutrients e.g. ascorbic acid which act as anti-oxidants and scavenges free radicals. 
(805–807). Mice fed a HFHS diet have increased circulating glucose and lipid levels, 
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and serum stimulation of bEnd3 cells increased the rates of glycolysis and 
mitochondrial respiration compared to chow serum-stimulated cells, accounting for 
higher ROS measurements.  
 
The changes in nutrient levels, transport ability and pro-inflammatory mediators will 
also impact the metabolism of other cells such as the astrocytes, microglia and neurons 
resulting in impaired metabolism and excess ROS generation (808). Importantly, the 
cells of the NVU are not just producers of ROS but also the target of oxidative stress. 
For example, NO is produced by the brain to maintain blood flow (809) and for 
neurotransmission (810); however excessive production of NO by iNOS, nNOS and 
eNOS can result in the build-up of RNS, such as peroxynitrate, which contributes to 
oxidative stress (811). The production of RNS has not been measured in the HFHS-
fed mice, however Figure 4.16 showed an enhanced expression of iNOS by endothelial 
cells of the brain microvessels and in microglia of HFHS-fed mice compared to chow-
fed mice. 
Progressive oxidative damage can lead to cell death and significant loss of cellular 
function (812,813). Free radicals induce lipid peroxidation through attacking 
phospholipid components of cellular membranes (814); the neuronal membrane is 
largely made up of polyunsaturated fatty acids and is therefore highly susceptible to 
lipid peroxidation, the 4-hyroxynonenal produced in this manner is cytotoxic to 
neurons (815,816). High levels of 4-hyroxynonenal have been reported in a number 
of neurodegenerative diseases (817). Oxidative stress in proposed as early event in the 
progressive neurodegeneration seen in cases of AD (818,819). Additionally, the 
selective loss of dopamine neurons in PD is due to the high levels of ROS due to 
enhanced dopamine metabolism (820). The production of ROS by the brain 
endothelial cells could be a key contributor to the neuroinflammatory state we show 
and downstream neurodegeneration reported in other diabetic studies (674). 
Additionally, a hyperglycaemic environment leads to the non-enzymatic glycosylation 
of proteins to form AGEs (821). Excess glucose is shunted into other pathways such 
as polyol pathway where it is converted to sorbitol; a reaction that further depletes 
NADPH and increases ROS. In turn sorbitol, is converted to fructose leading to 
production of 3-deoxyglucsone, a reactive aldehyde that contributes to AGE formation 
Page | 312  
 
(822). Increased concentrations of AGEs have been found in serum and tissues of 
diabetic patients and are proposed to play a role in insulin resistance, β-cell failure and 
diabetic complications through inducing RAGE signalling; thereby increasing ROS 
formation and downstream inflammatory signalling pathways (823). Whilst the levels 
of AGEs themselves have not been measured in this current mouse model, Figure 5.8B 
found an increased expression of RAGE at the brain microvessels of HFHS-fed mice 
compared to chow-fed mice; abnormal over-expression of RAGE is triggered through 
inflammation and accumulation of AGEs (821,824). Increased binding of AGE to its 
receptor can trigger microglia response and chemokine release, and triggers neuronal 
loss, as seen in AD (825).  
Together the measurement of ROS and indirect measurement of RNS and AGEs 
through expression of iNOS and RAGE show that there are a number of characteristic 
features within the diabetic mouse model that increase the opportunity for oxidative 
stress at the BBB and cells of the NVU, to cause neurotoxicity and cell death (378). 
 
One of the major mechanisms for oxidative stress-induced damage at the BBB is 
through MMP activation (826,827). Previously the role of MMPs in contributing to 
BBB breakdown have been discussed in Chapter 4 & 5. It was noted in Figure 4.6 that 
the expression and activity of MMP-2 and MMP-9 was increased at the brain 
microvessels of HFHS-fed mice in comparison to chow-fed mice. There are two 
proposed mechanisms by which ROS may regulate MMP activity, either directly or 
indirectly (826,827). Direct regulation occurs through oxidation or S-nitrosylation of 
the MMPs to unmask the pro-peptide for activation (828,829). Indirectly, ROS-
induced inflammatory cytokines such as IL-1, TNF-α, IL-6 etc. (827) can activate a 
number of signalling pathways such as MEK1-Erk, MAPK-p38, PI3K-Akt that result 
in the increased binding of transcription factors AP-1 and NF-κB to the redox-sensitive 
cis-regulatory elements in the MMP promoter region thereby increasing transcription 
of MMPs (830).  In this manner, we can hypothesise that the activity of MMPs in our 
model can be related to ROS and inflammatory mediators acting via several signalling 
pathways that have detrimental effects on BBB breakdown. Future studies will need 
to focus on the signalling mechanisms involved in the HFHS-fed mice by which this 
occurs, as these could be potential therapeutic targets.  
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6.3.3 Role of Annexin A1 in metabolism 
As seen in Chapter 5, the treatment of HFHS-fed with hrANXA1 attenuates T2DM 
development by lowering fasting glucose levels, serum cholesterol and serum 
triglycerides. Metabolically, the ECAR and OCR profile of cells stimulated with 
HFHS-fed + hrANXA1 treated mice serum show improvement, with a reduction in 
glycolysis and mitochondrial respiration, resulting in reduced ROS production. 
HFHS-fed + hrANXA1 treated mice have reduced iNOS activity (Figure 5.16) and 
reduced RAGE expression at the brain microvessels, therefore reducing RNS and 
AGEs (Figure 5.8), contributing to the lowering of oxidative stress. This decline in 
oxidative reduces the inflammatory mediators and thus lowers MMP activation, 
contributing to the restoration of BBB integrity seen with hrANXA1 treatment. Other 
studies have also reported ANXA1 treatment to reduce oxidative stress. For example 
ANXA1 protected against benzo[a]pyrene (Bap)-induced bronchial epithelium injury 
through regulating the activity of anti-oxidant defence mechanisms such as glutathione 
peroxidases and superoxide dismutase, reducing the expression of apoptotic protein 
Bcl-2 and restoring the PTEN/FAK/PI3K/Akt signalling pathway (831). This is in line 
with another study, in which the ANXA1 cleavage product Ac2-26 reduced oxidative 
stress via an FPR1/NOX1-dependent signalling pathway involving PI3K and NF-κB, 
to orchestrate epithelial repair (832). These results were subsequently confirmed by 
another study in which ANXA1 overexpression in PC12 cells decreased levels of 
ROS, IL-6, iNOS and NF-κB (833). Undeniably, HFHS-fed + hrANXA1 treated mice 
have reduced ROS production, reduced IL-6 levels (Figure 5.8) and reduced iNOS 
activity (Figure 5.16). 
 
Interestingly, review of oxidative phosphorylation shows that although HFHS-fed + 
hrANXA1 treated mice serum-stimulated cells retain a high basal respiration rate, the 
maximal respiration and spare capacity is significantly decreased compared to HFHS-
fed mice serum-stimulated cells and is similar to the profile seen in chow-fed mice 
serum-stimulated cells. This reduction coincides with restored serum glucose and 
lipids levels (Figure 5.2) and the diminished requirement of energy as a result of 
reduced metaflammation. On the other hand, the total ATP produced from the cell, 
irrespective of metabolic pathways shows that HFHS-fed + hrANXA1 treated mice 
serum-stimulated cells have the highest ATP production compared to chow and HFHS 
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serum-stimulated cells. These results therefore highlight that although mitochondrial 
respiration and glycolysis is reduced in HFHS-fed + hrANXA1 treated mice serum-
stimulated cells, alternative pathways are being utilised to produce energy. The results 
clearly demonstrate the endothelial cells are less activated with hrANXA1 treatment, 
with down-regulation of adhesion molecules and MMPs, therefore the increased 
energy production serves to question the need for ATP? It can be hypothesised that 
the extra ATP is required for ANXA1 binding to the actin cytoskeleton for 
maintenance of TJs. This is supported by a number of studies in which ATP depletion 
causes disruption to actin cytoskeleton (834–836) binding with TJ proteins ZO-1, ZO-
2 and cingulin, thereby causing a reduction in TEER (837).  
Importantly, in this study, only the glycolytic and oxidative phosphorylation pathways 
have been investigated. In order to fully understand the interplay and dynamic shifts 
between metabolic pathways under stress and inflammation, it would be important to 
assess the use of other nutrients e.g. glutamine and lactate alongside reviewing the 
other metabolic pathways of β-oxidation and the citric cycle. 
 
Remarkably, the proton leak in HFHS-fed + hrANXA1 treated mice serum-stimulated 
cells remains high which indicates that there is still a degree of mitochondrial 
dysfunction despite the significantly reduced ROS levels. This raises the question of 
whether ANXA1 has the ability to improve anti-oxidant defence mechanisms or 
whether ANXA1 itself acts an anti-oxidant to scavenge free radicals.  
   
The effect of ANXA1 on GLUT-1 and insulin receptor expression also warrants 
further investigation, as the transporter and receptor expression is decreased in HFHS-
fed + hrANXA1 treated serum-stimulated cells compared to chow serum-stimulated 
cells. The lack of glucose transport may affect the function of other cells in the NVU; 
indeed ANXA1 has been shown to reduce T-cell glycolysis, activation and 
proliferation (293). In the peripheral system, hrANXA1 in HFHS mice re-sensitized 
insulin receptor substrate mediated signalling to restore insulin sensitivity (512). This 
needs to be investigated at the level of the BBB, particularly as ANXA1 treatment in 
AD mice improves cognitive behaviour, through reducing local inflammation and 
reducing loss of neurons (Reis et al., manuscript submitted).  
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The re-establishment of the BBB structure through astrocyte end-feet association to 
the blood vessel and further metabolic improvements in the brain endothelial cells 
with hrANXA1 treatment will likely be a key component in the improved 
neuroinflammatory and neurological state. Astrocytes provide support to neuronal 
activity (167) through provision of metabolites, neurotransmitter precursors and ion 
buffering via gap junctions or direct contacts (168,169). Improved, structural, 
functional, and metabolic activity of the BBB with hrANXA1 treatment will have far 
reaching impacts within the brain. 
 
 
6.3.4 Other metabolic factors involved in BBB metabolism  
So far, the work investigating metabolism at the brain endothelial cells was conducted 
in the bEnd3 cell line stimulated with serum extracted from mice. Using the R&D 
Cytokine Array Panel A Kit, various other metabolic factors were detected in primary 
brain microvessels isolated from the different mice groups. The differential expression 
and presence of these factors confirm that the disruption at the BBB is also metabolic 
in nature and warrants further investigation. Moreover, the investigation of these 
factors has also been performed in HFHS – Chow reversion diet mice. Although the 
previous investigations are required to be carried out in this subset of mice, the ability 
of HFHS – Chow reversion diet mice to restore these metabolic factors implicates that 
metabolic disruption is occurring as a result of the MetS/T2DM traits and its associated 
metaflammation.   
 
6.3.4.1 Lipids at the BBB 
The role of lipids in brain endothelial cell metabolism was beyond the scope of this 
study. Nevertheless, the HFHS-fed mice had hyperlipidaemia as seen by raised levels 
of serum cholesterol and triglyceride compared to chow-fed and HFHS-fed + 
hrANXA1 treated mice (Figure 5.2). HFHS – Chow reversion diet mice, also had 
reduced levels of cholesterol and triglycerides compared to HFHS-fed mice, but the 
levels did not return to chow-fed mice levels. 
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At the brain microvessels, the expression the expression of LDL-R and protein 
PCKS9, which are involved in lipid metabolism were detected. The LDL-R is 
responsible for increasing cholesterol uptake and maintaining lipid homeostasis (838).  
At the brain microvessels, there was decreased expression of LDL-R in the HFHS-fed 
mice compared to chow-fed mice. PCSK9 is a protein that binds to LDL-R to prevent 
LDL-R recycling; blockage of this protein can lower LDL concentrations from the 
circulation (839). Interestingly the levels of PCSK9 were increased in the brain 
microvessels of the HFHS-fed mice. The combination of increased PCSK9 and 
decreased LDL-R in HFHS-fed mice suggest that lipid transport is being affected; and 
requires pursuit in future studies. Within the brain, fatty acids are taken up by 
astrocytes for synthesis and transport of cholesterol to neurons for synaptic signalling 
(840). The decreased uptake of lipids at the BBB could therefore impact the 
neurotransmission and subsequently memory/cognition. Studies in LDLR-/- mice fed 
a western diet found a decrease in cognitive processes in these mice versus control 
mice (841). Crucially, pharmacological and dietary intervention both restored levels 
of LDL-R and PCSK9 suggesting that lipid metabolism is involved in maintaining the 
BBB integrity. It would be crucial to investigate whether hrANXA1 and dietary 
intervention have the ability to restore cognition and memory processes in mice.    
 
 
6.3.4.2 Adipokines at the BBB 
Adipokines are adipose-derived factors which have been implicated to be involved in 
brain homeostasis and function. A number of these function through affecting food 
intake and energy expenditure. Four different adipokines were detected in the brain 
microvessels of chow-fed, HFHS-fed, HFHS-fed + hrANXA1 treated and HFHS – 
Chow reversion diet mice; these include adiponectin, chemerin, leptin and resistin. 
Further studies are warranted to understand the exact role of these adipokines within 
the BBB of the HFHS-fed mice, however the following passages aim to highlight the 
potential of these hormones to affect the CNS and lead to diabetes-induced neuro-
inflammation/degeneration.   
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Adiponectin is the most abundant adipokine and is involved in mediating a wide range 
of effects including regulation of insulin sensitivity through controlling glucose and 
lipid metabolism, improving endothelial function through anti-atherogenic effects, 
decreasing vascular inflammation, and regulating body weight (842–846). At the 
BBB, adiponectin supresses IL-6 and TNF-α release from endothelial cells; although 
it does not cross the BBB itself (847). In the HFHS-fed mice, there is decreased 
expression of adiponectin in brain microvessels compared to chow-fed mice; 
decreased adiponectin may contribute to damage induced at the BBB through a rise in 
pro-inflammatory mediators. There was some restoration of adiponectin levels in 
HFHS-fed + hrANXA1 mice and significantly increased levels of adiponectin in 
HFHS – Chow reversion diet mice. This is concomitant with reduced inflammation at 
the BBB, which is more apparent in the HFHS – Chow reversion diet mice compared 
to HFHS + hrANXA1 mice (Figure 5.8). Notably, adiponectin also affects astrocytes 
and neurons. Within neurons, adiponectin has neuroprotective effects through 
activating the AMPK pathway and regulating NO release (848,849). In contrast, in 
astrocytes,  adiponectin induces a pro-inflammatory response to increase IL-6 levels 
(850). As adiponectin it is not transported across the BBB, it must enter the brain via 
the BCSF. The widespread and beneficial vs deleterious effects of adiponectin 
implicate that changes in levels will affect normal cell and tissue functions.  
Resistin levels are positively correlated to adiposity. Like adiponectin, it also regulates 
the synthesis and secretion of pro-inflammatory TNF-α and IL-6. It mediates its affect 
through binding to TLR4 and causing activation of pro-inflammatory signalling 
pathways (851,852). Within the CNS it can affect the hypothalamic insulin response 
(853). The increased expression of resistin in the HFHS-fed mice compared to chow-
fed mice implicates that it may also contribute to the inflammatory state at the BBB. 
Resistin expression is decreased in HFHS-fed + hrANXA1 treated and HFHS – Chow 
reversion diet mice, in which inflammation at the BBB is reduced.  Moreover, resistin 
up-regulated PCSK9 which down-modulates LDL-R (854–857). In the HFHS-fed 
mice, there is increased resistin, increased PCSK9 and decreased LDL-R. Treatment 
with hrANXA1 and changes in diet restore resistin levels and subsequently PCSK9 
and LDL-R. Thus, resistin may be a potential candidate for improving lipid 
metabolism at the BBB, with implications on neuronal signalling and synaptic 
plasticity.  
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Chemerin is associated with regulating glucose metabolism through feeding behaviour 
(858). High levels of chemerin are a biomarker for obesity and MetS (859–862). 
Moreover chemerin has shown to be upregulated in AD patients and mouse models, 
functioning as a receptor for Aβ (863). In the mouse brain microvessels, chemerin 
levels are increased in HFHS-fed mice compared to chow-fed, HFHS-fed + hrANXA1 
treated and HFHS – Chow reversion diet mice. Similarly, low leptin levels have been 
associated with an increased risk for cardiovascular disease (864) as well as increased 
risk of AD development (865). In fact, leptin deficiency is thought to impact insulin-
controlled pathways. Chronic administration of leptin to AD-transgenic mice reduces 
the Aβ burden and tau-phosphorylation contributing to improved neurological 
outcomes (866,867). There appeared to be no differences in the expression of leptin at 
the BBB of chow-fed and HFHS-fed mice, however levels were increased in HFHS-
fed + hrANXA1 treated and HFHS – Chow reversion diet mice. Perhaps hrANXA1 
exerts indirect effects on insulin signalling at the CNS via leptin. The potential role of 
both chemerin and leptin in T3DM development requires further investigation, as 
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6.3.5 Conclusion 
In summary the in vitro data on paracellular permeability, junctional proteins and 
adhesion molecule expression from cells stimulated with mice serum were similar to 
the in vivo and ex vivo data of the same parameters. This data confirms that serum-
stimulation models are appropriate for the investigation into disease pathology. This 
is welcome news for the 3Rs of research, as well as for translation studies using human 
samples in vitro to model disease phenotypes.  
To our knowledge, our group is the first to investigate the role played by brain 
endothelial cell metabolism in affecting CNS pathology. To date, the large focus of 
metabolism-based studies in the CNS have focused on astrocytes and neurons, with 
the role of brain endothelial cells largely neglected. However, changes to the structural 
and functional integrity of the BBB implies that metabolic disruption is occurring 
within these cells. In fact, here we see that HFHS-feeding impairs the glycolytic and 
oxidative phosphorylation pathways. In the immediate, the increased activity of these 
pathways provides greater ATP to meet the energetic demand placed upon the cells 
due to the enhanced inflammatory and immune status. On the other hand, the up-
regulation of metabolic pathways contributes to increased oxidative stress. The 
accumulation of ROS, RNS and AGEs are known to be fatal to neurons leading to 
neuronal apoptosis. The role of oxidative stress in neurodegenerative disorders of AD 
and PD have been well-recognised. Given the similarities in T2DM and AD brain 
pathology, major studies are required into understanding the impact of 
metaflammation on neuronal activity and subsequently cognition in the HFHS-fed 
model. Moreover, ROS production can be linked to increased activity of MMPs 
through direct and indirect regulation via up-regulation of inflammatory mediators and 
pathways. The results from the previous chapters together with the results from this 
chapter serve to demonstrate how peripheral inflammation can trigger a neuro-
inflammatory response which is self-perpetuating, resulting in a vicious ongoing cycle 
of damage to the BBB and consequently the brain tissue.  
One of the roles of the BBB is to serve as a transport barrier, and therefore alterations 
to the transport of nutrients and hormones across the BBB will have consequences for 
the health and functionality of the other cells of the NVU. The results from this chapter 
have only briefly alluded to the possible effects that changes in insulin, lipid and 
adipokine transport across the BBB could have for brain activity. Unquestionably, in 
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depth studies are required to investigate the exact role played by these factors in 
contributing to T2DM-induced brain neuroinflammation. Notably, insulin signalling 
is paramount in maintaining the health of neurons, with impaired signalling resulting 
in Aβ accumulation and cognitive defects. The adipokines resistin and chemerin are 
also linked to the control of insulin signalling pathways. Our results have shown that 
peripheral inflammation is the trigger to neuroinflammation through inducing a leaky 
BBB phenotype impairing its immunological integrity. It can be hypothesised from 
this chapter that disruption to metabolic transport occurring as a result of the impaired 
BBB triggers the onset on neurodegeneration that is controlled by nutrient and 
hormonal factors.  
The ability of the intervention arms to restore the metabolism of these cells to the state 
seen in the chow-fed mice serum stimulated cells is vital, as it serves to demonstrate 
that these interventions are not merely patching up the cells on the surface but truly 
working to provide a mechanism to combat the damage that is incurred and to restore 
the vascular health of these cells. This opens up a huge potential for these interventions 














































Chapter 7 – Metabolic disorders & the brain:  
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The goal of this thesis was to understand whether and how chronic peripheral 
inflammation arising from metabolic disorders such as MetS or T2DM can impact the 
brain to initiate a neuroinflammatory response that could lead to neurodegenerative 
disorders. The BBB serves as the main interface between the peripheral and central 
systems, protecting the brain microenvironment from damage from peripheral blood-
borne materials such as toxins, immune cells and inflammatory mediators (88). Due 
to the critical role played by the BBB in linking the peripheral and central systems, the 
focus of this study was to examine changes occurring to the structure, function, and 
immunological integrity of the BBB under metaflammation.  
 
 
7.1 The effect of metabolic disorders on the brain: from peripheral 
inflammation to neuroinflammation  
Overall, the results from this project demonstrate that damage to the brain 
microvasculature is a secondary complication to T2DM, similar to retinopathy, 
nephropathy and neuropathy. HFHS-feeding caused obesity, hyperglycaemia, 
hyperlipidaemia, and hyperinsulinemia prompting a low-grade chronic inflammatory 
state, also known as metaflammation. This metaflammation resulted in the complete 
breakdown of the BBB vessel structure triggering neuroinflammation. Figure 7.1 
provides an overview of the metaflammation-induced damaged at the BBB.  
The significant loss of the BBB structure in HFHS-fed mice compared to the chow-
fed mice implicates how chronic inflammation is a requirement in initiating the 
damage to the BBB. In fact, several neurodegenerative disease such as AD, PD, MS, 
ALS and HD report the presence of pro-inflammatory cytokines and activated immune 
cells within the peripheral blood (392,571–573). The presence of these circulating 
factors and immune cells cause brain endothelial dysfunction, leading to increased 
production of interleukins, cytokines, chemokines and adhesion molecules 
(320,328,329).  
Importantly, immune cell migration is the rate-limiting step in disease onset (156,251). 
However, as discussed previously, optimal migration of leukocytes across an 
endothelium barrier requires chemokine signals that initiate from within the CNS 
(629–631). Astrocytes, microglia and neurons do produce chemotactic factors to 
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induce leukocyte infiltration (253), highlighting that these cells sense perturbations in 
the brain or blood milieu early on. In fact, activation of astrocytes and microglia 
further contributes to the negative inflammatory status through subsequent release of 
acute-phase proteins, complement components, prostaglandins, cytokines, MMPs and 
ROS/RNS that promote neuronal cell death (575,576). In addition, the data from this 
project initiates the conversation on how altered metabolism and transport of nutrients 
and hormones in the brain endothelial cells of HFHS-fed mice can contribute to 
oxidative stress build-up and impaired neuronal signalling, which can be huge triggers 
in neurodegeneration (349,350,821).    
Interestingly, the HFHS-fed model not only shows an increase in pro-inflammatory 
mediators but also anti-inflammatory mediators, indicative of attempts to resolve and 
combat the damage. Inflammation is an evolutionary-conserved protective response 
mechanism which involves the coordinated communication of cells through intrinsic 
molecular signalling cascades. The simultaneous rise of pro- and anti-inflammatory 
mediators triggers aberrant activation of multiple signalling cascades (340,349–351). 
This over-active response likely causes confusion in cells and tissues, eventually 
resulting in loss of control and thereby contributing negatively to the pathological 
outcome.  
These concepts provide a clear pathway between peripheral inflammation and 
neuroinflammatory response that leads to neurodegeneration (577). In metabolic 
disorders, where peripheral inflammation is chronic and sustained, the inflammatory 
microenvironment is likely to propagate a vicious cycle of self-propelling 
inflammation from the endothelial cells, astrocytes, microglia and neurons that 
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Figure 7.1 | Overview of the effect of a HFHS-diet on the disruption of the NVU  
The traits of metabolic disorders – obesity, hyperglycaemia, dyslipidaemia, insulin resistance 
and hypertension, create a low-grade chronic inflammatory state termed metaflammation 
which results over time in the development of T2DM. Chronic metaflammation is responsible 
for producing a number of cytokines, chemokines and oxidative stress as well as activating 
the immune system. The damage by inflammation and the immune system leads to a leaky 
BBB phenotype that can be correlated to the loss TJs and AJs, the actin cytoskeleton, and the 
loss of basal lamina α4 on endothelial cells and α2 astrocytic end-feet. This breakdown is 
mediated by the imbalance of MMPs/TIMPs and results in complete loss of the BBB structure 
with the disassociation of the astrocytes to the blood vessel. The accumulation of 
inflammatory mediators and oxidative stress, through increased metabolism of glycolysis and 
mitochondrial respiration, contributes to the production of these MMPs. The pro-
inflammatory microenvironment activates the innate and adaptive arms of the immune system, 
resulting in the expansion of neutrophils, macrophages, dendritic cells, and T-cells. Within 
CD4+ T-cells, a diabetic microenvironment encourages the differentiation of T-cells into Teff 
cells particularly of the TH17 subset, with reduced Treg presence. Additionally, there are 
greater TEM and TCM cells. This allows for increased TEM of leukocytes into the brain 
parenchyma. Here, the peripherally-activated immune cells trigger the activation of microglia 
cells, skewed towards an M1 phenotype, responsible for producing iNOS which is neurotoxic. 
The astrocytes, microglia and neurons also sense changes in the brain microenvironment and 
are likely to respond to the increased presence of inflammatory mediator passage by further 
up-regulating the release of cytokines, chemokines, MMPs and ROS production that triggers 
pro-inflammatory signalling pathways. The disruption to the brain endothelial cells alters the 
transport of nutrients such as glucose and lipids and adipokines such as insulin, adiponectin 
and chemerin, which likely impact the functional activity of the brain cells. These events 
together creating a self-destructing environment within the brain triggering 
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7.1.2 Potential mechanism of action for BBB breakdown 
In the HFHS-fed mice, the breakdown of the BBB can be correlated to the surge in 
MMP levels, which are responsible for degrading TJs and the basal laminas (187,547). 
MMP activity is regulated transcriptionally by cytokines, growth factors, ROS and 
hormones (187,547,548). Notably, no single factor has been identified to be 
exclusively responsible for MMP overexpression, although TNF-α and IL-1 are often 
implicated (868). The activity of MMPs is regulated by transcription, pro-peptide 
activation and inhibition by TIMPs. The overall inflammatory profile in the HFHS-
fed mice creates the perfect mix of factors that aid in the overexpression of MMPs; 
and as discussed in Chapter 4, the sustained chronic inflammation results in the loss 
of TIMP-mediated control of MMP expression. Indeed, in the HFHS-fed + hrANXA1 
treated mice and HFHS – Chow reversion diet mice, where the inflammatory profile 
is improved, the MMP expression is reduced and the TIMP-1 levels increase. 
Although, as discussed in Chapter 5, the balance of MMPs/TIMPs is not fully restored 
in the HFHS – Chow reversion diet mice in comparison to HFHS-fed + hrANXA1 
treated mice; correlating with the different improvements seen in TJ and basal lamina 
re-establishment between these two groups. 
Several studies have been undertaken to uncover the signalling pathways involved in 
MMP transcription, as the full regulation of MMPs is still largely unknown. Mapping 
of the MMP-9 promoter regions reveals specific transcription factor binding sites for 
AP-1 and NF-κB. In contrast, MMP-2 transcription is regulated through NF-κB and 
caspase-8 (187).  
The binding of pro-inflammatory cytokines such as TNF-α or IL-1, growth factors 
such as VEGF, PAMPs and ROS species to receptors mediates a number of MAPK 
signalling pathways including ERK 1/2, JNK and p38 which are all upstream to AP-1 
(869–872). We therefore propose that the inflammatory environment induced by 
metaflammation activates these signalling pathways in the brain endothelial cells of 
HFHS-fed mice, to result in the transcription of MMPs to cause BBB breakdown. 
Additionally, pro-inflammatory mediators and ROS activate the PI3K/Akt/NF-κB 
pathway which further promotes MMP transcription (869,873,874) along with further 
production of IL-1β, IL-6, TNF-α and iNOS (875), creating a vicious circle of 
inflammation and breakdown in the brain, as previously suggested. In the HFHS-fed 
mice, the presence of these inflammatory markers, iNOS and MMPs is significantly 
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enhanced. Moreover, the activation of these pathways has been previously proposed 
in diabetic models (134,876–879) and in CNS inflammation (872,875,880).  
In the HFHS – Chow reversion diet mice, the switch to a chow-diet removes the 
original source of hyperglycaemia and hyperlipidaemia, thereby resulting in reduced 
serum glucose and lipid levels and significantly improved inflammatory mediator 
profile. Importantly, future studies need to confirm that dietary changes also lower 
ROS and iNOS production by brain endothelial cells. Nonetheless, it can be 
hypothesised that the reduction of these mediators reduces the activation of the 
MAPKs and PI3K-Akt signalling pathway, thus limiting MMP transcription. The 
HFHS – Chow reversion diet mice have reduced MMP-2, MMP-3, and MMP-9 
levels/activity.  
Cytokines, growth factors, PAMPs and ROS largely bind to G-protein coupled 
receptors which mediate their downstream effect to MAPKs through the Rho family 
of GTPases, including Ras, Rac, RhoA and Cdc42 (881–883). Studies in human 
hepatocellular carcinoma cells and human bladder cancer cells have shown the 
inhibition of RhoA using anti-tumorigenic compounds Sinulariolide (869) and 
Flaccidoxide-13-Acetate (874). These compounds reduce transcription of MMP-2 and 
MMP-9 through supressing the MAPKs and PI3K/Akt pathways. Previous work in 
our lab, has clearly demonstrated that ANXA1 mediates its affects through the 
inhibition of RhoA, with ANXA-/- mice having constitutively activated RhoA that 
contributes to the heightened BBB permeability (297). We can therefore hypothesise, 
that ANXA1 treatment in HFHS-fed mice reduces the MAPK activity and thus MMP 
transcription, not only through reduced inflammatory mediators but also direct effects 
via RhoA. Overall, this contributes to the improved integrity of the BBB vasculature 
in the HFHS-fed + hrANXA1 treated mice. Moreover, we have previously also 
demonstrated that inhibition of RhoA in HFHS-fed + hrANXA1 treatment mice is 
responsible for the attenuation of T2DM and peripheral microvascular complication 
of nephropathy, through restoring the IRS-1/Akt/GSK-3 signalling pathway (512).  
To confirm these hypotheses, signalling pathway studies are currently being 
undertaken in our lab. Figure 7.2 shows a proposed mechanism of MMP-mediated 
BBB breakdown in T2DM.    
 




Figure 7.2 | Proposed mechanism of MMP-mediated BBB breakdown in T2DM    
MMP activity is regulated transcriptionally by cytokines, growth factors, oxidative, hormones 
and other cytotoxic molecules. The binding of pro-inflammatory cytokines such as TNF-α or 
IL-1, growth factors such as VEGF, PAMPs and ROS species to receptors mediates a number 
of MAPKs signalling pathways including ERK 1/2, JNK and p38 which are all upstream to 
AP-1. Additionally, pro-inflammatory mediators and ROS activate the PI3K/Akt/NF-κB 
pathway which further promotes MMP transcription, along with further production of IL-1β, 
IL-6, TNF-α and iNOS. We propose that the activation of these pathways in the brain 
endothelial cells of HFHS-fed mice, is responsible of the production of MMPs which degrade 
the BBB. These inflammatory mediates largely bind to GPCRs which mediate their 
downstream effects through the Rho family of GTPases including Ras, Rac, RhoA and Cdc42. 
Dietary reversion and hrANXA1 treatment both have anti-inflammatory effects reducing the 
presence of these inflammatory triggers and thus we propose the reduced activation of these 
pathways attenuates MMP production. Additionally, ANXA1has direct effects on inhibiting 
RhoA and this also mediates the reduction in MMP and pro-inflammatory mediator 
transcription.   
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7.2 Metaflammation-induced neuroinflammation: a cocktail for T3DM 
The data from this thesis provides an insight into the pathophysiology of how diabetes 
can trigger inflammatory events within the brain. Whilst this project has not shown 
the effects on neurons, it is clear that the altered brain microenvironment and CNS 
inflammation will impact neuronal function adversely. One particular study has shown 
degenerating neurons in the cortex and hippocampal regions in rodents fed a high-fat 
and high-fructose diet for 24 weeks (674). Moreover, these mice had impaired spatial 
learning and memory, as tested using the Morris Water Maze test, that could be linked 
to the neuronal losses (674). Other studies have also reported impaired cognition in 
rodents (451,452) and patients (392,450) with T2DM. It is therefore not surprising that 
epidemiological studies have long reported metabolic disorders to be a risk factor for 
cognitive decline (5,6) and the development of dementias (7,8). In fact, individuals 
with T2DM have twice the risk of developing dementia, particularly AD, compared to 
those without T2DM (9,787). 
Further consolidation between T2DM and AD link was shown by a series of studies 
conducted by Carvalho and colleagues. These studies found that T2DM mice (induced 
by 20% sucrose feeding for 7 months) and 3x transgenic AD mice presented with 
similar vascular dysfunction. Both groups of mice showed comparable Evans blue dye 
leakage into the hippocampus and cortex, accumulation of Aβ and phosphorylated Tau 
and impaired mitochondrial enzyme activity. Furthermore, both groups of mice also 
showed similar behavioural and cognitive abnormalities as seen through increased fear 
and anxiety and impaired learning and memory (394,395).  The similarities in the two 
conditions to cause equivalent CNS dysfunction supports the theory that T2DM causes 
the development of dementia, namely AD. In line with similar cerebrovascular 
abnormalities seen in T2DM and AD mice, it has also been reported that AD mice fed 
a high fat diet have T2DM-like peripheral insulin resistance (390). This results in 
decreased insulin signalling in the brain that contributes to Aβ burden and cognitive 
defects (390,391,786). The similarities in the T2DM and AD mice linked with insulin 
sensitivity has therefore lead to the concept that AD is in fact a continuum of DM, 
termed T3DM (133,396). 
In the HFHS-fed mice, the data demonstrates how disruption to the BBB integrity can 
impact the transport for nutrients and hormones to other cells of the NVU with 
particular consequences for neurons. In the HFHS-fed mice there was a downwards 
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trends towards decreased insulin receptor expression at the brain endothelial cells, as 
well reduced expression of hormones adiponectin, resistin and chemerin. These 
adipokines all perform a role in insulin signalling and impairment of their transport 
will have detrimental effects on neurons, which rely on insulin-mediated uptake of 
glucose (136) for neuronal growth, plasticity or neurotransmitters release (137). In 
addition, the increased metabolism (glycolysis and oxidative phosphorylation) of the 
brain endothelial cells, as a result of high circulating glucose and lipids, can result in 
the build-up of oxidative stress that contributes to insulin resistance (823).  
The central role of insulin in AD has been further confirmed by a phase III clinical 
trial, in which nasally administered insulin improved cognitive function in AD patients 
(393). Subsequent studies have shown that insulin administration improves AD 
pathology through restoring metabolic function of neurons (786), further emphasizing 
the role played by metabolic dysfunction of the BBB in T2DM to contribute to CNS 
pathology.  
Combined, these studies make a clear case for metaflammation-induced 
neuroinflammation to be termed T3DM. However, the ability of T2DM to cause AD 
is a serious cause for concern for the health care and economic system. By 2030, it is 
projected that 439 million people will have T2DM (310). Diabetes is the third leading 
cause of death. T2DM patients are 2.5 times more likely to develop CVDs (311,312), 
which remains the leading cause of death globally, claiming more than 17 million 
lives/year (313). Equally, the number of people projected to have dementia by 2050 is 
150 million (388), of which AD constitutes 60-70% of cases (389). Dementia is the 
fifth leading cause of death worldwide (309). Both T2DM and dementias are 
progressive long-term conditions (13). Given that people are living longer and obesity 
is on the rise (14) we are facing an epidemic crisis, whereby the numbers of individuals 
who suffer from T2DM, CVDs and AD (or T3DM) is likely to outstrip those who do 
not suffer from these chronic diseases. 
In Chapter 4, it was briefly shown using young (6-week old) mice vs aged (20-week 
old) mice that a significant degree of damage to the BBB occurs over time, with aged 
mice having increased paracellular permeability and reduced TEER. The mice fed a 
HFHS diet were also 20-weeks old, and the ability of T2DM to accelerate the 
deterioration of the BBB compared to 20-week old chow-fed mice, serves to highlight 
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how metabolic disorders speed-up the natural aging process to induce 
neuroinflammatory and neurodegenerative disorders.  
Importantly, T2DM is no longer associated with an aged population. Due to the 
increase incidence in obesity through consumptions of food high in fat and sugar 
combined with a sedentary lifestyle, individuals are starting to develop T2DM at a 
younger age (884), with reports of cases of T2DM in children as young as 10 years 
old (885). Additionally, reports suggest that parental obesity (886) or early-life obesity 
(887) corresponds to developmental delays in early childhood. Furthermore, 
childhood and adolescent obesity is related to reduced executive function and attention 
and lower mathematics and reading achievements (888). These reports implicate how 
obesity could lead to a significant percentage of the population suffering from 
cognitive impairments, which is a real cause for concern. 
 
 
7.2.1. SARS-CoV-2 and Diabetes 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative 
agent of coronavirus disease 2019 (COVID-19), which has created the most recent 
pandemic, as declared on 11th March 2020. Since 31st December 2019 to 7th July 2020, 
SARS-CoV-2 has infected over 11 million individuals and claimed the lives of over 
500,000 persons (889).    
Since early in the pandemic, diabetes was classed as a major risk factor for 
hospitalisation and mortality from SARS-CoV-2 (890). This is perhaps not surprising, 
as individuals with diabetes demonstrate a higher susceptibility to several infectious 
diseases including influenza, pneumonia, and tuberculosis. In fact, data from the H1N1 
influenza pandemic in 2009 has shown that the disease was more severe and lasted for 
a longer duration in obese patients. Similarly, small retrospective cohort studies from 
COVID-19 Chinese patients have begun to report that infection rates and deaths are 
higher in individuals suffering from DM (891,892). DM is a risk factor for infectious 
diseases due to the low-grade chronic inflammatory state, arising from impaired 
glycaemic control, which impairs immune response (cytokine production and immune 
cell activation) to infections (725,728). Moreover, DM patients with abdominal 
obesity present with mechanical respiratory problems with reduced lung function and 
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reduced oxygen saturation of the blood (893), pre-disposing to respiratory viruses such 
as SARS-CoV-2.  
Nonetheless, COVID-19 is far from a typical respiratory disorder, with reports 
emerging of the virus causing neurological defects (894). In the UK, review of 125 
seriously ill coronavirus patients have found that nearly half suffered a stroke whilst 
others have shown brain inflammation, psychosis or dementia-like symptoms (895). 
A brain autopsy from a patient who developed encephalopathy after presenting with 
SARS-CoV-2 showed swelling, hyperplasia of glial cells and neuronal necrosis. This 
was associated with elevated expression of cytokine CXCL9 that corresponded with 
an infiltration of monocytes, macrophages, and T-cells, as seen by immuno-
histochemical analysis (895).  
This thesis project demonstrates the link between the peripheral and central system in 
T2DM, with peripheral inflammation as a responsible factor for the initiation of 
neuroinflammatory response through BBB breakdown and subsequent T-cell 
infiltration. Given that we have demonstrated the link of T2DM and the brain through 
inflammation; this coupled with reports of COVID-19 to produce negative outcomes 
for both diabetes and the brain as a result of impaired immune responses, suggests 
there could be a potential link. It has been shown that SARS-CoV-2 can damage 
endothelial cells, activating inflammatory and thrombotic pathways to cause 
coagulation resulting in macrovascular damage. So far, SARS-CoV-2 has been linked 
with inflammation and apoptosis of endothelial cells in the lung, heart, bowel, and 
kidney, however the effect on the cerebral microvessels has yet to be investigated. 
Only retrospective cohort studies will be able to determine whether those who suffer 
from neurological defects, as a side-effect of the virus, are also those individuals who 
present with underlying metaflammation. We have also discussed the impact of age, 
and although it appears that mortality rates from coronavirus are higher in the older 
population (896), investigations will need to be made to determine whether younger 
individuals who lost their lives suffered from other co-morbidities such as obesity, 
MetS or T2DM.   
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7.3 Implications for health care guidance: prevention and management  
The progressive development of obesity to T2DM, and T2DM to dementias, in all age 
groups, poses fundamental calls for the prevention and management of these diseases. 
In the past two decades, a large proportion of focus has been on the prevention and 
management of obesity, T2DM and CVDs (897–899), with evidence-based 
recommendations using a multi-factorial approach of lifestyle, medical and 
behavioural therapies to produce improvements in disease outcome. Overall 
comprehensive strategies can reduce the development of micro- and macro-vascular 
complications in T2DM patients by 50% in approximately 8 years (716).  
In the HFHS – Chow reversion diet mice, used in our study, BBB integrity is 
significantly improved. The key mechanism of this improvement can be related to the 
ability of dietary changes to reduce inflammation resulting in weight loss and 
improved peripheral glucose, insulin, and cholesterol levels. Managing these risk 
factors are the backbone to halting T2DM progression (681,682,684), thereby 
consolidating the notion that brain microvasculature disruption is a secondary 
complication of T2DM and should be managed clinically in the same manner.  
Currently, WHO prevention guidelines for cognitive decline and dementia do 
acknowledge that the risk factors for dementia are shared with those of other non-
communicable diseases and similar prevention strategies on diet, alcohol and tobacco 
use and physical activity recommendations should be applied (900). Interestingly, 
however, the current guidance for the management of individuals who have developed 
dementias do not offer extensive nutritional therapy approaches other than for VaD. 
VaD is treated differently as it occurs after stroke which is classed as a CVD and 
macrovascular complication of T2DM, suggesting that other dementias such AD are 
treated differently because it is believed that they do not have the same vascular 
dysfunction. However, as discussed in Section 7.2, AD and T2DM share the same 
vascular pathologies, suggesting that the management of this dementia or T3DM at 
least, should also be treated as a complication of T2DM.  
The data from the HFHS-fed mice after 10 weeks of feeding clearly demonstrates that 
the brain microvasculature has been disrupted leading to neuroinflammation that is 
likely to result in neurodegenerative processes. In the first study of its kind, our data 
from the HFHS – Chow reversion diet mice prove that dietary change can revert and 
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restore the damage to the BBB and reduce neuroinflammation. The reduction in 
inflammatory mediators and MMPs, reduced TH17 migration, restoration of microglia 
pro-inflammatory M1 and anti-inflammatory M2 phenotypic balance implicates that 
signalling responses are being rewired in these mice. This will help to limit neuronal 
damage and thus improve cognition and memory. Figure 7.3 provides an overview of 
dietary intervention-based improvement on the BBB and the brain.  
Notably, optimal glycaemic control was not achieved in the HFHS – Chow reversion 
diet mice after 5 weeks on a chow diet which may account for the lack of restoration 
of TJs and basal laminas at the BBB, along with high activation of immune cells. 
Previous studies that report improved insulin sensitivity with dietary interventions 
such as  food or calorie restriction (717–719), ketogenic diets (720), herbal formulas 
(721), reduced glycoxidation products (722) or addition of extra virgin olive oil (723) 
are employed over a period of 8-24 weeks. Placing the HFHS – Chow reversion diet 
mice on a longer reversion period is likely to induce significantly greater 
improvements in BBB integrity. Additionally, further studies are required to 
understand the effect of BBB metabolism and transport. Nevertheless, the 
improvement in the adipokine and lipid receptor expression at the BBB serves to 
demonstrate how diet can repair the functionality of the BBB. The adipokines are key 
players in insulin signalling, and the restored transport will therefore have huge 
implications for neuronal function, and reduction of AD-like pathology.  
Currently, there is no cure for dementia and no treatment that slows or stops its 
progression. Medications are largely prescribed to alleviate symptoms such as 
depression, sleep disturbances, hallucinations, parkinsonism, or agitation and to help 
improve brain function through boosting levels of chemical messengers involved in 
memory or learning (901). Our study provides crucial evidence on how dietary change 
could attenuate T3DM development. Without doubt, more detailed studies are 
required to understand the impact on neurons, cognition, and behaviour, however this 
study provides a strong foundation to continue this research with a huge potential for 
impacting future guidance and management of dementias.  
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Figure 7.3 | Overview of the effect of dietary reversion (from a HFHS diet to a chow-diet) 
on the BBB and the NVU  
Dietary intervention of HFHS – Chow reversion diet causes significant weight loss to reduce 
obesity and improve the glucose, insulin and lipid levels thereby significantly reducing the 
inflammatory profile and production of MMPs. After 5 weeks of diet intervention, brain 
endothelial cells show tight junction restoration, and reduced activation via reduced adhesion 
molecule presence accounting for reduced permeability and improved TEER. However, 
improvement to the basal lamina is not apparent over 5 weeks of feeding and this prevents the 
reassociation of the astrocytic end-feet with blood vessel. At the immune cell levels is a 
reduction in the TH17/Treg ratio and restored TEM and TCM balance. Whilst there is a reduction 
in adhesion/migration of TH17 cells, the Treg cells still transmigrate implicating that T-cells 
have not lost their ability to migrate however there are changes being made immunologicaly 
to restore the disease status. Within the brain parenchyma there is considerably reduced 
microglia activation suggesting that less damaging cells or molecules are passing through. 
Microglia also show a restoration of balance between M1/M2 phenotype. The reduction in 
inflammation coupled with improved transport of nutrients and adipokines is likely to prevent 
activation and production of inflammatory mediators by astrocytes, microglia and neurons 
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7.4 Targeting brain damage with ANXA1: the most beneficial brain 
therapeutic to date? 
Aside from dietary intervention, the large focus of this project has been to investigate 
the use of hrANXA1 as a pharmacological intervention. The role of ANXA1 has been 
investigated in a number of different conditions including MS, atherosclerosis, 
inflammatory bowel diseases, rheumatoid arthritis and cancers (294). 
Previous studies undertaken in our lab, showed the potential of hrANXA1 as a 
therapeutic agent in modulating T1DM and T2DM. Prophylactic treatment with 
hrANXA1 in STZ-induced T1DM mice prevented development of microvascular 
complications (nephropathy and cardiomyopathy) (678). Furthermore, the therapeutic 
treatment of hrANXA1 in these STZ-induced T1DM mice which had developed 
microvascular complications, prevented further decline in cardiac and renal function 
(678). In a T2DM model of HFHS-feeding, treatment with hrANXA1 prevented 
further deterioration of T2DM through restoring insulin sensitivity and attenuated the 
development of renal nephropathy and lipid accumulation within the liver. These 
studies suggested the potential for hrANXA1 to also prevent T2DM-induced brain 
microvascular complications such as T3DM.  
In fact, in this project we demonstrate that hrANXA1 treatment does reduce, restore, 
and revert the damage incurred to the BBB under metaflammation. This is not 
surprising, as the role of ANXA1 in maintaining the BBB integrity has been well-
documented, due to its ability to restore junctional proteins through localisation with 
the actin cytoskeleton (297). Here, we further demonstrate that the role of ANXA1 
can be extended to its ability to restore the essential components of the BM, the basal 
laminas, through rebalancing the MMPs/TIMPs ratio which help to reseal the leaky 
BBB phenotype.  
Immunologically, hrANXA1 treatment in the HFHS-fed mice helped reduce the 
migratory capacity of T-cells across the BBB through various mechanisms such as 
reduction of α4β1 integrin-mediated leukocyte binding (482) , L-selectin shedding 
(280), reduced T-cell activation and balancing of TH17/Treg levels and thus reducing 
microglia activation. ANXA1 also mediates neuroprotection through a prominent 
increase in the percentage of M2 cells that allow for decreased iNOS production. 
These effects have been previously shown to reduce phagocytosis of non-apoptotic 
Page | 338  
 
neurons (279), thereby limiting neurodegeneration. Metabolically, ANXA1 reduced 
glycolysis and mitochondrial respiration of brain endothelial cells to reduce oxidative 
stress thereby lowering the inflammatory environment within the brain. In addition, 
ANXA1 restored the expression of adipokines which would have huge potential for 
restoring insulin sensitivity, although this requires further investigation.  
In summary, ANXA1 confers neuroprotection against metaflammation-induced BBB 
damage and could be beneficial to limit the progression of neurodegenerative 
disorders such as T3DM. An overview of ANXA1’s effects on the BBB is shown in 
Figure 7.4. 
 
The use of ANXA1 as a treatment for AD specifically has also been investigated. It 
has been shown that ANXA1 and the FPR2 receptor are reduced in brain capillaries 
of AD mice resulting in disruption of the BBB that can be attributed to Aβ-induced 
RhoA activation (902). Treatment with ANXA1 restores this BBB integrity through 
inhibiting RhoA. Moreover, ANXA1 is shown to be involved in the degradation and 
clearance of Aβ through increasing the expression and activity of Aβ-degrading 
enzyme neprilysin and by increasing microglial Aβ phagocytosis. In addition, ANXA1 
reduces Aβ-induced microglial cytokine production (304). Further work has also 
shown that these effects can be correlated to reduced loss of neurons and improved 
cognitive behaviour (Reis et al., manuscript submitted). Given the similarities in the 
T2DM and AD brain pathology with Aβ accumulation, it is likely that ANXA1 will 
be able to induce the same beneficial effects described above in the brain of T2DM 
mice to attenuate the development T3DM.  
The management of T2DM and CVDs recommends a multi-factorial approach to 
disease management through lifestyle, medical and behavioural therapies. In a similar 
way, management of T2DM-related dementias i.e. T3DM would also require a 
comprehensive management style. The ability of both ANXA1 and dietary changes to 
induce significant improvement on the BBB integrity implicates that combined, the 
two interventions could produce even better outcomes.  
In addition, the treatment of ANXA1 is provided via i.p.. The ability of ANXA1 to 
induce such strong anti-inflammatory effects within the CNS without having to 
consider special drug delivery mechanisms at the BBB further implicates the potential 
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use of this endogenous molecule as a regulator and therapeutic in neurovascular and 
neurodegenerative disorders. To date, no other molecule, to our knowledge, has been 
able to induce similar widespread beneficial effects in the peripheral system, at the 
BBB and within the brain. ANXA1’s potential to limit leukocyte extravasation is 
mediated through the same mechanism as the current treatment for MS – Natalizumab, 
a humanised monoclonal antibody against α4β1 integrin (299). Given that ANXA1 is 
an endogenous molecule, its potential to induce side-effects would be considerably 
lower, making it further suitable as a therapeutic candidate. Of course, ADME and 
toxicology studies would be required in primates before considering trials in man. 
However, the vast array of positive research into ANXA1 implicates its vast 
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Figure 7.4 | Overview of the effect of hrANXA1 treatment in HFHS-feeding on the BBB 
and the NVU  
Treatment with hrANXA1 attenuates the development of T2DM, by restoring insulin 
sensitivity and improvement of glucose and lipid levels. At the level of the BBB, treatment 
with hrANXA1 in the HFHS model has profound effects on restoring the BBB integrity 
through restoration of TJs (actin-mediated) and BM laminins to allow a resealing of the BBB 
vasculature through reassociation of astrocytic end-feet to the vessel. This contributes to 
reduced permeability and TEM. Improved glycaemia and insulin levels reduces glycolysis and 
mitochondrial respiration, resulting in reduced oxidative stress which contributes to reduced 
MMP and cytokine production. At the immunological level, hrANXA1 treatment limits T-cell 
activation and reduces the TH17/Treg ratio, which can be accounted for by alterations in the 
interleukins and cytokines. Reduced T-cell activation accompanied by prevention of leukocyte 
adhesion via L-selectin shedding, amongst possible other mechanisms such as endothelial cell 
ANXA1 shedding, significantly reduces the migration of peripherally-activated immune cells 
into the brain parenchyma. Within the brain, hrANXA1 reduces the number of microglia cells 
and induces a shift from the pro-inflammatory M1 to resolving M2 phenotype, this can have 
a huge impact on preventing damage to neurons through reduced iNOS production and 
controlled apoptosis. Additionally, the reinstatement of transport mechanisms for nutrients 
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7.5 Limitations and Future Work 
The major limitation of the project is the use of all male mice to conduct the studies. 
Almost 80% of animal-based studies employ the use of male mice to carry out 
investigations, this is due to the fluctuation of hormones in female mice that can render 
results uninterpretable (903). However, pre-clinical studies should employ the use of 
both male and female mice, as this often leads to problems at the clinical stage with 
differing drug responses. Between 1997-2000, it was estimated that 8-10 drugs were 
withdrawn by the FDA due to the greater health risks posed for women than for men 
(904). 
Importantly, certain diseases come with their own gender bias. For example, males are 
more prone to the development of obesity, T2DM and CVDs (905). In contrast, 
females are more likely to develop dementias (906). It is hypothesised that oestrogen 
is protective in middle age and when menopause takes place, the risk of CVD and thus 
dementia development becomes more common in women. Additionally, the results 
from the Framingham health study suggest that because more men die in middle age 
due to heart disease, those who survive past 65 may have healthier hearts that provide 
some protection (907). However, this relies on the concept that dementias begin in old 
age. As discussed previously, with the rise in obesity, the age at which chronic 
conditions such as T2DM, CVDs and dementias occur is changing. Only long-term 
observational studies will be able to determine whether the cases of these conditions 
at a young age are more prevalent in males or females. Nevertheless, future work on 
this project should consider the use of male and female mice to determine whether 
metaflammation-induced neuroinflammation occurs equivalently in both sexes.  
Interestingly, previous work from our lab has reported oestrogen-mediated differences 
at the BBB. Using hCMEC/D3 cells, results showed oestrogen-treatment was 
protective against inflammation-induced (TNF-α and IFN-γ) barrier defects (908). 
Oestrogen-treated cells had reduced paracellular permeability, higher TEER, intact TJ 
integrity and fewer transmigration of leukocytes compared to non-treated cells. 
Interestingly, these protective effects were mediated through oestrogen-controlled 
production of ANXA1. However, importantly in this study, it was shown that although 
young adult female mice (2 months old) had significantly reduced Evans blue leakage 
compared to male counterparts after LPS-stimulation, reproductively senescent female 
mice (15 months old) exhibited significantly enhanced Evan’s blue dye leakage 
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compared to 15 month old males (908). We showed in this project that T2DM 
accelerates the BBB damage in male mice, and therefore a comparison in female mice 
would be beneficial.  
Aside from the potential sex-bias of this study, there is also the limitation of the HFHS 
– Chow reversion diet mice age difference compared to chow-fed, HFHS-fed and 
HFHS-fed + hrANXA1 mice. The HFHS – Chow reversion mice are 25-weeks old at 
cull, compared to 20-weeks old in other 3 groups. The results of this project 
demonstrate in Figure 4.2, that age itself is a factor in inducing BBB leakage. 
Therefore, it is possible that the intervention of dietary change could have greater 
effects on improving BBB integrity and neurovascular health than shown in our results 
here. Unfortunately, due to limitations of time and money constraints, this preliminary 
study was unable to compare the effects of dietary intervention against mice of the 
same age. However, any future studies assessing dietary intervention should be 
conducted against mice of the same age at cull to remove age as a cofounding factor 
and to allow for a better comparison of results. Overall, this will help to consolidate 
the true benefits of dietary changes on improving our neurovascular health.  
 
Another limitation of this study was the use of a 2D in vitro model, in which the bEnd3 
cells were used. The discussions from this project constantly highlight the complex 
and dynamic nature of the brain microenvironment due to the interaction of the 
different cells with each other and the 2D model here does not address the effect on 
astrocytes or microglia cells. Therefore, to truly mimic the BBB data in vitro the use 
of a 3D culture system needs to be employed. The most ideal 3D culture system would 
incorporate all the cells of the NVU including brain endothelial cells, astrocytes, 
pericytes, microglia and neurons (43). In reality, this is not so simple to re-create due 
to difficulties in set-up, maintenance and cost. Aside from co-culturing, dynamic 
models are also of benefit such as a cone-plate apparatus in order to place cells under 
shear stress. Shear stress which is generated by the flow of blood in physiological 
conditions also affects TJs, transporter expression and leukocyte adhesion (909,910). 
The best model to incorporate co-culture and shear stress conditions is a microfluidics 
model, which offers a more robust representation of the BBB (911–915). To date, a 
true model of the BBB which offers all these conditions has yet to be designed. 
Moreover, whilst some models are good for examining TJs, they are not sufficient for 
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measuring permeability and therefore choosing a single model that can be used to 
investigate a variety of effects often hinders the use of costly in vitro models (910). 
Therefore, the large majority of in vitro studies continue to be conducted in 2D models. 
Perhaps, one way to improve our 2D model in this project would be to use primary 
brain endothelial cell cultures in place of bEnd3 cells for stimulation with mouse 
serum.  
 
Finally, a key method to consolidate the findings in this project would be to use 
human samples of serum and PBMCs to determine whether diabetic patients have 
raised inflammatory factors that mediate BBB damage in vitro that can induce 
leukocyte migration. Using 3D models, it would be beneficial to see examine the 
effects of microglia activation and cytokine production, and potentially on neuronal 
damage/apoptosis. To conduct such studies, samples would be required from healthy 
individuals, patients with MetS who are not on medication and patients with T2DM 
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7.6 Closing remarks   
In conclusion, the data from this thesis demonstrates a clear mechanistic link and 
pathway between metaflammation to neuroinflammation. The BBB is the interface 
between the peripheral and central systems, therefore structural, functional, metabolic, 
and immunological integrity of the BBB is of paramount importance for maintaining 
brain health.  
The results collectively showcase how neurovascular complications of the brain 
microvasculature must also be termed under the umbrella of T2DM-related secondary 
complications. For many years, the brain has been considered a ‘separate’ entity from 
the rest of the body. However, research is accumulating which continually breaks this 
paradigm – from the discovery of the glymphatic system, the role of the gut-brain axis 
and the link of the peripheral to central immune systems, all indicating the need for a 
holistic approach to disease management.  
As the way we live changes, so do the diseases we encounter. Therefore, our 
management and treatment of these conditions must also change with time. This 
requires constant review of disease management guidelines, public health measures 
and treatment strategies. The work here combines several different fields of science 
including inflammation, metabolism, immunology and pharmacology; giving us a new 
perspective on the way we view T2DM and neurological disorders. The ability of 
hrANXA1 and a dietary intervention to reduce and restore the metaflammation-
induced BBB damage provides hope for the way we can slow down T3DM disease 
progression. The growing population of individuals with chronic conditions such as 
obesity, T2DM and dementias requires the need for innovative therapeutic approaches 
for healthcare. I hope the work here helps to serve to this need, with the hope that this 
work will be taken further for exploration into the benefit it can serve to provide for 
effective therapies and a better quality of life. 
Importantly the discoveries here are only one piece of a larger puzzle, with many more 
avenues to explore being opened. The intricacies and details of our body and how it 
works continues to fascinate scientists around the world. Afterall, this is the beauty of 
science – there is always more to learn.  
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